<SEC-DOCUMENT>0001438533-18-000032.txt : 20181101
<SEC-HEADER>0001438533-18-000032.hdr.sgml : 20181101
<ACCEPTANCE-DATETIME>20181101164709
ACCESSION NUMBER:		0001438533-18-000032
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20181101
DATE AS OF CHANGE:		20181101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Retrophin, Inc.
		CENTRAL INDEX KEY:			0001438533
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262383102
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36257
		FILM NUMBER:		181154474

	BUSINESS ADDRESS:	
		STREET 1:		3721 VALLEY CENTRE DR.
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		760-260-8600

	MAIL ADDRESS:	
		STREET 1:		3721 VALLEY CENTRE DR.
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Desert Gateway, Inc.
		DATE OF NAME CHANGE:	20080625
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rtrx-20180930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s551002A2480C5CA4BD171136960EA844"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">_________________________________</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">_________________________________</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#254;</font></div><div style="font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the quarterly period ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">or</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;font-weight:bold;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">For the transition period from ___________ to ___________</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commission File Number:  001-36257</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font><font style="font-family:Arial Narrow;font-size:9pt;">RETROPHIN, INC.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:39%;"></td><td style="width:3%;"></td><td style="width:39%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">27-4842691</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(I.R.S. Employer Identification No.)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:60%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">3721 Valley Centre Drive, Suite 200, San Diego, CA 92130</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:31%;"></td><td style="width:38%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">(760) 260-8600</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(Registrant&#8217;s Telephone number including area code)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;Yes </font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:42%;"></td><td style="width:8%;"></td><td style="width:38%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Large accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#254;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Smaller reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;&#160;&#160;Yes &#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">&#254;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;The number of shares of outstanding common stock, par value $0.0001 per share, of the Registrant as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">November&#160;1, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">41,247,609</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sBFAF999010BF5558804ABB5849EA38AC"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;text-align:center;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">RETROPHIN, INC.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Form 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">For the Fiscal Quarter Ended </font><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:81%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Page&#160;No.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s32E2B2D542A25B92A438DCFF6BB6234F"><font style="font-family:Arial Narrow;font-size:9pt;">PART I &#8211; FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s10D3819BD2F652DA883A27C287E4812C"><font style="font-family:Arial Narrow;font-size:9pt;">Item 1.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s10D3819BD2F652DA883A27C287E4812C"><font style="font-family:Arial Narrow;font-size:9pt;">Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s18BDF35B98215064AB04E9DD5B1964BC"><font style="font-family:Arial Narrow;font-size:9pt;">Condensed Consolidated Balance Sheets as of September 30, 2018 (Unaudited) and December 31, 2017</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#s2C76501454AB5DB5897D258A2514E6AD">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s92147193CCF15CB5B0D52A8EB0CE46C4"><font style="font-family:Arial Narrow;font-size:9pt;">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#s92147193CCF15CB5B0D52A8EB0CE46C4">4</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s92147193CCF15CB5B0D52A8EB0CE46C4"><font style="font-family:Arial Narrow;font-size:9pt;">Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#sC2C40B7E53E25CC4A98FE33440C137A9">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s04CED689681D53F398F38C22AF9E0F48"><font style="font-family:Arial Narrow;font-size:9pt;">Notes to Unaudited Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#s04CED689681D53F398F38C22AF9E0F48">6</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s33A77C1707ED50089F30D32EE91625DD"><font style="font-family:Arial Narrow;font-size:9pt;">Item 2.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s33A77C1707ED50089F30D32EE91625DD"><font style="font-family:Arial Narrow;font-size:9pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#s33A77C1707ED50089F30D32EE91625DD">19</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s41C6A78C196D54B0A3B28F230F5DC186"><font style="font-family:Arial Narrow;font-size:9pt;">Item 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s41C6A78C196D54B0A3B28F230F5DC186"><font style="font-family:Arial Narrow;font-size:9pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#s41C6A78C196D54B0A3B28F230F5DC186">27</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sE69D5A380FBC5D7DBE829457CC617DF6"><font style="font-family:Arial Narrow;font-size:9pt;">Item 4.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sE69D5A380FBC5D7DBE829457CC617DF6"><font style="font-family:Arial Narrow;font-size:9pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#sE69D5A380FBC5D7DBE829457CC617DF6">27</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s97E420A17B3150658B186D105686CB9E"><font style="font-family:Arial Narrow;font-size:9pt;">PART II &#8211; OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sB992249C0BD6593D8C0E9EF8E83518F4"><font style="font-family:Arial Narrow;font-size:9pt;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sB992249C0BD6593D8C0E9EF8E83518F4"><font style="font-family:Arial Narrow;font-size:9pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#sB992249C0BD6593D8C0E9EF8E83518F4">27</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sC8007D35C027572B9822E17D47640AB9"><font style="font-family:Arial Narrow;font-size:9pt;">Item 1A.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sC8007D35C027572B9822E17D47640AB9"><font style="font-family:Arial Narrow;font-size:9pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#sC8007D35C027572B9822E17D47640AB9">27</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sD9B0719901ED52B7BD0BD1E8D2BFC51B"><font style="font-family:Arial Narrow;font-size:9pt;">Item 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sD9B0719901ED52B7BD0BD1E8D2BFC51B"><font style="font-family:Arial Narrow;font-size:9pt;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#sD9B0719901ED52B7BD0BD1E8D2BFC51B">46</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s91295CB052B551E0B2D54165FD722E86"><font style="font-family:Arial Narrow;font-size:9pt;">Item 3.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s91295CB052B551E0B2D54165FD722E86"><font style="font-family:Arial Narrow;font-size:9pt;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#s91295CB052B551E0B2D54165FD722E86">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s9938B287D5BE5651B6CAA38E360EDB3D"><font style="font-family:Arial Narrow;font-size:9pt;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s9938B287D5BE5651B6CAA38E360EDB3D"><font style="font-family:Arial Narrow;font-size:9pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#s9938B287D5BE5651B6CAA38E360EDB3D">46</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sF2688B93497655AA808E9DBAE23F8FDF"><font style="font-family:Arial Narrow;font-size:9pt;">Item 5.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#sF2688B93497655AA808E9DBAE23F8FDF"><font style="font-family:Arial Narrow;font-size:9pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#sF2688B93497655AA808E9DBAE23F8FDF">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s967AF0D7CBD35770BA73E4FF799225BE"><font style="font-family:Arial Narrow;font-size:9pt;">Item 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;" href="#s967AF0D7CBD35770BA73E4FF799225BE"><font style="font-family:Arial Narrow;font-size:9pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><a style="font-family:Arial Narrow;font-size:9pt;color:#000000;text-decoration:none;" href="#s967AF0D7CBD35770BA73E4FF799225BE">47</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">1</font></div></div><hr style="page-break-after:always"><div><a name="sAD352BC8AC975CC78D6F79BE11D35EFD"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">FORWARD LOOKING STATEMENTS</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our annual report on Form 10-K for the fiscal year ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(the "2017 10-K"), and in this Form 10-Q and information contained in other reports that we file with the Securities and Exchange Commission (the &#8220;SEC&#8221;). You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us. You can also read and copy any materials we file with the SEC at the SEC&#8217;s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2</font></div></div><hr style="page-break-after:always"><div><a name="s32E2B2D542A25B92A438DCFF6BB6234F"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I - FINANCIAL INFORMATION</font></div><div><a name="s10D3819BD2F652DA883A27C287E4812C"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Financial Statements</font></div><div><a name="s2C76501454AB5DB5897D258A2514E6AD"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-weight:bold;">RETROPHIN, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">(in thousands, except share amounts)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Current assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">154,820</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">99,394</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">13,450</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">13,872</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Inventory, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,456</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,112</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Prepaid taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">502,989</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">325,807</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,556</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Investment-equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">186,545</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">184,817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">716,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">520,346</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Liabilities and Stockholders' Equity </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Current liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">9,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">43,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">36,018</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Guaranteed minimum royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,833</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,902</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Business combination-related contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">19,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">9,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Convertible debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Derivative financial instruments, warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,710</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">99,872</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">85,668</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Convertible debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">192,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">45,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other non-current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,885</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Guaranteed minimum royalty, less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">13,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Business combination-related contingent consideration, less current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">87,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">80,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">397,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">227,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Stockholders' Equity:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Preferred stock $0.0001 par value; 20,000,000 shares authorized; 0 issued and outstanding as of September 30, 2018 and December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Common stock $0.0001 par value; 100,000,000 shares authorized;  41,167,942 and 39,373,745 issued and outstanding as of September 30, 2018 and December 31, 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">582,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">471,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(262,562</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(177,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,083</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total stockholders' equity </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">319,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">293,134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total liabilities and stockholders' equity </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">716,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">520,346</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">3</font></div></div><hr style="page-break-after:always"><div><a name="s92147193CCF15CB5B0D52A8EB0CE46C4"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-weight:bold;">RETROPHIN, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">(in thousands, except share and per share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">112,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Operating expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">32,448</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">19,610</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">91,762</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">58,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">26,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">24,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">77,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">74,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Legal fee settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">16,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Restructuring</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,132</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">76,289</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">50,948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">195,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">151,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(35,583</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(10,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(75,055</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(38,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other income (expenses), net:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(90</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">557</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(372</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,065</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2,533</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(660</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(4,848</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(3,315</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Loss on early extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Change in fair value of derivative instruments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,901</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,921</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(18,518</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,409</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(19,357</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,711</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(54,101</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(19,017</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(94,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(47,325</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(54,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(95,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(42,113</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net loss per common share:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Basic and Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Weighted average common shares outstanding:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Basic and Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,717,440</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">38,654,086</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,149,184</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">38,301,893</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Comprehensive loss:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(54,516</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,794</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(95,223</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(42,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Foreign currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unrealized gain (loss) on marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(97</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">256</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(54,447</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(95,291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(42,218</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4</font></div></div><hr style="page-break-after:always"><div><a name="sC2C40B7E53E25CC4A98FE33440C137A9"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-weight:bold;">RETROPHIN, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">(unaudited, in thousands)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Cash Flows From Operating Activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(95,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(42,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">13,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">13,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Deferred income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(7,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Interest income from notes receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Amortization of premiums on marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Amortization of debt discount and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">980</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">460</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Provision for Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Share based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,114</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21,292</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Change in fair value of liability classified warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">8,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,387</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,057</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Payments related to change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(6,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Loss on the extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">17,042</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unrealized foreign currency transaction gain (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">164</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Changes in operating assets and liabilities, net of business acquisitions:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,346</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,064</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other current and non-current operating assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2,183</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(3,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accounts payable and accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other current and non-current operating liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,094</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,561</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net cash provided by (used in) operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(21,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">8,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Cash Flows From Investing Activities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Purchase of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cash paid for intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(15,108</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(9,632</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Proceeds from the sale/maturity of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">96,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">76,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Purchase of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(219,820</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(67,552</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Proceeds from maturity of note receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">47,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cash paid for investments - equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(15,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net cash provided by (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(154,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">45,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Cash Flows From Financing Activities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Payment of acquisition-related contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(5,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Payment of guaranteed minimum royalty</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Payment of other liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Proceeds from exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,274</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,645</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">10,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Proceeds from 2025 convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">276,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Repayment of 2019 convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(40,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Payment of debt issuance and financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,820</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">231,338</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,084</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Effect of exchange rate changes on cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">55,426</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">57,989</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cash and cash equivalents, beginning of year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">99,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">41,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">154,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">98,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">5</font></div></div><hr style="page-break-after:always"><div><a name="s04CED689681D53F398F38C22AF9E0F48"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-weight:bold;">RETROPHIN, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-weight:bold;">NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATMENTS</font></div><div><a name="s50119D14C78A5E0EAEDD250F63B1A2A0"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1.&#160;&#160;DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (&#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;Retrophin&#8221; and the &#8220;Company&#8221;) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration (&#8220;PKAN&#8221;). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. There are currently no viable treatment options for patients with PKAN. Fosmetpantotenate is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan (RE-021) is an investigational product candidate which acts as both a potent </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">angiotensin receptor blocker (&#8220;ARB&#8221;), as well as a selective endothelin receptor antagonist (&#8220;ERA&#8221;), with in vitro selectivity toward endothelin receptor type A. The Company secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Focal segmental glomerulosclerosis ("FSGS")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is a leading cause of end-stage renal disease and nephrotic syndrome (&#8220;NS&#8221;). There are no U.S. Food and Drug Administration ("FDA") approved pharmacologic treatments for FSGS and off-label resources are limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Immunoglobulin A nephropathy ("IgAN")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is characterized by hematuria, proteinuria, and variable rates of progressive renal failure. There is no FDA approved treatment for IgAN.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a party to a&#160;joint development agreement with&#160;Censa Pharmaceuticals Inc. ("Censa"), a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria ("PKU"). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin ("BH4") with the potential to provide improved phenylalanine ("Phe") reduction in patients with PKU when compared to BH4.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">PKU is a rare, genetic metabolic condition in which the body cannot breakdown Phe due to a missing or defective phenylalanine hydroxylase ("PAH") enzyme. High Phe levels can lead to developmental and physical growth delay, executive function impairment, seizures, and microcephaly caused by toxic Phe accumulation in the brain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is party to a three-way Cooperative Research and Development Agreement ("CRADA")&#160;with the National Institutes of Health&#8217;s National Center for Advancing Translational Sciences and patient advocacy foundation NGLY1.org&#160;to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for N-glycanase deficiency ("NGLY1").</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">NGLY1 is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition has been characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). The Company obtained the rights to L-UDCA in 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">&#32;products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal&#174; (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam&#174; (cholic acid capsules) is approved in the United States (approved and marketed in Europe for select indications as Kolbam) for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola&#174; (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><a name="s7DD4F496B3E455E8AA40B43C27E0027D"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2.&#160;&#160;BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2017 10-K filed with the SEC on February 27, 2018. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information, the instructions for Form&#160;10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods.&#160;The </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;balance sheet information was derived from the audited financial statements as of that date.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain reclassifications have been made to the prior period consolidated financial statements to&#160;conform&#160;to&#160;the current period presentation.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">A summary of the significant accounting policies applied in the preparation of the accompanying condensed consolidated financial statements follows:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The unaudited condensed consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Effective January 1, 2018, the Company adopted Accounting Standards Codification (" ASC"), Topic 606,&#160;Revenue from Contracts with Customers, using the full retrospective transition method. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. See Note 3 for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Research and development expenses are comprised of salaries and bonuses, benefits, non-cash share-based compensation, license fees, costs paid to third-party contractors to perform research, conduct clinical trials and pre/non-clinical trials, develop drug materials, and associated overhead expenses and facilities. We also incur indirect costs that are not allocated to specific programs because such costs benefit multiple development programs and allow us to increase our pharmaceutical development capabilities. These consist of internal shared resources related to the development and maintenance of systems and processes applicable to all of our programs.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Clinical Trial Expenses</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We record expenses in connection with our clinical trials under contracts with contract research organizations (CROs) that support conducting and managing clinical trials. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up, initiation activities, enrollment, treatment of patients, or the completion of other clinical trial activities.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We currently have three Phase 3 clinical trials in process that are in varying stages of activity, with ongoing non-clinical support trials. As such, clinical trial expenses will vary depending on the all the factors set forth above and may fluctuate significantly from quarter to quarter.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. See Note 6 for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In January 2017, the FASB issued&#160;ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. The new guidance dictates that, when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">asset or a group of similar identifiable assets, it should be treated as an acquisition or disposal of an asset. The guidance was adopted as of January 1, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In February 2016, the FASB issued ASU No. 2016-02, Leases.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach or a </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;are both options for transition. The Company is in the process of identifying and quantifying all leases.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As of September 30, 2018, the Company held </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$324.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in available for sale debt securities. If adopted as of September 30, 2018, this ASU update would not have a material impact on the Company's financial statements.</font></div><div><a name="sCF33F15EB45B55FBBF0F3D01F1568F84"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. REVENUE RECOGNITION</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Product Revenue, Net</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company sells Chenodal and Cholbam (Kolbam), which are </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">aggregated as bile acid products,</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and Thiola through direct-to-patient distributors.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;The Company sells its products worldwide, with more than </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">95%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;of the revenue generated in North America.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Revenues from product sales are recognized when the customer obtains control of the Company&#8217;s product, which occurs upon delivery to the customer.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Deductions from Revenue</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Revenues from product sales are recorded at the net sales price, which includes provisions resulting from discounts, rebates and co-pay assistance that is offered to its customers, health care providers, payors and other indirect customers relating to the Company&#8217;s sales of its products. These provisions are based on the amounts earned or to be claimed on the related sales and are classified as a reduction of accounts receivable (if the amount is payable to the customer) or as a current liability (if the amount is payable to a party other than a customer). Where appropriate, these reserves take into consideration the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. If actual results in the future vary from the Company&#8217;s provisions, the Company will adjust the provision, which would affect net product revenue and earnings in the period such variances become known. Our historical experience is that such adjustments have been immaterial.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Government Rebates:</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;We calculate the rebates that we will be obligated to provide to government programs and deduct these estimated amounts from our gross product sales at the time the revenues are recognized. Allowances for government rebates and discounts are established based on actual payer information, which is reasonably estimated at the time of delivery, and the government-mandated discounts applicable to government-funded programs.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Commercial Rebates: </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">calculate the rebates that we incur due to contracts with certain commercial payors and deduct these amounts from our gross product sales at the time the revenues are recognized. Allowances for commercial rebates are established based on actual payer information, which is reasonably estimated at the time of delivery.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Prompt Pay Discounts: </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;offer discounts to certain customers for prompt payments. We accrue for the calculated prompt pay discount based on the gross amount of each invoice for those customers at the time of sale.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Product Returns:</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;Consistent with industry practice, we offer our customers a limited right to return product purchased directly from the Company, which is principally based upon the product&#8217;s expiration date. Generally, shipments are only made upon a patient prescription thus returns are minimal.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Co-pay Assistance:&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;offer a co-pay assistance program, which is intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an identification of claims and the cost per claim associated with product that has been recognized as revenue.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes net product revenues for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Bile acid products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">55,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">52,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Thiola</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,654</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21,501</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">65,322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">60,098</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total net product revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">112,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sE5F6A8C5E68958B0B95EC2C6F92511C3"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4.  MARKETABLE SECURITIES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company's marketable securities as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;were comprised of available-for-sale marketable securities which are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. Interest and dividends on securities classified as available-for-sale are included in interest income. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. During the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, investment activity for the Company included </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$96.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in maturities and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$219.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in purchases, all relating to debt based marketable securities. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Marketable securities&#160;consisted of the following (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable Securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,897</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">266,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">164,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government sponsored entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,042</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total marketable securities:</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following is a summary of short-term&#160;marketable securities classified as available-for-sale as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:38%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Remaining Contractual Maturity<br>(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Aggregate Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">138,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">138,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government-sponsored entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity less than 1 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">196,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">196,064</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1 to 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">128,174</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(249</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">127,929</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity 1 to 2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">128,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">127,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">324,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following is a summary of short-term&#160;marketable securities classified as available-for-sale as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:50%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Remaining Contractual Maturity</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Aggregate Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,911</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,897</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">86,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">86,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government-sponsored entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(90</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity less than 1 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">123,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">123,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1 to 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">78,388</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(424</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">77,964</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity 1 to 2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">78,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">77,964</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The primary objective of the Company&#8217;s investment portfolio is to enhance overall returns while preserving capital and liquidity. The Company&#8217;s investment policy limits interest-bearing security&#160;investments&#160;to certain types of instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.  All available for sale securities are held in current assets regardless of contractual maturities exceeding one year, as the Company could sell them within the next twelve months.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company reviews the available-for-sale&#160;investments&#160;for other-than-temporary declines in fair value below cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security, and the intent to sell, or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security. As of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company believed the cost basis for available-for-sale&#160;investments&#160;was recoverable in all material respects.</font></div><div><a name="sE5FAC59D240F51ADB39DFB56173C9B39"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Censa Pharmaceuticals Inc.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In December 2017, the Company entered into a Future Acquisition Right and Joint Development Agreement (the &#8220;Option Agreement&#8221;) with Censa, which became effective in January 2018.  The Company has agreed to fund certain development activities of Censa&#8217;s&#160;CNSA-001&#160;program, in an aggregate amount expected to be approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$17 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;through proof of concept, and has the right, but not the obligation, to acquire Censa (the &#8220;Option&#8221;) on the terms and subject to the conditions set forth in a separate Agreement and Plan of Merger. In exchange for the Option, the Company paid </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, and an additional </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;upon Censa&#8217;s completion of a specified development milestone set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If the Company exercises the Option, the Company will acquire Censa for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$65 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in upfront consideration, subject to certain adjustments, paid as a combination of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">20%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in cash and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">80%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in shares of the Company&#8217;s common stock, valued at a fixed price of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$21.40</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;per share; provided, however, that Censa may elect on behalf of its equity holders to receive the upfront consideration in </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">100%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;cash if the average price per share of the Company&#8217;s common stock for the ten trading days ending on the date the Company provides a notice of interest to exercise the Option is less than </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$19.26</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. In addition, if the Company exercises the Option and acquires Censa, the Company would be required to make further cash payments to Censa&#8217;s equity holders of up to an aggregate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$25 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;if the&#160;CNSA-001 program achieves specified development and commercial milestones.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company determined that Censa is a variable interest entity ("VIE") and concluded that the Company is not the primary beneficiary of the VIE. As such, the Company did not consolidate Censa&#8217;s results into its consolidated financial statements. The Company will continue to monitor facts and circumstances for changes that could potentially result in the Company becoming the primary beneficiary.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Through&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company has paid Censa </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;as an upfront payment, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$15.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in development funding, and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$5.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;related to a development milestone. The Company capitalized the upfront and milestone payments, and expensed the development funding paid. The Company is treating the upfront payment and milestone payment, both of which are compensation for the Option, as a cost-method investment with a total carrying value of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$15.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. </font></div><div><a name="s4234F22FB02F5D15B3CB19676E6D2B14"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6.&#160;&#160;DERIVATIVE FINANCIAL INSTRUMENTS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Since 2013, the Company has issued </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">five</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;tranches of common stock purchase warrants to secure financing, remediate covenant violations and provide consideration for amendments with respect to a credit facility extinguished in 2015.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Historically, the Company accounted for these instruments, which do not have fixed settlement provisions, as derivative instruments in accordance with FASB ASC 815-40, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Derivative and Hedging &#8211; Contracts in Entity&#8217;s Own Equity. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">This was due to an anti-dilution provision for the warrants that provides for a reduction to the exercise price if the Company issues equity or equity linked instruments in the future at an effective price per share less than the exercise price then in effect for the warrant ("down round provision"). As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value were recorded as non-cash adjustments within other income (expenses), net, in the Company&#8217;s </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.&#160;&#160;The Company recorded a loss on the change in the estimated fair value of warrants of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$8.9 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;for each of the three and nine months ended September 30, 2017.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of January 1, 2018 the Company early adopted ASU 2017-11, which </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">revised the guidance for instruments with down round provisions. As such the Company treats outstanding warrants as free-standing equity linked instruments that will be recorded to equity in the Consolidated Balance Sheet. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The fair value of the derivative liability balance as of December 31, 2017 of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$15.7 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;was reclassified by </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">means of a cumulative-effect adjustment to equity as of January 1, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company calculated the fair value of the warrants using the Black-Scholes Model as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Fair value of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Remaining life of the warrants (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">0.1 - 2.0 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Risk-free interest rate*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1.39 - 1.89%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Expected volatility**</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">33 - 43%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">*The risk-free interest rate is based on the U.S. Treasury security rates for the remaining term of the warrants at the measurement date.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">**Expected volatility is based on an analysis of the Company&#8217;s historical volatility.</font></div><div><a name="s90DCF7F1B21655519FAEA323E1C3EA47"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7.&#160;&#160;FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Financial Instruments and Fair Value</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company accounts for financial instruments in accordance with ASC 820, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(&#8220;ASC 820&#8221;).  ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.&#160;&#160;The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).&#160;&#160;The three levels of the fair value hierarchy under ASC 820 are described below:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 1</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;&#8211; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 2</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;&#8211; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 3</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;&#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The valuation techniques used to measure the fair value of the Company&#8217;s marketable securities and all other financial instruments, all of which have counter-parties with high credit ratings, were valued based on quoted market prices or model driven valuations using significant inputs derived from or corroborated by observable market data. Based on the fair value hierarchy, the Company classified marketable securities within Level 2.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In estimating the fair value of the Company&#8217;s derivative liabilities as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company used the Black Scholes Model.  Based on the fair value hierarchy, the Company classified the derivative liability within Level 3. The Company adopted ASU 2017-11 as of January 1, 2018 and is no longer required to treat outstanding warrants as derivative liabilities measured at fair value. See Note 6 for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In estimating the fair value of the Company&#8217;s contingent consideration, the Company used the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Monte Carlo Simulation model as of September 30,  2018 and a probability-based expected method for royalty payments based on projected revenues as of December 31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. Based on the fair value hierarchy, the Company classified the fair value measurement of contingent consideration within Level 3.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, and accounts payable, due to their short term nature. As of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the estimated fair value of the Company's </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;Senior Convertible Notes due 2019 was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$38.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and the estimated fair value of the  Company's </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;Convertible Senior Notes due 2025 was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$283.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, considering factors such as market conditions, prepayment and make-whole provisions, variability in pricing from multiple lenders and the term of the debt.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">As of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total carrying and estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Quoted prices in active markets<br>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant other observable inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant unobservable inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities, available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Business combination-related contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total carrying and estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Quoted prices in active markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant other observable inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant unobservable inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities, available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Derivative liability related to warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Business combination-related contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">105,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">105,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth a summary of changes in the estimated fair value of the Company's business combination-related contingent consideration for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Fair Value Measurements of Acquisition-Related Contingent Consideration<br>(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Increase from revaluation of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,387</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual payments included in accrued liabilities at September 30, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(4,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Balance at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The key assumptions included in the calculations for contingent consideration were the future number of patients in treatment, projected revenues, discount rate, and the timing of payments. The present value of the expected payments considers the time at which the obligations are expected to be settled and a discount rate that reflects the risk associated with the performance payments. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">During the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company incurred charges of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$16.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$22.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, in operating expenses on the Condensed Consolidated Statements of Operations and Comprehensive Loss for the revaluation of the contingent consideration liabilities.  For the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;of the charges were related to the increase in contingent consideration liabilities for the products Chenodal and Cholbam and product candidate L-UDCA, respectively. In each case, the value increased due to </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">changes in the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">discount factors, estimated timing of payments, and changes in projections</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">During the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company incurred charges of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$4.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$11.1 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, in operating expenses on the Condensed Consolidated Statement of Operations and Comprehensive Loss for the change in fair value of the contingent consideration liabilities. For the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine months ended September 30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$5.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;of the charges were related to the increase in contingent consideration liabilities for the products Chenodal and Cholbam and product candidate L-UDCA, respectively. In each case, the value increased due to </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">changes in the discount factor, estimated timing of payments and expected payments.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div><a name="sF8EFA5B1FA6E517CBE845391CA87CDB4"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8.  INTANGIBLE ASSETS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the net book value of amortizable intangible assets was approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$186.5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth amortizable intangible assets as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Finite-lived intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">250,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">235,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less: accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(64,279</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(51,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net carrying value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">186,545</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">184,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes amortization expense for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br></font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,635</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,752</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total amortization expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">13,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sDF3F5B27B07A53068B960A4644580727"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9.&#160;&#160;CONVERTIBLE NOTES PAYABLE</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Convertible Senior Notes Due 2025</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On September 10, 2018, the Company completed its registered underwritten public offering of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$276 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;aggregate principal amount of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.50%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;Convertible Senior Notes due 2025 ("2025 Notes"), and entered into a base indenture and supplemental indenture agreement ("2025 Indenture") with respect to the 2025 Notes. The 2025 Notes will mature on September 15, 2025 ("Maturity Date&#8221;), unless earlier repurchased, redeemed, or converted. The 2025 Notes are senior unsecured obligations of the Company and bear interest at an annual rate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.50%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2019.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The composition of the Company&#8217;s 2025 Notes are as follows (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:437px;"></td><td style="width:9px;"></td><td style="width:107px;"></td><td style="width:3px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:107px;"></td><td style="width:3px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2.50% convertible senior notes due 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">276,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(76,951</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(6,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total 2025 Notes, net of unamortized debt discount and debt issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">192,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The net proceeds from the issuance of the 2025 Notes were approximately&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$267.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, after deducting commissions and the offering expenses payable by the Company. A portion of the net proceeds from the 2025 Notes were used by the Company to repurchase </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$23.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;aggregate principal amount of its then-outstanding </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;senior convertible notes due in 2019 in privately-negotiated transactions. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Holders may convert their 2025 Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2018 (and only during such calendar quarter), if the last reported sale price per share of the Company&#8217;s common stock for each of at least </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">20</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;trading days, whether or not consecutive, during the period of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">30</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">130%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;of the conversion price on the applicable trading day; (2) during the five consecutive business days immediately after any </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">10</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;consecutive trading day period (&#8220;measurement period&#8221;) if the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">98%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;of the product of the last reported sale price per share of the Company&#8217;s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company&#8217;s common stock; (4) if the Company calls the 2025 Notes for redemption; and (5) at any time from, and including, May 15, 2025 until the close of business on the scheduled trading day immediately before the Maturity Date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company&#8217;s common stock, or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s election, based on the applicable conversion rate.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The initial conversion rate for the 2025 Notes is </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">25.7739</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;shares of the Company&#8217;s common stock per $1,000 principal amount of 2025 Notes, which represents an initial conversion price of approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$38.80</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;per share. If a &#8220;make-whole fundamental change&#8221; (as defined in the 2025 Indenture) occurs, then the company will, in certain circumstances, increase the conversion rate for a specified period of time.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after September 15, 2022 and, in the case of any partial redemption, on or before the 40th scheduled trading day before the Maturity Date, at a cash redemption price equal to the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company&#8217;s common stock exceeds </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">130%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;of the conversion price on each of at least 20 trading days </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. If a fundamental change (as defined in the 2025 Indenture) occurs, then, subject to certain exceptions, holders may require the Company to repurchase their 2025 Notes at a cash repurchase price equal to the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of&#160;September 30, 2018, the 2025 Notes had a market price of&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$1,027</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;per&#160;$1,000&#160;principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$276.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;in principal value and any conversion premium in any combination of cash and shares of its common stock at the Company&#8217;s option. In addition, calling the 2025 Notes for redemption will constitute a &#8220;make whole fundamental change &#8221;.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes are the Company&#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2025 Notes, and equal in right of payment to the Company&#8217;s unsecured indebtedness. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes are currently classified on the Company&#8217;s consolidated balance sheet at&#160;September 30, 2018&#160;as long-term debt.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Under ASC 470-20,&#160;Debt with Conversion and Other Options, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2025 Notes) that may be settled entirely or partially in cash upon conversion, in a manner that reflects the issuer&#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component was&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$198.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.&#160;The equity component of&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$77.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2025 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2025 Notes, which is amortized over the seven year term of the 2025 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.&#160;The Company allocated the total transaction costs of approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$8.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;related to the issuance of the 2025 Notes to the liability and equity components of the 2025 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the seven-year term of the 2025 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The effective interest rate on the liability components of the 2025 Notes for the period from the date of issuance through September 30, 2018 was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">7.7%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. The following table sets forth total interest expense recognized related to the 2025 Notes (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Three and Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">468</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total interest expense for the 2025 Notes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">901</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2025 Indenture contains customary events of default with respect to the 2025 Notes, including that upon certain events of default,&#160;100%&#160;of the principal and accrued and unpaid interest on the 2025 Notes will automatically become due and payable.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Senior Convertible Notes Due 2019</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On May 29, 2014, the Company entered into a Note Purchase Agreement relating to a private placement by the Company of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$46.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;aggregate principal senior convertible notes due in 2019 (the &#8220;2019 Notes&#8221;) which are convertible into shares of the Company&#8217;s common stock at an initial conversion price of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$17.41</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;per share. The conversion price is subject to customary anti-dilution protection. The 2019 Notes bear interest at a rate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;per annum, payable semiannually in arrears on May 15 and November 15 of each year. The 2019 Notes mature on May 30, 2019 unless earlier converted or repurchased in accordance with their terms, and there are no contractual payments due prior to that date. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In September 2018, the Company used part of the net proceeds from the issuance of the 2025 Notes discussed above to repurchase </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$23.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;aggregate principal value of the 2019 Notes in privately-negotiated transactions for approximately&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$40.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;in cash. The partial repurchase of the 2019 Notes resulted in a&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$17.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;loss on early extinguishment of debt.  At&#160;September 30, 2018, approximately&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$22.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;of principal remained outstanding on the 2019 Notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The composition of the Company&#8217;s 2019 Notes are as follows (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:437px;"></td><td style="width:9px;"></td><td style="width:107px;"></td><td style="width:3px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:107px;"></td><td style="width:3px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.50% senior convertible notes due 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total 2019 Notes, net of unamortized debt discount and debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,377</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">45,077</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s5C47538CBD375252898A7412E5ED8945"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10.  ACCRUED EXPENSES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Accrued expenses at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;consisted of the following (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Government rebates payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">10,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Compensation related costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">9,292</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,749</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accrued royalties and contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,969</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,989</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Restructuring expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Miscellaneous accrued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">43,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">36,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s189968BAACD4540A94B5E04588EE34D2"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11.&#160;&#160;LOSS PER COMMON SHARE</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Basic and diluted net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The Company&#8217;s potentially dilutive shares, which include outstanding stock options, restricted stock units, warrants, and shares issuable upon conversion of the 2019 and 2025 Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Basic and diluted net loss per share is calculated as follows </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">(net loss amounts are stated in thousands)</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:35%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40,717,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(54,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">38,654,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(17,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(0.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:35%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40,149,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(95,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(2.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">38,301,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(42,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(1.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following common stock equivalents have been excluded because they were anti-dilutive (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:33%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Convertible debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">8,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">2,642</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">8,411</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">2,642</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">6,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">1,159</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">377</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">1,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Total anti-dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">16,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">11,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">16,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">10,936</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sD7B3E8E22A2E53D5869089D0BDFC9250"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12.&#160;&#160;COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Leases and Sublease Agreements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Facilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Annual Base Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Lease Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Comments</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;">Occupied Locations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Corporate Headquarters</font></div><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">San Diego, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$2.1 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">July 2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;">Vacated Locations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">New York, NY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$0.5 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">November 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Sublet through expiration</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Research Collaboration and Licensing Agreements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreements with unrelated companies, scientific collaborators, universities, and consultants. These agreements contain varying terms and provisions which include fees and milestones to be paid by the Company, services to be provided, and ownership rights to certain proprietary technology developed under the agreements. Some of these agreements contain provisions which require the Company to pay royalties, in the event the Company sells or licenses any proprietary products developed under the respective agreements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In August 2017, Martin Shkreli, the Company&#8217;s former Chief Executive Officer, was convicted on securities fraud charges following investigations by the U.S. Attorney for the Eastern District of New York and the U.S Securities and Exchange Commission. The Company was not a target of these investigations and cooperated with them fully.  </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Mr. Shkreli has appealed his conviction to the United States Court of Appeals for the Second Circuit, and the appeal will likely not be decided until 2019.  In connection with the trial and pending appeal proceedings, Mr. Shkreli sought advancement of his legal fees from the Company, and the Company has advanced a total of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$5.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in legal fees, of which </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;has been reimbursed by its directors&#8217; and officers&#8217; insurance carriers. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Pending the outcome of Mr. Shkreli's appeal, the insurance carriers have reserved their rights to assert that certain of the advanced funds pertain to claims excluded from coverage under the relevant insurance policy and are therefore recoverable by the carriers. As a result, the final amount of the reimbursement from the insurance carriers is not currently estimable. In addition, a portion of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">these and the other</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;legal fees the Company has advanced to Mr. Shkreli will be subject to reimbursement by Mr. Shkreli under Delaware law in the event it is ultimately determined that Mr. Shkreli is not entitled to be indemnified by the Company in these proceedings.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In August 2015, the Company filed a lawsuit in federal district court for the Southern District of New York against Mr. Shkreli, asserting that he breached his fiduciary duty of loyalty during his tenure as the Company&#8217;s Chief Executive Officer and a member of its Board of Directors. Mr. Shkreli served a demand for JAMS arbitration on Retrophin, claiming that Retrophin had breached his December 2013 employment agreement. In response to Mr. Shkreli&#8217;s arbitration demand, the Company asserted counterclaims in the arbitration that are substantially similar to the claims it previously asserted in the federal lawsuit against Mr. Shkreli.  The federal Court granted a stay of the federal lawsuit pending a determination by the arbitration panel whether the Company&#8217;s counterclaims would be litigated in the arbitration, as the Company is seeking. In April 2016, the arbitration panel granted the parties&#8217; request for a stay of the proceedings pending settlement discussions. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Earlier this year, the parties asked the panel to lift the stay</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. On June 29, 2018, Mr. Shkreli applied to the federal court to enjoin the arbitration panel from hearing the Company&#8217;s counterclaims. On July 2, 2018, the federal court denied Mr. Shkreli&#8217;s application</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;Mr. Shkreli at first filed a notice of appeal indicating his intent to appeal the federal court&#8217;s decision, but then agreed to voluntarily dismiss the appeal. On September 13, 2018, the Clerk of the United States Court of Appeals for the Second Circuit ordered the appeal dismissed</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.  On October 2, 2018, the arbitration panel determined that Retrophin's counterclaims were arbitrable. On October 5, 2018, Retrophin voluntarily dismissed the federal action without prejudice. Mr. Shkreli's claims and the Company's counterclaims in the arbitration are scheduled to be heard by the arbitration panel in June 2019. In connection with these proceedings, Mr. Shkreli sought advancement of his legal fees from the Company relating to his defense of the Company&#8217;s claims against him. The Company has advanced, and expects to continue to advance, certain of these legal fees to Mr. Shkreli.          </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and nine months ended September 30, 2018, the Company recorded and paid zero in expenses under the settlement agreement. For the three and nine months ended September 30, 2017, the Company recorded </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">zero</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;in expenses, respectively, and paid </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">zero</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, under the settlement agreement.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">During the nine months ended September 30, 2018 and 2017, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$0.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;of reimbursements from the Company's directors&#8217; and officers&#8217; insurance carriers were received. Of the total </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;reimbursed by the insurance carriers, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;is recorded as a liability on the Consolidated Balance Sheet pending the outcome of Mr. Shkreli's appeal.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">From time to time the Company is involved in legal proceedings arising in the ordinary course of business.&#160; On October 23, 2018, Spring Pharmaceuticals, LLC (Spring) filed a lawsuit against the Company, Martin Shkreli, Mission Pharmacal Company and Alamo Pharma Services, Inc. in the United States District Court for the Eastern District of Pennsylvania alleging that the Company violated various federal and state antitrust and unfair competition laws (and that Defendants were unjustly enriched) by implementing a distribution system that prevented Plaintiff from obtaining sufficient samples of Thiola to conduct bioequivalence testing.&#160; Spring&#8217;s complaint seeks injunctive relief compelling Defendants to sell Thiola to it and damages. The Company intends to vigorously defend against Spring&#8217;s claims.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is not aware of any other  proceedings or claims that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div><a name="s62765A1ADCB75AF2AB145D034ABF85C7"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 13.&#160; SHARE BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Shares</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Service and Performance Based Restricted Stock Units</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes the Company&#8217;s restricted stock unit activity during the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Number of Restricted Stock Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unvested December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">345,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">20.51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">449,811</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">25.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(56,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">20.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Forfeited/canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(30,216</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">24.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unvested September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">708,426</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">23.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, unamortized stock compensation for restricted stock units was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, with a weighted-average recognition period of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.2</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;years. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Performance Based Restricted Stock Units</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company granted </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">10,000</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">66,500</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;performance based restricted stock units during the three and nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Stock Options</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes stock option activity during the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:53%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,153,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">17.16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">6.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">39,010</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,242,550</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">25.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(737,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Forfeited/canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(427,587</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">24.56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Outstanding at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,230,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">76,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, unamortized stock compensation for stock options was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$32.5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, with a weighted-average recognition period of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.8 years</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, outstanding options to purchase </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;shares of common stock were exercisable with a weighted-average exercise price per share of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$16.72</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Share Based Compensation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth total stock-based compensation for the three and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general &amp; administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,282</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,962</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">10,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14,179</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Exercise of Warrants</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company issued </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">532,830</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">956,887</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;shares of common stock upon the exercise of outstanding warrants during the three and nine months ended September 30, 2018, respectively, for cash received by the Company in the amount of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.1 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$4.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively. See Note 6 for changes in warrant accounting.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, warrants to purchase </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">79,167</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">1,159,424</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;shares of common stock, respectively, were outstanding.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div><a name="s8EFABA8BD7E555B195180A367A1FA69C"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 14.&#160;&#160;INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes our effective tax rate and income tax benefit (expense) for the three and nine months ended September 30, 2018 and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">dollars</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in millions</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and six nine ended September 30, 2018, we recognized an income tax expense of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$0.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$0.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, representing an effective tax rate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(0.8)%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(0.9)%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">,</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;respectively. Under GAAP, quarterly effective tax rates may vary significantly depending on the actual operating results in the various tax jurisdictions, and significant transactions, as well as changes in the valuation allowance related to the expected recovery of deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and nine months ended September 30, 2018, when compared to the same periods in 2017, the change in the tax benefit and decrease in the effective income tax rate was primarily attributable to the increase of the U.S. federal valuation allowance in 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The difference between the expected statutory federal tax benefit of 21% and the effective tax expense for three and nine months ended September&#160;30, 2018, was primarily attributable to the valuation allowance against our deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At&#160;September 30, 2018, we had </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">no</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;unrecognized tax benefits. We did not recognize any interest or penalties related to unrecognized tax benefits during the three and nine months ended September 30, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On&#160;December 22,&#160;2017, the President of the United States signed into law the Tax Cuts and Jobs Act. The Tax Cuts and Jobs Act reduces the US federal corporate tax rate from 35% to 21%, as well as making several other significant changes to the tax law, effective January 1, 2018. Pursuant to the Securities and Exchange Commission Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), given the amount and complexity of the changes in tax law resulting from the Tax Cuts and Jobs Act, the Company has not finalized the accounting for the income tax effects of the Tax Cuts and Jobs Act. This includes the provisional amounts recorded related to the re-measurement of the deferred taxes and the change to our valuation allowance. The impact of the Tax Cuts and Jobs Act may differ from this estimate during the one-year measurement period due to, among other things, further refinement of the Company's calculation, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the Tax Cuts and Jobs Act.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At September 30, 2018, the Company is still analyzing certain aspects of the Tax Cuts and Jobs Act and refining its calculations, which could potentially affect the analysis of the Company&#8217;s deferred tax assets and liabilities and its valuation allowance.&#160; Any subsequent adjustment is not expected to be material to the Company&#8217;s financial position or results of operations.</font></div><div><a name="s72CE3C764E94541A8D36A4A523BF2BDE"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 15.  INVENTORY</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Inventory, net of reserves, consisted of the following at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,857</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,916</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The inventory reserve was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$1.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$0.7 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively.</font></div><div><a name="s9C064D823D855118BAA0A31ED46E2A2F"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 16.  ACCOUNTS RECEIVABLE</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$13.5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$13.9 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively. The total reserves for both periods were immaterial.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div><a name="s33A77C1707ED50089F30D32EE91625DD"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. &#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">&#32;and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">, filed with the Securities and Exchange Commission (SEC) on February 27, 2018. Past operating results are not necessarily indicative of results that may occur in future periods.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item IA, &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div><a name="s3D39D632A6D451A0BAEC5BEE5D0E8B14"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases.</font></div><div><a name="s05264166D5F65D608F28D0A1B6A1C18D"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Our Product Candidates and Products on the Market</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;"><img src="pipelineq318a02.jpg" alt="pipelineq318a02.jpg" style="height:498px;width:682px;"></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">* CNSA-001 is being developed in a strategic collaboration with Censa Pharmaceuticals.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">**Acquired rights in 2016; activities underway with the intention of making the liquid formulation commercially available in the United States.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">We are developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Fosmetpantotenate</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We are developing fosmetpantotenate, a novel small molecule, as a potential treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration (&#8220;PKAN&#8221;). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. PKAN is estimated to affect up to 5,000 patients worldwide. There are currently no viable treatment options for patients with PKAN. Fosmetpantotenate is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients. Certain international health regulators have approved the initiation of dosing fosmetpantotenate in PKAN patients under physician-initiated studies in accordance with local regulations in their respective countries.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In 2015 and 2016 we filed an IND, completed a Phase I clinical trial and obtained both orphan drug and fast track designations in the United States. Additionally, we received orphan drug designation in the European Union and reached an agreement with the&#160;U.S. Food and Drug administration ("FDA") under the Special Protocol Assessment process for a Phase 3 clinical trial for PKAN. In the third quarter of 2017, the first patient was dosed in our Phase 3 FORT (FOsmetpantotenate Replacement Therapy) study, and enrollment continues.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Sparsentan</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan is an investigational product candidate which acts as both a potent </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">angiotensin receptor blocker (&#8220;ARB&#8221;), as well as a selective endothelin receptor antagonist (&#8220;ERA&#8221;), with in vitro selectivity toward endothelin receptor type A. We have secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). We are developing sparsentan as a treatment for:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Focal segmental glomerulosclerosis ("FSGS"), a leading cause of end-stage renal disease and nephrotic syndrome (&#8220;NS&#8221;). There are currently no FDA approved pharmacologic treatments for FSGS and off-label resources are limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients. Every year approximately 5,400 patients are diagnosed with FSGS and we estimate that there are up to 40,000 FSGS patients in the United States with approximately half of them being candidates for sparsentan.  In 2015 and 2016 we received orphan drug designation in the United States and European Union and received positive data from our Phase 2 DUET study of sparsentan for the treatment of FSGS. In the second quarter of 2018, we announced the initiation of the Phase 3 DUPLEX Study of sparsentan in FSGS, and enrollment continues. This pivotal DUPLEX Study is designed to include an interim analysis of modified partial remission of proteinuria. We expect that successful achievement of this endpoint will serve as the basis for Subpart H accelerated approval of sparsentan in the United States and Conditional Marketing Authorization ("CMA") consideration in Europe. The confirmatory endpoint of the study will compare changes in slope of estimated glomerular filtration rate, or eGFR.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Immunoglobulin A nephropathy ("IgAN"), which is characterized by hematuria, proteinuria, and variable rates of progressive renal failure. With an estimated prevalence between 83,000 to 165,000 in the United States and greater numbers in Europe and Asia, IgAN is the most common primary glomerular disease. Most patients are diagnosed between the ages of 16 and 35, with up to 40% progressing to end stage renal disease within 15 years. There are currently no FDA approved treatments for IgAN.  The current standard of care is renin-angiotensin-aldosterone system (RAAS) blockade with immunosuppression also being commonly used for patients with significant proteinuria or rapidly progressive glomerulonephritis. Based on recent interactions we have had with the FDA and European Medicines Agency, we are planning to initiate a single Phase 3 clinical trial designed to serve as the basis for an NDA filing for sparsentan for the treatment of IgAN. We expect to initiate this study during the fourth quarter of 2018.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">CNSA-001</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In December 2017, we entered into a Future Acquisition Right and Joint Development Agreement with Censa Pharmaceuticals, Inc. ("Censa"), which became effective on January 4, 2018 upon the satisfaction of certain conditions. Pursuant to the agreement, we agreed to fund certain development activities of Censa&#8217;s&#160;CNSA-001&#160;program, in an aggregate amount expected to be approximately $17 million through proof of concept, and have the right, but not the obligation, to acquire Censa (the &#8220;Option&#8221;) on the terms and subject to the conditions set forth in a separate Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;). In exchange for the Option, we paid Censa $10 million, and an additional $5 million upon Censa&#8217;s completion of a specified development milestone set forth in the Option Agreement, all of which will be distributed to Censa&#8217;s equityholders.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Censa, a privately held biotechnology company focused on developing therapies for the orphan metabolic diseases, is developing CNSA-001 for the treatment of phenylketonuria ("PKU"). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin ("BH4") with the potential to provide improved phenylalanine ("Phe") reduction in patients with PKU when compared to BH4. Preclinical research has suggested CNSA-001 may provide improved bioavailability, plasma stability and tissue exposure, leading to higher intracellular BH4 levels and subsequent greater Phe reduction when compared to the current standard of care in PKU. In pre-clinical models, CNSA-001 has also shown an ability to cross the blood-brain barrier which, if supported by clinical data, may lead to broader utility in additional indications such as primary BH4 deficiency (PBD) and Segawa syndrome. CNSA-001 has completed both the single and multiple ascending dose studies. In October 2018, the first patient was dosed in the Phase 2 proof of concept study of CNSA-001 for PKU, and enrollment continues.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">PKU is a rare, genetic metabolic condition in which the body cannot breakdown Phe due to a missing or defective phenylalanine hydroxylase ("PAH") enzyme. High Phe levels can lead to developmental and physical growth delay, executive function impairment, seizures, and microcephaly caused by toxic Phe accumulation in the brain. PKU is typically diagnosed at birth </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">and has an estimated addressable population of 45,000 to 50,000</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If we exercise the Option, pursuant to the terms of the Merger Agreement, we will acquire Censa for $65 million in upfront consideration, subject to certain adjustments, paid as a combination of 20% in cash and 80% in shares of our common stock, valued at a fixed price of $21.40 per share; provided, however, that Censa may elect on behalf of its equityholders to receive the upfront consideration in 100% cash if the average price per share of our common stock for the ten trading days ending on the date we provide a notice of interest to exercise the Option is less than $19.26. In addition to the upfront consideration, if we exercise the Option and acquire Censa, we would be required to make further cash payments to Censa&#8217;s equityholders of up to an aggregate of $25 million if the&#160;CNSA-001 program achieves specified development and commercial milestones.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">NGLY1 Deficiency Discovery Efforts</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">N-glycanase deficiency, or NGLY1 deficiency, is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition is characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We are party to a three-way&#160;Cooperative Research and Development agreement with the National Institutes of Health&#8217;s National Center for Advancing Translational Sciences and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Liquid Ursodeoxycholic Acid</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). We obtained L-UDCA in 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing. There are no liquid formulations of ursodeoxycholic acid currently approved by the FDA.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">We sell the following three products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Chenodal</font><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">&#32;(chenodiol)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal is a synthetic oral form of chenodeoxycholic acid, a naturally occurring primary bile acid synthesized from cholesterol in the liver, indicated for the treatment of radiolucent stones in well-opacifying gallbladders in patients in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal administration is known to reduce biliary cholesterol and the dissolution of radiolucent gallstones through suppression of hepatic synthesis of cholesterol, cholic acid and deoxycholic acid in the bile pool. Chenodal was first approved by the FDA in 1983 for the management of gallstones but its marketing was later discontinued due to lack of commercial success. In 2009, Nexgen Pharma Inc.'s ANDA for Chenodal was approved by the FDA for the treatment of gallstones; Chenodal is manufactured for Manchester Pharmaceuticals LLC ("Manchester") under this ANDA. Manchester subsequently obtained orphan drug designation for Chenodal for the treatment of CTX, a rare autosomal recessive lipid storage disease, in 2010. Manchester was acquired by us in March 2014. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">While Chenodal is not labeled for CTX, it has been used as the standard of care for over three decades. We are working to obtain FDA approval of Chenodal for the treatment of CTX. The prevalence of CTX is estimated in the literature to be as high as 1 in 70,000 in the overall United States population. Pathogenesis of CTX involves deficiency of the enzyme 27-hydroxylase (encoded by the gene CYP27A1), a rate-limiting enzyme in the synthesis of primary bile acids, including CDCA, from cholesterol. The disruption of primary bile acid synthesis in CTX leads to toxic accumulation of cholesterol and cholestanol in most tissues. Most patients present with intractable diarrhea, premature cataracts, tendon xanthomas, atherosclerosis, and cardiovascular disease in childhood and adolescence. Neurological manifestations of the disease, including dementia and cognitive and cerebellar deficiencies, emerge during late adolescence and adulthood. Oral administration of CDCA has been shown to normalize primary bile acid synthesis in patients with CTX.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Cholbam</font><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">&#32;(cholic acid)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The FDA approved Cholbam (cholic acid capsules) in March 2015, the first FDA approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders (including Zellweger spectrum disorders).&#160; The effectiveness of Cholbam has been demonstrated in clinical trials for bile acid synthesis disorders and the adjunctive treatment of peroxisomal disorders. The estimated incidence of bile acid synthesis disorders due to single enzyme defects is 1 to 9 per million live births.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Thiola</font><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">&#32;(tiopronin)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola is approved by the FDA for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The resulting long-term damage can cause loss of kidney function in addition to substantial pain and loss of productivity associated with renal colic and stone passage.  The prevalence of cystinuria in the United States is estimated to be 10,000 to 12,000, indicating that there may be as many as 4,000 to 5,000 affected individuals with cystinuria in the United States that would be candidates for Thiola. We are currently developing a new, more patient-friendly, formulation of Thiola for which an NDA filing is expected in 2018.</font></div><div><a name="s7C508F5CACCB5B4FAA0B42631CF7062E"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Results of operations for the </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">three and nine</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">&#32;months ended </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">September 30,</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">&#32;</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">2018</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">&#32;compared to the </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">three and nine</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">&#32;months ended </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">September 30,</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">&#32;</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">2017</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Net Product Sales:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table provides information regarding net product sales (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net product revenues by product:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Bile acid products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,052</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,839</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(787</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">55,153</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">52,662</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,491</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Thiola</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,654</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21,501</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">65,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">60,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total net product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">366</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">112,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,715</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The sales increase for the three months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;compared to the three months ended September 30, 2017 was due to increased patient counts for Thiola.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The sales increase for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;as compared to the nine months ended September 30, 2017 was due to increased patient counts for Bile acid products and Thiola.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Operating Expenses:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table provides information regarding operating expenses (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">32,448</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">19,610</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,838</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">91,762</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">58,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">33,170</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">26,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">24,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">77,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">74,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Legal fee settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">16,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Restructuring</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">76,289</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">50,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">25,341</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">195,530</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">151,374</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">44,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Research and development expenses</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We make significant investments in research and development in support of our development programs. Research and development costs are expensed as incurred and include salaries and bonuses, benefits, non-cash share based compensation, license fees, costs paid to third-party contractors to perform research, conduct clinical trials, and develop drug materials, and associated overhead expenses and facility costs. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;as compared to the three and nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company increased its research and development expenses by </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$12.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$33.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, which is </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">due to increased clinical trial expenses related to our two on-going Phase 3 studies, fosmetpantotenate in PKAN and sparsentan in FSGS, start-up costs to support our planned Phase 3 study of sparsentan in IgAN, and funding for development of CNSA-001.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Selling, general and administrative expenses </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Selling, general and administrative expenses include salaries and bonuses, benefits, non-cash share based compensation, professional fees, rent, depreciation and amortization, travel, insurance, business development, sales and marketing programs, and other operating expenses. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;as compared to the three months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company increased its selling, general and administrative expenses by </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$1.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">which reflects additional marketing initiatives to support the Company's commercial portfolio and corporate initiatives.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;as compared to the nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company increased its selling, general and administrative expenses by </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">which reflects an increase in the Company's activities to support corporate initiatives.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Change in the valuation of contingent consideration</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;as compared to the three and nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">,</font><font style="font-family:Arial Narrow;font-size:9pt;">&#32;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the change in fair value of contingent consideration is due to changes in the discount factors, timing of payments and changes in projections.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes the Company's change in valuation of contingent consideration (in thousands):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Chenodal</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">8,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">9,949</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cholbam</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">9,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,594</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,466</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">10,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,814</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">L-UDCA</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(500</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,200</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(300</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">16,601</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,429</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,387</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,057</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Other Income/(Expenses):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table provides information regarding other income (expenses), net (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(372</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,065</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,147</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">595</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,460</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">445</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(4,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(3,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(1,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Loss on early extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,042</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,042</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,042</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(17,042</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Change in fair value of derivative instruments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">8,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">8,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(18,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,409</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(10,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(19,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(8,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(10,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The changes in the Company's other income (expenses) for the three and nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.1 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, is primarily due to the partial early extinguishment of the Company's Senior Convertible Notes due in 2019 ("2019 Notes") and changes in the accounting method for the fair value of derivative instruments related to warrants. See Note 6 and Note 9 of the Consolidated Financial Statements for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Income Tax Benefit:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and nine months ended September 30, 2018, we recognized an income tax expense of $0.4 million and $0.8 million, respectively, representing an effective tax rate of (0.8)% and (0.9)%, respectively. Under GAAP, quarterly effective tax rates may vary significantly depending on the actual operating results in the various tax jurisdictions, and significant transactions, as well as changes in the valuation allowance related to the expected recovery of deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and nine months ended September 30, 2018, when compared to the same periods in 2017, the change in the tax benefit and decrease in the effective income tax rate was primarily attributable to the increase of the U.S. federal valuation allowance in 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The difference between the expected statutory federal tax benefit of 21% and the effective tax expense for three and nine months ended September 30, 2018, was primarily attributable to the valuation allowance against our deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At&#160;September 30, 2018, we had no unrecognized tax benefits. We did not recognize any interest or penalties related to unrecognized tax benefits during the three and nine months ended September 30, 2018.</font></div><div><a name="s712EC7A5FE8E510FBEFCD504D2C188A2"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We believe that our available cash and short-term investments as of the date of this filing will be sufficient to fund our anticipated level of operations for at least the next 12 months. Management believes that our operating results will vary from quarter to quarter and year to year depending upon various factors including revenues, general and administrative expenses, and research and development expenses.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company had the following financial performance at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Cash &amp; Cash Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">154,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">99,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accumulated Deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(262,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(177,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Stockholders' Equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">319,065</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">293,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net Working Capital*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">403,117</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">240,139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net Working Capital Ratio**</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">* Current assets less current liabilities.</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">**Current assets divided by current liabilities.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Convertible Notes Payable</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Convertible Senior Notes Due 2025</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On September 10, 2018, the Company completed its registered underwritten public offering of $276 million aggregate principal amount of 2.50% Convertible Senior Notes due 2025, ("2025 Notes"), and entered into a base indenture and supplemental indenture agreement ("2025 Indenture") with respect to the 2025 Notes. The 2025 Notes will mature on September 15, 2025 ("Maturity Date&#8221;), unless earlier repurchased, redeemed, or converted. The 2025 Notes are senior unsecured obligations of the Company and bear interest at an annual rate of 2.50%, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2019.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The composition of the Company&#8217;s 2025 Notes are as follows (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:437px;"></td><td style="width:9px;"></td><td style="width:107px;"></td><td style="width:3px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:107px;"></td><td style="width:3px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2.50% convertible senior notes due 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">276,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(76,951</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(6,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total 2025 Notes, net of unamortized debt discount and debt issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">192,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The net proceeds from the issuance of the 2025 Notes were approximately&#160;$267.2 million, after deducting commissions and the offering expenses payable by the Company. A portion of the net proceeds from the 2025 Notes were used by the Company to repurchase $23.4 million aggregate principal amount of its then-outstanding 2019 Notes in privately-negotiated transactions for approximately $40.2 million in cash.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Holders may convert their 2025 Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2018 (and only during such calendar quarter), if the last reported sale price per share of the Company&#8217;s </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">common stock for each of at least 20 trading days, whether or not consecutive, during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price on the applicable trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the &#8220;measurement period&#8221;) if the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company&#8217;s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company&#8217;s common stock; (4) if the Company calls the 2025 Notes for redemption; and (5) at any time from, and including, May 15, 2025 until the close of business on the scheduled trading day immediately before the Maturity Date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company&#8217;s common stock, or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s election, based on the applicable conversion rate.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The initial conversion rate for the 2025 Notes is 25.7739 shares of the Company&#8217;s common stock per $1,000 principal amount of 2025 Notes, which represents an initial conversion price of approximately $38.80 per share. If a &#8220;make-whole fundamental change&#8221; (as defined in the 2025 Indenture) occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after September 15, 2022 and, in the case of any partial redemption, on or before the 40th scheduled trading day before the Maturity Date, at a cash redemption price equal to the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date but only if the last reported sale price per share of the Company&#8217;s common stock exceeds 130% of the conversion price on each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. If a fundamental change (as defined in the 2025 Indenture) occurs, then, subject to certain exceptions, holders may require the Company to repurchase their 2025 Notes at a cash repurchase price equal to the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of&#160;September 30, 2018, the 2025 Notes had a market price of&#160;$1,027&#160;per&#160;$1,000&#160;principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the&#160;$276.0 million&#160;in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#8217;s option).</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Convertible Senior Notes Due 2019</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On May 29, 2014, the Company entered into a Note Purchase Agreement relating to a private placement by the Company of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$46.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;aggregate principal of 2019 Notes which are convertible into shares of the Company&#8217;s common stock at an initial conversion price of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$17.41</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;per share. The conversion price is subject to customary anti-dilution protection. The 2019 Notes bear interest at a rate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;per annum, payable semiannually in arrears on May 15 and November 15 of each year. The 2019 Notes mature on May 30, 2019 unless earlier converted or repurchased in accordance with their terms, and there are no contractual payments due prior to that date. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In September 2018, the Company used part of the net proceeds from the issuance of the 2025 Notes discussed above to repurchase $23.4 million&#160;aggregate principal value of the 2019 Notes in privately-negotiated transactions for approximately&#160;$40.2 million&#160;in cash. The partial repurchase of the 2019 Notes resulted in a&#160;$17.0 million loss on early extinguishment of debt. At&#160;September 30, 2018, approximately&#160;$22.6 million&#160;of principal remained outstanding on the 2019 Notes.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The composition of the Company&#8217;s 2019 Notes are as follows (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:437px;"></td><td style="width:9px;"></td><td style="width:107px;"></td><td style="width:3px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:107px;"></td><td style="width:3px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.50% senior convertible notes due 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(56.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total 2019 Notes, net of debt discount and debt issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,377</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">45,077</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Cash Flows from Operating Activities</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cash used in operating activities was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$21.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;for the nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;compared to cash provided of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$8.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;for the nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. After disregarding non-cash changes such as derivative liability fluctuations, share based compensation, contingent consideration charges and deferred tax asset reserves, the change of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$29.7 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;was primarily due to increased clinical trial activity.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Cash Flows from Investing Activities</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cash used by investing activities for the nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$154.5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, compared to cash provided by of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$45.7 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;for the nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. The change was primarily due to the proceeds from the sales of the 2025 Notes invested in marketable securities during the current year, and the maturity of notes receivable in 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Cash Flows from Financing Activities</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cash provided by financing activities for the nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$231.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;compared to cash provided of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$4.1 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;for the nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. The change was due to the issuance of the 2025 Notes, offset by the partial repurchase of the 2019 Notes.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Funding Requirements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We believe that our available cash and short-term investments as of the date of this filing will be sufficient to fund our anticipated level of operations for at least the next 12 months. This belief is based on many factors, some of which are beyond our control. Factors that may affect financing requirements include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">revenue growth of our marketed products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the rate of progress and cost of our clinical trials, preclinical studies and other discovery and research and development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the timing of, and costs involved in, seeking and obtaining marketing approvals for our products, and in maintaining quality systems standards for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our ability to manufacture sufficient quantities of our products to meet expected demand;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the costs of preparing, filing, prosecuting, maintaining and enforcing any patent claims and other intellectual property rights, litigation costs and the results of litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our ability to enter into collaboration, licensing or distribution arrangements and the terms and timing of these arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the potential need to expand our business, resulting in additional payroll and other overhead expenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">debt service obligations on the 2019 Notes and 2025 Notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the potential in-licensing of other products or technologies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the emergence of competing technologies or other adverse market or technological developments.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies.</font></div><div><a name="sF39EDB66C2E4534C9EBB1D2600A87B74"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Other Matters</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">See Note 2 to our unaudited Condensed Consolidated Financial Statements in this report for a discussion of adoption of new accounting standards.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">See Note 2 to our unaudited Condensed Consolidated Financial Statements in this report for a discussion of recently issued accounting pronouncements.</font></div><div><a name="s6B9803EEE26A5223ABCD878EBDD1D40B"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Off Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In December 2017, the Company entered into an option agreement</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">with Censa, which became effective in January 2018. The Company determined that Censa is a variable interest entity ("VIE") and concluded that the Company is not the primary beneficiary of the VIE. As such, the Company did not consolidate Censa&#8217;s results into its consolidated financial statements. The Company will continue to monitor facts and circumstances for changes that could potentially result in the Company becoming the primary beneficiary. See Note 5 to the Unaudited Condensed Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div><a name="s41C6A78C196D54B0A3B28F230F5DC186"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. &#160;Quantitative and Qualitative Disclosures about Market Risk</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We invest our excess cash and marketable securities primarily in United States government backed securities, asset-backed securities, and debt instruments of financial institutions and corporations with investment-grade credit ratings. These instruments have various short and long-term maturities, not exceeding two years. We do not utilize derivative financial instruments, derivative commodity instruments, or other market risk sensitive instruments, positions or transactions. Accordingly, we believe that, while the instruments held are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive investments. A hypothetical 1% adverse move in interest rates along the entire interest rate yield curve would decrease our available for sale marketable securities by approximately $2.4 million if the Company were to sell the securities.</font></div><div><a name="sE69D5A380FBC5D7DBE829457CC617DF6"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. &#160;Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports required by the Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the timelines specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change to our internal control over financial reporting that occurred during the quarter covered by this report and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Our evaluation did not identify significant changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><a name="s97E420A17B3150658B186D105686CB9E"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II - OTHER INFORMATION&#160;</font></div><div><a name="sB992249C0BD6593D8C0E9EF8E83518F4"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. &#160;Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The information required by this Item is incorporated herein by reference to the Notes to the Unaudited Condensed Consolidated Financial Statements--Note 12 Commitments and Contingencies: Legal Proceedings&#160;in Part I, Item 1, of this Quarterly Report on Form 10-Q.</font></div><div><a name="sC8007D35C027572B9822E17D47640AB9"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following risk factors do not reflect any material changes to the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, other than the revisions to the risk factors set forth below with an asterisk (*) next to the title. The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on Form 10-Q and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to the Commercialization of Our Products</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">The commercial success of Chenodal, Cholbam</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">and Thiola depends on them being considered to be effective drugs with advantages over other therapies.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The commercial success of our products Chenodal, Cholbam and Thiola depends on them being considered to be effective drugs with advantages over other therapies. A number of factors, as discussed in greater detail below, may adversely impact the degree of acceptance of these products, including their efficacy, safety, price and benefits over competing therapies, as well as the reimbursement policies of third-party payers, such as government and private insurance plans.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If unexpected adverse events are reported in connection with the use of any of these products, physician and patient acceptance of the product could deteriorate and the commercial success of such product could be adversely affected. We are required to report to the FDA events associated </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">with our products relating to death or injury. Adverse events could result in additional regulatory controls, such as a requirement for costly post-approval clinical studies or revisions to our approved labeling which could limit the indications or patient population for a product or could even lead to the withdrawal of a product from the market.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">If physicians, patients and third-party payers do not accept our products, we may be unable to generate significant revenues.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our drugs may not gain or maintain market acceptance among physicians and patients. Effectively marketing our products and any of our drug candidates, if approved, requires substantial efforts, both prior to launch and after approval. Physicians may elect not to prescribe our drugs, and patients may elect not to request or take them, for a variety of reasons including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">lower demonstrated efficacy, safety and/or tolerability compared to other drugs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">prevalence and severity of adverse side-effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">lack of cost-effectiveness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">lack of coverage and adequate reimbursement availability from third-party payers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">a decision to wait for the approval of other therapies in development that have significant perceived advantages over our drug;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">convenience and ease of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">other potential advantages of alternative treatment methods; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">ineffective marketing and/or distribution support.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If our drugs fail to achieve or maintain market acceptance, we will not be able to generate significant revenues.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Changes in reimbursement practices of third-party payers could affect the demand for our products and the prices at which they are sold.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The business and financial condition of healthcare-related businesses will continue to be affected by efforts of governments and third-party payers to contain or reduce the cost of healthcare through various means. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for fosmetpantotenate, sparsentan, CNSA-001 and L-UDCA, or any other product candidate that we develop, restrict or regulate post-approval activities and affect our ability to profitably sell&#160;fosmetpantotenate, sparsentan, CNSA-001 and L-UDCA&#160;or any other product candidate for which we obtain marketing approval.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our products are sold to patients whose healthcare costs are met by third-party payers, such as government programs, private insurance plans and managed-care programs. These third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products and services. Levels of reimbursement, if any, may be decreased in the future, and future healthcare reform legislation, regulations or changes to reimbursement policies of third party payers may otherwise adversely affect the demand for and price levels of our products, which could have a material adverse effect on our sales and profitability.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Economic, social, and congressional pressure may result in individuals and government entities increasingly seeking to achieve cost savings through mechanisms that limit coverage or payment for our products. For example, state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization for use of drugs. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We may not be able to rely on orphan drug exclusivity for Cholbam/Kolbam or any of our products.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. We have obtained orphan designation for Cholbam/Kolbam in the United States and the European Union. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, that product is entitled to a period of marketing exclusivity, which precludes the applicable regulatory authority from approving another marketing application for the same drug for the same indication for that time period. The applicable period is seven years in the United States and ten years in Europe. Even though we have been awarded orphan drug exclusivity for Cholbam in the United States, we may not be able to maintain it. For example, if a competitive product that contains the same active moiety and treats the same disease as our product is shown to be clinically superior to our product, any orphan drug exclusivity we have obtained will not block the approval of such competitive product and we may effectively lose orphan drug exclusivity. Similarly, if a competitive product that contains the same active moiety and treats the same disease as our product candidate is approved for orphan drug exclusivity before our product candidate, we may not be able to obtain approval for our product candidate until the expiration of the competitive product&#8217;s orphan drug exclusivity unless our product candidate is shown to be clinically superior to the competitive product.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Additional competitors could enter the market, including with generic versions of our products, and sales of our affected products may decline materially.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Under the Hatch-Waxman Amendments of the Federal Food, Drug, and Cosmetic Act (the "FDC Act"), a pharmaceutical manufacturer may file an ANDA, seeking approval of a generic copy of an approved innovator product or an NDA under Section 505(b)(2) that relies on the FDA&#8217;s prior findings of safety and effectiveness in approving the innovator product. A Section 505(b)(2) NDA may be for a new or improved version of the original </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">innovator product. The Hatch-Waxman Amendments also provide for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA acceptance) of an ANDA or Section 505(b)(2) NDA. In addition, the FDC Act provides, subject to certain exceptions, a period during which an FDA-approved drug may be afforded orphan drug exclusivity. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; If there are patents listed in the Orange Book, a generic or Section 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in the ANDA what is known as a &#8220;Paragraph IV certification,&#8221; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45 days of receiving notice the innovator sues to enforce its patents, approval of the ANDA is stayed for 30 months, or as lengthened or shortened by the court.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal and Thiola are subject to immediate competition from compounded and generic entrants, as the ANDA and NDA for these drug products have no remaining patent or nonpatent exclusivity. There have been a number of recent regulatory and legislative initiatives designed to encourage generic competition. If a generic version is approved, sales of our product would be negatively impacted, which would have a material adverse impact on our sales and profitability.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We are dependent on third parties to manufacture and distribute our pharmaceutical products who may not fulfill their obligations.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We have no manufacturing capabilities and rely on third party manufacturers who are sole source suppliers for manufacturing of Chenodal, Cholbam and Thiola. The facilities used by our third party manufacturers must be approved by the FDA, or in the case of Kolbam in the European Union, the European Medicines Agency. Our dependence on third parties for the manufacture of our products may harm our profit margin on the sale of products and our ability to deliver products on a timely and competitive basis. If our third party manufacturers are unable to manufacture to specifications or in compliance with applicable regulatory requirements, our ability to commercialize our products will be adversely impacted and could affect our ability to gain market acceptance for our products and negatively impact our revenues.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We currently have no in-house distribution channels for Chenodal, Cholbam or Thiola and we are dependent on a third-party distributor, Dohmen Life Sciences Services, to distribute such products. We rely on this distributor for all of our proceeds from sales of Chenodal, Cholbam and Thiola in the United States. The outsourcing of our distribution function is complex, and we may experience difficulties that could reduce, delay or stop shipments of such products. If we encounter such distribution problems, and we are unable to quickly enter into a similar agreement with another distributor on substantially similar terms, distribution of Chenodal, Cholbam and/or Thiola could become disrupted, resulting in lost revenues, provider dissatisfaction, and/or patient dissatisfaction.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Governments outside the United States tend to impose strict price controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In some countries, particularly European Union countries, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time (6 to 12 months or longer) after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our prospects for generating revenue outside of the United States, if any, could be adversely affected and our business may suffer.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate product revenue outside of the United States.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to the Development of our Product Candidates</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">*Our clinical trials may fail to demonstrate the safety and efficacy of our product candidates which could prevent or significantly delay their regulatory approval.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and initial results from a clinical trial do not necessarily predict final results. There can be no assurance that the favorable responses we have seen with the physician-initiated treatment of fosmetpantotenate in PKAN patients outside the United States will translate to positive data in the Phase 3 clinical trial of fosmetpantotenate or that the positive results from the DUET study of sparsentan in FSGS will be repeated in the Phase 3 clinical trial. Similarly, there can be no assurance that our clinical experience with sparsentan in FSGS will translate to favorable data in IgAN.  We cannot assure that any current or future clinical trials of fosmetpantotenate, sparsentan and/or CNSA-001 will ultimately be successful.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Before obtaining regulatory approval to conduct clinical trials of our product candidates, we must conduct extensive preclinical tests to demonstrate the safety of our product candidates in animals. Preclinical testing is expensive, difficult to design and implement, and can take many years to complete. In addition, during the clinical development process, additional nonclinical toxicology studies are routinely conducted concurrently with the clinical development of a product candidate.  If any of our product candidates show unexpected findings in concurrent toxicology studies, we could experience potentially significant delays in, or be required to abandon, development of that product candidate.  A failure of one or more of our nonclinical studies can occur at any stage of testing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We will only obtain regulatory approval to commercialize a product candidate if we can demonstrate to the satisfaction of the FDA, and in the case of foreign commercialization, to the applicable foreign regulatory authorities, in well-designed and conducted clinical trials, that our product candidates are safe and effective and otherwise meet the appropriate standards required for approval for a particular indication.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Although we have obtained a Special Protocol Assessment ("SPA") agreement from the FDA for the Phase 3 clinical trial of fosmetpantotenate for the treatment of PKAN, this agreement does not guarantee any particular outcome from regulatory review.  The SPA is intended to provide assurance that if the agreed upon clinical trial protocols are followed and the clinical trial endpoints are achieved, the data may serve as the primary basis for an efficacy claim in support of an NDA. However, a SPA is not a guarantee of an approval of a product candidate or any permissible claims about the product candidate. In particular, a SPA agreement is not binding on the FDA if previously unrecognized public health concerns arise during the performance of the clinical trial, if other new scientific concerns regarding product candidate safety or efficacy arise or if the sponsoring company fails to comply with the agreed upon clinical trial protocols. Moreover, a SPA does not address all of the variables and details that may go into planning for or conducting a clinical trial, and changes in the protocol for a clinical trial can invalidate a SPA or require that the FDA agree in writing to the modified protocol. In addition, while a SPA addresses the requirements for submission of an NDA, the results of the related clinical trial may not support FDA approval. There can be no assurance that the Phase 3 clinical trial for fosmetpantotenate will demonstrate that fosmetpantotenate is safe and effective for treating PKAN or that the data will support an application for approval by the FDA.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In 2018, we initiated a single Phase 3 clinical trial designed to serve as the basis for an NDA filing for sparsentan for the treatment of FSGS.   Although we received feedback from the FDA at an End of Phase 2 meeting during which the FDA communicated that it was open to accepting a substantial treatment effect on proteinuria in this trial as a basis for accelerated approval pursuant to Subpart H of the FDA regulations and although we subsequently gained alignment that our statistical modeling supported initiating a Phase 3 trial that proceeds on the Subpart H pathway, there can be no guarantee that the data generated from such analyses will be sufficient to serve as the basis for an NDA filing, including an NDA under Subpart H or accelerated approval.  In addition, our statistical modeling that supports proceeding on the Subpart H pathway is based on data from other FSGS studies.  To the extent that the model population is not representative of the Phase 3 study population, the FDA may not agree that the new results continue to support a Subpart H pathway. Furthermore, even if sparsentan is granted accelerated approval under Subpart H, there can be no assurance that the post-marketing confirmatory data will support full approval of sparsentan as a treatment for FSGS.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We are also pursuing the development of sparsentan as a treatment for IgAN.  Based on our recent interactions with the FDA and EMA, we are planning to initiate a single Phase 3 clinical trial designed to serve as the basis for an NDA and MAA filing for sparsentan for the treatment of IgAN.  We are currently working to harmonize the protocol design for this Phase 3 study by incorporating the feedback to guide our clinical activity.  Although we expect to initiate this study in the fourth quarter of 2018, there can be no assurance that the study will initiate on our expected timelines or proceed as planned.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Clinical trials can be lengthy, complex and extremely expensive processes with uncertain results. Our product candidates are intended to treat PKAN, FSGS and IgAN, each of which is a rare disease. Given that these development candidates are still undergoing required testing, we may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients willing and able to participate in the clinical trials required by the FDA or foreign regulatory agencies. In addition, as other companies and researchers may be concurrently developing therapies for the same or similar indications that we are focused on, we could face competition for a limited number of patients, investigators and clinical trial sites willing to participate in clinical trials. Our inability to enroll a sufficient number of patients for any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We may experience numerous unforeseen events during, or as a result of, preclinical or nonclinical testing and the clinical trial process that could delay or prevent our ability to obtain regulatory approval or commercialize our product candidates, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our preclinical or nonclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical testing or clinical trials or we may abandon projects that we expect to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">regulators may require us to conduct studies of the long-term effects associated with the use of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">regulators or institutional review boards may not authorize us to commence a clinical trial or conduct a clinical trial at a prospective trial site;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the FDA or any non-United States regulatory authority may impose conditions on us regarding the scope or design of our clinical trials or may require us to resubmit our clinical trial protocols to institutional review boards for re-inspection due to changes in the regulatory environment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the number of patients required for our clinical trials may be larger than we anticipate or participants may drop out of our clinical trials at a higher rate than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our third-party contractors or clinical investigators may fail to comply with regulatory requirements or fail to meet their contractual obligations to us in a timely manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">we might have to suspend or terminate one or more of our clinical trials if we, regulators or institutional review boards determine that the participants are being exposed to unacceptable health risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the cost of our clinical trials may be greater than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the supply or quality of our product candidates or other materials necessary to conduct our clinical trials may be insufficient or inadequate or we may not be able to reach agreements on acceptable terms with prospective clinical research organizations; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the effects of our product candidates may not be the desired effects or may include undesirable side effects or the product candidates may have other unexpected characteristics.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete our clinical trials or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">be delayed in obtaining, or may not be able to obtain, marketing approval for one or more of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">obtain approval for indications that are not as broad as intended or entirely different than those indications for which we sought approval; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">have the product removed from the market after obtaining marketing approval.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our product development costs will also increase if we experience delays in testing or approvals. We do not know whether any preclinical tests or clinical trials will be initiated as planned, will need to be restructured or will be completed on schedule, if at all. Significant preclinical or clinical trial delays also could shorten the patent protection period during which we may have the exclusive right to commercialize our product candidates. Such delays could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or product candidates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In addition, we depend on independent clinical investigators and contract research organizations (&#8220;CROs&#8221;) to conduct our clinical trials under agreements with us. The CROs play a significant role in the conduct of our clinical trials. Failure of the CROs to meet their obligations could adversely affect clinical development of our product candidates. The independent clinical investigators are not our employees and we cannot control the timing or amount of resources they devote to our studies. If their performance is substandard, it could delay or prevent approval of our FDA applications.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">FDA approval for a product requires substantial or extensive preclinical and clinical data and supporting documentation. The approval process may take years and may involve on-going requirements as well as post marketing obligations. For example, we have certain post marketing requirements and commitments associated with Cholbam.  FDA approval once obtained, may be withdrawn. If the regulatory approval for  Chenodal, Cholbam and/or Thiola are withdrawn for any reason, it would have a material adverse impact on our sales and profitability. Further, we face risks relating to the post marketing obligations and commercial acceptance of Cholbam, which was approved by the FDA on March 17, 2015.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We face substantial risks related to the commercialization of our product candidates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We have invested a significant portion of our efforts and financial resources in the development and acquisition of our most advanced product candidates, fosmetpantotenate, sparsentan, CNSA-001 and L-UDCA. Our ability to generate product revenue from these development stage compounds, which we do not expect will occur for at least the next several years, if ever, may depend heavily on the successful development and commercialization of these product candidates. The successful commercialization of our future product candidates will depend on several factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">obtaining supplies of fosmetpantotenate, sparsentan, CNSA-001 and subsequent product candidates for completion of our clinical trials on a timely basis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">successful completion of pre-clinical and clinical studies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">with respect to L-UDCA, our ability to complete the activities necessary to submit an NDA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">obtaining marketing approvals from the FDA and similar regulatory authorities outside the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">establishing commercial-scale manufacturing arrangements with third-party manufacturers whose manufacturing facilities are operated in compliance with cGMP regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">launching commercial sales of the product, whether alone or in collaboration with others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">acceptance of the product by patients, the medical community and third-party payers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">reimbursement from medical, medicaid or private payers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">competition from other companies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">successful protection of our intellectual property rights from competing products in the United States and abroad; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">a continued acceptable safety and efficacy profile of our product candidates following approval.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Furthermore, we have entered into a joint development agreement with Censa to evaluate CNSA-001 for the treatment of PKU. Under this agreement, we have agreed to fund certain development activities of Censa&#8217;s CNSA-001 program, in an aggregate amount expected to be approximately $17 million through proof of concept.&#160; However, we have limited control over the development activities of Censa&#8217;s CNSA-001 program and face the risk that the development program for CNSA-001 will not be successful, that Censa does not conduct the development activities in a timely manner, or that the development program for CNSA-001 may cost more than expected to reach proof of concept.&#160; If any of these issues arise, our investment in Censa&#8217;s CNSA-001 program may be adversely affected and our business may suffer.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Undesirable side effects caused by our product candidates could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing our product candidates and generating revenues from their sale.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In addition, if any of our product candidates receive marketing approval and we or others later identify undesirable side effects caused by the product:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">regulatory authorities may require the addition of restrictive labeling statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">regulatory authorities may withdraw their approval of the product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">we may be required to change the way the product is administered or conduct additional clinical trials.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase the costs and expenses of commercializing the product candidate, which in turn could delay or prevent us from generating significant revenues from its sale or adversely affect our reputation.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">*We may not be able to obtain orphan drug exclusivity for our product candidates. If our competitors are able to obtain orphan drug exclusivity for their products that are the same drug as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Although we have obtained orphan designation for chenodal, fosmetpantotenate and sparsentan, there can be no assurance that there will be any benefits associated with such designation.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, that product is entitled to a period of marketing exclusivity, which precludes the applicable regulatory authority from approving another marketing application for the same drug for the same indication for that time period. The applicable period is seven years in the United States and ten years in Europe. Even if we have orphan drug exclusivity, we may not be able to maintain it. For example, if a competitive product that contains the same active moiety and treats the same disease as our product candidate is shown to be clinically superior to our product candidate, any orphan drug exclusivity we have obtained will not block the approval of such competitive product and we may effectively lose what had previously been orphan drug exclusivity. Similarly, if a competitive product that contains the same active moiety and treats the same disease as our product candidate is approved before our product candidate is approved, we may not be able to obtain approval for our product candidate until the expiration of the competitive product&#8217;s orphan drug exclusivity unless our product candidate is shown to be clinically superior to the competitive product.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to our Products and Product Candidates</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Our products may not achieve or maintain expected levels of market acceptance or commercial success.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The success of our products is dependent upon achieving and maintaining market acceptance. Commercializing products is time consuming, expensive and unpredictable. There can be no assurance that we will be able to, either by ourselves or in collaboration with our partners or through our licensees, successfully commercialize new products or current products or gain market acceptance for such products. New product candidates that appear promising in development may fail to reach the market or may have only limited or no commercial success.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of the affected products. Accordingly, new data about our products, or products similar to our products, could negatively impact demand for our products due to real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our current products and any products that we bring to the market, including fosmetpantotenate, sparsentan, CNSA-001 and L-UDCA, if they receive marketing approval, may not gain market acceptance by physicians, patients, third-party payers, and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our current products and product candidates, if approved for commercial sale, will depend on a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the efficacy and potential advantages over alternative treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the pricing of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">relative convenience and ease of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the strength of marketing and distribution support and timing of market introduction of competitive products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">publicity concerning our products or competing products and treatments; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">sufficient third-party insurance coverage and/or reimbursement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Even if a potential or current product displays a favorable efficacy and safety profile in preclinical and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate patients, the medical community, and third-party payers on the benefits of our product may require significant resources and may never be successful. Such efforts to educate the marketplace may require more resources than are required by the conventional marketing technologies employed by our competitors.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain of the diseases that our current and future product candidates are being developed to address, such as PKAN, PKU, FSGS and IgAN, are relatively rare. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, may not be accurate.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Currently, most reported estimates of the prevalence of PKAN and FSGS are based on studies of small subsets of the population of specific geographic areas, which are then extrapolated to estimate the prevalence of the diseases in the broader world population. As new studies are performed the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of PKAN and FSGS in the study populations accurately reflect the prevalence of these diseases in the broader world population. If our estimates of the prevalence of PKAN, PKU, FSGS, or IgAN or of the number of patients who may benefit from treatment with fosmetpantotenate, sparsentan, and CNSA-001 prove to be incorrect, the market opportunities for our product candidates may be smaller than we believe they are, our prospects for generating revenue may be adversely affected and our business may suffer.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We do not currently have patent protection for certain of our products and product candidates. If we are unable to obtain and maintain protection for the intellectual property relating to our technology and products, the value of our technology and products will be adversely affected.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our success will depend in large part on our ability to obtain and maintain protection in the United States and other countries for the intellectual property covering, or incorporated into, our technology and products. The patent situation in the field of biotechnology and pharmaceuticals generally is highly uncertain and involves complex legal, technical, scientific and factual questions. We may not be able to obtain additional issued patents relating to our technology or products. Even if issued, patents issued to us or our licensors may be challenged, narrowed, invalidated, held to be unenforceable or circumvented, which could limit our ability to stop competitors from marketing similar products or reduce the term of patent protection we may have for our products. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. Fosmetpantotenate is covered by our U.S. Patent No. 8,673,883, which was granted in 2014 and expires in 2033. In addition, our U.S. Patent No. 9,181,286, which was granted on November 10, 2015 and expires in 2033, covers the use of fosmetpantotenate for the treatment of PKAN, and our U.S. Patent No. 9,629,862, which was granted on April 25, 2017 and also expires in 2033, covers pharmaceutical compositions that contain fosmetpantotenate. Sparsentan is covered by U.S. Patent No. 6,638,937, which expires in 2019 and to which we have an exclusive license. In addition, U.S. Patent No. 9,662,312, to which we also have an exclusive license and which was granted on May 30, 2017 and expires in 2030, covers the use of sparsentan for treating glomerulosclerosis, including FSGS. And U.S. Patent No.9,993,461, to which we also have an exclusive license and which was granted on June 12, 2018 and expires in 2030, covers the use of sparsentan for treating IgA nephropathy as well as glomerulosclerosis, including FSGS.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For products we develop based on a new chemical entity not previously approved by the FDA, we expect that in addition to the protection afforded by our patent filings that we will be able to obtain either five years regulatory exclusivity via the provisions of the FDC Act or seven years regulatory exclusivity via the orphan drug provisions of the FDC Act. In addition, we may be able to obtain up to five years patent term extension (to compensate for regulatory approval delay) for a patent covering such a product.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">we or our licensors were the first to make the inventions covered by each of our pending patent applications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">we or our licensors were the first to file patent applications for these inventions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">any patents issued to us or our licensors that provide a basis for commercially viable products will provide us with any competitive advantages or will not be challenged by third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">we will develop additional proprietary technologies that are patentable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">we will file patent applications for new proprietary technologies promptly or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the claims we make in our patents will be upheld by patent offices in the United States and elsewhere;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our patents will not expire prior to or shortly after commencing commercialization of a product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the patents of others will not have a negative effect on our ability to do business.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We have negotiated a license agreement with Ligand Pharmaceuticals for the rights to sparsentan which we are initially developing for the treatment of FSGS. This license subjects us to various commercialization, reporting and other obligations. If we were to default on our obligations, we could lose our rights to sparsentan.  We have obtained a U.S. and European patent covering the use of sparsentan for treating glomerulosclerosis, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">including FSGS.  However, we cannot be certain  that we will be able to obtain patent protection for various other  potential indications for  sparsentan, or whether, if granted, we would be able to enforce such patents.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our patents also may not afford us protection against competitors with similar technology. Because patent applications in the United States and many other jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in the scientific literature often lag behind the actual discoveries, neither we nor our licensors can be certain that we or they were the first to make the inventions claimed in our or their issued patents or pending patent applications, or that we or they were the first to file for protection of the inventions set forth in these patent applications. If a third party has also filed a United States patent application prior to the effective date of the relevant provisions of the America Invents Act (i.e. before March 16, 2013) covering our product candidates or a similar invention, we may have to participate in an adversarial proceeding, known as an interference, declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial and it is possible that our efforts could be unsuccessful, resulting in a loss of our United States patent position.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us with respect to technologies used in our products. If patent infringement suits were brought against us, we may be unable to commercialize some of our products which could severely harm our business. Litigation proceedings, even if not successful, could result in substantial costs and harm our business.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We expect to rely on orphan drug status to develop and commercialize certain of our product candidates, but our orphan drug designations may not confer marketing exclusivity or other expected commercial benefits.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We expect to rely on orphan drug exclusivity for fosmetpantotenate and sparsentan and potential future product candidates that we may develop. Orphan drug status currently confers seven years of marketing exclusivity in the United States under the FDC Act, and up to ten years of marketing exclusivity in Europe for a particular product in a specified indication. The FDA and EMA have granted orphan designation for fosmetpantotenate and sparsentan for the treatment of PKAN and FSGS, respectively. While we have been granted these orphan designations, we will not be able to rely on these designations to exclude other companies from manufacturing or selling these molecules for the same indication beyond these time frames. Furthermore, any marketing exclusivity in Europe can be reduced from ten years to six years if the initial designation criteria have significantly changed since the market authorization of the orphan product.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For any product candidate for which we have been granted orphan drug designation in a particular indication, it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company's period of exclusivity expires. Even if we are the first to obtain marketing authorization for an orphan drug indication in the United States, there are circumstances under which a competing product may be approved for the same indication during the seven-year period of marketing exclusivity, such as if the later product is shown to be clinically superior to our orphan product, or if the later product is deemed a different product than ours. Further, the seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation, or for the use of other types of products in the same indications as our orphan product.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">*Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In March 2010, President Obama signed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "PPACA"), a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The PPACA revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the law imposes a significant annual fee on companies that manufacture or import certain branded prescription drug products. There have been judicial, Congressional, and political challenges to certain aspects of the PPACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the PPACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the PPACA have been signed into law. The Tax Cuts and Jobs Act of 2017  (the "Tax Act of 2017") includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain PPACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share,&#160;and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018 ("BBA"), among other things, amends the PPACA, effective January 1, 2019, to increase the discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D from 50 percent to 70 percent, and closes the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. More recently, in July 2018, the Centers for Medicare and Medicaid Services ("CMS") published a final rule permitting further collections and payments to and from certain PPACA qualified health plans and health insurance issuers under the PPACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. It is likely the PPACA, or a replacement of it under the current administration, will continue to put pressure on pharmaceutical pricing. We continue to evaluate the potential impact of the PPACA and its possible repeal or replacement on our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If we are unable to obtain coverage and adequate reimbursement from governments or third-party payers for any products that we may develop or if we are unable to obtain acceptable prices for those products, our prospects for generating revenue and achieving profitability will suffer.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our prospects for generating revenue and achieving profitability will depend heavily upon the availability of coverage and adequate reimbursement for the use of our approved product candidates from governmental and other third-party payers, both in the United States and in other markets. Reimbursement by a third-party payer may depend upon a number of factors, including the third-party payer&#8217;s determination that use of a product is:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">a covered benefit under its health plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">safe, effective and medically necessary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">appropriate for the specific patient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">cost-effective; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">neither experimental nor investigational.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Obtaining reimbursement approval for a product from each government or other third-party payer is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to each payer. We may not be able to provide data sufficient to gain acceptance with respect to reimbursement or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to such payers&#8217; satisfaction. Such studies might require us to commit a significant amount of management time and financial and other resources. Even when a payer determines that a product is eligible for reimbursement, the payer may impose coverage limitations that preclude payment for some uses that are approved by the FDA or non-United States regulatory authorities. Also prior authorization for a product may be required. In addition, there is a risk that full reimbursement may not be available for high-priced products. Moreover, eligibility for coverage does not imply that any product will be reimbursed in all cases or at a rate that allows us to make a profit or even cover our costs. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. A primary trend in the United States healthcare industry and elsewhere is toward cost containment. We expect recent changes in the Medicare program and increasing emphasis on managed care to continue to put pressure on pharmaceutical product pricing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Further, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices, including several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, increase drug pricing transparency, expedite generic competition, review relationships between pricing and manufacturer patient assistance programs, and reform government program drug reimbursement methodologies. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the current administration released a "Blueprint" to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, CMS proposed a new rule that would require direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. Although a number of these, and other potential proposals, will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;Any reduction in reimbursement from Medicare, Medicaid or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. Additionally, we are currently unable to predict what additional legislation or regulation, if any, relating to the healthcare industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The use of any of our potential products in clinical trials, and the sale of any approved products, may expose us to liability claims. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling our products. We have obtained limited product liability insurance coverage for our clinical trials in the amount of $10 million per occurrence and $10 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. On occasion, juries have awarded large judgments in class action lawsuits based on drugs that had unanticipated </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">side effects. A successful product liability claim or series of claims brought against us would decrease our cash reserves and could cause our stock price to fall.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. Our operating results will suffer if we fail to compete effectively.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Several of our competitors have substantially greater financial, research and development, distribution, manufacturing and marketing experience and resources than we do and represent substantial long-term competition for us. Other companies may succeed in developing and marketing products that are more effective and/or less costly than any products that may be developed and marketed by us, or that are commercially accepted before any of our products. Factors affecting competition in the pharmaceutical and drug industries vary, depending on the extent to which a competitor is able to achieve a competitive advantage based on its proprietary technology and ability to market and sell drugs. The industry in which we compete is characterized by extensive research and development efforts and rapid technological progress. Although we believe that our orphan drug status for Cholbam and proprietary position with respect to fosmetpantotenate and sparsentan may give us a competitive advantage, new developments are expected to continue and there can be no assurance that discoveries by others will not render such potential products noncompetitive.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our competitive position also depends on our ability to enter into strategic alliances with one or more large pharmaceutical and contract manufacturing companies, attract and retain qualified personnel, develop effective proprietary products, implement development and marketing plans, obtain patent protection, secure adequate capital resources and successfully sell and market our approved products. There can be no assurance that we will be able to successfully achieve all of the foregoing objectives.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Use of third parties to manufacture and distribute our products and product candidates may increase the risk that we will not have sufficient quantities of our product and product candidates or such quantities at an acceptable cost, and clinical development and commercialization of our product and product candidates could be delayed, prevented or impaired.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We do not own or operate manufacturing facilities for clinical or commercial production of our products. We have limited personnel with experience in drug manufacturing and we lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We outsource all manufacturing and packaging of our preclinical, clinical, and commercial products to third parties. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up initial production and in maintaining required quality control. These problems include difficulties with production costs and yields and quality control, including stability of the product candidate.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We do not currently have any agreements with third-party manufacturers for the long-term commercial supply of any of our development stage product candidates. We may be unable to enter into agreements for commercial supply with third-party manufacturers, or may be unable to do so on acceptable terms. Even if we enter into these agreements, the manufacturers of each product candidate will be single source suppliers to us for a significant period of time. Reliance on third-party manufacturers entails risks to which we may not be subject if we manufactured our product candidates or products ourselves, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">reliance on the third party for regulatory compliance and quality assurance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">limitations on supply availability resulting from capacity and scheduling constraints of the third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">impact on our reputation in the marketplace if manufacturers of our products fail to meet the demands of our customers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the possible breach of the manufacturing agreement by the third party because of factors beyond our control; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the possible termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or inconvenient for us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The failure of any of our contract manufacturers to maintain high manufacturing standards could result in injury or death of clinical trial participants or patients using our products. Such failure could also result in product liability claims, product recalls, product seizures or withdrawals, delays or failures in testing or delivery, cost overruns or other problems that could seriously harm our business or profitability.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our contract manufacturers will be required to adhere to FDA regulations setting forth cGMP. These regulations cover all aspects of the manufacturing, testing, quality control and recordkeeping relating to our product candidates and any products that we may commercialize. Our manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our manufacturers are subject to unannounced inspections by the FDA, state regulators and similar regulators outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect regulatory approval and supplies of our product candidates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our product and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing for us and willing to do so. If the third parties that we engage to manufacture products for our developmental or commercial products should cease to continue to do so for any reason, we likely would experience interruptions in cash flows and/or delays in advancing our clinical trials while we identify and qualify replacement suppliers, and we may be unable to obtain replacement supplies on terms that are favorable to us. Later relocation to another manufacturer will also require notification, review and other regulatory approvals from the FDA and other regulators and will subject our production to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">further cost and instability in the availability of our product candidates. In addition, if we are not able to obtain adequate supplies of our product candidates, or the drug substances used to manufacture them, it will be more difficult for us to sell our products and to develop our product candidates. This could greatly reduce our competitiveness.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that obtain regulatory approval on a timely and competitive basis.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Materials necessary to manufacture our products and product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our products and product candidates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We rely on the manufacturers of our products and product candidates to purchase from third-party suppliers the materials necessary to produce the compounds for our preclinical and clinical studies and rely on these other manufacturers for commercial distribution if we obtain marketing approval for any of our product candidates. Suppliers may not sell these materials to our manufacturers at the time we need them or on commercially reasonable terms and all such prices are susceptible to fluctuations in price and availability due to transportation costs, government regulations, price controls, and changes in economic climate or other foreseen circumstances. We do not have any control over the process or timing of the acquisition of these materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these materials. If our manufacturers are unable to obtain these materials for our preclinical and clinical studies, product testing and potential regulatory approval of our product candidates would be delayed, significantly impacting our ability to develop our product candidates. If our manufacturers or we are unable to purchase these materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would materially affect our ability to generate revenues from the sale of our product candidates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Our limited operating history makes it difficult to evaluate our future prospects, and our profitability in the future is uncertain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We face the problems, expenses, difficulties, complications and delays, many of which are beyond our control, associated with any business in its early stages and have a limited operating history on which an evaluation of our prospects can be made. Such prospects should be considered in light of the risks, expenses and difficulties frequently encountered in the establishment of a business in a new industry, characterized by a number of market entrants and intense competition, and in the shift from development to commercialization of new products based on innovative technologies.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We have experienced significant growth over the past three years in the number of our employees and the scope of our operations. We have added sales and marketing, compliance and legal functions in addition to expansion of all functions to support a commercial organization.  To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability on the part of our management to manage growth could delay the execution of our business plans or disrupt our operations.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Factors that may inhibit our efforts to commercialize our products without strategic partners or licensees include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the inability of sales personnel to obtain access to or educate adequate numbers of physicians to prescribe our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the lack of complementary products to be offered by our sales personnel, which may put us at a competitive disadvantage against companies with broader product lines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">unforeseen costs associated with expanding our own sales and marketing team for new products or with entering into a partnering agreement with an independent sales and marketing organization; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">efforts by our competitors to commercialize competitive products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Moreover, though we generate revenues from product sales arrangements, we may incur significant operating losses over the next several years. Our ability to achieve profitable operations in the future will depend in large part upon successful in-licensing of products approved by the FDA, selling and manufacturing these products, completing development of our products, obtaining regulatory approvals for these products, and bringing these products to market. The likelihood of the long-term success of our company must be considered in light of the expenses, difficulties and delays frequently encountered in the development and commercialization of new drug products, competitive factors in the marketplace, as well as the regulatory environment in which we operate.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We will likely experience fluctuations in operating results and could incur substantial losses.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We expect that our operating results will vary significantly from quarter-to-quarter and year-to-year as a result of investments in research and development, specifically our clinical and preclinical development activities. We have not completed development of any drugs and we anticipate that our expenses will increase substantially as we:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">continue our ongoing clinical development of fosmetpantotenate for the treatment of PKAN;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">continue the open label portion of DUET and conduct the planned Phase 3 trials of sparsentan indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">continue funding the clinical development of CNSA-001 for PKU;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">complete requirements necessary for an NDA filing of L-UDCA and the next generation of Thiola;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">continue the research and development of additional product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">expand our sales and marketing infrastructure to commercialize our current products and any new products for which we may obtain regulatory approval; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">expand operational, financial, and management information systems and personnel, including personnel to support product development efforts and our obligations as a public company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">To attain and sustain profitability, we must succeed in developing and commercializing drugs with significant market potential. This will require us to be successful in a range of challenging activities, including the discovery of product candidates, successful completion of preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We are only in the preliminary stages of these activities. We may not be successful enough in these activities to generate revenues that are substantial enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become or remain profitable could depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our common stock may also cause a loss of a part or all of your investment.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Negative publicity regarding any of our products could impair our ability to market any such product and may require us to spend time and money to address these issues.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to consumers and/or subject to FDA enforcement action, our ability to successfully market and sell our products could be impaired. Because of our dependence on patient and physician perceptions, any adverse publicity associated with illness or other adverse effects resulting from the use or misuse of our products or any similar products distributed by other companies could limit the commercial potential of our products and expose us to potential liabilities.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We may not have sufficient insurance to cover our liability in any current or future litigation claims either due to coverage limits or as a result of insurance carriers seeking to deny coverage of such claims.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We face a variety of litigation-related liability risks.&#160; Our certificate of incorporation, bylaws, other applicable agreements, and/or Delaware law require us to indemnify (and advance expenses to) our current and past directors and officers and employees from reasonable expenses related to the defense of any action arising from their service to us, including circumstances under which indemnification is otherwise discretionary. While our directors and officers are included in a director and&#160;officer&#160;liability insurance policy, which covers all our directors and officers in some circumstances, our insurance coverage does not cover all of our indemnification obligations and may not be adequate to cover any indemnification or other claims against us. In addition, the underwriters of our present coverage may seek to avoid coverage in certain circumstances based upon the terms of the respective policies. If we incur liabilities that exceed our coverage under our directors and officers insurance policy or incur liabilities not covered by our insurance, we would have to self-fund any indemnification amounts owed to our directors and officers and employees in which case our results of operations and financial condition could be materially adversely affected. &#160;Further, if D&amp;O insurance becomes prohibitively expensive to maintain in the future, we may be unable to renew such insurance on economic terms or unable renew such insurance at all. The lack of D&amp;O insurance may make it difficult for us to retain and attract talented and skilled directors and officers to serve our company, which could adversely affect our business</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">*We may need substantial funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We expect our general and research and development expenses to increase in connection with our ongoing and planned activities, particularly as we conduct Phase 3 clinical trials of fosmetpantotenate and sparsentan, continue funding the clinical development of CNSA-001 and potentially acquire Censa, complete requirements for filings of L-UDCA, and conduct any other later-stage clinical trials of our product candidates. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur significant commercialization expenses for product sales and marketing, securing commercial quantities of product from our manufacturers, and product distribution. We currently have no additional commitments or arrangements for any additional financing to fund the research and development and commercial launch of our product candidates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Management believes our ability to continue our operations depends on our ability to sustain and grow revenue, results of operations and our ability to access capital markets when necessary to accomplish our strategic objectives. Management believes that we may incur losses in the immediate future. For the twelve months ended December&#160;31, 2017, we generated a positive cash flow from operations; however, we expect that our operating results will vary significantly from quarter-to-quarter and year-to-year as a result of investments in research and development, specifically our clinical and preclinical development activities. We expect to finance our cash needs from cash on hand and results of operations, and depending on results of operations we may either need additional equity or debt financing, or need to enter into strategic alliances on products in development to continue our operations until we can achieve sustained profitability and positive cash flows from operating activities. Additional funds may not be available to us when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to reduce or eliminate research development programs or commercial efforts.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our future capital requirements will depend on many factors, including:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the progress and results of our pre-clinical and clinical studies of fosmetpantotenate, sparsentan, CNSA-001 and other drug candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the costs, timing and outcome of regulatory review of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the number and development requirements of other product candidates that we pursue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the costs of commercialization activities, including product marketing, sales and distribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the emergence of competing technologies and other adverse market developments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property related claims;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">debt service obligations on the 2019 Notes and 2025 Notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the extent to which we acquire or invest in businesses, products and technologies, including the extent to which we exercise our option to acquire Censa; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our ability to establish collaborations and obtain milestone, royalty or other payments from any such collaborators.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">The market price for shares of our common stock may be volatile and purchasers of our common stock could incur substantial losses.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The price of our stock is likely to be volatile. The stock market in general, and the market for biotechnology companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">results of clinical trials of our product candidates or those of our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our entry into or the loss of a significant collaboration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">regulatory or legal developments in the United States and other countries, including changes in the health care payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our ability to obtain and maintain marketing approvals from the FDA or similar regulatory authorities outside the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors and issuance of new or changed securities analysts&#8217; reports or recommendations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">general economic, industry and market conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">results of clinical trials conducted by others on drugs that would compete with our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">developments or disputes concerning patents or other proprietary rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">public concern over our product candidates or any products approved in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">communications from government officials regarding health care costs or pharmaceutical pricing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">future sales or anticipated sales of our common stock by us or our stockholders; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the other factors described in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In addition, the stock markets, and in particular, the Nasdaq Global Market, have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many pharmaceutical companies. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;Risk Factors&#8221; could have a dramatic and material adverse impact on the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We may be unable to successfully integrate new products or businesses we may acquire.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We intend to expand our product pipeline by pursuing acquisition of pharmaceutical products. If an acquisition is consummated, including the extent to which we exercise our option to acquire Censa, the integration of the acquired business, product or other assets into our company may also be complex and time- consuming and, if such businesses, products and assets are not successfully integrated, we may not achieve the anticipated benefits, cost-savings or growth opportunities. Potential difficulties that may be encountered in the integration process include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">integrating personnel, operations and systems, while maintaining focus on producing and delivering consistent, high quality products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">coordinating geographically dispersed organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">distracting employees from operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">retaining existing customers and attracting new customers; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">managing inefficiencies associated with integrating the operations of the Company.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Furthermore, these acquisitions and other arrangements, even if successfully integrated, may fail to further our business strategy as anticipated, expose us to increased competition or challenges with respect to our products or geographic markets, and expose us to additional liabilities associated with an acquired business, product, technology or other asset or arrangement. Any one of these challenges or risks could impair our ability to realize any benefit from our acquisitions or arrangements after we have expended resources on them.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">If we are unable to maintain an effective and specialized sales force, we will not be able to commercialize our products successfully.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In order to successfully commercialize our products, we have built a specialized sales force. Factors that may hinder our ability to successfully market and commercially distribute our products include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">inability of sales personnel to obtain access to or convince adequate numbers of physicians to prescribe our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">inability to recruit, retain and effectively manage adequate numbers of effective sales personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive product lines; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">unforeseen delays, costs and expenses associated with maintaining our sales organization.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If we are unable to maintain our sales force for our products, we may not be able to generate sufficient product revenue.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We will need to continue to expend significant time and resources to train our sales forces to be credible, persuasive and compliant in discussing our products with the specialists treating the patients indicated under the product&#8217;s label. In addition, if we are unable to effectively train our sales force and equip them with effective marketing materials our ability to successfully commercialize our products could be diminished, which would have a material adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our business exposes us to potential liability risks inherent in the research, development, manufacturing and marketing of pharmaceutical products. If any of our product candidates in clinical trials or commercialized products harm people we may be subject to costly and damaging product liability claims. We have clinical trial insurance and commercial product liability coverage. However, this insurance may not be adequate to cover all claims. We may be exposed to product liability claims and product recalls, including those which may arise from misuse or malfunction of, or design flaws in, such products, whether or not such problems directly relate to the products and services we have provided. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">decreased demand for any product candidates or products that we may develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">damage to our reputation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">regulatory investigations that could require costly recalls or product modifications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">withdrawal of clinical trial participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">costs to defend the related litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">substantial monetary awards to trial participants or patients, including awards that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available, and would damage our ability to obtain liability insurance at reasonable costs, or at all, in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">loss of revenue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the diversion of management&#8217;s attention from managing our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the inability to commercialize any products that we may develop.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">A successful product liability claim or a series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our available cash and adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We are involved in certain litigation matters, any of which&#160;could result in substantial costs, divert management's attention and otherwise have a material adverse effect on our business, operating results or financial condition.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We are involved in certain litigation matters, including those described in Note 12 of the Consolidated Financial Statements included in this report. Although we intend to vigorously defend our interests in each matter, there is no guarantee that we will be successful and we may have to pay damages awards or otherwise may enter into settlement arrangements in connection with such matters. Any such payments or settlement arrangements could have material adverse effects on our business, operating results or financial condition. Even if we are successful in defending our interests in each matter, litigation with respect to such matters could result in substantial costs and significant adverse impact on our reputation and divert management's attention and resources, which could have a material adverse effect on our business, operating results or financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We are subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense and may limit our commercial success.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We are subject to significant ongoing regulatory obligations, such as safety reporting requirements and additional post-marketing obligations, including regulatory oversight of the promotion and marketing of our products. In addition, the manufacture, quality control, labeling, packaging, safety surveillance, adverse event reporting, storage and recordkeeping for our products are subject to extensive and ongoing regulatory requirements. If we become aware of previously unknown problems with any of our products, a regulatory agency may impose restrictions on our products, our contract manufacturers or us. If we, our products and product candidates, or the manufacturing facilities for our products and product candidates fail to comply with applicable regulatory requirements, a regulatory agency, including the FDA, may send enforcement letters, mandate labeling changes, suspend or withdraw regulatory approval, suspend any ongoing clinical trials, refuse to approve pending applications or supplements filed by us, suspend or impose restrictions on manufacturing operations, request a recall of, seize or detain a product, seek criminal prosecution or an injunction, or impose civil or criminal penalties or monetary fines. In such instances, we could experience a significant drop in the sales of the affected products, our product revenues and reputation in the marketplace may suffer, and we could become the target of lawsuits.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We are also subject to regulation by national, regional, state and local agencies, including but not limited to the FDA, CMS, Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies. The FDC Act, Social Security Act, Public Health Service Act and other federal and state statutes and regulations govern to varying degrees the research, development, manufacturing and commercial activities relating to prescription pharmaceutical products, including preclinical testing, clinical research, approval, production, labeling, sale, distribution, post-market surveillance, advertising, dissemination of information, promotion, marketing, and pricing to government purchasers and government health care programs. Our manufacturing partners are subject to many of the same requirements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Companies may not promote drugs for &#8220;off-label&#8221; uses-that is, uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA or other applicable regulatory agencies. A company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil and administrative remedies as well as criminal sanctions. In addition, management&#8217;s attention could be diverted from our business operations and our reputation could be damaged.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The federal health care program Anti-Kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted broadly to apply to arrangements that pharmaceutical companies have with prescribers, purchasers and formulary managers, among others. Further, the PPACA, among other things, amends the intent requirement of the federal anti-kickback statute so that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Although there are a number of statutory exceptions and regulatory safe harbors under the federal anti-kickback statute protecting certain common manufacturer business arrangements and activities from prosecution, the exceptions and safe harbors are drawn narrowly and an arrangement must meet all of the conditions specified in order to be fully protected from scrutiny under the federal anti-kickback statute. We seek to comply with the exceptions and safe harbors whenever possible, but our practices, such as our patient assistance programs and prompt pay discounts with certain customers, may not in all cases meet all of the criteria for protection from anti-kickback liability and may be subject to scrutiny.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The federal false claims laws, including the federal False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Many pharmaceutical and other health care companies have been investigated and have reached substantial financial settlements with the federal government under the federal False Claims Act for a variety of alleged marketing activities, including providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees, grants, free travel, and other benefits to physicians to induce them to prescribe the company&#8217;s products; and inflating prices reported to private price publication services, which may be used by states to set drug payment rates under government health care programs. Companies have been prosecuted for causing false claims to be submitted because of the marketing of their products for unapproved uses. Pharmaceutical and other health care companies have also been prosecuted on other legal theories of Medicare and Medicaid fraud.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. It is not clear whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of any Retrophin products, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject Retrophin to more stringent product labeling and post-marketing testing and other requirements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Many states also have statutes or regulations similar to the federal Anti-Kickback Statute and False Claims Act and civil monetary penalty laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, which apply regardless of the payer. In addition, several states require pharmaceutical companies to implement compliance programs or marketing codes as does the U.S. Department of Health and Human Services.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We also could become subject to government investigations and related subpoenas. Such subpoenas are often associated with previously filed qui tam actions, or lawsuits filed under seal under the federal False Claims Act. Qui tam actions are brought by private plaintiffs suing on behalf of the federal government for alleged violations of the federal False Claims Act. The time and expense associated with responding to such subpoenas, and any related qui tam or other actions, may be extensive, and we cannot predict the results of our review of the responsive documents and underlying facts or the results of such actions. Responding to government investigations, defending any claims raised, and any resulting fines, restitution, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">damages and penalties, settlement payments or administrative actions, as well as any related actions brought by stockholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating our business.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The number and complexity of both federal and state laws continues to increase, and additional governmental resources are being added to enforce these laws and to prosecute companies and individuals who are believed to be violating them. In particular, the PPACA includes a number of provisions aimed at strengthening the government&#8217;s ability to pursue anti-kickback and false claims cases against pharmaceutical manufacturers and other healthcare entities, including substantially increased funding for healthcare fraud enforcement activities, enhanced investigative powers, amendments to the federal False Claims Act that make it easier for the government and whistleblowers to pursue cases for alleged kickback and false claim violations and, for payments made on or after August 1, 2013, public reporting of payments by pharmaceutical manufacturers to physicians and teaching hospitals nationwide. We anticipate that government scrutiny of pharmaceutical sales and marketing practices will continue for the foreseeable future and subject us to the risk of further government investigations and enforcement actions. Responding to a government investigation or enforcement action would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The U.S. Foreign Corrupt Practices Act, and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws. We operate in parts of the world that have experienced governmental corruption to some degree and in certain circumstances, strict compliance with antibribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than in the United States. We cannot assure that our internal control policies and procedures will protect us from reckless or criminal acts committed by our employees or agents. Violations of these laws, or allegations of such violations, could disrupt our business and result in criminal or civil penalties or remedial measures, any of which could have a material adverse effect on our business, financial condition and results of operations and could cause the market value of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), created new federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal anti-kickback statute, the PPACA amended the intent standard for certain healthcare fraud provisions under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Additionally, the civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Also, many states have similar fraud and abuse statutes or regulations, including state anti-kickback and false claims laws, that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act ("HITECH"), and their respective implementing regulations, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH, through its implementing regulations, makes certain of HIPAA&#8217;s privacy and security standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains or transmits protected health information for or on behalf of a covered entity for a function or activity regulated by HIPAA.  International data protection laws also impose strict obligations on the ability to process health related and other personal information of citizens of member states, including in relation to collection, analysis and transfer.  The&#160;EU General Data Protection Regulation was officially adopted in April 2016 and has been in effect since May 2018. The&#160;EU General Data Protection Regulation introduced new data protection requirements in the European Union, as well as substantial fines for breaches of the data protection rules. The&#160;EU General Data Protection Regulation&#160;will increase our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Additionally, the federal Physician Payments Sunshine Act within the PPACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biologicals and medical supplies to report annually information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Moreover, the Drug Supply Chain Security Act imposes new obligations on manufacturers of pharmaceutical products related to product tracking and tracing. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the current regulations, guidance or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">interpretations will be changed, or what the impact of such changes on our business, if any, may be. Several states now require pharmaceutical companies to report their expenses relating to the marketing and promotion of pharmaceutical products in those states and to report gifts and payments to certain individual health care providers in those states. Some of these states also prohibit certain marketing-related activities, including the provision of gifts, meals, and other items to certain health care providers. Other state and local laws now require the registration of pharmaceutical sales representatives.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If we or any of our partners fail to comply with applicable regulatory requirements, we or they could be subject to a range of regulatory actions that could affect our or our partners' ability to commercialize our products and could harm or prevent sales of the affected products, or could substantially increase the costs and expenses of commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Compliance with applicable federal and state laws is difficult and time consuming, and companies that violate them may face substantial penalties. The potential sanctions include criminal fines, civil monetary penalties, administrative penalties, disgorgement, exclusion from participation in federal health care programs, individual imprisonment, injunctions, recall or seizure of products, total or partial suspension of production, reputational harm, administrative burdens, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar agreement to resolve allegation of non-compliance with these laws, diminished profits and future earnings, and the curtailment or restructuring of our operations, and other sanctions. Because of the breadth of these laws, it is possible that some of our business activities could be subject to challenge under one or more of these laws. Such a challenge, irrespective of the underlying merits of the challenge or the ultimate outcome of the matter, could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">If we are not able to obtain and maintain required regulatory approvals, we will not be able to commercialize our products, and our ability to generate revenue will be materially impaired.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our product candidates, once approved, and the activities associated with their manufacture, marketing, distribution, and sales are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Failure to adhere to regulations set out by these bodies for one or more of our commercial products could prevent us from commercializing the product candidate in the jurisdiction of the regulatory authority. We have only limited experience in meeting the regulatory requirements incumbent on the sale of drugs in the United States and elsewhere, and expect to rely on third-parties to assist us in these processes. If these third parties fail to adequately adhere to the regulations governing drug distribution and promotion we may be unable to sell our products, which could have a material effect on our ability to generate revenue.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our product candidates and the activities associated with their development and commercialization, including testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Failure to obtain regulatory approval for a product candidate will prevent us from commercializing the product candidate in the jurisdiction of the regulatory authority. We have only limited experience in filing and prosecuting the applications necessary to obtain regulatory approvals and expect to rely on third-party contract research organizations to assist us in this process.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Securing FDA approval requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing FDA approval also requires the submission of information about the product manufacturing process to, and successful inspection of manufacturing facilities by, the FDA. Our future products may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our product candidates may fail to obtain regulatory approval for many reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our failure to demonstrate to the satisfaction of the FDA or comparable regulatory authorities that a product candidate is safe and effective for a particular indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable regulatory authorities for approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our inability to demonstrate that a product candidate&#8217;s benefits outweigh its risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">our inability to demonstrate that the product candidate presents an advantage over existing therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">the FDA&#8217;s or comparable regulatory authorities&#8217; disagreement with the manner in which we interpret the data from preclinical studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">failure of the third-party manufacturers with which we contract for clinical or commercial supplies to satisfactorily complete an FDA pre-approval inspection of the facility or facilities at which the product is manufactured to assess compliance with the FDA&#8217;s cGMP regulations to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">a change in the approval policies or regulations of the FDA or comparable regulatory authorities or a change in the laws governing the approval process.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in regulatory approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">product application may cause delays in the approval or rejection of an application. The FDA and non-United States regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post approval commitments that render the approved product not commercially viable. Any FDA or other regulatory approval of our product candidates, once obtained, may be withdrawn, including for failure to comply with regulatory requirements or if clinical or manufacturing problems follow initial marketing.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Our internal computer systems, or those of our CROs or other contractors and vendors who host our applications or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors or vendors who host our applications and those of our consultants are vulnerable to damage or disruption from computer viruses, software bugs, unauthorized access including cyber-attack, natural disasters, terrorism, war, and telecommunication, equipment and electrical failures. While we have not, to our knowledge, experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data from completed or ongoing clinical trials for any of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure or theft of confidential or proprietary information, we could incur liability, the further development of our product candidates could be delayed, our competitive position could be compromised, or our business reputation could be harmed.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">We face risks related to research and the ability to develop new drugs.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our growth and survival depends on our ability to consistently discover, develop and commercialize new products and find new and improve on existing technology and platforms. As such, if we fail to make sufficient investments in research, be attentive to consumer needs or do not focus on the most advanced technology, our current and future products could be surpassed by more effective or advanced products of other companies.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On December 22, 2017, President Trump signed into law the Tax Act of 2017 that significantly revises the Internal Revenue Code of 1986, as amended.&#160; The Tax Act of 2017, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.&#160; Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act of 2017 is uncertain and our business and financial condition could be adversely affected.&#160; In addition, it is uncertain if and to what extent various states will conform to the Tax Act of 2017.&#160; The impact of this tax reform on holders of our common stock is also uncertain and could be adverse.&#160; We urge our stockholders to consult with their legal and tax advisors with respect to the Tax Act of 2017 and the potential tax consequences of investing in or holding our common stock.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. &#160;In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. &#160;Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of the Tax Act of 2017, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Our ability to use net operating losses to offset future taxable income may be subject to limitations.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of December 31, 2017, we had federal net operating loss carryforwards of $5.2 million. These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited.&#160; In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. It is possible that we have experienced an ownership change limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">*Our search for a new Chief Executive Officer involves risks and our ability to successfully manage this transition could impact our business. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On July 26, 2018, we announced that Stephen Aselage, our Chief Executive Officer, plans to retire. Our board of directors has initiated a global search for his successor that will include both internal and external candidates. Mr. Aselage will remain in his role as Chief Executive Officer until his replacement is appointed. Leadership transitions can be difficult to manage and may cause disruptions to our operations. The search for a new Chief Executive Officer and the related transition may increase the likelihood of turnover among our employees and result in changes in our business strategy, which may create uncertainty and negatively impact our ability to execute our business strategy quickly and effectively. The presence of a new Chief Executive Officer may also impact our relationships with customers and suppliers, and create uncertainty among investors, employees, creditors and others concerning our future direction and performance. Any significant disruption, uncertainty or change in business strategy could adversely affect our business, financial condition and operating results. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to our Indebtedness and Investments</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">*Our indebtedness could adversely affect our financial condition.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, we had approximately $299.0 million of total debt outstanding, classified as short and long term. As a result of our indebtedness, a portion of our cash flow will be required to pay interest and principal on the 2019 Notes and 2025 Notes if the notes are not converted to shares of common stock prior to maturity. We may not generate sufficient cash flow from operations or have future borrowings available to enable us to repay our indebtedness or to fund other liquidity needs.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Our indebtedness pursuant to the 2019 Notes and 2025 Notes could have important consequences. For example, it could:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">make it more difficult for us to satisfy our obligations with respect to any other debt we may incur in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness and related interest, thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate purposes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">increase our cost of borrowing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">place us at a competitive disadvantage compared to our competitors that may have less debt; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">limit our ability to obtain additional financing for working capital, capital expenditures, acquisitions, debt service requirements or general corporate purposes.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We expect to use cash flow from operations and outside financings to meet our current and future financial obligations, including funding our operations, debt service and capital expenditures. Our ability to make these payments depends on our future performance, which will be affected by financial, business, economic and other factors, many of which we cannot control. Our business may not generate sufficient cash flow from operations in the future, which could result in our being unable to repay indebtedness, or to fund other liquidity needs. If we do not generate sufficient cash from operations, we may be forced to reduce or delay our business activities and capital expenditures, sell assets, obtain additional debt or equity capital or restructure or refinance all or a portion of our debt, including the 2019 Notes and 2025 Notes, on or before maturity. We cannot make any assurances that we will be able to accomplish any of these alternatives on terms acceptable to us, or at all. In addition, the terms of existing or future indebtedness may limit our ability to pursue any of these alternatives.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">*We may be unable to raise the funds necessary to repurchase the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">&#32;for cash following a fundamental change, or to pay any cash amounts due upon conversion, and our future indebtedness may limit our ability to repurchase the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">&#32;or pay cash upon their conversion. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Noteholders may require us to repurchase their 2025 Notes following a fundamental change at a cash repurchase price generally equal to the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, upon conversion, we will satisfy part or all of our conversion obligation in cash unless we elect to settle conversions solely in shares of our common stock. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Further, the indenture governing the 2019 Notes contains a similar definition of fundamental change, and noteholders of the 2019 Notes will likely have the right to require us to repurchase their 2019 Notes for cash upon the occurrence of a fundamental change at a repurchase price equal to 100% of the principal amount of the 2019 Notes to be repurchased, plus accrued and unpaid interest, if any. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We may not have enough available cash or be able to obtain financing at the time we are required to repurchase the 2025 Notes and/or the 2019 Notes or pay the cash amounts due upon conversion of the 2025 Notes. In addition, applicable law, regulatory authorities and the agreements governing our future indebtedness may restrict our ability to repurchase the 2025 Notes and/or the 2019 Notes or pay the cash amounts due upon conversion of the 2025 Notes. Our failure to repurchase the 2025 Notes and/or the 2019 Notes or to pay the cash amounts due upon conversion of the 2025 Notes when required will constitute a default under the base and supplemental indentures that will govern the 2025 Notes, which we refer to collectively as the &#8220;indenture,&#8221; and/or a default under the indenture governing the 2019 Notes. A default under the indenture and/or the indenture </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">governing the 2019 Notes or the fundamental change itself could also lead to a default under agreements governing our other indebtedness, which may result in that other indebtedness becoming immediately payable in full. We may not have sufficient funds to satisfy all amounts due under the other indebtedness, the 2019 Notes and the 2025 Notes.</font></div><div style="line-height:174%;padding-bottom:4px;padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">A default under the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">&#32;may have a material adverse effect on our financial condition.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If an event of default under the 2025 Notes occurs, the principal amount of the 2025 Notes, plus accrued and unpaid interest (including additional interest, if any) may be declared immediately due and payable, subject to certain conditions set forth in the indenture governing such notes. Events of default include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">failure to pay (for more than 30 days) interest when due;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">failure to pay principal when due;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">failure to deliver shares of common stock upon conversion of a 2025 Notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">failure to provide notice of a fundamental change;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">acceleration on our other indebtedness in excess of $10 million (other than indebtedness that is non-recourse to us); or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">certain types of bankruptcy or insolvency involving us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Accordingly, the occurrence of a default under the 2025 Notes, unless cured or waived, may have a material adverse effect on our results of operations.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#2c2c2c;font-weight:bold;">*</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Provisions of the 2019 Notes and 2025 Notes could discourage an acquisition of us by a third party.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain provisions of the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;could make it more difficult or more expensive for or prevent a third party to acquire us. Upon the occurrence of certain transactions constituting a fundamental change, holders of the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;will have the right, at their option, to require us to repurchase all of their </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;or any portion of the principal amount of such Notes in integral multiples of $1,000. We may also be required to increase the conversion rate for conversions in connection with certain fundamental changes.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">*Conversion of the Notes may dilute the ownership interest of existing stockholders, including holders who had previously converted their 2019 Notes and 2025 Notes.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">To the extent we issue shares of common stock upon conversion of the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the conversion of some or all of the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;will dilute the ownership interests of existing stockholders. Any sales in the public market of shares of the common stock issuable upon such conversion could adversely affect prevailing market prices of shares of our common stock. In addition, the existence of the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;may encourage short selling by market participants because the conversion of the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">2019 Notes and 2025 Notes</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;could depress the price of shares of our common stock.</font></div><div><a name="sD9B0719901ED52B7BD0BD1E8D2BFC51B"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. &#160;Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">None.</font></div><div><a name="s91295CB052B551E0B2D54165FD722E86"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. &#160;Defaults Upon Senior Securities</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">None.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">&#160;</font></div><div><a name="s9938B287D5BE5651B6CAA38E360EDB3D"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. &#160;Mine Safety Disclosures</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Not applicable.</font></div><div><a name="sF2688B93497655AA808E9DBAE23F8FDF"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. &#160;Other Information</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div><a name="s967AF0D7CBD35770BA73E4FF799225BE"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;-sec-extract:summary;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. &#160;Exhibits</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(a) Exhibits</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000122527910000211/exhibit31certinc.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Certificate of Incorporation of the Company (incorporated by reference to Exhibit&#160;3.1 to Amendment No. 2 to the Company&#8217;s General Form for Registration of Securities on&#160;Form&#160;10-12G, filed with the SEC on October&#160;28, 2010).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000119312515220676/d939823dex31.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 11, 2015).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000119312515220676/d939823dex32.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 11, 2015).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000119380514001396/e612489_ex4-1.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Form of Warrant Certificate, dated June 30, 2014, issued to the Lenders under the Credit Agreement (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 7, 2014).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000119380514001161/e612380_ex10-1.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Form of Note Purchase Agreement for&#160;principal senior convertible notes with an interest rate of 4.50% due 2019 (&#8220;2019 Notes&#8221;), dated May 29, 2014, by and among the Company and the investors identified therein (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 4, 2014).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000119380514001161/e612380_ex10-2.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Form of Indenture for 2019 Notes, dated May 30, 2014&#160;(incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 4, 2014).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000119380514001161/e612380_ex10-3.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Form of Note for 2019 Notes, dated May 30, 2014&#160;(incorporated by reference to&#160;Exhibit&#160;10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 4, 2014).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.5</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000119312518270154/d620797dex41.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Base Indenture, dated September 10, 2018, between the Company and U.S. Bank National Association, as Trustee&#160;(incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on September 10, 2018).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.6</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1438533/000119312518270154/d620797dex42.htm"><font style="font-family:Arial Narrow;font-size:9pt;">First Supplemental Indenture, dated September 10, 2018, between the Company and U.S. Bank National Association, as Trustee&#160;(including the form of 2.50% Convertible Senior Note due 2025)&#160;(incorporated by reference to Exhibit&#160;4.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on September 10, 2018).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex09302018311.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Executive Officer's Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex09302018312.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Financial Officer's Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex09302018321.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Executive Officer&#8217;s Certification pursuant to Section 906 of the Sarbanes Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">32.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex09312018322.htm"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Financial Officer&#8217;s Certification pursuant to Section 906 of the Sarbanes Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Taxonomy Extension Presentation Linkbase Document</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div><a name="sD9374A0D2E95537F9783949A7CA07618"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><a style="font-family:Arial Narrow;font-size:9.5pt;" href="#sBFAF999010BF5558804ABB5849EA38AC"><font style="font-family:Arial Narrow;font-size:9.5pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:49%;"></td><td style="width:5%;"></td><td style="width:7%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Date: November&#160;1, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">RETROPHIN, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">By:</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">/s/ Stephen Aselage</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Stephen Aselage</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">By:</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">/s/ Laura Clague</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Laura Clague</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">48</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex09302018311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s763C5F509CB754FA95F6B52596B6353D"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:right;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;text-indent:32px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">I, Stephen Aselage, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">I have reviewed this Quarterly Report on Form 10-Q of Retrophin, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:43%;"></td><td style="width:10%;"></td><td style="width:4%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Date: November&#160;1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">/s/ Stephen Aselage&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Stephen Aselage</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex09302018312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEC0B293143915569A598339F7C4B220F"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:right;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Exhibit 31.2 </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;text-indent:32px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">I, Laura Clague, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">I have reviewed this Quarterly Report on Form 10-Q of Retrophin, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:1px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:30px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:43%;"></td><td style="width:10%;"></td><td style="width:4%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Date: November&#160;1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">/s/ Laura Clague</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Laura Clague</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(Principle Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex09302018321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4077A48ADDD45688B4EDE7C55B7811A7"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:right;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">CERTIFICATION OF </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">CHIEF EXECUTIVE OFFICER </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350 </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">AS ADOPTED PURSUANT TO </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In connection with the accompanying Quarterly Report on Form 10-Q of Retrophin, Inc. (the &#8220;Company&#8221;), for the period ending </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(the &#8220;Report&#8221;), the undersigned officer of the Company hereby certifies pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to such officer&#8217;s knowledge: </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;text-indent:32px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;text-indent:32px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.&#160;The information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:43%;"></td><td style="width:10%;"></td><td style="width:4%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Date: November&#160;1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">/s/ Stephen Aselage</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Stephen Aselage</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex09312018322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s104603C652AE55AAA9ED7D2AD649326A"></a></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:right;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Exhibit 32.2 </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">CERTIFICATION OF </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">CHIEF FINANCIAL OFFICER </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350 </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">AS ADOPTED PURSUANT TO </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In connection with the accompanying Quarterly Report on Form 10-Q of Retrophin, Inc. (the &#8220;Company&#8221;), for the period ending </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#32;(the &#8220;Report&#8221;), the undersigned officer of the Company hereby certifies pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to such officer&#8217;s knowledge: </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;text-indent:32px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;text-indent:32px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2. The information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:43%;"></td><td style="width:10%;"></td><td style="width:4%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Date: November&#160;1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">/s/ Laura Clague&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Laura Clague</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>rtrx-20180930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:F406BCCEC348547AB1E50B5F425D1F89,x:61cb5b38fbd84d96a7d184b703b2b346-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:rtrx="http://www.retrophin.com/20180930" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink">
	<link:schemaRef xlink:href="rtrx-20180930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4November2018">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_srt_ProductOrServiceAxis_rtrx_ThiolaLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rtrx:ThiolaLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_srt_ProductOrServiceAxis_rtrx_BileAcidProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rtrx:BileAcidProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_srt_ProductOrServiceAxis_rtrx_BileAcidProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rtrx:BileAcidProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_srt_ProductOrServiceAxis_rtrx_ThiolaLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rtrx:ThiolaLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_rtrx_BileAcidProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rtrx:BileAcidProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_rtrx_ThiolaLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rtrx:ThiolaLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_rtrx_BileAcidProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rtrx:BileAcidProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_rtrx_ThiolaLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rtrx:ThiolaLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-31</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:CensaPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-31</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan31_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsIncEquityHoldersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:CensaPharmaceuticalsIncEquityHoldersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsIncEquityHoldersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:CensaPharmaceuticalsIncEquityHoldersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:CensaPharmaceuticalsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1_dei_LegalEntityAxis_rtrx_CensaPharmaceuticalsInc.Member_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_rtrx_CNSA001ProgramMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_PurchaseProvisionTermsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rtrx:CensaPharmaceuticalsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rtrx:CNSA001ProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:PurchaseProvisionTermsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-31</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_ProductRightsChenodalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rtrx:ProductRightsChenodalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:ConvertibleNotesDue2019Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:SeniorNotesDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_AcquiredProductRightsLUDCAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rtrx:AcquiredProductRightsLUDCAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_ProductRightsChenodalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rtrx:ProductRightsChenodalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_AcquiredProductRightsCholbamMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rtrx:AcquiredProductRightsCholbamMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_AcquiredProductRightsLUDCAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rtrx:AcquiredProductRightsLUDCAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_AcquiredProductRightsCholbamMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rtrx:AcquiredProductRightsCholbamMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:SeniorNotesDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:SeniorNotesDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:SeniorNotesDue2025Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:SeniorNotesDue2025Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:ConvertibleNotesDue2019Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2May29_rtrx_AgreementAxis_rtrx_NotePurchaseAgreementMember_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="rtrx:AgreementAxis">rtrx:NotePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-05-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:ConvertibleNotesDue2019Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3September102018_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:SeniorNotesDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rtrx:SeniorNotesDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_rtrx_AgreementAxis_rtrx_LeaseAgreementMember_srt_StatementGeographicalAxis_rtrx_SanDiegoCACorporateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="rtrx:AgreementAxis">rtrx:LeaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rtrx:SanDiegoCACorporateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_rtrx_AgreementAxis_rtrx_LeaseAgreementMember_srt_StatementGeographicalAxis_stpr_NY">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="rtrx:AgreementAxis">rtrx:LeaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:MartinShkreliMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_srt_LitigationCaseAxis_rtrx_RetrophinInc.v.ShkreliMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">rtrx:RetrophinInc.v.ShkreliMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:MartinShkreliMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Sept30_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:MartinShkreliMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:MartinShkreliMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rtrx:MartinShkreliMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001438533</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="tranche">
		<xbrli:measure>rtrx:tranche</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="day">
		<xbrli:measure>rtrx:day</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Year">
		<xbrli:measure>rtrx:Year</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="product">
		<xbrli:measure>rtrx:product</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2018Q3YTD" id="Fact-B3877B8A1EF631F50E6308014465FB08">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q3YTD" id="Fact-41243DF7B63762DA610E08014464B0DB">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q3YTD" id="Fact-040102523DC6A5D9851508014467F5CE">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q3YTD" id="Fact-D63F38BB00E33F63266D0801446594AE">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q3YTD" id="Fact-C72F2F2A67862F7D30EF0801446692D6">2018-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q3YTD" id="Fact-0A06257A9E88B2672D77080144BC6962">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q3YTD" id="Fact-217D71D9FD7F267F126E08014466E84C">0001438533</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q4November2018" decimals="INF" id="Fact-F8154ACBD3B2DA641C2F080144BDF196" unitRef="shares">41247609</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityEmergingGrowthCompany contextRef="FD2018Q3YTD" id="Fact-B4981B8F0F55ABF82E79C230855FC1FB">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="FD2018Q3YTD" id="Fact-95697927CE71D2DDFAA7080144BBF836">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2018Q3YTD" id="Fact-0F9F6E18717ADA88C1750801446563AA">Retrophin, Inc.</dei:EntityRegistrantName>
	<dei:EntitySmallBusiness contextRef="FD2018Q3YTD" id="Fact-74035CC52E9835574A57C2345E62AEE0">false</dei:EntitySmallBusiness>
	<dei:TradingSymbol contextRef="FD2018Q3YTD" id="Fact-90B87DCE615519763B4E0801446702AE">rtrx</dei:TradingSymbol>
	<rtrx:AccruedLiabilitiesMiscellaneous contextRef="FI2017Q4" decimals="-3" id="Fact-290B5749E9DC89DCDFCC0801449C263F" unitRef="usd">1523000</rtrx:AccruedLiabilitiesMiscellaneous>
	<rtrx:AccruedLiabilitiesMiscellaneous contextRef="FI2018Q3" decimals="-3" id="Fact-13AC229011F85CAB8CCF0801449C5A6B" unitRef="usd">2465000</rtrx:AccruedLiabilitiesMiscellaneous>
	<rtrx:AccruedLiabilitiesResearchandDevelopmentCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-FC6F50DD334F2AFEFD31080144B34936" unitRef="usd">6989000</rtrx:AccruedLiabilitiesResearchandDevelopmentCurrent>
	<rtrx:AccruedLiabilitiesResearchandDevelopmentCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-BDEC20D04E5FDC12F0FB0801448B54D7" unitRef="usd">11969000</rtrx:AccruedLiabilitiesResearchandDevelopmentCurrent>
	<rtrx:AccruedLiabilitiesSellingGeneralandAdministrativeCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C44A37C694F9135B05FC080144AFAF61" unitRef="usd">3896000</rtrx:AccruedLiabilitiesSellingGeneralandAdministrativeCurrent>
	<rtrx:AccruedLiabilitiesSellingGeneralandAdministrativeCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-04F6A24490006DA4AEAA080144B1AADA" unitRef="usd">2913000</rtrx:AccruedLiabilitiesSellingGeneralandAdministrativeCurrent>
	<rtrx:AccruedRoyaltiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-4FF162EC4042C745244E08014480E59C" unitRef="usd">13095000</rtrx:AccruedRoyaltiesNoncurrent>
	<rtrx:AccruedRoyaltiesNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-0FE2B7BB1E771EE3EDD80801446FB562" unitRef="usd">12611000</rtrx:AccruedRoyaltiesNoncurrent>
	<rtrx:AccruedRoyaltyandContingentConsideration contextRef="FI2017Q4" decimals="-3" id="Fact-C923897D3458042DCA5C080144B11A71" unitRef="usd">6429000</rtrx:AccruedRoyaltyandContingentConsideration>
	<rtrx:AccruedRoyaltyandContingentConsideration contextRef="FI2018Q3" decimals="-3" id="Fact-94C10DC36FD4027A40A0080144BE17F1" unitRef="usd">6332000</rtrx:AccruedRoyaltyandContingentConsideration>
	<rtrx:AcquisitionRelatedContingentConsideration contextRef="FI2017Q4" decimals="-3" id="Fact-63BB507BCB04C290CB040801447F02C3" unitRef="usd">9100000</rtrx:AcquisitionRelatedContingentConsideration>
	<rtrx:AcquisitionRelatedContingentConsideration contextRef="FI2018Q3" decimals="-3" id="Fact-C583C0BA92D87A2A800C08014467BD50" unitRef="usd">19000000</rtrx:AcquisitionRelatedContingentConsideration>
	<rtrx:AcquisitionRelatedContingentConsiderationNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-FB148E2F87750D3FACC708014476F2FA" unitRef="usd">80900000</rtrx:AcquisitionRelatedContingentConsiderationNoncurrent>
	<rtrx:AcquisitionRelatedContingentConsiderationNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-95BAA25F9D5EAF0A20A70801446E7FB1" unitRef="usd">87000000</rtrx:AcquisitionRelatedContingentConsiderationNoncurrent>
	<rtrx:AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding contextRef="FI2018Q3_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsIncEquityHoldersMember" decimals="-5" id="Fact-B5D814D3BFF8E8E619410801449BF07D" unitRef="usd">15000000</rtrx:AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding>
	<rtrx:AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones contextRef="FI2018Q3_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsIncEquityHoldersMember" decimals="-5" id="Fact-041C7FC9C4F1B4FE70C60801448F6BE4" unitRef="usd">5000000</rtrx:AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones>
	<rtrx:AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones contextRef="I2018Q1Jan31_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsIncEquityHoldersMember" decimals="-6" id="Fact-5E8F3CD6B764EA9B3C6B080144985596" unitRef="usd">5000000</rtrx:AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones>
	<rtrx:BusinessCombinationOptionAgreementContingentConsideration contextRef="I2018Q1Jan31" decimals="-6" id="Fact-D7520F0ADE016C675FE9080144AA1408" unitRef="usd">25000000</rtrx:BusinessCombinationOptionAgreementContingentConsideration>
	<rtrx:BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold contextRef="D2018Q1" decimals="INF" id="Fact-DE6AA301C1067B8A42090801449A21FE" unitRef="number">1</rtrx:BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold>
	<rtrx:BusinessCombinationOptionAgreementPurchasePrice contextRef="D2018Q1" decimals="-6" id="Fact-EE98424A58BE2511A356080144AA76C2" unitRef="usd">65000000</rtrx:BusinessCombinationOptionAgreementPurchasePrice>
	<rtrx:BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity contextRef="D2018Q1" decimals="INF" id="Fact-57E63468883C0C7B865E080144AB6BB5" unitRef="number">0.8</rtrx:BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity>
	<rtrx:BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash contextRef="D2018Q1" decimals="INF" id="Fact-FF1519DBD36923E4194F0801449294CE" unitRef="number">0.2</rtrx:BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash>
	<rtrx:BusinessCombinationOptionAgreementSharePrice contextRef="I2018Q1Jan31" decimals="INF" id="Fact-943477AF5BBAE43C2C980801449A9360" unitRef="usdPerShare">21.40</rtrx:BusinessCombinationOptionAgreementSharePrice>
	<rtrx:BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment contextRef="D2018Q1" decimals="2" id="Fact-74ABB967AFE0165C3F1808014499EF69" unitRef="usdPerShare">19.26</rtrx:BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment>
	<rtrx:ChangeinFairValueofContingentConsideration contextRef="FD2017Q3QTD" decimals="-5" id="Fact-5C79E5D4D7B53432021CCAFD41AC193F" unitRef="usd">4400000</rtrx:ChangeinFairValueofContingentConsideration>
	<rtrx:ChangeinFairValueofContingentConsideration contextRef="FD2017Q3QTD" decimals="-3" id="Fact-9CB3CFB9838425F3A5B508014499CD41" unitRef="usd">4429000</rtrx:ChangeinFairValueofContingentConsideration>
	<rtrx:ChangeinFairValueofContingentConsideration contextRef="FD2017Q3YTD" decimals="-5" id="Fact-F2758ACEE5A10A0101640801449B8C67" unitRef="usd">11100000</rtrx:ChangeinFairValueofContingentConsideration>
	<rtrx:ChangeinFairValueofContingentConsideration contextRef="FD2017Q3YTD" decimals="-3" id="Fact-36CF25E443B679107A390801447DDE70" unitRef="usd">11057000</rtrx:ChangeinFairValueofContingentConsideration>
	<rtrx:ChangeinFairValueofContingentConsideration contextRef="FD2018Q3QTD" decimals="-5" id="Fact-D48E97F330BE3D22CB7D0801449CA922" unitRef="usd">16600000</rtrx:ChangeinFairValueofContingentConsideration>
	<rtrx:ChangeinFairValueofContingentConsideration contextRef="FD2018Q3QTD" decimals="-3" id="Fact-839ED742DA881CAEA424CD83E7A718DA" unitRef="usd">16601000</rtrx:ChangeinFairValueofContingentConsideration>
	<rtrx:ChangeinFairValueofContingentConsideration contextRef="FD2018Q3YTD" decimals="-5" id="Fact-4B1E7BAE44F7281EAE790801449020B3" unitRef="usd">22400000</rtrx:ChangeinFairValueofContingentConsideration>
	<rtrx:ChangeinFairValueofContingentConsideration contextRef="FD2018Q3YTD" decimals="-3" id="Fact-CDD31907DA3B3C248B02CD83E7925303" unitRef="usd">22387000</rtrx:ChangeinFairValueofContingentConsideration>
	<rtrx:ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants contextRef="FD2018Q3QTD" decimals="INF" id="Fact-592FFA153E9A9A8F6E2D080144B167ED" unitRef="shares">532830</rtrx:ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants>
	<rtrx:ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants contextRef="FD2018Q3YTD" decimals="INF" id="Fact-8D4D5C6CFF38544A161608014464EA5A" unitRef="shares">956887</rtrx:ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants>
	<rtrx:ContingentFutureLegalFeeAdvancePayment contextRef="D2018Q3Sept30_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember" decimals="-5" id="Fact-2C5E3B568ACD8A3B2FB1BBA60CC97825" unitRef="usd">5400000</rtrx:ContingentFutureLegalFeeAdvancePayment>
	<rtrx:DebtConversionEquity contextRef="FD2018Q3YTD" decimals="-5" id="Fact-F166B1F16909C06A617FB7C969F4B200" unitRef="usd">77400000</rtrx:DebtConversionEquity>
	<rtrx:DebtConversionLiability contextRef="FI2018Q3" decimals="-5" id="Fact-0727E6C88BE7F8DD41C2B7C8578997ED" unitRef="usd">198600000</rtrx:DebtConversionLiability>
	<rtrx:DebtInstrumentConvertibleNoteMarketPricePer1000 contextRef="FI2018Q3" decimals="0" id="Fact-CFA99E227197A33D07BDB7D153A68325" unitRef="usd">1027</rtrx:DebtInstrumentConvertibleNoteMarketPricePer1000>
	<rtrx:DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-6541030786E656101D39C6B4053AA431" unitRef="day">10</rtrx:DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-7BA66C0F20109226E323C6AAD0373805" unitRef="usd">0</rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-73503F0AC9D27274CE6CC6AAD02EC473" unitRef="usd">0</rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-AB35E9B64E4A3DEF0A6EC6AAD0339CE5" unitRef="usd">0</rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-47179D8D741F877AD80DC6AAD0287EB5" unitRef="usd">0</rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-C26BE4DC96F000D9154BC6AC23D6D2A9" unitRef="usd">4000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-CB896C97639F0D3943D6C6AAD03B463B" unitRef="usd">4000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-717614CB0960423B84E40801446F74B5" unitRef="usd">302000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-8F1247524E325285957A0801446A7372" unitRef="usd">14000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-D1C9D7BA29E56EF9D6D50801448BFE2B" unitRef="usd">198000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-8B98C13AC4020D9118F3080144833218" unitRef="usd">90000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-D2C2600126AC0C6B54610801446E874A" unitRef="usd">559000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-78088AA091C3F3148752080144889D2F" unitRef="usd">38000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-095811013AF0E9C88C3B0801446FDEC5" unitRef="usd">521000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-A0704DB718AD384EC0D40801447978FB" unitRef="usd">0</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossCurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-A3C14B913A145BF705BB080144834CFB" unitRef="usd">424000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-4B8DCAD5DED8A2E1CA7E0801446B683C" unitRef="usd">424000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-BA37450C90B02C4DDB410801447834FB" unitRef="usd">249000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent>
	<rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-41FD667004076994EE38080144778C44" unitRef="usd">249000</rtrx:DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-B78A8A6062B9D4F8A7E80801448C8B89" unitRef="usd">123574000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C3697BEA2E8B163330D30801446CD08F" unitRef="usd">6911000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-C18C1C5AE4C7E2BC90B90801446E80D1" unitRef="usd">86531000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-FFDF6B3412D99DD6F8AF08014484AE61" unitRef="usd">30132000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-6941791B8B1ABFD1C54D08014484CDA7" unitRef="usd">196623000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-B13629BCC031DD0B6B1108014467CBEB" unitRef="usd">54649000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-ACA82363441EEA9525A60801448771F1" unitRef="usd">138724000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-65D1D5AC3ACCE3677498080144680857" unitRef="usd">3250000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-4DAD4F39A8B82060258F0801446AF877" unitRef="usd">78388000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-D614715B802B3B5A592908014475BA92" unitRef="usd">78388000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-F291890A0B8412AF128E0801446B772C" unitRef="usd">128174000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent>
	<rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-5C48D6998579C160759B0801447ACFD7" unitRef="usd">128174000</rtrx:DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent>
	<rtrx:GovernmentRebatesPayable contextRef="FI2017Q4" decimals="-3" id="Fact-0F0F9B9C7E7E67C195A3080144A1FE9A" unitRef="usd">5883000</rtrx:GovernmentRebatesPayable>
	<rtrx:GovernmentRebatesPayable contextRef="FI2018Q3" decimals="-3" id="Fact-B95EC09A4014F6142DBD080144BDED39" unitRef="usd">10377000</rtrx:GovernmentRebatesPayable>
	<rtrx:InterestReceivablefromNotesReceivable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9C95E02B79684DE10D6D0801446CEA8D" unitRef="usd">651000</rtrx:InterestReceivablefromNotesReceivable>
	<rtrx:InterestReceivablefromNotesReceivable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E317FE787E0099C6AC360801448551C7" unitRef="usd">0</rtrx:InterestReceivablefromNotesReceivable>
	<rtrx:LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers contextRef="D2018Q3Sept30_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember" decimals="-5" id="Fact-D920B8430B51E47C2D2BBBA6C59CE79E" unitRef="usd">3800000</rtrx:LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers>
	<rtrx:LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers contextRef="D2018Q3_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember" decimals="-5" id="Fact-1AA1F42105D6CE5093E30801449C0748" unitRef="usd">3800000</rtrx:LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers>
	<rtrx:LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers contextRef="FD2017Q3YTD_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember" decimals="-5" id="Fact-1D76860F823F909574ADBBA26FBBC4E1" unitRef="usd">2600000</rtrx:LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers>
	<rtrx:LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers contextRef="FD2018Q3YTD_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember" decimals="-5" id="Fact-56067C489F715F6E0537BBA25FA5F393" unitRef="usd">600000</rtrx:LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers>
	<rtrx:NoncashInterestExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1A75EBDCD984E4E834DD0801446A173D" unitRef="usd">1353000</rtrx:NoncashInterestExpense>
	<rtrx:NoncashInterestExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E8F8FFBC52BB045382EE0801448CFE82" unitRef="usd">1115000</rtrx:NoncashInterestExpense>
	<rtrx:NumberOfProductsSold contextRef="FI2018Q3" decimals="INF" id="Fact-DA366C186E580B77B3FB080144A92D45" unitRef="product">3</rtrx:NumberOfProductsSold>
	<rtrx:NumberofTranches contextRef="FD2018Q3YTD_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-3CED6846DE936AA06EC4080144919F36" unitRef="tranche">5</rtrx:NumberofTranches>
	<rtrx:PaymentOfGuaranteedMinimumRoyalty contextRef="FD2017Q3YTD" decimals="-3" id="Fact-14B5DF8A6BA30E0A329B0801447B128C" unitRef="usd">1500000</rtrx:PaymentOfGuaranteedMinimumRoyalty>
	<rtrx:PaymentOfGuaranteedMinimumRoyalty contextRef="FD2018Q3YTD" decimals="-3" id="Fact-57EA98FF004B78E47B9208014497D99D" unitRef="usd">1500000</rtrx:PaymentOfGuaranteedMinimumRoyalty>
	<rtrx:PaymentsForTheOptionToAcquireBusiness contextRef="D2018Q1_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsInc.Member" decimals="-6" id="Fact-70F7ED25722ABDBFBF77080144A8F36F" unitRef="usd">10000000</rtrx:PaymentsForTheOptionToAcquireBusiness>
	<rtrx:PaymentsForTheOptionToAcquireBusiness contextRef="FD2018Q3YTD_srt_CounterpartyNameAxis_rtrx_CensaPharmaceuticalsInc.Member" decimals="-5" id="Fact-D83F2B147F697CC8B7040801449031CF" unitRef="usd">10000000</rtrx:PaymentsForTheOptionToAcquireBusiness>
	<rtrx:ProceedsfromMaturityofNoteReceivable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-6A66E0E98BEA9BB75E1A080144AAF264" unitRef="usd">47500000</rtrx:ProceedsfromMaturityofNoteReceivable>
	<rtrx:ProceedsfromMaturityofNoteReceivable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-50BC50B6207BBB7A4E500801446934AF" unitRef="usd">0</rtrx:ProceedsfromMaturityofNoteReceivable>
	<rtrx:ProvisionForInventory contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2D42F071CF3D9090588108014477BA5A" unitRef="usd">-252000</rtrx:ProvisionForInventory>
	<rtrx:ProvisionForInventory contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4C03C6B0C1078D6CF64208014479BAC0" unitRef="usd">-1625000</rtrx:ProvisionForInventory>
	<rtrx:TradingPricePerPrincipalPercentage contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-C82CAEF34FBA371D0ED3C6E22AA2A320" unitRef="number">0.98</rtrx:TradingPricePerPrincipalPercentage>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-7B495C7B1542A64A7BCB0801446479AE" unitRef="usd">18938000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-320BB2D036472B5E42E80801447782D6" unitRef="usd">9314000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-B44D3F2D2162D1FDDD8FCB0805A68BCE" unitRef="usd">13900000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C3DE7FE306D2F2FB4AAF0801446C3F2D" unitRef="usd">13872000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q3" decimals="-5" id="Fact-AEC9827D02B0EBF16C7CCFDA45F751A4" unitRef="usd">13500000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-A7408C612FDF44CB8F3608014478FE4D" unitRef="usd">13450000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2017Q3YTD" decimals="-3" id="Fact-97EBE7D60B30E9B3652E0801446B210A" unitRef="usd">-972000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-DEFF445572935F61BAF40801447B4AAC" unitRef="usd">-749000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-EE8CB83152C76DFED66E080144671380" unitRef="usd">36018000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-38577C4BC7ED5E8160120801446BDA08" unitRef="usd">43348000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-6AC00D2231AA525D15D108014469DFAE" unitRef="usd">2000000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-341F43F32D4EA7C477270801447BE4FC" unitRef="usd">2000000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedSalariesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3D3284DF847A868FFC2F080144AE58B5" unitRef="usd">7749000</us-gaap:AccruedSalariesCurrent>
	<us-gaap:AccruedSalariesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-127465BC4E2DE5853014080144A18FF1" unitRef="usd">9292000</us-gaap:AccruedSalariesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-BAF219A0A29B4618F46508014468B02C" unitRef="usd">-1015000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q3" decimals="-3" id="Fact-7B2E143BDDB2F6423BEB0801447A9455" unitRef="usd">-1083000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="-3" id="Fact-68BC0CE75301C1825F5C0801446794D9" unitRef="usd">471800000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q3" decimals="-3" id="Fact-3C4115D15CC192C588F10801447AA846" unitRef="usd">582706000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5DB5F146E77CF6385023080144AD86B6" unitRef="usd">6960000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-54370687E04F1F6D8684080144BDBF4D" unitRef="usd">1998000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-9F3C2161CA64A09DB43B080144B2AFFA" unitRef="usd">4962000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-20DF0112F5D3FAB5AB0B080144B46445" unitRef="usd">21292000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-6F5D566A1C9DCC269772080144B417CF" unitRef="usd">7113000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-5E11D6BF2B2315A40582080144BE3AFB" unitRef="usd">14179000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-CDB0635890250A4D4E52080144AECC91" unitRef="usd">4885000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-D0AAA4DBD0B35BE4C02C080144B60FDC" unitRef="usd">1603000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-D2A3A1299DF376B0D1D908014465ABAE" unitRef="usd">3282000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-1BD408CE616A46F2D159080144AFB733" unitRef="usd">14920000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-316293F1D07C9DB25EF0080144B164C8" unitRef="usd">4592000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-79A25EE7732B6A89357108014464AB3C" unitRef="usd">10328000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-41B005249AE2C7CA5DAEB701B86F05AA" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-3D32074306B5176A16D7B701B890A9B9" unitRef="usd">50000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-903ED2381697E43EE1CBB701305B703F" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-5C3018E1D7F25661D3EDB701305149CC" unitRef="usd">468000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-B8F0962F05D25F0E40580D7369C789ED" unitRef="usd">460000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5F108E4DC1168C27AB080D7369E11D18" unitRef="usd">980000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3QTD" decimals="-3" id="Fact-20CE67BE1061A63D51240801448CBD21" unitRef="usd">4506000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-7E4EE5520F76B0EEC21A0801449F3F6F" unitRef="usd">82000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-5E5145DE22E3C4DD85A90801449B6A9F" unitRef="usd">4424000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5CA5CDBCB28A21FD3A4A0801449DDCA3" unitRef="usd">12996000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-F86FE70D83AB8BB5AA2E080144A4CA61" unitRef="usd">244000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-64F82F9E72D56C0C92CA0801449D1C8F" unitRef="usd">12752000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3QTD" decimals="-3" id="Fact-50F85EC8E564C40F29F8080144A04542" unitRef="usd">4625000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-C2F20358A0BEAE95D68E0801448B80FE" unitRef="usd">292000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-A5AFDCAAFA5551CB8D510801448E34E7" unitRef="usd">4333000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-886BF6C00DCC6BC8AF1F0801449FB0EA" unitRef="usd">13319000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-E3A08A23718DDBC047BA0801449F0708" unitRef="usd">684000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-70AD5E8C1D6A45FE67FF08014498DD8A" unitRef="usd">12635000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3QTD" decimals="-3" id="Fact-CE50D38F145B695B16D9080144BD31F1" unitRef="shares">11461000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-1E3BCDE27C9F0497E565080144A5DBE0" unitRef="shares">2642000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-5C8D7D7873458B32D73D080144A51952" unitRef="shares">7515000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-432B13884B754A80C111080144A83556" unitRef="shares">145000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-4F49A300A06898937996080144A4F999" unitRef="shares">1159000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9EC651F8F2CD1D4BD387080144AD03BF" unitRef="shares">10936000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-0B2CA13C601A7F9641B0080144ACA06B" unitRef="shares">2642000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-F61989F63D47E3EC6AEB080144A75DAB" unitRef="shares">6960000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-1A9B1453655A9643899A080144A2A9D0" unitRef="shares">175000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-C707130A8DC25555C672080144AFF0B3" unitRef="shares">1159000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3QTD" decimals="-3" id="Fact-46BC771C7BECAE3E368E080144AE3F2A" unitRef="shares">16318000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-F9DAAAE3A82AA4FBD720080144A325A7" unitRef="shares">8411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-C0EF8F89CCC0428CE080080144B5E00E" unitRef="shares">7390000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-790D11B19819D0A5ACE90801449F8B1F" unitRef="shares">477000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-F35A5BD5625435693A57080144A57A19" unitRef="shares">40000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD" decimals="-3" id="Fact-22E86D7CAE236548B6C8080144B156AE" unitRef="shares">16325000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-6A89F414FB5EEA7404ED080144A995EA" unitRef="shares">8411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-C68D3ED4DE59D25D094F080144AC33F6" unitRef="shares">7202000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="-3" id="Fact-F7099194E45421945DC2080144AE4738" unitRef="shares">335000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-3" id="Fact-D6072172ED2E5EEB1EEB080144A09A24" unitRef="shares">377000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-503BC3CF1D874D472D070801447E46EE" unitRef="usd">520346000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q3" decimals="-3" id="Fact-4016A57911AB0E86D9880801446CB5CD" unitRef="usd">716186000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-7A97BDB6BACD540AC1C908014468D5C7" unitRef="usd">325807000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-06F2C165A480DBFEFD900801446A6A3D" unitRef="usd">502989000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-68D892B8A99B8FA5CD75080144642AE1" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5328599C9F92300519C1080144AC29FD" unitRef="usd">201236000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DAE3A26E4DA08FED9FFD0801446D0BBA" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CA150F8165BE4A3244640801447C4EAF" unitRef="usd">201236000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9D44B15DCF0BABCC35330801447C6428" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F562C6A0A73584947606080144872909" unitRef="usd">323993000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4F3196A9A79A4C94E5CF0801447A2DC4" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5E9B82E50FFCCB5090A9080144886E4A" unitRef="usd">323993000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q3" decimals="-3" id="Fact-61F3B3D70BF37B2EF651C6AC23DBEC47" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-103DF0A5D27A7FAE3592080144876944" unitRef="usd">726000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q3" decimals="-3" id="Fact-C914EAC51E4A7DFFCCEA0801448509BF" unitRef="usd">808000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-3" id="Fact-EC113DCA813E8406292D080144827F12" unitRef="usd">201962000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q3" decimals="-3" id="Fact-883D9E1918A776B7629C0801448B87A0" unitRef="usd">324797000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4" decimals="-3" id="Fact-435DB5416E8EF45BA9BC08014478E963" unitRef="usd">201236000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C30EE5F2888F861CD2DC0801447C2E8B" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9636C885566E7B1553F308014478967F" unitRef="usd">201236000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-18140DDC03DDC47532AB0801447A4B9A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-284DCB4D25F815F335E1080144694A2B" unitRef="usd">201236000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q3" decimals="-3" id="Fact-83ABCFFFC2D60F0FC3DE080144755DB6" unitRef="usd">323993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q3" decimals="-5" id="Fact-DB10D270B940D0D22135CC55690BCFEF" unitRef="usd">324000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B80683D529AEE057576F080144865E0E" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CB80EA0859FCA65D05EC08014489D2D1" unitRef="usd">323993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5083078E3404BF6E76DC08014488228B" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DCE7B147A1BA413DE2CB08014482342F" unitRef="usd">323993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-950E7FE9CBCA9FBA76DF080144779C7A" unitRef="usd">123272000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-229DD04D0EF7178BD80108014476C49E" unitRef="usd">6897000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-0C9FB66E01B8B92440760801446A7802" unitRef="usd">86333000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-B76219FDFEA010512BC508014488B20D" unitRef="usd">30042000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-334DEEB8C8FEB4F0512E08014477CFFD" unitRef="usd">196064000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-E538075440A9088291770801448ECF22" unitRef="usd">54611000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-F7BF406AF5956ED50E310801448458AE" unitRef="usd">138203000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-3ADF87F377E548B0ACDF0801446CFB63" unitRef="usd">3250000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-7FA0E56305F37F8F4D3A08014478B9BF" unitRef="usd">77964000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-C647A813C599222BCD8D0801448D4E1C" unitRef="usd">77964000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-E798A3B071069D60BB000801448B2BA0" unitRef="usd">127929000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-B90386BE97B1EBD5BBD90801446EB720" unitRef="usd">127929000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2017Q3YTD" decimals="-3" id="Fact-DAE2E22460574717F00E08014484EB28" unitRef="usd">-885000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_AcquiredProductRightsCholbamMember" decimals="-5" id="Fact-78E99186DF4F288E01990801448FB41E" unitRef="usd">3800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_AcquiredProductRightsLUDCAMember" decimals="-5" id="Fact-7BD551ED8FC8D3D36B69080144985F83" unitRef="usd">2300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_ProductRightsChenodalMember" decimals="-5" id="Fact-88B2ED2D5777B3EC82AF0801448F156C" unitRef="usd">5000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q3YTD" decimals="-3" id="Fact-756C6835ED84F4B2D6BC0801448951C1" unitRef="usd">-6852000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_AcquiredProductRightsCholbamMember" decimals="-5" id="Fact-EF20D0C2B4A2ED97E3B6080144A0D35C" unitRef="usd">10400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_AcquiredProductRightsLUDCAMember" decimals="-5" id="Fact-C121E42A9CC7A50B061A080144A9E3D3" unitRef="usd">2000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q3YTD_us-gaap_BusinessAcquisitionAxis_rtrx_ProductRightsChenodalMember" decimals="-5" id="Fact-877EF7B9CB51F96C4C15080144A61199" unitRef="usd">10000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q3YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-35DB38176969BCA15C14080144652F0A" unitRef="usd">22387000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9D5D92DD5D5FA2387FE80801449A6356" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-ADE1513F822F460801C50801447D0082" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E9F5997F8DECD714F1030801446BB0F4" unitRef="usd">90000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-33219F2FF95E97004A390801449E4ADE" unitRef="usd">90000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D570804298C08568823F08014489A504" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-660EBF0211EF923B7E9608014485598B" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C437AA00443A9D4E740908014486B0FC" unitRef="usd">106000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-596637922B6E17E48089080144842123" unitRef="usd">106000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-FFE7A98AFD5590B325020801448AB4F1" unitRef="usd">41002000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q3" decimals="-3" id="Fact-1C6E4C2B1929860108A0080144AB0E7D" unitRef="usd">98991000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-61A1FBCF38E129CCEB6B0801447AAA70" unitRef="usd">99394000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q3" decimals="-3" id="Fact-C571A431E79F920922CE0801446D1997" unitRef="usd">154820000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1D350FE5EBE9309AD4780801446CDF7B" unitRef="usd">57989000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2018Q3YTD" decimals="-3" id="Fact-659C940ABD92B5880F960801449103D8" unitRef="usd">55426000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-1592A34F8DE221CF5D5E080144B4B639" unitRef="shares">1159424</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q3" decimals="INF" id="Fact-493020530FD39273548E080144AEAD5B" unitRef="shares">79167</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-FBA2C2F84C1702CBBE2A0801448C4AB6" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q3" decimals="INF" id="Fact-DB131029FC289378D5E508014491CD5B" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-2A2D73654993A9B6276E0801449CA4F0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q3" decimals="INF" id="Fact-27DD6726A1C0D479A073080144A2D8BC" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-CA74597C4D0EAAA1039C0801449E02FD" unitRef="shares">39373745</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q3" decimals="INF" id="Fact-0775D089E59D90169FC20801449D9D2F" unitRef="shares">41167942</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-DE064902700B7CD599E20801448D018F" unitRef="shares">39373745</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q3" decimals="INF" id="Fact-EDEA68E8DE082BBFD9A8080144A1B202" unitRef="shares">41167942</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-88C3A9DD2AF1D01867250801446646E1" unitRef="usd">4000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q3" decimals="-3" id="Fact-3C0D20992D81BB55AB210801447DA722" unitRef="usd">4000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q3QTD" decimals="-3" id="Fact-F93FBDF11D5AF247973F0801446AC9A3" unitRef="usd">-17813000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q3YTD" decimals="-3" id="Fact-85938FE6B488018B712C0801447F980A" unitRef="usd">-42218000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-1F5807CACC04AC3905F00801448CC2E5" unitRef="usd">-54447000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F7EF4BA648B4F067D02B080144AD1123" unitRef="usd">-95291000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q3YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" decimals="2" id="Fact-2CED106E5E723F602ADA0801446E36E7" unitRef="number">0.95</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-914AF2DAC96E078840FC08014469885F" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-9060A666D3E07B332EEB0801447DBB41" unitRef="usd">22377000</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-5" id="Fact-CC70FED72D9FD0B2827B080144A19573" unitRef="usd">38800000</us-gaap:ConvertibleDebtFairValueDisclosures>
	<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-5" id="Fact-ECB11EFD9D6F0EFC4015C6781BC3E4B9" unitRef="usd">283400000</us-gaap:ConvertibleDebtFairValueDisclosures>
	<us-gaap:ConvertibleDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-FE733B48879865F1A68C0801446EE525" unitRef="usd">45077000</us-gaap:ConvertibleDebtNoncurrent>
	<us-gaap:ConvertibleDebtNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-801AB5F961C2C2F41D97080144662BD0" unitRef="usd">192753000</us-gaap:ConvertibleDebtNoncurrent>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q3QTD" decimals="-3" id="Fact-FC5EA141A4CA62881D12080144824889" unitRef="usd">925000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A78CA5094FE10F337A4E080144680FA7" unitRef="usd">2431000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q3QTD" decimals="-3" id="Fact-C050E438AEA3803130660801446FA3FB" unitRef="usd">1133000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D9657FCE8D41EECAB1B5080144759563" unitRef="usd">3924000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-A15570B99CC46BDECC0FB68C13FA037D" unitRef="usd">46000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-F3584266CEE34B6F837CB67A20F6C3AA" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-92617E3575240E3BF1F9B68C0B140B05" unitRef="usd">22590000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-7E7DC4A45724EDC414EBB676CA36DD30" unitRef="usd">276000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="2" id="Fact-7058CC11F5BCA7A3F9C2B73555A3DA79" unitRef="usdPerShare">38.80</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2014Q2May29_rtrx_AgreementAxis_rtrx_NotePurchaseAgreementMember_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-2A1ECC0DC715A8E1096D080144A3783F" unitRef="usdPerShare">17.41</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="4" id="Fact-65A6EA3DCB31815A21E5C728FDA3F325" unitRef="number">0.0258</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-E80DFD706E8865013364C6B34C36B543" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
	<us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="FD2018Q3YTD" decimals="INF" id="Fact-014799DE3F5687A7F306C68A113313F5" unitRef="number">1.3</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
	<us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-E345F744B98AAAEE06C8BBD98C792C19" unitRef="number">1.3</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
	<us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-36E730563C99C6BF1A2DC6B3A461AA04" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2014Q2May29_rtrx_AgreementAxis_rtrx_NotePurchaseAgreementMember_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-C9D3D7C7E4A6DD62FA01080144A027B2" unitRef="usd">46000000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2018Q3" decimals="INF" id="Fact-9D5F245AC9074FA8E099B72DFA91061F" unitRef="number">0.077</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-16414908CAACDB2B56ADC668619E10E9" unitRef="number">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-2DD0FD6E3710692E030CC65438D2AA06" unitRef="number">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2014Q2May29_rtrx_AgreementAxis_rtrx_NotePurchaseAgreementMember_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-6171242AAD86F18B5CFF080144A15243" unitRef="number">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2018Q3September102018_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-A1A0946F10BB25194752B671C3137CB1" unitRef="number">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentRepurchaseAmount contextRef="FI2018Q3" decimals="-5" id="Fact-4E2057F0969899A63674B6FE34E51415" unitRef="usd">23400000</us-gaap:DebtInstrumentRepurchaseAmount>
	<us-gaap:DebtInstrumentRepurchaseAmount contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-5" id="Fact-2F95722C3B8112FAFF22B7CD920D723F" unitRef="usd">40200000</us-gaap:DebtInstrumentRepurchaseAmount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-16297760630C4F35F387B68C1FA8AE20" unitRef="usd">867000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-6D821EAFFBCE8FF6FE38B67A25B8004B" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-6CDE8316B220BAB889FEB68C1C6E7EB6" unitRef="usd">200000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-969C5E5FD118D75FC00AB677A6B0749B" unitRef="usd">76951000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-E2B1F6AA0E5570F41912B68C251F8380" unitRef="usd">56000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-B6A83A95A222FAA95FDCB67A27C932CC" unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2018Q3" decimals="-5" id="Fact-16E1F0F0EFE23D1997CBB72FDA398F82" unitRef="usd">8800000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-5CE7DE2DCD0E120EDD18B68C22563F7A" unitRef="usd">13000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-55E522043023480834F4B67979ECC758" unitRef="usd">6296000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0BE0B06F643C5507152F0801448D8FE3" unitRef="usd">-7811000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-89BEED0E730F73D006CF0801448DA13E" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D38096EC670F7821908D080144AA1E1F" unitRef="usd">13336000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q3YTD" decimals="-3" id="Fact-2860CE041F6885286B8508014481E319" unitRef="usd">13789000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AB5874E2966B4A27655F08014481BCBC" unitRef="usd">15710000</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B5DF8FF40B65E8710097080144689903" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C5F715F954278B915A5E08014464FF9F" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5BBC831ADDC0BF25FED9080144651D17" unitRef="usd">15710000</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3A6AE1DB4430955E5AAB0801446B85D5" unitRef="usd">15710000</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-AB11129548490FCA45CF0801447C571D" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
	<us-gaap:DerivativeLiabilityMeasurementInput contextRef="FI2017Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" decimals="1" id="Fact-A48F8ECA956A7D479F140801446D8613" unitRef="Year">2.0</us-gaap:DerivativeLiabilityMeasurementInput>
	<us-gaap:DerivativeLiabilityMeasurementInput contextRef="FI2017Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" decimals="2" id="Fact-AC6B85FC5664B612911F0801449BF967" unitRef="number">0.43</us-gaap:DerivativeLiabilityMeasurementInput>
	<us-gaap:DerivativeLiabilityMeasurementInput contextRef="FI2017Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="4" id="Fact-75027EF2E8D7FF4435C30801449A7D96" unitRef="number">0.0189</us-gaap:DerivativeLiabilityMeasurementInput>
	<us-gaap:DerivativeLiabilityMeasurementInput contextRef="FI2017Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" decimals="1" id="Fact-A1266E2606C189AA23080801449975E5" unitRef="Year">0.1</us-gaap:DerivativeLiabilityMeasurementInput>
	<us-gaap:DerivativeLiabilityMeasurementInput contextRef="FI2017Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" decimals="2" id="Fact-A58FD9009DE0C8C879E6080144972E1C" unitRef="number">0.33</us-gaap:DerivativeLiabilityMeasurementInput>
	<us-gaap:DerivativeLiabilityMeasurementInput contextRef="FI2017Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="4" id="Fact-798ECCA5BF7CB60C05A6080144984379" unitRef="number">0.0139</us-gaap:DerivativeLiabilityMeasurementInput>
	<us-gaap:DerivativeLiabilityMeasurementInput contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember" decimals="INF" id="Fact-C8E0807CD8C3CC0E98A80C27CDA65D58" unitRef="number">0</us-gaap:DerivativeLiabilityMeasurementInput>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-D07F01FDBA659A5C875F080144693D3A" unitRef="usdPerShare">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3YTD" decimals="2" id="Fact-ADF8FE87EF8E1C19AEA80801448497C7" unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3QTD" decimals="2" id="Fact-3E476EEE8CD9F206212108014481EEAC" unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3YTD" decimals="2" id="Fact-9B4F87DCFAA983615C390801448631C5" unitRef="usdPerShare">-2.37</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q3YTD" decimals="-3" id="Fact-16F0C136D181C1E902870801447AAF60" unitRef="usd">-57000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2018Q3YTD" decimals="-3" id="Fact-886E7DCE54B39101A3DB08014481AD10" unitRef="usd">-30000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q3QTD" decimals="3" id="Fact-56EB0BB961439F765571080144B2C48A" unitRef="number">0.064</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q3YTD" decimals="3" id="Fact-772A381262817BC90784080144B2843C" unitRef="number">0.110</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q3QTD" decimals="3" id="Fact-ADC5CECBB92A5E80A226BBB8BC79F4F1" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q3YTD" decimals="3" id="Fact-8E931DFA60400A3DA18308014469491E" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-9B3FA63B3CE12F5AC106080144AF006E" unitRef="usd">32500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-EF4E03824D706D7F0A91080144A21459" unitRef="usd">10600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-38C4BD82D74420F68D20080144B1A5B1">P2Y9M18D
</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-630B113DAABF57E0274D08014464A161">P2Y2M12D
</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EquityMethodInvestments contextRef="FI2017Q4" decimals="-3" id="Fact-F3D433C4337F36E4E2DE0801447B0016" unitRef="usd">0</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2018Q3" decimals="-5" id="Fact-CC579AFB78C2B63D8CC808014490B73D" unitRef="usd">15000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2018Q3" decimals="-3" id="Fact-C6E2D7E9346DF644CE0708014466F5EF" unitRef="usd">15000000</us-gaap:EquityMethodInvestments>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q3QTD" decimals="-5" id="Fact-6593427E64C30D7DBA340801449C3174" unitRef="usd">8900000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q3QTD" decimals="-3" id="Fact-8023F35AD1B42D2B49F7080144A62050" unitRef="usd">8901000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q3YTD" decimals="-5" id="Fact-59EC503EBCC37821989FBBC2D5E80C88" unitRef="usd">8900000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A9D9AC65E4A1145A9ACE0801447E672B" unitRef="usd">8921000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2018Q3QTD" decimals="-3" id="Fact-56C02E4459717C1C653308014468282E" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4C4D133E5B0FDB4712AA08014483260C" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2018Q3YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-322124357AA53408928B08014465B086" unitRef="usd">2092000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2018Q3YTD_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-043D193B0769B9E1C014080144ADEBAE" unitRef="usd">4295000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7D49E71CBEF67EC517490801446BFB7F" unitRef="usd">90000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C49227FC1DE5945B3D89080144669607" unitRef="usd">106000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4" decimals="-3" id="Fact-7269B706488BBFCF15020801448EC277" unitRef="usd">51046000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q3" decimals="-3" id="Fact-59ACC0F532A05A9482020801449A02DC" unitRef="usd">64279000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-FD6E02D469BF754DA0D3080144A26D35" unitRef="usd">235863000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q3" decimals="-3" id="Fact-760D003187A32810B9620801448E63F1" unitRef="usd">250824000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-7025C1839F9D619A86CE0801447DAA86" unitRef="usd">184817000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q3" decimals="-5" id="Fact-DFF1E6E7A42B03111BCECC58B44AB67E" unitRef="usd">186500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q3" decimals="-3" id="Fact-5A046DAAFE758709086CCD0DC28EAA32" unitRef="usd">186545000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q3YTD" decimals="-3" id="Fact-E6115A182B0EE1B9B40C08014484E20A" unitRef="usd">1074000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D914A304C53F9A5015F20801446D0BD5" unitRef="usd">-270000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="FD2017Q3QTD" decimals="-3" id="Fact-6BA91ACDB7DF3B0A0D26080144755EA7" unitRef="usd">-102000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
	<us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F1A22EB11DD3F50C74010801448375A3" unitRef="usd">-361000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
	<us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="FD2018Q3QTD" decimals="-3" id="Fact-CF0E932B03C4CCE752DB0801447F08B2" unitRef="usd">5000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
	<us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="FD2018Q3YTD" decimals="-3" id="Fact-ABF3C225515FD87BC5640801448B9D04" unitRef="usd">29000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q3QTD" decimals="-3" id="Fact-EDA752902E795F13C8A8B647B494CE6E" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2FAA6A02F1759939C7D9B647B4849FAB" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2018Q3QTD" decimals="-3" id="Fact-7CC5873176838DBD1CA1B647B4E856BC" unitRef="usd">-17042000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F0B5CC5D8BD94C43B3D9B647B4B080AC" unitRef="usd">-17042000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-5" id="Fact-6D7DCFED8008BA6EBBECB6F9A24EF8E2" unitRef="usd">-17000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-3" id="Fact-26CA11A9526CC55D6FF90801446A5EA6" unitRef="usd">936000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q3" decimals="-3" id="Fact-419CE2896C209E84E7EF0801446A7418" unitRef="usd">936000</us-gaap:Goodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q3QTD" decimals="-3" id="Fact-103F6BE7064BAF716DA108014478517C" unitRef="usd">-19017000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q3YTD" decimals="-3" id="Fact-EFE0520F1DBEF3E9B1CA080144A40F02" unitRef="usd">-47325000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3QTD" decimals="-3" id="Fact-EFE1098977CFD7C191A608014482CCC0" unitRef="usd">-54101000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3YTD" decimals="-3" id="Fact-733F15F000883E1F1B670801448352C0" unitRef="usd">-94412000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD" decimals="-3" id="Fact-6F615E581F652D4E0718080144A94172" unitRef="usd">-1223000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD" decimals="-5" id="Fact-7DCDE84EB784F0B2E344CD849920C29E" unitRef="usd">-1200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="-3" id="Fact-661556E213A533AA6E29080144BE1E08" unitRef="usd">-5212000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="-5" id="Fact-B16B1D356372483F741FCD849CEEFCBB" unitRef="usd">-5200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3QTD" decimals="-5" id="Fact-DB30E48AC4B9423ED43FCBD948D120F8" unitRef="usd">400000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3QTD" decimals="-3" id="Fact-2BB234A6B7A5E6FC5830080144A6FE6B" unitRef="usd">415000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-5" id="Fact-5B65DAEF1DF0B7C55859080144ABA706" unitRef="usd">800000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0897A0765F5F3A279E32080144A45506" unitRef="usd">811000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-8F500C091C632058A41B0801449D9CD6" unitRef="usd">425000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-00AB5A9E363E60A5DF290801448A299D" unitRef="usd">6797000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-E3B2B88D8CD35F4376D208014479F850" unitRef="usd">-4064000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-912525638070FAE0FF5308014483E643" unitRef="usd">-1346000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q3YTD" decimals="-3" id="Fact-3682B4053BD689883B6F0801448505DB" unitRef="usd">319000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q3YTD" decimals="-3" id="Fact-A7FEED0839FD4F9FD2780801448E4B67" unitRef="usd">1428000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q3YTD" decimals="-3" id="Fact-FBB74A7D268DA1C5753F0801448A9503" unitRef="usd">3747000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0E059B52945316912925080144996B51" unitRef="usd">2183000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5797E8B0B04ADE1210B30801447D0B76" unitRef="usd">2561000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5AED9122C770EFE2F7A408014488FFBF" unitRef="usd">3094000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:InterestExpenseDebt contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member" decimals="-3" id="Fact-9369274DBD56404F86E7B702728C049B" unitRef="usd">0</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2017Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-FC241A39AB36908A2234B700DDDDCBE6" unitRef="usd">0</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member" decimals="-3" id="Fact-C549211F5EA60493ED4CB70272877090" unitRef="usd">901000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-44A695EC4AE8C99967B9B700DE04B432" unitRef="usd">383000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-558106256D70BB0EC6FFC245E42BEC3B" unitRef="usd">595000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7737121976B3891B3933C245E4513EBD" unitRef="usd">2460000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q3QTD" decimals="-3" id="Fact-6B10DDC9C1D9C2E4596FC245E4403C4C" unitRef="usd">1147000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q3YTD" decimals="-3" id="Fact-14D2A5198837139737F2C245E468368E" unitRef="usd">2905000</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-B57D1066D81109AE4CD108014482AF2B" unitRef="usd">-660000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-87EEADD9EA61CEDA9D9B08014484B02B" unitRef="usd">-3315000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9C1B20478D5B050E809E08014481CAE4" unitRef="usd">-2533000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2018Q3YTD" decimals="-3" id="Fact-10492B1E27E8A9E69E31080144829450" unitRef="usd">-4848000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2017Q4" decimals="-3" id="Fact-C8857CCBF3B1147E9857080144B1B9A5" unitRef="usd">1916000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2018Q3" decimals="-3" id="Fact-2D6BF23C596778919327080144B0D6F9" unitRef="usd">1857000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="-3" id="Fact-03F210A91A03B6AC24AE08014476F956" unitRef="usd">5351000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2018Q3" decimals="-3" id="Fact-19B56E6E14874BEBBED008014479D802" unitRef="usd">5129000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2017Q4" decimals="-3" id="Fact-2F376CBD87C5E0369AC7080144BBA92E" unitRef="usd">3435000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2018Q3" decimals="-3" id="Fact-EB077214E4431C9EA9C4080144B0A742" unitRef="usd">3272000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryValuationReserves contextRef="FI2017Q4" decimals="-5" id="Fact-E5E4A520C910C2DC69E4080144B54745" unitRef="usd">700000</us-gaap:InventoryValuationReserves>
	<us-gaap:InventoryValuationReserves contextRef="FI2018Q3" decimals="-5" id="Fact-E1B72D47944432E791CC080144B0E7F7" unitRef="usd">1300000</us-gaap:InventoryValuationReserves>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2018Q3YTD_rtrx_AgreementAxis_rtrx_LeaseAgreementMember_srt_StatementGeographicalAxis_rtrx_SanDiegoCACorporateMember" decimals="-5" id="Fact-7B944D2871033554A513080144A1419C" unitRef="usd">2100000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2018Q3YTD_rtrx_AgreementAxis_rtrx_LeaseAgreementMember_srt_StatementGeographicalAxis_stpr_NY" decimals="-5" id="Fact-5903E4C389F97E12C6070801449C49E4" unitRef="usd">500000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LegalFees contextRef="FD2017Q3QTD" decimals="INF" id="Fact-F41066DB6AE0691F8A61BBA767CB730B" unitRef="usd">0</us-gaap:LegalFees>
	<us-gaap:LegalFees contextRef="FD2017Q3YTD" decimals="-5" id="Fact-F8F647D07591D233E51E080144AEE418" unitRef="usd">2000000</us-gaap:LegalFees>
	<us-gaap:LegalFees contextRef="FD2018Q3QTD" decimals="INF" id="Fact-C351390402A0BA607938BC7ACBE6B46D" unitRef="usd">0</us-gaap:LegalFees>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-18E29377BB0641138A990801447A0A88" unitRef="usd">227212000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q3" decimals="-3" id="Fact-42D74A5F288A8C503A4E0801446CFF4E" unitRef="usd">397121000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-DB0C375B69FD3591558D0801447D1F5F" unitRef="usd">520346000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q3" decimals="-3" id="Fact-2D9A78995485A115B4190801446959EF" unitRef="usd">716186000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-0F9509EF19266AE129770801446FD6A4" unitRef="usd">85668000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-28C273863F88EDC69C8D080144675EA5" unitRef="usd">99872000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A744F6EF6293D142F67C0801447E2719" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-AAACB6658DB4E5FC576D080144807465" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-38DD1A814DA817F04A32080144B21E30" unitRef="usd">105710000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-84124596EA2E87898F490801446620AD" unitRef="usd">105710000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8F4222E90E94540B41B70801447E7D43" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-49957C5F9C4A47FB2D5F08014477A058" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1190BBCB3561E2EAF4D7080144798878" unitRef="usd">106000000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-131EC33F3DF4697B22AF0801448750D6" unitRef="usd">106000000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LitigationSettlementExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-462CB9C78541B5970BE90801449817FF" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1C7F111F5B32C79EE8ABB6494DC0E5D4" unitRef="usd">2000000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-E45A2BAB7D5221878FA608014482D6DE" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-813AF7BE07E77E581C48B6494C88AB75" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LongTermDebt contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-1945C17297612351D732B68C2F206BE3" unitRef="usd">45077000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-C44AA7E1365534773094B67EB074502C" unitRef="usd">0</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_ConvertibleNotesDue2019Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-70E9CC348748023F7B97B68C2741AD37" unitRef="usd">22377000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-3A552DD321C5207C4E80B67EB05F9134" unitRef="usd">192753000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2018Q3" decimals="-5" id="Fact-2DF27B195B001386C135B6DD0CA025AC" unitRef="usd">22600000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-5" id="Fact-2E799793FC8E4AD6DD8BB66F11E3F7E8" unitRef="usd">276000000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="I2018Q3September102018_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-6" id="Fact-D352B922AD2DF39D3426B6676BC6CC6F" unitRef="usd">276000000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2018Q3_srt_LitigationCaseAxis_rtrx_RetrophinInc.v.ShkreliMember" decimals="-5" id="Fact-984DE1B08A4501C495CE080144986177" unitRef="usd">3200000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:MarketableSecurities contextRef="FI2017Q4" decimals="-3" id="Fact-AF420B70CFFAD679449D0801448EF4CA" unitRef="usd">201236000</us-gaap:MarketableSecurities>
	<us-gaap:MarketableSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C57B54C6ECCAEB54B9C00801449180CB" unitRef="usd">6897000</us-gaap:MarketableSecurities>
	<us-gaap:MarketableSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-D111DFE53DA0B5D6DDF7080144982901" unitRef="usd">164297000</us-gaap:MarketableSecurities>
	<us-gaap:MarketableSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-54E853EE22659CB7889408014498B9D9" unitRef="usd">30042000</us-gaap:MarketableSecurities>
	<us-gaap:MarketableSecurities contextRef="FI2018Q3" decimals="-3" id="Fact-03C1665B3B6862BDD6CC08014491406F" unitRef="usd">323993000</us-gaap:MarketableSecurities>
	<us-gaap:MarketableSecurities contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-148A99F016B02481B53A080144992829" unitRef="usd">54611000</us-gaap:MarketableSecurities>
	<us-gaap:MarketableSecurities contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-CBE822A19188ACA6CBD3080144910273" unitRef="usd">266132000</us-gaap:MarketableSecurities>
	<us-gaap:MarketableSecurities contextRef="FI2018Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-DC391E0E8D6C452564B60801449F753A" unitRef="usd">3250000</us-gaap:MarketableSecurities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-4AEF242C2EADC439656A08014486F086" unitRef="usd">4084000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-404610B91146392FBB9108014479F65B" unitRef="usd">231338000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7C87EFC3DA03859605E00801449B594B" unitRef="usd">45705000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-AECA914976FF852A1689080144760E13" unitRef="usd">-154489000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9A6F3548DEB7DFC9FFC7080144869994" unitRef="usd">8257000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-55AC5B617EA3475439260801447B23D0" unitRef="usd">-21393000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-B0B4AC7C4DA0182C2641080144870D68" unitRef="usd">-17794000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-BB0F0D7FB2415FB9F39A080144656AA2" unitRef="usd">-42113000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-47323E54DD5DCD28D47008014476005A" unitRef="usd">-54516000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D073D3158F8B458BED8408014486AC3B" unitRef="usd">-95223000</us-gaap:NetIncomeLoss>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-E69174617BE53BA5F5190801448AA769" unitRef="usd">-8409000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-ACB8A46A66F8DCAD3A0E080144B3C4D6" unitRef="usd">-8711000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-08224C6B79D3F37D6ADE08014489A4A7" unitRef="usd">-18518000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-1ECF76B28C99EB6CF00908014487E804" unitRef="usd">-19357000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3QTD" decimals="-3" id="Fact-E0490645BEBD070337F30801448A83BC" unitRef="usd">50948000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3YTD" decimals="-3" id="Fact-2F3C8F8F4EFAF230D6300801448AA3FC" unitRef="usd">151374000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3QTD" decimals="-3" id="Fact-5027D4D53E1741C9F8FC080144AFB507" unitRef="usd">76289000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0FC69549374B4B3ABB6B08014464F46F" unitRef="usd">195530000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-919E971013BD5BE2585F08014487C436" unitRef="usd">-10608000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-50A8CA538DABFA748D240801448462E1" unitRef="usd">-38614000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-31A94C35405AF022F55A080144809EAD" unitRef="usd">-35583000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-54C79FC971A8BAE6A2140801447BB422" unitRef="usd">-75055000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-6514FBDD5EC27750B8AE08014477A81D" unitRef="usd">5556000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-E44933AC0236A8D14FE5080144649992" unitRef="usd">7393000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2017Q3QTD" decimals="-3" id="Fact-EC2D486D0480D7A80C350801448113E7" unitRef="usd">83000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2017Q3YTD" decimals="-3" id="Fact-28CD758B7BBB9E4303630801448B8920" unitRef="usd">256000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2018Q3QTD" decimals="-3" id="Fact-E3CFFEC57F12DF7A36C20801448EA4B0" unitRef="usd">64000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2018Q3YTD" decimals="-3" id="Fact-87DE2538158BE3A4BD5808014487F948" unitRef="usd">-97000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-73614526CF12DE7689B70801446D5A55" unitRef="usd">3902000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-D4C97BF0EC77528527C8080144667791" unitRef="usd">3833000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-1402B202EA0344B5B05B0801446E5E96" unitRef="usd">2472000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-DA78B8FE91F95B84CC0A08014480259E" unitRef="usd">4885000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5D8BD9A8C8545F706283080144821760" unitRef="usd">-164000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8D36219862BCA1E7D3D508014490046C" unitRef="usd">15000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-FB3E77ECDF6BA120E769080144758BC0" unitRef="usd">557000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-7C935A5D81E3766BE1AB08014481A02A" unitRef="usd">1065000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-4F5593F96B55C1289F83080144AD400B" unitRef="usd">-90000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4A8352E7308191477A3C08014485F9BC" unitRef="usd">-372000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1E829D8845A81656CE2A0801449C5420" unitRef="usd">5006000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
	<us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5E05D1FB0734A394D7320801447B98CF" unitRef="usd">8842000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
	<us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C093F345F95D161337D2B64F896DE877" unitRef="usd">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
	<us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4FE60E4CE8F37707DBC5B64F898D53B1" unitRef="usd">8820000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
	<us-gaap:PaymentsForLegalSettlements contextRef="FD2017Q3QTD_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember" decimals="INF" id="Fact-E7C9226EBD67C409B4E0BBA98EAC7EDF" unitRef="usd">0</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsForLegalSettlements contextRef="FD2017Q3YTD_srt_CounterpartyNameAxis_rtrx_MartinShkreliMember" decimals="-5" id="Fact-519C022068CDD73421C3BBA9B824A1A6" unitRef="usd">3000000</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-D3393F564985AC0215B208014487B6EF" unitRef="usd">67552000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2018Q3YTD" decimals="-5" id="Fact-F5C0D0E69000D1D8590ACC4C7CCE754F" unitRef="usd">219800000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-16F0AD6738DD45E3DCC508014499D98E" unitRef="usd">219820000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5D9BF56D10A5C9A72628080144857377" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F45466FC7B894BDA25F80801448D00E7" unitRef="usd">15000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2017Q3YTD" decimals="-3" id="Fact-50A72C4991A92DD912A8080144AB0F49" unitRef="usd">9632000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-886724DE591CFB50E3A7080144766118" unitRef="usd">15108000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q3YTD" decimals="-3" id="Fact-866A5635ADE2CA36FED70801447931DD" unitRef="usd">1437000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B20B63BEB84D4819A1E008014489D0B8" unitRef="usd">727000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-592102E45D2CD85F06C90801448F4326" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q3" decimals="INF" id="Fact-92FB63124CE4CBC315690801449D7B7E" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-1AA40B9F5409D413CF8D080144A2265F" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q3" decimals="INF" id="Fact-D645A80E51B73CEDCBFC0801448C3319" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-789D53163FB7CD99408B0801448D6BAD" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q3" decimals="INF" id="Fact-063650BA46C770AD35E20801448B1779" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-085016FFF130F537E3A608014497D59B" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q3" decimals="INF" id="Fact-80AC6FEE65CB53F04ED408014491BA8C" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-8AB2235947955834CE9B08014467BF23" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q3" decimals="-3" id="Fact-0BFBD3AF0652E10616E10801447703AB" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D3B86CBA21A795CA2CBD0801447D6F9D" unitRef="usd">3112000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-B831E9B190FC78A471790801447F371E" unitRef="usd">3456000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidTaxes contextRef="FI2017Q4" decimals="-3" id="Fact-0326136B20EDEDBE790708014465C6F1" unitRef="usd">2842000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2018Q3" decimals="-3" id="Fact-4C45D9CF0258ABC2AE7E0801447F135B" unitRef="usd">2141000</us-gaap:PrepaidTaxes>
	<us-gaap:ProceedsFromIssuanceOfDebt contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_rtrx_SeniorNotesDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-5" id="Fact-18C7F14ED1543286A747B66FF9682145" unitRef="usd">267200000</us-gaap:ProceedsFromIssuanceOfDebt>
	<us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F6090EC17F8575322C23B7DA23DA513A" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D02B4DEA174C204B334BB7DA19CFF0BA" unitRef="usd">276000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-00E8B0EC53AA0B7738010801447F15D6" unitRef="usd">3645000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="FD2018Q3YTD" decimals="-3" id="Fact-09AA40F20CB6DCEEAC6F0801446EA8B4" unitRef="usd">4274000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-B763EE1F79A6CEC47C5B080144ADE144" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F199F03D749B8D76036B0801447EBEB0" unitRef="usd">800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-90902C99547F1D8C2E360801449B00AD" unitRef="usd">76826000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6598ABE3DBDED86BE29A08014480B84E" unitRef="usd">96166000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0C5AF76ADD95A336E0950801449E0DB7" unitRef="usd">7695000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q3YTD" decimals="-3" id="Fact-15EDA33EED66DF66CB980801446DC35A" unitRef="usd">10379000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2018Q3QTD" decimals="-5" id="Fact-DF7748AC3EB10F5A892A080144B2B837" unitRef="usd">2100000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2018Q3YTD" decimals="-5" id="Fact-AAFB0137455C9264679A080144B37B7C" unitRef="usd">4300000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-16025FD0B2DD01EB4CC20801447E1205" unitRef="usd">3230000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q3" decimals="-3" id="Fact-D78AB80A10E862E1DE550801446D1E14" unitRef="usd">3323000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-3F60CC882B42826CD0F1080144A58D94" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-7E7D4796A731AB92E506080144881E07" unitRef="usd">17042000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0DBCD40F3CBCE9138CE8B7DF63CC8076" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-10ACD90A05CA012A9AE9B7DF63C62916" unitRef="usd">40203000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfOtherDebt contextRef="FD2017Q3YTD" decimals="-3" id="Fact-CFE35219A82D31309F710801448CF62C" unitRef="usd">750000</us-gaap:RepaymentsOfOtherDebt>
	<us-gaap:RepaymentsOfOtherDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FC59482985D74711003808014486FB46" unitRef="usd">750000</us-gaap:RepaymentsOfOtherDebt>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="D2018Q1_dei_LegalEntityAxis_rtrx_CensaPharmaceuticalsInc.Member_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_rtrx_CNSA001ProgramMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_PurchaseProvisionTermsMember" decimals="-6" id="Fact-8B5B96DA64D1C37300830801449EAAEC" unitRef="usd">17000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-D10842A411276B65EFF0080144A98446" unitRef="usd">19610000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C53ECE0BDDE3E862297C0801446872A9" unitRef="usd">58592000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-6EBCF3DC1B08BCEBC8DB08014485F526" unitRef="usd">32448000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-EE03D12753977D93365D08014466259F" unitRef="usd">91762000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3QTD" decimals="-3" id="Fact-488F2EC220A376D69C2A0801448056ED" unitRef="usd">1132000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3YTD" decimals="-3" id="Fact-E5640A311C7EAC962047B648DCDCDCBA" unitRef="usd">2611000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q3QTD" decimals="-3" id="Fact-8E0D1F800A4E2DBF28A80801448A7C35" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5E63658FC6B5B65D139DB648DB594BBC" unitRef="usd">-242000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringReserve contextRef="FI2017Q4" decimals="-3" id="Fact-32CB6B2A4442FF52DB26080144B498FE" unitRef="usd">3549000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2018Q3" decimals="-3" id="Fact-845C15D1D4B442B2E1E5080144BC4B53" unitRef="usd">0</us-gaap:RestructuringReserve>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-2EDD896F29B980233E0F0801447A22FF" unitRef="usd">-177655000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q3" decimals="-3" id="Fact-EE4CB36255D7065A65A90801446FC38F" unitRef="usd">-262562000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q3QTD" decimals="-3" id="Fact-43B979B2CBADCBDF4CFE08014478C321" unitRef="usd">40340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q3QTD_srt_ProductOrServiceAxis_rtrx_BileAcidProductsMember" decimals="-3" id="Fact-E70CBA52F3187294A559080144859C70" unitRef="usd">18839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q3QTD_srt_ProductOrServiceAxis_rtrx_ThiolaLicenseMember" decimals="-3" id="Fact-608FE005AE6CB626CA050801447F45CC" unitRef="usd">21501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C2E527779FCF36BB7C5D080144867BEC" unitRef="usd">112760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q3YTD_srt_ProductOrServiceAxis_rtrx_BileAcidProductsMember" decimals="-3" id="Fact-73EF2A2A7C01B1C4EB12080144814CB1" unitRef="usd">52662000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q3YTD_srt_ProductOrServiceAxis_rtrx_ThiolaLicenseMember" decimals="-3" id="Fact-84D73EBBC2AFEAA93AFB0801447549AC" unitRef="usd">60098000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-18F4EEA0F8B9CBD088E208014483377D" unitRef="usd">40706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_rtrx_BileAcidProductsMember" decimals="-3" id="Fact-E6930E4C33F9303C3F080801446B17F4" unitRef="usd">18052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_rtrx_ThiolaLicenseMember" decimals="-3" id="Fact-5F9DC03B291AB2CA885B0801446D9152" unitRef="usd">22654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0B98C3FA195FB7AE4D3708014487A7B1" unitRef="usd">120475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_rtrx_BileAcidProductsMember" decimals="-3" id="Fact-A10366BE0574B45C96730801447597E9" unitRef="usd">55153000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_rtrx_ThiolaLicenseMember" decimals="-3" id="Fact-7724ADBAE3DA61EEAD95080144801396" unitRef="usd">65322000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5D756EE6970BF39EE9050801447CD67A" unitRef="usd">24852000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1152B0C233D03B819959080144B6C5F4" unitRef="usd">74683000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-5237DA46DD3F0B0AE3FE08014482E893" unitRef="usd">26107000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C45DF2F1E2E3BB0C347808014476D177" unitRef="usd">77699000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A9807950004081EFA9670801446B9EF9" unitRef="usd">21292000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5942BDB79E76368476B40801446A2EE1" unitRef="usd">15114000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-F8BEE71ABDA77742736E080144BC63BB" unitRef="shares">30216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-FEBFFC077A33E5520E8C080144ABAA89" unitRef="usdPerShare">24.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-36094F2D4E3DEE08E8B7080144B4A96A" unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-EB81E8978E4ECEBC3A7EC619EC0C8D36" unitRef="shares">66500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-FA3F7D2B056E9CB84430080144B5612E" unitRef="shares">449811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-66F3AC4E9BC1EAFDA6F3080144BC716F" unitRef="usdPerShare">25.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-9A83F275CA652B408A03080144B5F441" unitRef="usdPerShare">20.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-9DFF5DB008CF36B66CAC080144B5F61C" unitRef="usdPerShare">23.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-15A9A4D15CBEF88539A6080144B30B31" unitRef="shares">56501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-64124BB80566FD928075080144A78687" unitRef="usdPerShare">20.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-B92CFEE475F1FF400080080144A82B20" unitRef="shares">345332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-F18ED3BC545CD8E28927080144B4D9E5" unitRef="shares">708426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2018Q3" decimals="-5" id="Fact-8416EB8C2BDD6F7AC7F9080144B3A20F" unitRef="shares">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2018Q3" decimals="INF" id="Fact-EA619BF8879BC2D167BC080144AA4FDE" unitRef="usdPerShare">16.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-90C77B9E620A27C7F85D080144BD1A36" unitRef="shares">427587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-620F0E01EB4F1B4A9BD3080144A0D84D" unitRef="usdPerShare">14.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-CAECD41E8E1B55395465080144AF4212" unitRef="shares">1242550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-F468F5064FCF293B613D080144A5E291" unitRef="usd">39010000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-EA28AE5E750C6CD80FCE080144B6D7FD" unitRef="usd">76529000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-A71325ACAA359FD33421080144ACF1D2" unitRef="shares">7153668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-29A19B29CB9D4698E853080144A08978" unitRef="shares">7230983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-16B899F2246D87A3DBCB080144AF1F12" unitRef="usdPerShare">17.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-B4010316F3DF0AA1DED1080144A4E019" unitRef="usdPerShare">18.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-4C22E98B2C4781E6EEB9080144B2CB87" unitRef="usdPerShare">24.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-27DBBB594F72F5754CC7080144B54D09" unitRef="usdPerShare">25.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember" decimals="INF" id="Fact-B8F2590DE42DBF1D876A080144A664E2" unitRef="usdPerShare">21.07</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-B1D803FFC93AF4F9E2E5080144BD2237">P6Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-A7374915A2F15E6EEE47080144B6A6DC">P7Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-9DF0C96E4D530A37DF0D080144B649D1" unitRef="shares">737648</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-BBEB6C86580E4D9F43560801447F78EB" unitRef="usd">293134000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3" decimals="-3" id="Fact-3608FB5BD7FAF3BBCDD10801447517B7" unitRef="usd">319065000</us-gaap:StockholdersEquity>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q3" decimals="INF" id="Fact-0865A7871D384661E6E5BBB569F538EA" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense contextRef="FD2018Q3QTD" decimals="INF" id="Fact-E0808DA5954FD709F0B1080144BC152D" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense contextRef="FD2018Q3YTD" decimals="INF" id="Fact-65A58E87D14CDF617D27C62046E70033" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3QTD" decimals="0" id="Fact-5E9CE07F3A2A58124BEF0801448CD3C7" unitRef="shares">38654086</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3YTD" decimals="0" id="Fact-4A4A58C3EF8F9E98C9BC0801448919AC" unitRef="shares">38301893</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3QTD" decimals="0" id="Fact-37BD11E8054036EC76140801447E2DBB" unitRef="shares">40717440</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3YTD" decimals="0" id="Fact-5AE4326DC82EAC2AAF2C0801448D54B4" unitRef="shares">40149184</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<rtrx:ClinicalTrialExpensePolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-F2257A51DDFB80DA84A1C62B562ECDFF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Clinical Trial Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;We record expenses in connection with our clinical trials under contracts with contract research organizations (CROs) that support conducting and managing clinical trials. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up, initiation activities, enrollment, treatment of patients, or the completion of other clinical trial activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;We currently have three Phase 3 clinical trials in process that are in varying stages of activity, with ongoing non-clinical support trials. As such, clinical trial expenses will vary depending on the all the factors set forth above and may fluctuate significantly from quarter to quarter.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</rtrx:ClinicalTrialExpensePolicyTextBlock>
	<rtrx:ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock contextRef="FD2018Q3YTD" id="Fact-140CA613EF2C97F1180C080144A534A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table sets forth a summary of changes in the estimated fair value of the Company's business combination-related contingent consideration for the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements of Acquisition-Related Contingent Consideration&lt;br clear="none"/&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Balance at January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;90,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Increase from revaluation of contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;22,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Contractual payments included in accrued liabilities at September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(2,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Contractual payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(4,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Balance at September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</rtrx:ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-8CB6A9B8C79A1D1997B40801449B589E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt; ACCRUED EXPENSES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Accrued expenses at &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; consisted of the following (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Government rebates payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;10,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;5,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Compensation related costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;9,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Accrued royalties and contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;11,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Restructuring expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Miscellaneous accrued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;43,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;36,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-27F2DCC0D2CC99910F430801449903BA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Leases and Sublease Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Facilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Annual Base Rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Lease Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Comments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Occupied Locations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Corporate Headquarters&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;San Diego, CA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$2.1 million&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;July 2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Vacated Locations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;New York, NY&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$0.5 million&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;November 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Sublet through expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Research Collaboration and Licensing Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreements with unrelated companies, scientific collaborators, universities, and consultants. These agreements contain varying terms and provisions which include fees and milestones to be paid by the Company, services to be provided, and ownership rights to certain proprietary technology developed under the agreements. Some of these agreements contain provisions which require the Company to pay royalties, in the event the Company sells or licenses any proprietary products developed under the respective agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"&gt;&lt;font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;In August 2017, Martin Shkreli, the Company&amp;#8217;s former Chief Executive Officer, was convicted on securities fraud charges following investigations by the U.S. Attorney for the Eastern District of New York and the U.S Securities and Exchange Commission. The Company was not a target of these investigations and cooperated with them fully.  &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Mr. Shkreli has appealed his conviction to the United States Court of Appeals for the Second Circuit, and the appeal will likely not be decided until 2019.  In connection with the trial and pending appeal proceedings, Mr. Shkreli sought advancement of his legal fees from the Company, and the Company has advanced a total of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in legal fees, of which &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; has been reimbursed by its directors&amp;#8217; and officers&amp;#8217; insurance carriers. &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Pending the outcome of Mr. Shkreli's appeal, the insurance carriers have reserved their rights to assert that certain of the advanced funds pertain to claims excluded from coverage under the relevant insurance policy and are therefore recoverable by the carriers. As a result, the final amount of the reimbursement from the insurance carriers is not currently estimable. In addition, a portion of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;these and the other&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; legal fees the Company has advanced to Mr. Shkreli will be subject to reimbursement by Mr. Shkreli under Delaware law in the event it is ultimately determined that Mr. Shkreli is not entitled to be indemnified by the Company in these proceedings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;In August 2015, the Company filed a lawsuit in federal district court for the Southern District of New York against Mr. Shkreli, asserting that he breached his fiduciary duty of loyalty during his tenure as the Company&amp;#8217;s Chief Executive Officer and a member of its Board of Directors. Mr. Shkreli served a demand for JAMS arbitration on Retrophin, claiming that Retrophin had breached his December 2013 employment agreement. In response to Mr. Shkreli&amp;#8217;s arbitration demand, the Company asserted counterclaims in the arbitration that are substantially similar to the claims it previously asserted in the federal lawsuit against Mr. Shkreli.  The federal Court granted a stay of the federal lawsuit pending a determination by the arbitration panel whether the Company&amp;#8217;s counterclaims would be litigated in the arbitration, as the Company is seeking. In April 2016, the arbitration panel granted the parties&amp;#8217; request for a stay of the proceedings pending settlement discussions. &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Earlier this year, the parties asked the panel to lift the stay&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. On June 29, 2018, Mr. Shkreli applied to the federal court to enjoin the arbitration panel from hearing the Company&amp;#8217;s counterclaims. On July 2, 2018, the federal court denied Mr. Shkreli&amp;#8217;s application&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; Mr. Shkreli at first filed a notice of appeal indicating his intent to appeal the federal court&amp;#8217;s decision, but then agreed to voluntarily dismiss the appeal. On September 13, 2018, the Clerk of the United States Court of Appeals for the Second Circuit ordered the appeal dismissed&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;.  On October 2, 2018, the arbitration panel determined that Retrophin's counterclaims were arbitrable. On October 5, 2018, Retrophin voluntarily dismissed the federal action without prejudice. Mr. Shkreli's claims and the Company's counterclaims in the arbitration are scheduled to be heard by the arbitration panel in June 2019. In connection with these proceedings, Mr. Shkreli sought advancement of his legal fees from the Company relating to his defense of the Company&amp;#8217;s claims against him. The Company has advanced, and expects to continue to advance, certain of these legal fees to Mr. Shkreli.          &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;For the three and nine months ended September 30, 2018, the Company recorded and paid zero in expenses under the settlement agreement. For the three and nine months ended September 30, 2017, the Company recorded &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in expenses, respectively, and paid &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, respectively, under the settlement agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;During the nine months ended September 30, 2018 and 2017, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; of reimbursements from the Company's directors&amp;#8217; and officers&amp;#8217; insurance carriers were received. Of the total &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; reimbursed by the insurance carriers, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; is recorded as a liability on the Consolidated Balance Sheet pending the outcome of Mr. Shkreli's appeal.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;From time to time the Company is involved in legal proceedings arising in the ordinary course of business.&amp;#160; On October 23, 2018, Spring Pharmaceuticals, LLC (Spring) filed a lawsuit against the Company, Martin Shkreli, Mission Pharmacal Company and Alamo Pharma Services, Inc. in the United States District Court for the Eastern District of Pennsylvania alleging that the Company violated various federal and state antitrust and unfair competition laws (and that Defendants were unjustly enriched) by implementing a distribution system that prevented Plaintiff from obtaining sufficient samples of Thiola to conduct bioequivalence testing.&amp;#160; Spring&amp;#8217;s complaint seeks injunctive relief compelling Defendants to sell Thiola to it and damages. The Company intends to vigorously defend against Spring&amp;#8217;s claims.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company is not aware of any other  proceedings or claims that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-28DF78A6C68FE5753B4C080144BDCA45">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The unaudited condensed consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-13AE3BE716A649C6A57A080144A522B5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;CONVERTIBLE NOTES PAYABLE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Convertible Senior Notes Due 2025&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;On September 10, 2018, the Company completed its registered underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$276 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;2.50%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; Convertible Senior Notes due 2025 ("2025 Notes"), and entered into a base indenture and supplemental indenture agreement ("2025 Indenture") with respect to the 2025 Notes. The 2025 Notes will mature on September 15, 2025 ("Maturity Date&amp;#8221;), unless earlier repurchased, redeemed, or converted. The 2025 Notes are senior unsecured obligations of the Company and bear interest at an annual rate of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;2.50%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The composition of the Company&amp;#8217;s 2025 Notes are as follows (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:437px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2.50% convertible senior notes due 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;276,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unamortized debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(76,951&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(6,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total 2025 Notes, net of unamortized debt discount and debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;192,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The net proceeds from the issuance of the 2025 Notes were approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$267.2 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, after deducting commissions and the offering expenses payable by the Company. A portion of the net proceeds from the 2025 Notes were used by the Company to repurchase &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$23.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; aggregate principal amount of its then-outstanding &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;4.5%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; senior convertible notes due in 2019 in privately-negotiated transactions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Holders may convert their 2025 Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2018 (and only during such calendar quarter), if the last reported sale price per share of the Company&amp;#8217;s common stock for each of at least &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;20&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; trading days, whether or not consecutive, during the period of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;30&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;130%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; of the conversion price on the applicable trading day; (2) during the five consecutive business days immediately after any &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;10&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; consecutive trading day period (&amp;#8220;measurement period&amp;#8221;) if the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;98%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; of the product of the last reported sale price per share of the Company&amp;#8217;s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company&amp;#8217;s common stock; (4) if the Company calls the 2025 Notes for redemption; and (5) at any time from, and including, May 15, 2025 until the close of business on the scheduled trading day immediately before the Maturity Date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company&amp;#8217;s common stock, or a combination of cash and shares of the Company&amp;#8217;s common stock, at the Company&amp;#8217;s election, based on the applicable conversion rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The initial conversion rate for the 2025 Notes is &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;25.7739&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; shares of the Company&amp;#8217;s common stock per $1,000 principal amount of 2025 Notes, which represents an initial conversion price of approximately &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$38.80&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; per share. If a &amp;#8220;make-whole fundamental change&amp;#8221; (as defined in the 2025 Indenture) occurs, then the company will, in certain circumstances, increase the conversion rate for a specified period of time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The 2025 Notes will be redeemable, in whole or in part, at the Company&amp;#8217;s option at any time, and from time to time, on or after September 15, 2022 and, in the case of any partial redemption, on or before the 40th scheduled trading day before the Maturity Date, at a cash redemption price equal to the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company&amp;#8217;s common stock exceeds &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;130%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; of the conversion price on each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. If a fundamental change (as defined in the 2025 Indenture) occurs, then, subject to certain exceptions, holders may require the Company to repurchase their 2025 Notes at a cash repurchase price equal to the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;As of&amp;#160;September 30, 2018, the 2025 Notes had a market price of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$1,027&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#160;per&amp;#160;$1,000&amp;#160;principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$276.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#160;in principal value and any conversion premium in any combination of cash and shares of its common stock at the Company&amp;#8217;s option. In addition, calling the 2025 Notes for redemption will constitute a &amp;#8220;make whole fundamental change &amp;#8221;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The 2025 Notes are the Company&amp;#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2025 Notes, and equal in right of payment to the Company&amp;#8217;s unsecured indebtedness. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The 2025 Notes are currently classified on the Company&amp;#8217;s consolidated balance sheet at&amp;#160;September 30, 2018&amp;#160;as long-term debt.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Under ASC 470-20,&amp;#160;Debt with Conversion and Other Options, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2025 Notes) that may be settled entirely or partially in cash upon conversion, in a manner that reflects the issuer&amp;#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component was&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$198.6 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;.&amp;#160;The equity component of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$77.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2025 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2025 Notes, which is amortized over the seven year term of the 2025 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.&amp;#160;The Company allocated the total transaction costs of approximately &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$8.8 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; related to the issuance of the 2025 Notes to the liability and equity components of the 2025 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the seven-year term of the 2025 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&amp;#8217; equity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The effective interest rate on the liability components of the 2025 Notes for the period from the date of issuance through September 30, 2018 was &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;7.7%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. The following table sets forth total interest expense recognized related to the 2025 Notes (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Three and Nine months ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Contractual interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Amortization of debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Amortization of debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total interest expense for the 2025 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The 2025 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2025 Indenture contains customary events of default with respect to the 2025 Notes, including that upon certain events of default,&amp;#160;100%&amp;#160;of the principal and accrued and unpaid interest on the 2025 Notes will automatically become due and payable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Senior Convertible Notes Due 2019&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;On May 29, 2014, the Company entered into a Note Purchase Agreement relating to a private placement by the Company of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; aggregate principal senior convertible notes due in 2019 (the &amp;#8220;2019 Notes&amp;#8221;) which are convertible into shares of the Company&amp;#8217;s common stock at an initial conversion price of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$17.41&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; per share. The conversion price is subject to customary anti-dilution protection. The 2019 Notes bear interest at a rate of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;4.5%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; per annum, payable semiannually in arrears on May 15 and November 15 of each year. The 2019 Notes mature on May 30, 2019 unless earlier converted or repurchased in accordance with their terms, and there are no contractual payments due prior to that date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;In September 2018, the Company used part of the net proceeds from the issuance of the 2025 Notes discussed above to repurchase &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$23.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#160;aggregate principal value of the 2019 Notes in privately-negotiated transactions for approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$40.2 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#160;in cash. The partial repurchase of the 2019 Notes resulted in a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$17.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#160;loss on early extinguishment of debt.  At&amp;#160;September 30, 2018, approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$22.6 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#160;of principal remained outstanding on the 2019 Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The composition of the Company&amp;#8217;s 2019 Notes are as follows (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:437px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4.50% senior convertible notes due 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;22,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;46,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unamortized debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(867&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total 2019 Notes, net of unamortized debt discount and debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;22,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;45,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="FD2018Q3YTD" id="Fact-0B1C1BA292CFC3A67AE10801449930B9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following is a summary of short-term&amp;#160;marketable securities classified as available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Remaining Contractual Maturity&lt;br clear="none"/&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Aggregate Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;54,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;54,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;138,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;138,203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Securities of government-sponsored entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total maturity less than 1 year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;196,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;196,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1 to 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;128,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;127,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total maturity 1 to 2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;128,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;127,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;324,797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following is a summary of short-term&amp;#160;marketable securities classified as available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Remaining Contractual Maturity&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Aggregate Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;86,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;86,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Securities of government-sponsored entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;30,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;30,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total maturity less than 1 year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;123,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;123,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1 to 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;78,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;77,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total maturity 1 to 2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;78,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;77,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(726&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
	<us-gaap:DerivativesPolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-52F8B4292D3AF533736E0801448EF7DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Historically, the Company accounted for these instruments, which do not have fixed settlement provisions, as derivative instruments in accordance with FASB ASC 815-40, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Derivative and Hedging &amp;#8211; Contracts in Entity&amp;#8217;s Own Equity. &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;This was due to an anti-dilution provision for the warrants that provides for a reduction to the exercise price if the Company issues equity or equity linked instruments in the future at an effective price per share less than the exercise price then in effect for the warrant ("down round provision"). As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value were recorded as non-cash adjustments within other income (expenses), net, in the Company&amp;#8217;s accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
	<us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="FD2018Q3YTD" id="Fact-73BEEC3AA77B9FBE3CEA0801448921EF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes net product revenues for the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and 2017 (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Bile acid products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;18,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;18,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;55,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;52,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Thiola&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;22,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;21,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;65,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;60,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total net product revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;40,706&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;40,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;120,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;112,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q3YTD" id="Fact-32A927474A9B423D7995080144B410C7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;SHARE BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Restricted Shares&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Service and Performance Based Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes the Company&amp;#8217;s restricted stock unit activity during the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Number of Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unvested December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;345,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;20.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;449,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;25.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(56,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;20.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Forfeited/canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(30,216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;24.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unvested September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;708,426&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;23.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, unamortized stock compensation for restricted stock units was &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$10.6 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, with a weighted-average recognition period of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;2.2&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Performance Based Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company granted &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;10,000&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;66,500&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; performance based restricted stock units during the three and nine months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes stock option activity during the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares Underlying Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7,153,668&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;17.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;"&gt;6.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;"&gt;39,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,242,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;25.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(737,648&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;14.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Forfeited/canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(427,587&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;24.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Outstanding at September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7,230,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;18.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;76,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, unamortized stock compensation for stock options was &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$32.5 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, with a weighted-average recognition period of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;2.8 years&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, outstanding options to purchase &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;4.6 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; shares of common stock were exercisable with a weighted-average exercise price per share of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$16.72&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Share Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table sets forth total stock-based compensation for the three and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Selling, general &amp;amp; administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;10,328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;14,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,960&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;14,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;21,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Exercise of Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company issued &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;532,830&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;956,887&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; shares of common stock upon the exercise of outstanding warrants during the three and nine months ended September 30, 2018, respectively, for cash received by the Company in the amount of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$4.3 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, respectively. See Note 6 for changes in warrant accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;At &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, warrants to purchase &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;79,167&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;1,159,424&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; shares of common stock, respectively, were outstanding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-E866B611E31E776039390801449A66C4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Basic and diluted net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The Company&amp;#8217;s potentially dilutive shares, which include outstanding stock options, restricted stock units, warrants, and shares issuable upon conversion of the 2019 and 2025 Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2018Q3YTD" id="Fact-16D48C39365FA27BBD040801449E2E0D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;LOSS PER COMMON SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Basic and diluted net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The Company&amp;#8217;s potentially dilutive shares, which include outstanding stock options, restricted stock units, warrants, and shares issuable upon conversion of the 2019 and 2025 Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Basic and diluted net loss per share is calculated as follows &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;(net loss amounts are stated in thousands)&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Net Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Net Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;40,717,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(54,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;38,654,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(17,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(0.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Net Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Net Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;40,149,184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(95,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(2.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;38,301,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(42,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(1.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following common stock equivalents have been excluded because they were anti-dilutive (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Convertible debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;8,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;2,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;8,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;2,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;7,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;7,515&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;7,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;6,960&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;1,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;1,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Total anti-dilutive shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;16,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;11,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;16,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;10,936&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q3YTD" id="Fact-E5D7EEAF221631E35215080144A25531">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Financial Instruments and Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company accounts for financial instruments in accordance with ASC 820, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&amp;#8220;ASC 820&amp;#8221;).  ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.&amp;#160;&amp;#160;The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).&amp;#160;&amp;#160;The three levels of the fair value hierarchy under ASC 820 are described below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Level 1&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; &amp;#8211; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Level 2&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; &amp;#8211; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Level 3&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; &amp;#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The valuation techniques used to measure the fair value of the Company&amp;#8217;s marketable securities and all other financial instruments, all of which have counter-parties with high credit ratings, were valued based on quoted market prices or model driven valuations using significant inputs derived from or corroborated by observable market data. Based on the fair value hierarchy, the Company classified marketable securities within Level 2.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;In estimating the fair value of the Company&amp;#8217;s derivative liabilities as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, the Company used the Black Scholes Model.  Based on the fair value hierarchy, the Company classified the derivative liability within Level 3. The Company adopted ASU 2017-11 as of January 1, 2018 and is no longer required to treat outstanding warrants as derivative liabilities measured at fair value. See Note 6 for further discussion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;In estimating the fair value of the Company&amp;#8217;s contingent consideration, the Company used the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Monte Carlo Simulation model as of September 30,  2018 and a probability-based expected method for royalty payments based on projected revenues as of December 31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. Based on the fair value hierarchy, the Company classified the fair value measurement of contingent consideration within Level 3.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, and accounts payable, due to their short term nature. As of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, the estimated fair value of the Company's &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;4.5%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; Senior Convertible Notes due 2019 was &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$38.8 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and the estimated fair value of the  Company's &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;2.5%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; Convertible Senior Notes due 2025 was &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$283.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, considering factors such as market conditions, prepayment and make-whole provisions, variability in pricing from multiple lenders and the term of the debt.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table presents the Company&amp;#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Total carrying and estimated fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Quoted prices in active markets&lt;br clear="none"/&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Significant other observable inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Significant unobservable inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable securities, available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Business combination-related contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table presents the Company&amp;#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Total carrying and estimated fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Quoted prices in active markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Significant other observable inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Significant unobservable inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable securities, available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Derivative liability related to warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;15,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;15,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Business combination-related contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;90,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;90,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;105,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;105,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table sets forth a summary of changes in the estimated fair value of the Company's business combination-related contingent consideration for the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements of Acquisition-Related Contingent Consideration&lt;br clear="none"/&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Balance at January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;90,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Increase from revaluation of contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;22,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Contractual payments included in accrued liabilities at September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(2,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Contractual payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(4,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Balance at September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The key assumptions included in the calculations for contingent consideration were the future number of patients in treatment, projected revenues, discount rate, and the timing of payments. The present value of the expected payments considers the time at which the obligations are expected to be settled and a discount rate that reflects the risk associated with the performance payments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, the Company incurred charges of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$16.6 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$22.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, respectively, in operating expenses on the Condensed Consolidated Statements of Operations and Comprehensive Loss for the revaluation of the contingent consideration liabilities.  For the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; of the charges were related to the increase in contingent consideration liabilities for the products Chenodal and Cholbam and product candidate L-UDCA, respectively. In each case, the value increased due to &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;changes in the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;discount factors, estimated timing of payments, and changes in projections&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, the Company incurred charges of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, respectively, in operating expenses on the Condensed Consolidated Statement of Operations and Comprehensive Loss for the change in fair value of the contingent consideration liabilities. For the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; of the charges were related to the increase in contingent consideration liabilities for the products Chenodal and Cholbam and product candidate L-UDCA, respectively. In each case, the value increased due to &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;changes in the discount factor, estimated timing of payments and expected payments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-496C0DDBB39CE1CE5980080144A0A88F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Financial Instruments and Fair Value&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company accounts for financial instruments in accordance with ASC 820, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&amp;#8220;ASC 820&amp;#8221;).  ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.&amp;#160;&amp;#160;The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).&amp;#160;&amp;#160;The three levels of the fair value hierarchy under ASC 820 are described below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Level 1&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; &amp;#8211; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Level 2&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; &amp;#8211; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Level 3&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; &amp;#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The valuation techniques used to measure the fair value of the Company&amp;#8217;s marketable securities and all other financial instruments, all of which have counter-parties with high credit ratings, were valued based on quoted market prices or model driven valuations using significant inputs derived from or corroborated by observable market data. Based on the fair value hierarchy, the Company classified marketable securities within Level 2.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;In estimating the fair value of the Company&amp;#8217;s derivative liabilities as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, the Company used the Black Scholes Model.  Based on the fair value hierarchy, the Company classified the derivative liability within Level 3. The Company adopted ASU 2017-11 as of January 1, 2018 and is no longer required to treat outstanding warrants as derivative liabilities measured at fair value. See Note 6 for further discussion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;In estimating the fair value of the Company&amp;#8217;s contingent consideration, the Company used the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Monte Carlo Simulation model as of September 30,  2018 and a probability-based expected method for royalty payments based on projected revenues as of December 31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. Based on the fair value hierarchy, the Company classified the fair value measurement of contingent consideration within Level 3.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, and accounts payable, due to their short term nature.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-18E13A3048C923BD353608014498ADCB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;DERIVATIVE FINANCIAL INSTRUMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Since 2013, the Company has issued &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;five&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; tranches of common stock purchase warrants to secure financing, remediate covenant violations and provide consideration for amendments with respect to a credit facility extinguished in 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Historically, the Company accounted for these instruments, which do not have fixed settlement provisions, as derivative instruments in accordance with FASB ASC 815-40, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;Derivative and Hedging &amp;#8211; Contracts in Entity&amp;#8217;s Own Equity. &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;This was due to an anti-dilution provision for the warrants that provides for a reduction to the exercise price if the Company issues equity or equity linked instruments in the future at an effective price per share less than the exercise price then in effect for the warrant ("down round provision"). As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value were recorded as non-cash adjustments within other income (expenses), net, in the Company&amp;#8217;s accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.&amp;#160;&amp;#160;The Company recorded a loss on the change in the estimated fair value of warrants of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$8.9 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; for each of the three and nine months ended September 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;As of January 1, 2018 the Company early adopted ASU 2017-11, which &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;revised the guidance for instruments with down round provisions. As such the Company treats outstanding warrants as free-standing equity linked instruments that will be recorded to equity in the Consolidated Balance Sheet. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The fair value of the derivative liability balance as of December 31, 2017 of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; was reclassified by &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;means of a cumulative-effect adjustment to equity as of January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company calculated the fair value of the warrants using the Black-Scholes Model as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Fair value of common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;21.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Remaining life of the warrants (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;0.1 - 2.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Risk-free interest rate*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1.39 - 1.89%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Expected volatility**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;33 - 43%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;*The risk-free interest rate is based on the U.S. Treasury security rates for the remaining term of the warrants at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;**Expected volatility is based on an analysis of the Company&amp;#8217;s historical volatility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-5B1DB96430D61AD2C7F9080144B49C3A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes our effective tax rate and income tax benefit (expense) for the three and nine months ended September 30, 2018 and 2017 (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;dollars&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in millions&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;For the three and six nine ended September 30, 2018, we recognized an income tax expense of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, respectively, representing an effective tax rate of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;(0.8)%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;(0.9)%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; respectively. Under GAAP, quarterly effective tax rates may vary significantly depending on the actual operating results in the various tax jurisdictions, and significant transactions, as well as changes in the valuation allowance related to the expected recovery of deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;For the three and nine months ended September 30, 2018, when compared to the same periods in 2017, the change in the tax benefit and decrease in the effective income tax rate was primarily attributable to the increase of the U.S. federal valuation allowance in 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The difference between the expected statutory federal tax benefit of 21% and the effective tax expense for three and nine months ended September&amp;#160;30, 2018, was primarily attributable to the valuation allowance against our deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;At&amp;#160;September 30, 2018, we had &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; unrecognized tax benefits. We did not recognize any interest or penalties related to unrecognized tax benefits during the three and nine months ended September 30, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;On&amp;#160;December 22,&amp;#160;2017, the President of the United States signed into law the Tax Cuts and Jobs Act. The Tax Cuts and Jobs Act reduces the US federal corporate tax rate from 35% to 21%, as well as making several other significant changes to the tax law, effective January 1, 2018. Pursuant to the Securities and Exchange Commission Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), given the amount and complexity of the changes in tax law resulting from the Tax Cuts and Jobs Act, the Company has not finalized the accounting for the income tax effects of the Tax Cuts and Jobs Act. This includes the provisional amounts recorded related to the re-measurement of the deferred taxes and the change to our valuation allowance. The impact of the Tax Cuts and Jobs Act may differ from this estimate during the one-year measurement period due to, among other things, further refinement of the Company's calculation, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the Tax Cuts and Jobs Act.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;At September 30, 2018, the Company is still analyzing certain aspects of the Tax Cuts and Jobs Act and refining its calculations, which could potentially affect the analysis of the Company&amp;#8217;s deferred tax assets and liabilities and its valuation allowance.&amp;#160; Any subsequent adjustment is not expected to be material to the Company&amp;#8217;s financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-5D2E432C51A18BD0C0ED080144ABD73C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INTANGIBLE ASSETS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, the net book value of amortizable intangible assets was approximately &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$186.5 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table sets forth amortizable intangible assets as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Finite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;250,824&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;235,863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less: accumulated amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(64,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(51,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Net carrying value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;186,545&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;184,817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes amortization expense for the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and 2017 (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;12,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;12,752&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total amortization expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;13,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;12,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-CB769739ED35E2D76B06080144B3DC1A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INVENTORY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Inventory, net of reserves, consisted of the following at &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;5,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;5,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The inventory reserve was &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; at &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-28C2B8D14216D45E495F08014492541A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;MARKETABLE SECURITIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company's marketable securities as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; were comprised of available-for-sale marketable securities which are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. Interest and dividends on securities classified as available-for-sale are included in interest income. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. During the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, investment activity for the Company included &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$96.2 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in maturities and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$219.8 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in purchases, all relating to debt based marketable securities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Marketable securities&amp;#160;consisted of the following (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable Securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;54,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;266,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;164,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Securities of government sponsored entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;30,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total marketable securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following is a summary of short-term&amp;#160;marketable securities classified as available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Remaining Contractual Maturity&lt;br clear="none"/&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Aggregate Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;54,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;54,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;138,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;138,203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Securities of government-sponsored entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total maturity less than 1 year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;196,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;196,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1 to 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;128,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;127,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total maturity 1 to 2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;128,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;127,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;324,797&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following is a summary of short-term&amp;#160;marketable securities classified as available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Remaining Contractual Maturity&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;(in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Aggregate Estimated Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;86,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;86,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Securities of government-sponsored entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less than 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;30,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;30,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total maturity less than 1 year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;123,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;123,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1 to 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;78,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;77,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total maturity 1 to 2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;78,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;77,964&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(726&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The primary objective of the Company&amp;#8217;s investment portfolio is to enhance overall returns while preserving capital and liquidity. The Company&amp;#8217;s investment policy limits interest-bearing security&amp;#160;investments&amp;#160;to certain types of instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.  All available for sale securities are held in current assets regardless of contractual maturities exceeding one year, as the Company could sell them within the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company reviews the available-for-sale&amp;#160;investments&amp;#160;for other-than-temporary declines in fair value below cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security, and the intent to sell, or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security. As of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, the Company believed the cost basis for available-for-sale&amp;#160;investments&amp;#160;was recoverable in all material respects.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
	<us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock contextRef="FD2018Q3YTD" id="Fact-A54D90A6A31795173751080144B129A3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;ACCOUNTS RECEIVABLE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$13.5 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$13.9 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; at &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, respectively. The total reserves for both periods were immaterial.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock>
	<us-gaap:MarketableSecuritiesPolicy contextRef="FD2018Q3YTD" id="Fact-D4D32A0D1FF5204F8CEC080144971993">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The primary objective of the Company&amp;#8217;s investment portfolio is to enhance overall returns while preserving capital and liquidity. The Company&amp;#8217;s investment policy limits interest-bearing security&amp;#160;investments&amp;#160;to certain types of instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.  All available for sale securities are held in current assets regardless of contractual maturities exceeding one year, as the Company could sell them within the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company reviews the available-for-sale&amp;#160;investments&amp;#160;for other-than-temporary declines in fair value below cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security, and the intent to sell, or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
	<us-gaap:MarketableSecuritiesTextBlock contextRef="FD2018Q3YTD" id="Fact-466638B051B67DCF34080801449257D7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Marketable securities&amp;#160;consisted of the following (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable Securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;54,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;266,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;164,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Securities of government sponsored entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;30,042&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total marketable securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2018Q3YTD" id="Fact-BF0E4CB1DA76477906400801448DCF10">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;DESCRIPTION OF BUSINESS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"&gt;&lt;font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization and Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Retrophin, Inc. (&amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221;, &amp;#8220;us&amp;#8221;, &amp;#8220;Retrophin&amp;#8221; and the &amp;#8220;Company&amp;#8221;) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;The Company is developing the following pipeline products:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;pantothenate kinase-associated neurodegeneration (&amp;#8220;PKAN&amp;#8221;). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. There are currently no viable treatment options for patients with PKAN. Fosmetpantotenate is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Sparsentan (RE-021) is an investigational product candidate which acts as both a potent &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;angiotensin receptor blocker (&amp;#8220;ARB&amp;#8221;), as well as a selective endothelin receptor antagonist (&amp;#8220;ERA&amp;#8221;), with in vitro selectivity toward endothelin receptor type A. The Company secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;"&gt;&amp;#9642;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;"&gt;Focal segmental glomerulosclerosis ("FSGS")&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, which is a leading cause of end-stage renal disease and nephrotic syndrome (&amp;#8220;NS&amp;#8221;). There are no U.S. Food and Drug Administration ("FDA") approved pharmacologic treatments for FSGS and off-label resources are limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;"&gt;&amp;#9642;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;"&gt;Immunoglobulin A nephropathy ("IgAN")&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, which is characterized by hematuria, proteinuria, and variable rates of progressive renal failure. There is no FDA approved treatment for IgAN.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company is a party to a&amp;#160;joint development agreement with&amp;#160;Censa Pharmaceuticals Inc. ("Censa"), a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria ("PKU"). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin ("BH4") with the potential to provide improved phenylalanine ("Phe") reduction in patients with PKU when compared to BH4.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;PKU is a rare, genetic metabolic condition in which the body cannot breakdown Phe due to a missing or defective phenylalanine hydroxylase ("PAH") enzyme. High Phe levels can lead to developmental and physical growth delay, executive function impairment, seizures, and microcephaly caused by toxic Phe accumulation in the brain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company is party to a three-way Cooperative Research and Development Agreement ("CRADA")&amp;#160;with the National Institutes of Health&amp;#8217;s National Center for Advancing Translational Sciences and patient advocacy foundation NGLY1.org&amp;#160;to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for N-glycanase deficiency ("NGLY1").&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;NGLY1 is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition has been characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). The Company obtained the rights to L-UDCA in 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;The Company sells the following &lt;/font&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;three&lt;/font&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt; products:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Chenodal&amp;#174; (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Cholbam&amp;#174; (cholic acid capsules) is approved in the United States (approved and marketed in Europe for select indications as Kolbam) for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Thiola&amp;#174; (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-1D8D5DB864B7ACAA9059CC2149D20C7E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Effective January 1, 2018, the Company adopted Accounting Standards Codification (" ASC"), Topic 606,&amp;#160;Revenue from Contracts with Customers, using the full retrospective transition method. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Adoption of New Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. See Note 6 for further discussion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;In January 2017, the FASB issued&amp;#160;ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. The new guidance dictates that, when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, it should be treated as an acquisition or disposal of an asset. The guidance was adopted as of January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach or a &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; are both options for transition. The Company is in the process of identifying and quantifying all leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As of September 30, 2018, the Company held &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$324.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in available for sale debt securities. If adopted as of September 30, 2018, this ASU update would not have a material impact on the Company's financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="FD2018Q3YTD" id="Fact-D99A87F54CFC5E96E72B080144AA9667">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes the Company&amp;#8217;s restricted stock unit activity during the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Number of Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unvested December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;345,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;20.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;449,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;25.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(56,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;20.11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Forfeited/canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(30,216&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;24.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unvested September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;708,426&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;23.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2018Q3YTD" id="Fact-FD378DD972C22457048CC628B2B79845">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Research and development expenses are comprised of salaries and bonuses, benefits, non-cash share-based compensation, license fees, costs paid to third-party contractors to perform research, conduct clinical trials and pre/non-clinical trials, develop drug materials, and associated overhead expenses and facilities. We also incur indirect costs that are not allocated to specific programs because such costs benefit multiple development programs and allow us to increase our pharmaceutical development capabilities. These consist of internal shared resources related to the development and maintenance of systems and processes applicable to all of our programs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="FD2018Q3YTD" id="Fact-DA7A68BD33391E68F532080144882F99">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Deductions from Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Revenues from product sales are recorded at the net sales price, which includes provisions resulting from discounts, rebates and co-pay assistance that is offered to its customers, health care providers, payors and other indirect customers relating to the Company&amp;#8217;s sales of its products. These provisions are based on the amounts earned or to be claimed on the related sales and are classified as a reduction of accounts receivable (if the amount is payable to the customer) or as a current liability (if the amount is payable to a party other than a customer). Where appropriate, these reserves take into consideration the Company&amp;#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&amp;#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. If actual results in the future vary from the Company&amp;#8217;s provisions, the Company will adjust the provision, which would affect net product revenue and earnings in the period such variances become known. Our historical experience is that such adjustments have been immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;Government Rebates:&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; We calculate the rebates that we will be obligated to provide to government programs and deduct these estimated amounts from our gross product sales at the time the revenues are recognized. Allowances for government rebates and discounts are established based on actual payer information, which is reasonably estimated at the time of delivery, and the government-mandated discounts applicable to government-funded programs.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;Commercial Rebates: &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;We&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;calculate the rebates that we incur due to contracts with certain commercial payors and deduct these amounts from our gross product sales at the time the revenues are recognized. Allowances for commercial rebates are established based on actual payer information, which is reasonably estimated at the time of delivery.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;Prompt Pay Discounts: &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;We&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; offer discounts to certain customers for prompt payments. We accrue for the calculated prompt pay discount based on the gross amount of each invoice for those customers at the time of sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;Product Returns:&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; Consistent with industry practice, we offer our customers a limited right to return product purchased directly from the Company, which is principally based upon the product&amp;#8217;s expiration date. Generally, shipments are only made upon a patient prescription thus returns are minimal.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;"&gt;Co-pay Assistance:&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;"&gt;We&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; offer a co-pay assistance program, which is intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an identification of claims and the cost per claim associated with product that has been recognized as revenue.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
	<us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="FD2018Q3YTD" id="Fact-A14F28780F2AF2AFC09C08014469BBB4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;REVENUE RECOGNITION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Product Revenue, Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company sells Chenodal and Cholbam (Kolbam), which are &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;aggregated as bile acid products,&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and Thiola through direct-to-patient distributors.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; The Company sells its products worldwide, with more than &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;95%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; of the revenue generated in North America.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Revenues from product sales are recognized when the customer obtains control of the Company&amp;#8217;s product, which occurs upon delivery to the customer.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Deductions from Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Revenues from product sales are recorded at the net sales price, which includes provisions resulting from discounts, rebates and co-pay assistance that is offered to its customers, health care providers, payors and other indirect customers relating to the Company&amp;#8217;s sales of its products. These provisions are based on the amounts earned or to be claimed on the related sales and are classified as a reduction of accounts receivable (if the amount is payable to the customer) or as a current liability (if the amount is payable to a party other than a customer). Where appropriate, these reserves take into consideration the Company&amp;#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&amp;#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. If actual results in the future vary from the Company&amp;#8217;s provisions, the Company will adjust the provision, which would affect net product revenue and earnings in the period such variances become known. Our historical experience is that such adjustments have been immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;Government Rebates:&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; We calculate the rebates that we will be obligated to provide to government programs and deduct these estimated amounts from our gross product sales at the time the revenues are recognized. Allowances for government rebates and discounts are established based on actual payer information, which is reasonably estimated at the time of delivery, and the government-mandated discounts applicable to government-funded programs.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;Commercial Rebates: &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;We&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;calculate the rebates that we incur due to contracts with certain commercial payors and deduct these amounts from our gross product sales at the time the revenues are recognized. Allowances for commercial rebates are established based on actual payer information, which is reasonably estimated at the time of delivery.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;Prompt Pay Discounts: &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;We&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; offer discounts to certain customers for prompt payments. We accrue for the calculated prompt pay discount based on the gross amount of each invoice for those customers at the time of sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;Product Returns:&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; Consistent with industry practice, we offer our customers a limited right to return product purchased directly from the Company, which is principally based upon the product&amp;#8217;s expiration date. Generally, shipments are only made upon a patient prescription thus returns are minimal.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;"&gt;Co-pay Assistance:&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;"&gt;We&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; offer a co-pay assistance program, which is intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an identification of claims and the cost per claim associated with product that has been recognized as revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes net product revenues for the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and 2017 (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Bile acid products&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;18,052&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;18,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;55,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;52,662&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Thiola&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;22,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;21,501&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;65,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;60,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total net product revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;40,706&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;40,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;120,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;112,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q3YTD" id="Fact-6F32026946AC31A320180801449EEB17">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Accrued expenses at &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; consisted of the following (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Government rebates payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;10,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;5,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Compensation related costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;9,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Accrued royalties and contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;11,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Restructuring expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Miscellaneous accrued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;43,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;36,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q3YTD" id="Fact-2842205D3EBCC9798F73080144A283D3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following common stock equivalents have been excluded because they were anti-dilutive (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;335&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Convertible debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;8,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;2,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;8,411&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;2,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;7,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;7,515&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;7,202&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;6,960&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;1,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;1,159&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Total anti-dilutive shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;16,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;11,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;16,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;10,936&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2018Q3YTD" id="Fact-3DAD17281A53482ADDF5080144A6D09D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table sets forth total stock-based compensation for the three and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,603&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,592&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Selling, general &amp;amp; administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;10,328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;14,179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6,960&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;14,920&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;21,292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2018Q3YTD" id="Fact-BF09F6A51E4DFBB956F5080144BC0860">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes our effective tax rate and income tax benefit (expense) for the three and nine months ended September 30, 2018 and 2017 (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;dollars&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in millions&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;6.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="FD2018Q3YTD" id="Fact-463877DE2B8295BEECDCB6DE4942EC60">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The effective interest rate on the liability components of the 2025 Notes for the period from the date of issuance through September 30, 2018 was &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;7.7%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. The following table sets forth total interest expense recognized related to the 2025 Notes (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Three and Nine months ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Contractual interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Amortization of debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Amortization of debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total interest expense for the 2025 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The composition of the Company&amp;#8217;s 2025 Notes are as follows (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:437px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;2.50% convertible senior notes due 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;276,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unamortized debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(76,951&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(6,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total 2025 Notes, net of unamortized debt discount and debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;192,753&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The composition of the Company&amp;#8217;s 2019 Notes are as follows (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:437px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4.50% senior convertible notes due 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;22,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;46,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unamortized debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(867&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total 2019 Notes, net of unamortized debt discount and debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;22,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;45,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2018Q3YTD" id="Fact-448548555C0B02C03A2F080144A4C48B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Basic and diluted net loss per share is calculated as follows &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;(net loss amounts are stated in thousands)&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Net Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Net Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;40,717,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(54,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;38,654,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(17,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(0.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Net Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Net Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;40,149,184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(95,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(2.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;38,301,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(42,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;(1.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2018Q3YTD" id="Fact-AC7E17E50E9BFFF026E0080144A4DE53">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table presents the Company&amp;#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Total carrying and estimated fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Quoted prices in active markets&lt;br clear="none"/&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Significant other observable inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Significant unobservable inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable securities, available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;323,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Business combination-related contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;106,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table presents the Company&amp;#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Total carrying and estimated fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Quoted prices in active markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Significant other observable inputs (Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Significant unobservable inputs (Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Marketable securities, available-for-sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;201,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Derivative liability related to warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;15,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;15,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Business combination-related contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;90,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;90,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;105,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;105,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="FD2018Q3YTD" id="Fact-ADD9A2B84DF31740DCF7080144AD6F05">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table sets forth amortizable intangible assets as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Finite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;250,824&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;235,863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Less: accumulated amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(64,279&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(51,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Net carrying value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;186,545&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;184,817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2018Q3YTD" id="Fact-1A86842A3F636699C99A080144BE09BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Inventory, net of reserves, consisted of the following at &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;3,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;5,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;5,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock contextRef="FD2018Q3YTD" id="Fact-FD79350E8C9150F7A163080144A13AF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"&gt;&lt;font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Leases and Sublease Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Facilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Annual Base Rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Lease Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Comments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Occupied Locations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Corporate Headquarters&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;San Diego, CA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$2.1 million&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;July 2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Vacated Locations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;New York, NY&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;$0.5 million&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;November 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;Sublet through expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q3YTD" id="Fact-33B0C86839BEEB14734D080144B02579">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes stock option activity during the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Shares Underlying Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7,153,668&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;17.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;"&gt;6.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;"&gt;39,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1,242,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;25.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(737,648&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;14.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Forfeited/canceled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;(427,587&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;24.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Outstanding at September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7,230,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;18.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;7.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;76,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q3YTD" id="Fact-DECEADEE5079401DF9870801449BC53E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company calculated the fair value of the warrants using the Black-Scholes Model as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Fair value of common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;21.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Remaining life of the warrants (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;0.1 - 2.0 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Risk-free interest rate*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;1.39 - 1.89%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Expected volatility**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;33 - 43%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;*The risk-free interest rate is based on the U.S. Treasury security rates for the remaining term of the warrants at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;**Expected volatility is based on an analysis of the Company&amp;#8217;s historical volatility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2018Q3YTD" id="Fact-46B4E09B616E77A45460080144AE16F4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The following table summarizes amortization expense for the &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; and 2017 (&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;in thousands&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;292&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;12,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;12,752&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;Total amortization expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;4,506&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;13,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9pt;"&gt;12,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q3YTD" id="Fact-491B9B027E824465CB820801448AE0F6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2017 10-K filed with the SEC on February 27, 2018. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information, the instructions for Form&amp;#160;10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods.&amp;#160;The &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; balance sheet information was derived from the audited financial statements as of that date.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Certain reclassifications have been made to the prior period consolidated financial statements to&amp;#160;conform&amp;#160;to&amp;#160;the current period presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;"&gt;A summary of the significant accounting policies applied in the preparation of the accompanying condensed consolidated financial statements follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The unaudited condensed consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Effective January 1, 2018, the Company adopted Accounting Standards Codification (" ASC"), Topic 606,&amp;#160;Revenue from Contracts with Customers, using the full retrospective transition method. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. See Note 3 for further discussion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Research and development expenses are comprised of salaries and bonuses, benefits, non-cash share-based compensation, license fees, costs paid to third-party contractors to perform research, conduct clinical trials and pre/non-clinical trials, develop drug materials, and associated overhead expenses and facilities. We also incur indirect costs that are not allocated to specific programs because such costs benefit multiple development programs and allow us to increase our pharmaceutical development capabilities. These consist of internal shared resources related to the development and maintenance of systems and processes applicable to all of our programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Clinical Trial Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;We record expenses in connection with our clinical trials under contracts with contract research organizations (CROs) that support conducting and managing clinical trials. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up, initiation activities, enrollment, treatment of patients, or the completion of other clinical trial activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;We currently have three Phase 3 clinical trials in process that are in varying stages of activity, with ongoing non-clinical support trials. As such, clinical trial expenses will vary depending on the all the factors set forth above and may fluctuate significantly from quarter to quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Adoption of New Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. See Note 6 for further discussion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;In January 2017, the FASB issued&amp;#160;ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. The new guidance dictates that, when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, it should be treated as an acquisition or disposal of an asset. The guidance was adopted as of January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach or a &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; are both options for transition. The Company is in the process of identifying and quantifying all leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As of September 30, 2018, the Company held &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$324.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in available for sale debt securities. If adopted as of September 30, 2018, this ASU update would not have a material impact on the Company's financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2018Q3YTD" id="Fact-CAF4BD86604AD8E83FA508014490DBAC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"&gt;&lt;font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Censa Pharmaceuticals Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;In December 2017, the Company entered into a Future Acquisition Right and Joint Development Agreement (the &amp;#8220;Option Agreement&amp;#8221;) with Censa, which became effective in January 2018.  The Company has agreed to fund certain development activities of Censa&amp;#8217;s&amp;#160;CNSA-001&amp;#160;program, in an aggregate amount expected to be approximately &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$17 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; through proof of concept, and has the right, but not the obligation, to acquire Censa (the &amp;#8220;Option&amp;#8221;) on the terms and subject to the conditions set forth in a separate Agreement and Plan of Merger. In exchange for the Option, the Company paid &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$10 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, and an additional &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$5 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; upon Censa&amp;#8217;s completion of a specified development milestone set forth in the Option Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;If the Company exercises the Option, the Company will acquire Censa for &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$65 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in upfront consideration, subject to certain adjustments, paid as a combination of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in cash and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;80%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in shares of the Company&amp;#8217;s common stock, valued at a fixed price of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$21.40&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; per share; provided, however, that Censa may elect on behalf of its equity holders to receive the upfront consideration in &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; cash if the average price per share of the Company&amp;#8217;s common stock for the ten trading days ending on the date the Company provides a notice of interest to exercise the Option is less than &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$19.26&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;. In addition, if the Company exercises the Option and acquires Censa, the Company would be required to make further cash payments to Censa&amp;#8217;s equity holders of up to an aggregate of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$25 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; if the&amp;#160;CNSA-001 program achieves specified development and commercial milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;The Company determined that Censa is a variable interest entity ("VIE") and concluded that the Company is not the primary beneficiary of the VIE. As such, the Company did not consolidate Censa&amp;#8217;s results into its consolidated financial statements. The Company will continue to monitor facts and circumstances for changes that could potentially result in the Company becoming the primary beneficiary.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;Through&amp;#160;&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;, the Company has paid Censa &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; as an upfront payment, &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; in development funding, and &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; related to a development milestone. The Company capitalized the upfront and milestone payments, and expensed the development funding paid. The Company is treating the upfront payment and milestone payment, both of which are compensation for the Option, as a cost-method investment with a total carrying value of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;September&amp;#160;30, 2018&lt;/font&gt;&lt;font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>rtrx-20180930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.retrophin.com/20180930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:rtrx="http://www.retrophin.com/20180930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rtrx-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rtrx-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rtrx-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rtrx-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccountsReceivable" roleURI="http://www.retrophin.com/role/AccountsReceivable">
        <link:definition>2119100 - Disclosure - ACCOUNTS RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableDetails" roleURI="http://www.retrophin.com/role/AccountsReceivableDetails">
        <link:definition>2419401 - Disclosure - ACCOUNTS RECEIVABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.retrophin.com/role/AccruedExpenses">
        <link:definition>2112100 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.retrophin.com/role/AccruedExpensesDetails">
        <link:definition>2412402 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.retrophin.com/role/AccruedExpensesTables">
        <link:definition>2312301 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails">
        <link:definition>2403402 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>2103100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.retrophin.com/role/CommitmentsAndContingencies">
        <link:definition>2115100 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>2415403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails">
        <link:definition>2415402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Leases and Subleases Commitment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2315301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayable" roleURI="http://www.retrophin.com/role/ConvertibleNotesPayable">
        <link:definition>2111100 - Disclosure - CONVERTIBLE NOTES PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayableCompositionOfNotesDetails" roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableCompositionOfNotesDetails">
        <link:definition>2411403 - Disclosure - CONVERTIBLE NOTES PAYABLE - Composition of Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayableConvertibleNotesPayableTables" roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableConvertibleNotesPayableTables">
        <link:definition>2311301 - Disclosure - CONVERTIBLE NOTES PAYABLE CONVERTIBLE NOTES PAYABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayableNarrativeDetails" roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableNarrativeDetails">
        <link:definition>2411402 - Disclosure - CONVERTIBLE NOTES PAYABLE  - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayableScheduleOfInterestExpenseDetails" roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableScheduleOfInterestExpenseDetails">
        <link:definition>2411404 - Disclosure - CONVERTIBLE NOTES PAYABLE - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.retrophin.com/role/DerivativeFinancialInstruments">
        <link:definition>2108100 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsDetails" roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsDetails">
        <link:definition>2408402 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>2308301 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsValuationAssumptionsDetails" roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsValuationAssumptionsDetails">
        <link:definition>2408403 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://www.retrophin.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessNarrativeDetails" roleURI="http://www.retrophin.com/role/DescriptionOfBusinessNarrativeDetails">
        <link:definition>2401401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.retrophin.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.retrophin.com/role/FairValueMeasurements">
        <link:definition>2109100 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" roleURI="http://www.retrophin.com/role/FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails">
        <link:definition>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Acquisition-related Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.retrophin.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2409402 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsAndLiabilitiesDetails" roleURI="http://www.retrophin.com/role/FairValueMeasurementsAssetsAndLiabilitiesDetails">
        <link:definition>2409403 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.retrophin.com/role/FairValueMeasurementsTables">
        <link:definition>2309301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FutureAcquisitionRightAndJointDevelopmentAgreement" roleURI="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement">
        <link:definition>2107100 - Disclosure - FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FutureAcquisitionRightAndJointDevelopmentAgreementDetails" roleURI="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreementDetails">
        <link:definition>2407401 - Disclosure - FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.retrophin.com/role/IncomeTaxes">
        <link:definition>2117100 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.retrophin.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2417403 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" roleURI="http://www.retrophin.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails">
        <link:definition>2417402 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate and Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.retrophin.com/role/IncomeTaxesTables">
        <link:definition>2317301 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.retrophin.com/role/IntangibleAssets">
        <link:definition>2110100 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAmortizableIntangibleAssetsDetails" roleURI="http://www.retrophin.com/role/IntangibleAssetsAmortizableIntangibleAssetsDetails">
        <link:definition>2410403 - Disclosure - INTANGIBLE ASSETS - Amortizable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAmortizationDetails" roleURI="http://www.retrophin.com/role/IntangibleAssetsAmortizationDetails">
        <link:definition>2410404 - Disclosure - INTANGIBLE ASSETS - Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsDetails" roleURI="http://www.retrophin.com/role/IntangibleAssetsDetails">
        <link:definition>2410402 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.retrophin.com/role/IntangibleAssetsTables">
        <link:definition>2310301 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.retrophin.com/role/Inventory">
        <link:definition>2118100 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.retrophin.com/role/InventoryDetails">
        <link:definition>2418402 - Disclosure - INVENTORY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.retrophin.com/role/InventoryTables">
        <link:definition>2318301 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.retrophin.com/role/LossPerCommonShare">
        <link:definition>2113100 - Disclosure - LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSharesDetails" roleURI="http://www.retrophin.com/role/LossPerCommonShareAntidilutiveSharesDetails">
        <link:definition>2413403 - Disclosure - LOSS PER COMMON SHARE - Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareEpsReconciliationDetails" roleURI="http://www.retrophin.com/role/LossPerCommonShareEpsReconciliationDetails">
        <link:definition>2413402 - Disclosure - LOSS PER COMMON SHARE - EPS Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.retrophin.com/role/LossPerCommonShareTables">
        <link:definition>2313301 - Disclosure - LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.retrophin.com/role/MarketableSecurities">
        <link:definition>2106100 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAdditionalInformationDetails" roleURI="http://www.retrophin.com/role/MarketableSecuritiesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - MARKETABLE SECURITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleSecuritiesDetails" roleURI="http://www.retrophin.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails">
        <link:definition>2406404 - Disclosure - MARKETABLE SECURITIES - Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesMarketableSecuritiesDetails" roleURI="http://www.retrophin.com/role/MarketableSecuritiesMarketableSecuritiesDetails">
        <link:definition>2406403 - Disclosure - MARKETABLE SECURITIES - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.retrophin.com/role/MarketableSecuritiesTables">
        <link:definition>2306301 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.retrophin.com/role/RevenueRecognition">
        <link:definition>2104100 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDetails" roleURI="http://www.retrophin.com/role/RevenueRecognitionDetails">
        <link:definition>2404402 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.retrophin.com/role/RevenueRecognitionTables">
        <link:definition>2304301 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.retrophin.com/role/ShareBasedCompensation">
        <link:definition>2116100 - Disclosure - SHARE BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationExerciseOfWarrantsDetails" roleURI="http://www.retrophin.com/role/ShareBasedCompensationExerciseOfWarrantsDetails">
        <link:definition>2416405 - Disclosure - SHARE BASED COMPENSATION - Exercise of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedStockActivityDetails" roleURI="http://www.retrophin.com/role/ShareBasedCompensationRestrictedStockActivityDetails">
        <link:definition>2416402 - Disclosure - SHARE BASED COMPENSATION - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.retrophin.com/role/ShareBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2416404 - Disclosure - SHARE BASED COMPENSATION - Stock based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.retrophin.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>2416403 - Disclosure - SHARE BASED COMPENSATION - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.retrophin.com/role/ShareBasedCompensationTables">
        <link:definition>2316301 - Disclosure - SHARE BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rtrx_AccruedLiabilitiesMiscellaneous" name="AccruedLiabilitiesMiscellaneous" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent" name="AccruedLiabilitiesResearchandDevelopmentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent" name="AccruedLiabilitiesSellingGeneralandAdministrativeCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_AccruedRoyaltiesNoncurrent" name="AccruedRoyaltiesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_AccruedRoyaltyandContingentConsideration" name="AccruedRoyaltyandContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="rtrx_AcquiredProductRightsCholbamMember" name="AcquiredProductRightsCholbamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_AcquiredProductRightsLUDCAMember" name="AcquiredProductRightsLUDCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_AcquisitionRelatedContingentConsideration" name="AcquisitionRelatedContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_AcquisitionRelatedContingentConsiderationNoncurrent" name="AcquisitionRelatedContingentConsiderationNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding" name="AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones" name="AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="rtrx_AgreementAxis" name="AgreementAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_AgreementDomain" name="AgreementDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_BileAcidProductsMember" name="BileAcidProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_BusinessCombinationOptionAgreementContingentConsideration" name="BusinessCombinationOptionAgreementContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold" name="BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_BusinessCombinationOptionAgreementPurchasePrice" name="BusinessCombinationOptionAgreementPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity" name="BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash" name="BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_BusinessCombinationOptionAgreementSharePrice" name="BusinessCombinationOptionAgreementSharePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment" name="BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_CNSA001ProgramMember" name="CNSA001ProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_CensaPharmaceuticalsInc.Member" name="CensaPharmaceuticalsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_CensaPharmaceuticalsIncEquityHoldersMember" name="CensaPharmaceuticalsIncEquityHoldersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_ChangeinFairValueofContingentConsideration" name="ChangeinFairValueofContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants" name="ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_ClinicalTrialExpensePolicyTextBlock" name="ClinicalTrialExpensePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_CommitmentAndContingencyLineItems" name="CommitmentAndContingencyLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_CommitmentAndContingencyTable" name="CommitmentAndContingencyTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_ContingentFutureLegalFeeAdvancePayment" name="ContingentFutureLegalFeeAdvancePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_ConvertibleNotesDue2019Member" name="ConvertibleNotesDue2019Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_DebtConversionEquity" name="DebtConversionEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="rtrx_DebtConversionLiability" name="DebtConversionLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000" name="DebtInstrumentConvertibleNoteMarketPricePer1000" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod" name="DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent" name="DebtSecuritiesAvailableForSaleUnrealizedGainCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent" name="DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent" name="DebtSecuritiesAvailableForSaleUnrealizedLossCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent" name="DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent" name="DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent" name="DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="rtrx_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_GovernmentRebatesPayable" name="GovernmentRebatesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="rtrx_InterestReceivablefromNotesReceivable" name="InterestReceivablefromNotesReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers" name="LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_MartinShkreliMember" name="MartinShkreliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_NotePurchaseAgreementMember" name="NotePurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_NumberOfProductsSold" name="NumberOfProductsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="rtrx_NumberofTranches" name="NumberofTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_PaymentOfGuaranteedMinimumRoyalty" name="PaymentOfGuaranteedMinimumRoyalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="rtrx_PaymentsForTheOptionToAcquireBusiness" name="PaymentsForTheOptionToAcquireBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="rtrx_ProceedsfromMaturityofNoteReceivable" name="ProceedsfromMaturityofNoteReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_ProductRightsChenodalMember" name="ProductRightsChenodalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_ProvisionForInventory" name="ProvisionForInventory" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_RetrophinInc.v.ShkreliMember" name="RetrophinInc.v.ShkreliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_SanDiegoCACorporateMember" name="SanDiegoCACorporateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock" name="ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_SeniorNotesDue2025Member" name="SeniorNotesDue2025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="rtrx_ThiolaLicenseMember" name="ThiolaLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="rtrx_TradingPricePerPrincipalPercentage" name="TradingPricePerPrincipalPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>rtrx-20180930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.retrophin.com/role/AccountsReceivable" xlink:href="rtrx-20180930.xsd#AccountsReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccountsReceivableDetails" xlink:href="rtrx-20180930.xsd#AccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpenses" xlink:href="rtrx-20180930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpensesDetails" xlink:href="rtrx-20180930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpensesTables" xlink:href="rtrx-20180930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingencies" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesTables" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheets" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayable" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableCompositionOfNotesDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableCompositionOfNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstruments" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsDetails" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DescriptionOfBusiness" xlink:href="rtrx-20180930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DescriptionOfBusinessNarrativeDetails" xlink:href="rtrx-20180930.xsd#DescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DocumentAndEntityInformation" xlink:href="rtrx-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurements" xlink:href="rtrx-20180930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsTables" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:href="rtrx-20180930.xsd#FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:href="rtrx-20180930.xsd#FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxes" xlink:href="rtrx-20180930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:href="rtrx-20180930.xsd#IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesTables" xlink:href="rtrx-20180930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssets" xlink:href="rtrx-20180930.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsAmortizationDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsTables" xlink:href="rtrx-20180930.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/Inventory" xlink:href="rtrx-20180930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/InventoryDetails" xlink:href="rtrx-20180930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/InventoryTables" xlink:href="rtrx-20180930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShare" xlink:href="rtrx-20180930.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareAntidilutiveSharesDetails" xlink:href="rtrx-20180930.xsd#LossPerCommonShareAntidilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareEpsReconciliationDetails" xlink:href="rtrx-20180930.xsd#LossPerCommonShareEpsReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareTables" xlink:href="rtrx-20180930.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecurities" xlink:href="rtrx-20180930.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesMarketableSecuritiesDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesTables" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognition" xlink:href="rtrx-20180930.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognitionDetails" xlink:href="rtrx-20180930.xsd#RevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognitionTables" xlink:href="rtrx-20180930.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensation" xlink:href="rtrx-20180930.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationExerciseOfWarrantsDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationExerciseOfWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationRestrictedStockActivityDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationTables" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/AccountsReceivable" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/AccountsReceivableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_GovernmentRebatesPayable" xlink:label="loc_rtrx_GovernmentRebatesPayable_b52fa40c-a834-d975-975e-0801557332b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_rtrx_GovernmentRebatesPayable_b52fa40c-a834-d975-975e-0801557332b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_a6800cd8-5421-aa7f-a4dc-501c17b7ce00" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedSalariesCurrent_a6800cd8-5421-aa7f-a4dc-501c17b7ce00" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedRoyaltyandContingentConsideration" xlink:label="loc_rtrx_AccruedRoyaltyandContingentConsideration_29972ad6-23cd-ea4e-c165-0801557969ce" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_rtrx_AccruedRoyaltyandContingentConsideration_29972ad6-23cd-ea4e-c165-0801557969ce" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent" xlink:label="loc_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_ae5dede5-ef04-e381-f9a0-0801556503e6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_ae5dede5-ef04-e381-f9a0-0801556503e6" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent" xlink:label="loc_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_38c28502-103f-f0a3-7c61-08015581a2fd" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_38c28502-103f-f0a3-7c61-08015581a2fd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_f629ab7c-c078-dabf-13b0-6f2405adc07d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_RestructuringReserve_f629ab7c-c078-dabf-13b0-6f2405adc07d" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesMiscellaneous" xlink:label="loc_rtrx_AccruedLiabilitiesMiscellaneous_2f79331c-f2a1-0015-9cb3-080155a66a05" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_rtrx_AccruedLiabilitiesMiscellaneous_2f79331c-f2a1-0015-9cb3-080155a66a05" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_5c64780a-8042-167d-1fc1-34577f9444e7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidTaxes_5c64780a-8042-167d-1fc1-34577f9444e7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_0682cfaa-83e6-dea4-d697-0d84430cc679" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_EquityMethodInvestments_0682cfaa-83e6-dea4-d697-0d84430cc679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_dd3f0ff4-453d-8a72-0356-517c43549266" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_dd3f0ff4-453d-8a72-0356-517c43549266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquisitionRelatedContingentConsideration" xlink:label="loc_rtrx_AcquisitionRelatedContingentConsideration_70fa35b9-7783-38a9-efce-08015575a7d4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_rtrx_AcquisitionRelatedContingentConsideration_70fa35b9-7783-38a9-efce-08015575a7d4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_c7c7a8e6-572a-9256-f376-4dd1f8619b3c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_c7c7a8e6-572a-9256-f376-4dd1f8619b3c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_690493cd-e4bf-5e73-1767-85beb84cea8f" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_690493cd-e4bf-5e73-1767-85beb84cea8f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedRoyaltiesNoncurrent" xlink:label="loc_rtrx_AccruedRoyaltiesNoncurrent_ae4433f3-1ce1-a3f8-567b-0801555654bf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_rtrx_AccruedRoyaltiesNoncurrent_ae4433f3-1ce1-a3f8-567b-0801555654bf" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquisitionRelatedContingentConsiderationNoncurrent" xlink:label="loc_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_4c99013e-8e8e-73d2-e7a0-08015578ce69" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_4c99013e-8e8e-73d2-e7a0-08015578ce69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_a41198df-b22a-3bd2-a600-5a29e5401161" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_a41198df-b22a-3bd2-a600-5a29e5401161" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8ca40fc7-564f-832a-56a7-2cfd188fe573" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8ca40fc7-564f-832a-56a7-2cfd188fe573" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_PaymentOfGuaranteedMinimumRoyalty" xlink:label="loc_rtrx_PaymentOfGuaranteedMinimumRoyalty_9f987792-155f-f7aa-7e4a-08015557c56e" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_rtrx_PaymentOfGuaranteedMinimumRoyalty_9f987792-155f-f7aa-7e4a-08015557c56e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_70880ab2-48d8-54d5-3a7f-b434da972fe2" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_70880ab2-48d8-54d5-3a7f-b434da972fe2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_10fbb3c9-1c28-35d7-5a0c-45b62dee404f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_10fbb3c9-1c28-35d7-5a0c-45b62dee404f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_1ffc3ea6-d4bd-26c0-3534-7aa00d7a2e4c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_1ffc3ea6-d4bd-26c0-3534-7aa00d7a2e4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_d27f3047-455e-c674-a905-591ddccb898b" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_d27f3047-455e-c674-a905-591ddccb898b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_38e7f3e2-9d1a-8772-e4aa-fb2cb7d8adc0" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_38e7f3e2-9d1a-8772-e4aa-fb2cb7d8adc0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33cd5d62-efc5-7725-6424-7800a10af341" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33cd5d62-efc5-7725-6424-7800a10af341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProceedsfromMaturityofNoteReceivable" xlink:label="loc_rtrx_ProceedsfromMaturityofNoteReceivable_6425acfb-d0f9-8cd5-c38f-0801559ceb4d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_rtrx_ProceedsfromMaturityofNoteReceivable_6425acfb-d0f9-8cd5-c38f-0801559ceb4d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1db37fac-6ce5-5d1f-3f25-b01134e09873" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1db37fac-6ce5-5d1f-3f25-b01134e09873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_InterestReceivablefromNotesReceivable" xlink:label="loc_rtrx_InterestReceivablefromNotesReceivable_e319a146-21b3-4b75-d143-0801558fae16" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_rtrx_InterestReceivablefromNotesReceivable_e319a146-21b3-4b75-d143-0801558fae16" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NoncashInterestExpense" xlink:label="loc_rtrx_NoncashInterestExpense_b16204d8-2b8f-5a5d-562a-08015583f16f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_rtrx_NoncashInterestExpense_b16204d8-2b8f-5a5d-562a-08015583f16f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1b3da715-8d28-869a-fc9e-cb75bcd8d652" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1b3da715-8d28-869a-fc9e-cb75bcd8d652" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProvisionForInventory" xlink:label="loc_rtrx_ProvisionForInventory_72ea3c3a-9d39-b78b-55cf-08015560364b" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_rtrx_ProvisionForInventory_72ea3c3a-9d39-b78b-55cf-08015560364b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ChangeinFairValueofContingentConsideration" xlink:label="loc_rtrx_ChangeinFairValueofContingentConsideration_852ff587-4165-3aa2-48c5-0801555ee33e" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_rtrx_ChangeinFairValueofContingentConsideration_852ff587-4165-3aa2-48c5-0801555ee33e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9dbcf839-4ba1-0e2b-8942-4c8a9981ac5b" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9dbcf839-4ba1-0e2b-8942-4c8a9981ac5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_72092153-6d23-6ed2-386d-5561faf5c226" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_72092153-6d23-6ed2-386d-5561faf5c226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="locator" />
    <link:calculationArc order="15" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="16" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="17" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="locator" />
    <link:calculationArc order="18" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="locator" />
    <link:calculationArc order="20" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_80036452-8f22-8b77-cf8f-49eda674198d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_80036452-8f22-8b77-cf8f-49eda674198d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b28ba7ff-6f6a-a222-c7cf-0da1704e7466" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b28ba7ff-6f6a-a222-c7cf-0da1704e7466" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_f6f76be7-79b0-7b7c-26ca-b40461ca94db" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_LitigationSettlementExpense_f6f76be7-79b0-7b7c-26ca-b40461ca94db" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ChangeinFairValueofContingentConsideration" xlink:label="loc_rtrx_ChangeinFairValueofContingentConsideration_852ff587-4165-3aa2-48c5-0801555ee33e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_rtrx_ChangeinFairValueofContingentConsideration_852ff587-4165-3aa2-48c5-0801555ee33e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_db31a483-6e91-bb9e-3d96-563ab3da2f2c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_db31a483-6e91-bb9e-3d96-563ab3da2f2c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c7333cca-378d-a6fc-ae13-b512babfcdeb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c7333cca-378d-a6fc-ae13-b512babfcdeb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayable" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableCompositionOfNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c4b02274-72e3-29b7-85b4-945f4b5c02e0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c4b02274-72e3-29b7-85b4-945f4b5c02e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_450782c6-2839-854f-cd33-795c87a08ecc" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_450782c6-2839-854f-cd33-795c87a08ecc" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/DescriptionOfBusinessNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_690493cd-e4bf-5e73-1767-85beb84cea8f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_690493cd-e4bf-5e73-1767-85beb84cea8f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eed137f7-f4cf-61e8-5dd4-67d3dd178f58" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eed137f7-f4cf-61e8-5dd4-67d3dd178f58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsAmortizationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a979ceab-3c76-a4d5-9d1d-ca902d5e8595" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a979ceab-3c76-a4d5-9d1d-ca902d5e8595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareAntidilutiveSharesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareEpsReconciliationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/MarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_EB138A5D8485F1F3CEA6C6AAC56661E6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_EB138A5D8485F1F3CEA6C6AAC56661E6" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_159B9F246E90833DB5FBC6AC1AFBF13F" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_159B9F246E90833DB5FBC6AC1AFBF13F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_be079aae-289b-18f4-8773-0801559b9421" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_be079aae-289b-18f4-8773-0801559b9421" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_5f9aaaca-fa35-0f29-a05c-080155b654db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_5f9aaaca-fa35-0f29-a05c-080155b654db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_2498357e-e574-2146-c95d-0801556e5ed6" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_2498357e-e574-2146-c95d-0801556e5ed6" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_EB138A5D8485F1F3CEA6C6AAC56661E6" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_2498357e-e574-2146-c95d-0801556e5ed6" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_be079aae-289b-18f4-8773-0801559b9421" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_2498357e-e574-2146-c95d-0801556e5ed6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_3cafb87e-a082-cd71-d921-0801556ad9d2" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_3cafb87e-a082-cd71-d921-0801556ad9d2" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_159B9F246E90833DB5FBC6AC1AFBF13F" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_3cafb87e-a082-cd71-d921-0801556ad9d2" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_5f9aaaca-fa35-0f29-a05c-080155b654db" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_3cafb87e-a082-cd71-d921-0801556ad9d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesMarketableSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/RevenueRecognition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/RevenueRecognitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/RevenueRecognitionTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationExerciseOfWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationRestrictedStockActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>rtrx-20180930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.retrophin.com/role/AccountsReceivable" xlink:href="rtrx-20180930.xsd#AccountsReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccountsReceivableDetails" xlink:href="rtrx-20180930.xsd#AccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpenses" xlink:href="rtrx-20180930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpensesDetails" xlink:href="rtrx-20180930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpensesTables" xlink:href="rtrx-20180930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingencies" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesTables" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheets" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayable" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableCompositionOfNotesDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableCompositionOfNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstruments" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsDetails" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DescriptionOfBusiness" xlink:href="rtrx-20180930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DescriptionOfBusinessNarrativeDetails" xlink:href="rtrx-20180930.xsd#DescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DocumentAndEntityInformation" xlink:href="rtrx-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurements" xlink:href="rtrx-20180930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsTables" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:href="rtrx-20180930.xsd#FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:href="rtrx-20180930.xsd#FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxes" xlink:href="rtrx-20180930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:href="rtrx-20180930.xsd#IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesTables" xlink:href="rtrx-20180930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssets" xlink:href="rtrx-20180930.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsAmortizationDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsTables" xlink:href="rtrx-20180930.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/Inventory" xlink:href="rtrx-20180930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/InventoryDetails" xlink:href="rtrx-20180930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/InventoryTables" xlink:href="rtrx-20180930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShare" xlink:href="rtrx-20180930.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareAntidilutiveSharesDetails" xlink:href="rtrx-20180930.xsd#LossPerCommonShareAntidilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareEpsReconciliationDetails" xlink:href="rtrx-20180930.xsd#LossPerCommonShareEpsReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareTables" xlink:href="rtrx-20180930.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecurities" xlink:href="rtrx-20180930.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesMarketableSecuritiesDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesTables" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognition" xlink:href="rtrx-20180930.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognitionDetails" xlink:href="rtrx-20180930.xsd#RevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognitionTables" xlink:href="rtrx-20180930.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensation" xlink:href="rtrx-20180930.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationExerciseOfWarrantsDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationExerciseOfWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationRestrictedStockActivityDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationTables" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/AccountsReceivable" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/AccountsReceivableDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CommitmentAndContingencyLineItems" xlink:label="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:type="locator" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CommitmentAndContingencyTable" xlink:label="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:to="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:to="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:to="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_RetrophinInc.v.ShkreliMember" xlink:label="loc_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:to="loc_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_04E44F0C14233D341662BC63D7C8DFCA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:to="loc_srt_CounterpartyNameAxis_04E44F0C14233D341662BC63D7C8DFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24EE785F1C6980B236EFBC63D7C87A99_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_04E44F0C14233D341662BC63D7C8DFCA" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24EE785F1C6980B236EFBC63D7C87A99_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24EE785F1C6980B236EFBC63D7C87A99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_04E44F0C14233D341662BC63D7C8DFCA" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24EE785F1C6980B236EFBC63D7C87A99" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_MartinShkreliMember" xlink:label="loc_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24EE785F1C6980B236EFBC63D7C87A99" xlink:to="loc_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ContingentFutureLegalFeeAdvancePayment" xlink:label="loc_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers" xlink:label="loc_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:to="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementAxis" xlink:label="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:to="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementDomain" xlink:label="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:to="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33_default" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementDomain" xlink:label="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:to="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_LeaseAgreementMember" xlink:label="loc_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:to="loc_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:to="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:to="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:to="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SanDiegoCACorporateMember" xlink:label="loc_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:to="loc_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="loc_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:to="loc_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:to="loc_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayable" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableCompositionOfNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2F5792B65688335CD318C7178B43FB61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2F5792B65688335CD318C7178B43FB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_14FE4DF68C87DD04494BC7178B445BA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2F5792B65688335CD318C7178B43FB61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_14FE4DF68C87DD04494BC7178B445BA1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_14FE4DF68C87DD04494BC7178B445BA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2F5792B65688335CD318C7178B43FB61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_14FE4DF68C87DD04494BC7178B445BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_6E208E56D6ECAB805CF4C7178B442D45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_14FE4DF68C87DD04494BC7178B445BA1" xlink:to="loc_us-gaap_SeniorNotesMember_6E208E56D6ECAB805CF4C7178B442D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0D0018FA349631AE951CC7178B44B011" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:to="loc_us-gaap_DebtInstrumentAxis_0D0018FA349631AE951CC7178B44B011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0D0018FA349631AE951CC7178B44B011" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0D0018FA349631AE951CC7178B44B011" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_79AB2D42B8536E1BBCF5C7178B451FE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E" xlink:to="loc_rtrx_SeniorNotesDue2025Member_79AB2D42B8536E1BBCF5C7178B451FE3" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ConvertibleNotesDue2019Member" xlink:label="loc_rtrx_ConvertibleNotesDue2019Member_3A865AB4D88C4B7F2EADC7178B45E5C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E" xlink:to="loc_rtrx_ConvertibleNotesDue2019Member_3A865AB4D88C4B7F2EADC7178B45E5C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:to="loc_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementAxis" xlink:label="loc_rtrx_AgreementAxis_C673FCD93336518D9FFCC7178B50A3E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:to="loc_rtrx_AgreementAxis_C673FCD93336518D9FFCC7178B50A3E8" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementDomain" xlink:label="loc_rtrx_AgreementDomain_004E932AA13E47D20380C7178B503651_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rtrx_AgreementAxis_C673FCD93336518D9FFCC7178B50A3E8" xlink:to="loc_rtrx_AgreementDomain_004E932AA13E47D20380C7178B503651_default" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementDomain" xlink:label="loc_rtrx_AgreementDomain_004E932AA13E47D20380C7178B503651" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rtrx_AgreementAxis_C673FCD93336518D9FFCC7178B50A3E8" xlink:to="loc_rtrx_AgreementDomain_004E932AA13E47D20380C7178B503651" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NotePurchaseAgreementMember" xlink:label="loc_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtrx_AgreementDomain_004E932AA13E47D20380C7178B503651" xlink:to="loc_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:to="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:to="loc_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ConvertibleNotesDue2019Member" xlink:label="loc_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:to="loc_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:to="loc_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtConversionLiability" xlink:label="loc_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtConversionEquity" xlink:label="loc_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod" xlink:label="loc_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_TradingPricePerPrincipalPercentage" xlink:label="loc_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000" xlink:label="loc_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:to="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2494CDFE8DF658C7D22BBC63D802406A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2494CDFE8DF658C7D22BBC63D802406A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_604A3E97BD72F84362A4BC63D802B1EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2494CDFE8DF658C7D22BBC63D802406A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_604A3E97BD72F84362A4BC63D802B1EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_604A3E97BD72F84362A4BC63D802B1EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2494CDFE8DF658C7D22BBC63D802406A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_604A3E97BD72F84362A4BC63D802B1EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_2E2F6EB1A7EC4E090D9BBC63D8035815" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_604A3E97BD72F84362A4BC63D802B1EB" xlink:to="loc_us-gaap_SeniorNotesMember_2E2F6EB1A7EC4E090D9BBC63D8035815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_FBF20F4D4F6F79EAD046BC63D8035CAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:to="loc_us-gaap_DebtInstrumentAxis_FBF20F4D4F6F79EAD046BC63D8035CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9D94854D82AC1A927458BC63D804FCD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_FBF20F4D4F6F79EAD046BC63D8035CAC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9D94854D82AC1A927458BC63D804FCD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9D94854D82AC1A927458BC63D804FCD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_FBF20F4D4F6F79EAD046BC63D8035CAC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9D94854D82AC1A927458BC63D804FCD0" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_DD77E73E76A63B960CC0BC63D804BFEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9D94854D82AC1A927458BC63D804FCD0" xlink:to="loc_rtrx_SeniorNotesDue2025Member_DD77E73E76A63B960CC0BC63D804BFEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:to="loc_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_CD3D7A47BE8F01FF5242BC63D863C023" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:to="loc_us-gaap_DerivativeTable_CD3D7A47BE8F01FF5242BC63D863C023" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_751512BA6BFECA6DDAA1BC63D8638700" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_CD3D7A47BE8F01FF5242BC63D863C023" xlink:to="loc_us-gaap_FinancialInstrumentAxis_751512BA6BFECA6DDAA1BC63D8638700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71046887D75C770B6F4ABC63D86408C0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_751512BA6BFECA6DDAA1BC63D8638700" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71046887D75C770B6F4ABC63D86408C0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71046887D75C770B6F4ABC63D86408C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_751512BA6BFECA6DDAA1BC63D8638700" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71046887D75C770B6F4ABC63D86408C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71046887D75C770B6F4ABC63D86408C0" xlink:to="loc_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NumberofTranches" xlink:label="loc_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:to="loc_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5F485F88EC5E24FA8E19BC63D86576FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5F485F88EC5E24FA8E19BC63D86576FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_3DF098E02E6D47880EF3BC63D8656362" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_3DF098E02E6D47880EF3BC63D8656362" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:to="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1813668A2984C09CAA9AC6E7CF208B7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:to="loc_us-gaap_WarrantMember_1813668A2984C09CAA9AC6E7CF208B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:to="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:to="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:to="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:to="loc_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:to="loc_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:to="loc_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/DescriptionOfBusinessNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F46F8ED93126BCD261840CBA724BADB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F46F8ED93126BCD261840CBA724BADB2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29CDDCB9F429E70D1F8F0CBA7244036D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29CDDCB9F429E70D1F8F0CBA7244036D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_76FBF3D285B430119F800CBA7244C8B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29CDDCB9F429E70D1F8F0CBA7244036D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_76FBF3D285B430119F800CBA7244C8B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_76FBF3D285B430119F800CBA7244C8B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29CDDCB9F429E70D1F8F0CBA7244036D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_76FBF3D285B430119F800CBA7244C8B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_82F3B05668A1652B61100CBA7245029C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_76FBF3D285B430119F800CBA7244C8B9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_82F3B05668A1652B61100CBA7245029C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DB2E1C9DB5BDC6770C900CBA72452B69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DB2E1C9DB5BDC6770C900CBA72452B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4A4CD0075FE16B5C8ACE0CBA7245E240_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DB2E1C9DB5BDC6770C900CBA72452B69" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4A4CD0075FE16B5C8ACE0CBA7245E240_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4A4CD0075FE16B5C8ACE0CBA7245E240" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DB2E1C9DB5BDC6770C900CBA72452B69" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4A4CD0075FE16B5C8ACE0CBA7245E240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4A4CD0075FE16B5C8ACE0CBA7245E240" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F46F8ED93126BCD261840CBA724BADB2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DAB3256B7799DB51CB07CBD76AB01D98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DAB3256B7799DB51CB07CBD76AB01D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B5C3540732941D594405CBD76AB09F74_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DAB3256B7799DB51CB07CBD76AB01D98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B5C3540732941D594405CBD76AB09F74_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B5C3540732941D594405CBD76AB09F74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DAB3256B7799DB51CB07CBD76AB01D98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B5C3540732941D594405CBD76AB09F74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_53E12616E0E38FA0B78CCBD76AB14351" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B5C3540732941D594405CBD76AB09F74" xlink:to="loc_us-gaap_SeniorNotesMember_53E12616E0E38FA0B78CCBD76AB14351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9FBD6416327AAA041BD1CBD76AB14073" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:to="loc_us-gaap_DebtInstrumentAxis_9FBD6416327AAA041BD1CBD76AB14073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9FBD6416327AAA041BD1CBD76AB14073" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9FBD6416327AAA041BD1CBD76AB14073" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ConvertibleNotesDue2019Member" xlink:label="loc_rtrx_ConvertibleNotesDue2019Member_58928872F8F951B44F1ECBD76AB24B3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3" xlink:to="loc_rtrx_ConvertibleNotesDue2019Member_58928872F8F951B44F1ECBD76AB24B3D" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_058E54CA91F922B1FC03CBD76AB2D054" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3" xlink:to="loc_rtrx_SeniorNotesDue2025Member_058E54CA91F922B1FC03CBD76AB2D054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProductRightsChenodalMember" xlink:label="loc_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:to="loc_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquiredProductRightsCholbamMember" xlink:label="loc_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:to="loc_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquiredProductRightsLUDCAMember" xlink:label="loc_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:to="loc_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6C40B64ADC7292F7616ACBD76AB5FAD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6C40B64ADC7292F7616ACBD76AB5FAD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ChangeinFairValueofContingentConsideration" xlink:label="loc_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1B8734FC141C3F77BA3FCBD76AB61260" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1B8734FC141C3F77BA3FCBD76AB61260" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CensaPharmaceuticalsInc.Member" xlink:label="loc_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:to="loc_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CensaPharmaceuticalsIncEquityHoldersMember" xlink:label="loc_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:to="loc_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:to="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:to="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CensaPharmaceuticalsInc.Member" xlink:label="loc_rtrx_CensaPharmaceuticalsInc.Member_5C5DAA50D5EBEF0B4C33C7178C050C00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:to="loc_rtrx_CensaPharmaceuticalsInc.Member_5C5DAA50D5EBEF0B4C33C7178C050C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:to="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:to="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CNSA001ProgramMember" xlink:label="loc_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:to="loc_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseProvisionTermsMember" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:to="loc_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_PaymentsForTheOptionToAcquireBusiness" xlink:label="loc_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones" xlink:label="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePrice" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementSharePrice" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementContingentConsideration" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding" xlink:label="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B41744D4D96792BBAB8C08017FC57F8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B41744D4D96792BBAB8C08017FC57F8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B41744D4D96792BBAB8C08017FC57F8C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B41744D4D96792BBAB8C08017FC57F8C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="loc_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="loc_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareEpsReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/MarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C3C450C9DCFD99F1C883CBE1B0D6ADD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C3C450C9DCFD99F1C883CBE1B0D6ADD2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_746D76B2B7EA2EA4D0D0CBE1B0D677DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C3C450C9DCFD99F1C883CBE1B0D6ADD2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_746D76B2B7EA2EA4D0D0CBE1B0D677DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_746D76B2B7EA2EA4D0D0CBE1B0D677DC" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_746D76B2B7EA2EA4D0D0CBE1B0D677DC" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DE3FDCE1ED39A1EBA0D8CBE1B0D715A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:to="loc_us-gaap_CommercialPaperMember_DE3FDCE1ED39A1EBA0D8CBE1B0D715A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0A8F0188095D8DFBA6DBCBE1B0D70C78" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0A8F0188095D8DFBA6DBCBE1B0D70C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0008380C297329458A0CCBE1B0D8D08B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0008380C297329458A0CCBE1B0D8D08B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_09B862413B84659D48CC0C41B09F1F77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:to="loc_us-gaap_FinancialInstrumentAxis_09B862413B84659D48CC0C41B09F1F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09B862413B84659D48CC0C41B09F1F77" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09B862413B84659D48CC0C41B09F1F77" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:to="loc_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:to="loc_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/RevenueRecognition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/RevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_A264FF48BCEA0F9E1441BBB9AB36E459" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_srt_StatementGeographicalAxis_A264FF48BCEA0F9E1441BBB9AB36E459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_FDF68B5FCEE8D120D4C4BBB9AB37050F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_A264FF48BCEA0F9E1441BBB9AB36E459" xlink:to="loc_srt_SegmentGeographicalDomain_FDF68B5FCEE8D120D4C4BBB9AB37050F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_FDF68B5FCEE8D120D4C4BBB9AB37050F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_A264FF48BCEA0F9E1441BBB9AB36E459" xlink:to="loc_srt_SegmentGeographicalDomain_FDF68B5FCEE8D120D4C4BBB9AB37050F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_FDF68B5FCEE8D120D4C4BBB9AB37050F" xlink:to="loc_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:to="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:to="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BileAcidProductsMember" xlink:label="loc_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:to="loc_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ThiolaLicenseMember" xlink:label="loc_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:to="loc_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/RevenueRecognitionTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationExerciseOfWarrantsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E35619597665B1AB3A97C60BBAFE6287" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E35619597665B1AB3A97C60BBAFE6287" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E35619597665B1AB3A97C60BBAFE6287" xlink:to="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:to="loc_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F28F9D87DB0E8CEC8CE008017E7D9CB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F28F9D87DB0E8CEC8CE008017E7D9CB5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F2143B873C15A41E5BD308017E7DAB43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F28F9D87DB0E8CEC8CE008017E7D9CB5" xlink:to="loc_us-gaap_AwardTypeAxis_F2143B873C15A41E5BD308017E7DAB43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72DCBD5CF5207AA9A5BB08017E7F9044_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_F2143B873C15A41E5BD308017E7DAB43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72DCBD5CF5207AA9A5BB08017E7F9044_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72DCBD5CF5207AA9A5BB08017E7F9044" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_F2143B873C15A41E5BD308017E7DAB43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72DCBD5CF5207AA9A5BB08017E7F9044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72DCBD5CF5207AA9A5BB08017E7F9044" xlink:to="loc_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_A67B5C58489F2A59F46708017E8B6C5A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_A67B5C58489F2A59F46708017E8B6C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_08056C246F1A4502B20A08017E8BD440" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_08056C246F1A4502B20A08017E8BD440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>rtrx-20180930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_41F9B31A50A6E3E223ED08017E0BC816_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_41F9B31A50A6E3E223ED08017E0BC816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_41F9B31A50A6E3E223ED08017E0BC816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_41F9B31A50A6E3E223ED08017E0BC816" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_41F9B31A50A6E3E223ED08017E0BC816" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992" xlink:to="lab_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754_verboseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of restricted stock activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock option issuances and balances outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share based compensation expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_33EBDF2382E8A458D81008017E997A2F_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_33EBDF2382E8A458D81008017E997A2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33EBDF2382E8A458D81008017E997A2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33EBDF2382E8A458D81008017E997A2F" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_33EBDF2382E8A458D81008017E997A2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Net Product Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0084C17E5C36A88189F08017FCAE3A1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0084C17E5C36A88189F08017FCAE3A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0084C17E5C36A88189F08017FCAE3A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0084C17E5C36A88189F08017FCAE3A1" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0084C17E5C36A88189F08017FCAE3A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of assumptions for valuation of warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_AF6D5A7E8C9665D18172CD869858BBC4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_AF6D5A7E8C9665D18172CD869858BBC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AF6D5A7E8C9665D18172CD869858BBC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AF6D5A7E8C9665D18172CD869858BBC4" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_AF6D5A7E8C9665D18172CD869858BBC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BAC70A18D3A292DBA78CD0F5B370806_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BAC70A18D3A292DBA78CD0F5B370806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BAC70A18D3A292DBA78CD0F5B370806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BAC70A18D3A292DBA78CD0F5B370806" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BAC70A18D3A292DBA78CD0F5B370806" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_511E11E5E5BF56AC265C08017E5EA3B1_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_511E11E5E5BF56AC265C08017E5EA3B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_511E11E5E5BF56AC265C08017E5EA3B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_511E11E5E5BF56AC265C08017E5EA3B1" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_511E11E5E5BF56AC265C08017E5EA3B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_78ACD1E9C0F421A6EEED08017DD82863_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_78ACD1E9C0F421A6EEED08017DD82863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_78ACD1E9C0F421A6EEED08017DD82863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_78ACD1E9C0F421A6EEED08017DD82863" xlink:to="lab_us-gaap_EarningsPerShareAbstract_78ACD1E9C0F421A6EEED08017DD82863" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:to="lab_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:to="lab_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1_label_en-US" xlink:label="lab_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:to="lab_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive shares excluded from the calculation</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66" xlink:to="lab_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD" xlink:to="lab_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of basic and diluted net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of common stock options, convertible debt and restricted stock units anti-dilutive</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_214CEF2BEF97B410925208017E93C96F_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_214CEF2BEF97B410925208017E93C96F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_214CEF2BEF97B410925208017E93C96F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_214CEF2BEF97B410925208017E93C96F" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_214CEF2BEF97B410925208017E93C96F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_BB6E9297F52412B50036B644DAD332FB_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_BB6E9297F52412B50036B644DAD332FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BB6E9297F52412B50036B644DAD332FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BB6E9297F52412B50036B644DAD332FB" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_BB6E9297F52412B50036B644DAD332FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property subject to or available for operating lease</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Property Subject to or Available for Operating Lease [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock" xlink:label="loc_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67" xlink:to="lab_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted prices in active markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant other observable inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability related to warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business combination-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding, basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C" xlink:to="lab_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted (in dollars/share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:to="lab_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_394A8FB4BE3408174638B644D87C50C3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_394A8FB4BE3408174638B644D87C50C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding, basic and diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_394A8FB4BE3408174638B644D87C50C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_394A8FB4BE3408174638B644D87C50C3" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_394A8FB4BE3408174638B644D87C50C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0BBDE999AA98C9BE6959B644D87D202D_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0BBDE999AA98C9BE6959B644D87D202D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0BBDE999AA98C9BE6959B644D87D202D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0BBDE999AA98C9BE6959B644D87D202D" xlink:to="lab_us-gaap_NetIncomeLoss_0BBDE999AA98C9BE6959B644D87D202D" xlink:type="arc" />
    <link:label id="lab_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29_terseLabel_en-US" xlink:label="lab_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government rebates payable</link:label>
    <link:label id="lab_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29_label_en-US" xlink:label="lab_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Rebates Payable</link:label>
    <link:label id="lab_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29_documentation_en-US" xlink:label="lab_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Rebates Payable</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_GovernmentRebatesPayable" xlink:label="loc_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29" xlink:to="lab_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation related costs</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8" xlink:to="lab_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8" xlink:type="arc" />
    <link:label id="lab_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31_terseLabel_en-US" xlink:label="lab_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalties and contingent consideration</link:label>
    <link:label id="lab_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31_label_en-US" xlink:label="lab_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalty and Contingent Consideration</link:label>
    <link:label id="lab_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31_documentation_en-US" xlink:label="lab_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Royalty and Contingent Consideration</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedRoyaltyandContingentConsideration" xlink:label="loc_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31" xlink:to="lab_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31" xlink:type="arc" />
    <link:label id="lab_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50_terseLabel_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50_label_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Research and Development, Current</link:label>
    <link:label id="lab_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50_documentation_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Research and Development, Current</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent" xlink:label="loc_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50" xlink:to="lab_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50" xlink:type="arc" />
    <link:label id="lab_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9_terseLabel_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9_label_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Selling, General, and Administrative, Current</link:label>
    <link:label id="lab_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9_documentation_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Selling, General, and Administrative, Current</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent" xlink:label="loc_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9" xlink:to="lab_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82" xlink:to="lab_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82" xlink:type="arc" />
    <link:label id="lab_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3_terseLabel_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous accrued</link:label>
    <link:label id="lab_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3_label_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Miscellaneous</link:label>
    <link:label id="lab_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3_documentation_en-US" xlink:label="lab_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Miscellaneous</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesMiscellaneous" xlink:label="loc_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3" xlink:to="lab_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:to="lab_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:type="arc" />
    <link:label id="lab_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427_terseLabel_en-US" xlink:label="lab_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427_label_en-US" xlink:label="lab_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427_documentation_en-US" xlink:label="lab_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information of agreement.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementAxis" xlink:label="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:to="lab_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:type="arc" />
    <link:label id="lab_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33_terseLabel_en-US" xlink:label="lab_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33_label_en-US" xlink:label="lab_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33_documentation_en-US" xlink:label="lab_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information of agreement.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementDomain" xlink:label="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:to="lab_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:type="arc" />
    <link:label id="lab_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073_terseLabel_en-US" xlink:label="lab_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Agreement</link:label>
    <link:label id="lab_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073_label_en-US" xlink:label="lab_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Agreement [Member]</link:label>
    <link:label id="lab_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073_documentation_en-US" xlink:label="lab_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about lease agreement.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_LeaseAgreementMember" xlink:label="loc_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:to="lab_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:to="lab_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:to="lab_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:type="arc" />
    <link:label id="lab_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452_terseLabel_en-US" xlink:label="lab_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego CA</link:label>
    <link:label id="lab_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452_label_en-US" xlink:label="lab_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego CA- Corporate [Member]</link:label>
    <link:label id="lab_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452_documentation_en-US" xlink:label="lab_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego CA- Corporate [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SanDiegoCACorporateMember" xlink:label="loc_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:to="lab_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:type="arc" />
    <link:label id="lab_stpr_NY_D109F41C2279321DC4CF11198AA4D02A_terseLabel_en-US" xlink:label="lab_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York, NY</link:label>
    <link:label id="lab_stpr_NY_D109F41C2279321DC4CF11198AA4D02A_label_en-US" xlink:label="lab_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="loc_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:to="lab_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Base Rent</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:to="lab_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2843BB3F5B758D75846708017F9D1C95_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2843BB3F5B758D75846708017F9D1C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2843BB3F5B758D75846708017F9D1C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2843BB3F5B758D75846708017F9D1C95" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2843BB3F5B758D75846708017F9D1C95" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_C41B76C64698FFC2AC1F08017F97FC71_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_C41B76C64698FFC2AC1F08017F97FC71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_C41B76C64698FFC2AC1F08017F97FC71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_C41B76C64698FFC2AC1F08017F97FC71" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_C41B76C64698FFC2AC1F08017F97FC71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_A4C77376B99504FE3210C7178B4E162C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_A4C77376B99504FE3210C7178B4E162C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A4C77376B99504FE3210C7178B4E162C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A4C77376B99504FE3210C7178B4E162C" xlink:to="lab_us-gaap_DebtDisclosureAbstract_A4C77376B99504FE3210C7178B4E162C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:to="lab_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:to="lab_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:type="arc" />
    <link:label id="lab_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C_verboseLabel_en-US" xlink:label="lab_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Note Purchase Agreement</link:label>
    <link:label id="lab_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C_label_en-US" xlink:label="lab_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
    <link:label id="lab_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C_documentation_en-US" xlink:label="lab_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents notes purchase agreement relating to the private placement.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NotePurchaseAgreementMember" xlink:label="loc_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:to="lab_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:to="lab_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:type="arc" />
    <link:label id="lab_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B_terseLabel_en-US" xlink:label="lab_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2025</link:label>
    <link:label id="lab_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B_label_en-US" xlink:label="lab_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B_documentation_en-US" xlink:label="lab_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2025 [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:to="lab_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:type="arc" />
    <link:label id="lab_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D_terseLabel_en-US" xlink:label="lab_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Due 2019</link:label>
    <link:label id="lab_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D_label_en-US" xlink:label="lab_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Due 2019 [Member]</link:label>
    <link:label id="lab_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D_documentation_en-US" xlink:label="lab_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Notes Due 2019 [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ConvertibleNotesDue2019Member" xlink:label="loc_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:to="lab_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior convertible notes due 2019</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:to="lab_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="lab_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, excluding current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59_terseLabel_en-US" xlink:label="lab_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, liability</link:label>
    <link:label id="lab_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59_label_en-US" xlink:label="lab_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Liability</link:label>
    <link:label id="lab_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59_documentation_en-US" xlink:label="lab_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion, Liability</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtConversionLiability" xlink:label="loc_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:to="lab_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA_terseLabel_en-US" xlink:label="lab_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, equity</link:label>
    <link:label id="lab_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA_label_en-US" xlink:label="lab_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Equity</link:label>
    <link:label id="lab_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA_documentation_en-US" xlink:label="lab_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion, Equity</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtConversionEquity" xlink:label="loc_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:to="lab_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, repurchase amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04_terseLabel_en-US" xlink:label="lab_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold consecutive days measuring period</link:label>
    <link:label id="lab_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04_label_en-US" xlink:label="lab_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Days Measuring Period</link:label>
    <link:label id="lab_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04_documentation_en-US" xlink:label="lab_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Days Measuring Period</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod" xlink:label="loc_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:to="lab_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:type="arc" />
    <link:label id="lab_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177_terseLabel_en-US" xlink:label="lab_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading price per principal, percentage</link:label>
    <link:label id="lab_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177_label_en-US" xlink:label="lab_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Price Per Principal, Percentage</link:label>
    <link:label id="lab_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177_documentation_en-US" xlink:label="lab_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trading Price Per Principal, Percentage</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_TradingPricePerPrincipalPercentage" xlink:label="loc_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:to="lab_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6_terseLabel_en-US" xlink:label="lab_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible note, market price</link:label>
    <link:label id="lab_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6_label_en-US" xlink:label="lab_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Note, Market Price, Per $1,000</link:label>
    <link:label id="lab_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6_documentation_en-US" xlink:label="lab_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Note, Market Price, Per $1,000</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000" xlink:label="loc_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:to="lab_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit agreement amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt and capital lease obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general &amp; administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_079BA15719B2DF04129ACFF600B06749_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_079BA15719B2DF04129ACFF600B06749" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_079BA15719B2DF04129ACFF600B06749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_079BA15719B2DF04129ACFF600B06749" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_079BA15719B2DF04129ACFF600B06749" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FC899E5956CC566D813DCFF600AF811C_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FC899E5956CC566D813DCFF600AF811C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FC899E5956CC566D813DCFF600AF811C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FC899E5956CC566D813DCFF600AF811C" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FC899E5956CC566D813DCFF600AF811C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, income tax penalties expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesAbstract_8C964A44B740415949B708017E3599D9_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract_8C964A44B740415949B708017E3599D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_8C964A44B740415949B708017E3599D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract_8C964A44B740415949B708017E3599D9" xlink:to="lab_us-gaap_ReceivablesAbstract_8C964A44B740415949B708017E3599D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCOUNTS RECEIVABLE</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans, Notes, Trade and Other Receivables, Excluding Allowance for Credit Losses [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_177ACAB4462BFAB8226C08017E1A3EA5_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_177ACAB4462BFAB8226C08017E1A3EA5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_177ACAB4462BFAB8226C08017E1A3EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_177ACAB4462BFAB8226C08017E1A3EA5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_177ACAB4462BFAB8226C08017E1A3EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:to="lab_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61652B5BF61A9FE62542CC28509AD490_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61652B5BF61A9FE62542CC28509AD490" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61652B5BF61A9FE62542CC28509AD490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61652B5BF61A9FE62542CC28509AD490" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61652B5BF61A9FE62542CC28509AD490" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62_label_en-US" xlink:label="lab_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62" xlink:to="lab_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5" xlink:to="lab_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC" xlink:to="lab_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment-equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3" xlink:to="lab_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7D69DE72A7FD4D2CAD9BCBF969185EBD_netLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7D69DE72A7FD4D2CAD9BCBF969185EBD" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7D69DE72A7FD4D2CAD9BCBF969185EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7D69DE72A7FD4D2CAD9BCBF969185EBD" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7D69DE72A7FD4D2CAD9BCBF969185EBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1_label_en-US" xlink:label="lab_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1" xlink:to="lab_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28_label_en-US" xlink:label="lab_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28" xlink:to="lab_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C" xlink:to="lab_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_F77695FDA3DA0B107D85CBF9691A6F8E_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_F77695FDA3DA0B107D85CBF9691A6F8E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_F77695FDA3DA0B107D85CBF9691A6F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_F77695FDA3DA0B107D85CBF9691A6F8E" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_F77695FDA3DA0B107D85CBF9691A6F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Guaranteed minimum royalty</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4" xlink:type="arc" />
    <link:label id="lab_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE_verboseLabel_en-US" xlink:label="lab_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business combination-related contingent consideration</link:label>
    <link:label id="lab_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE_label_en-US" xlink:label="lab_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition Related Contingent Consideration</link:label>
    <link:label id="lab_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE_documentation_en-US" xlink:label="lab_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying value as of the balance sheet date of the current portion of acquisition-related contingent consideration.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquisitionRelatedContingentConsideration" xlink:label="loc_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE" xlink:to="lab_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_42A443E379A1F471910ACBF9691C3BFE_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_42A443E379A1F471910ACBF9691C3BFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_42A443E379A1F471910ACBF9691C3BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_42A443E379A1F471910ACBF9691C3BFE" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_42A443E379A1F471910ACBF9691C3BFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D" xlink:to="lab_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2" xlink:type="arc" />
    <link:label id="lab_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37_terseLabel_en-US" xlink:label="lab_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guaranteed minimum royalty, less current portion</link:label>
    <link:label id="lab_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37_label_en-US" xlink:label="lab_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Noncurrent</link:label>
    <link:label id="lab_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37_documentation_en-US" xlink:label="lab_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Noncurrent</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedRoyaltiesNoncurrent" xlink:label="loc_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37" xlink:to="lab_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37" xlink:type="arc" />
    <link:label id="lab_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52_verboseLabel_en-US" xlink:label="lab_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business combination-related contingent consideration, less current portion</link:label>
    <link:label id="lab_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52_label_en-US" xlink:label="lab_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition Related Contingent Consideration Noncurrent</link:label>
    <link:label id="lab_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52_documentation_en-US" xlink:label="lab_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying value as of the balance sheet date of the noncurrent portion of acquisition-related contingent consideration.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquisitionRelatedContingentConsiderationNoncurrent" xlink:label="loc_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52" xlink:to="lab_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587_label_en-US" xlink:label="lab_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587" xlink:to="lab_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:to="lab_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock $0.0001 par value; 20,000,000 shares authorized; 0 issued and outstanding as of September 30, 2018 and December 31, 2017</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED" xlink:to="lab_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock $0.0001 par value; 100,000,000 shares authorized; 41,167,942 and 39,373,745 issued and outstanding as of September 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848" xlink:to="lab_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE" xlink:to="lab_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2018</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase from revaluation of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contractual payments included in accrued liabilities at September 30, 2018</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contractual payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F944A41145A23F7A5DDC0CBA724C02F1_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F944A41145A23F7A5DDC0CBA724C02F1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at September 30, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F944A41145A23F7A5DDC0CBA724C02F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F944A41145A23F7A5DDC0CBA724C02F1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F944A41145A23F7A5DDC0CBA724C02F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax (Expense) Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SHARE BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7" xlink:type="arc" />
    <link:label id="lab_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07_terseLabel_en-US" xlink:label="lab_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07_label_en-US" xlink:label="lab_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Common Stock Issued Upon Exercise of Warrants</link:label>
    <link:label id="lab_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07_documentation_en-US" xlink:label="lab_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Common Stock Issued Upon Exercise of Warrants</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants" xlink:label="loc_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07" xlink:to="lab_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53" xlink:type="arc" />
    <link:label id="lab_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5_terseLabel_en-US" xlink:label="lab_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products sold</link:label>
    <link:label id="lab_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5_label_en-US" xlink:label="lab_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Products Sold</link:label>
    <link:label id="lab_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5_documentation_en-US" xlink:label="lab_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Products Sold</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NumberOfProductsSold" xlink:label="loc_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5" xlink:to="lab_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:to="lab_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:to="lab_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:to="lab_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_FB964570FCDF609F6BC9C60BBB0D042E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_FB964570FCDF609F6BC9C60BBB0D042E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_FB964570FCDF609F6BC9C60BBB0D042E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_FB964570FCDF609F6BC9C60BBB0D042E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_FB964570FCDF609F6BC9C60BBB0D042E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2E20FF6E252E76E6FDFFC60BBB11E77F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2E20FF6E252E76E6FDFFC60BBB11E77F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2E20FF6E252E76E6FDFFC60BBB11E77F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2E20FF6E252E76E6FDFFC60BBB11E77F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2E20FF6E252E76E6FDFFC60BBB11E77F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized stock compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3_label_en-US" xlink:label="lab_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:to="lab_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining life of the warrants (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:to="lab_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26_label_en-US" xlink:label="lab_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:to="lab_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89_terseLabel_en-US" xlink:label="lab_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89_label_en-US" xlink:label="lab_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:to="lab_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF_label_en-US" xlink:label="lab_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:to="lab_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93_label_en-US" xlink:label="lab_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:to="lab_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:to="lab_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2_label_en-US" xlink:label="lab_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:to="lab_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D" xlink:type="arc" />
    <link:label id="lab_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5_terseLabel_en-US" xlink:label="lab_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial Expenses</link:label>
    <link:label id="lab_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5_label_en-US" xlink:label="lab_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Expense [Policy Text Block]</link:label>
    <link:label id="lab_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5_documentation_en-US" xlink:label="lab_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Expense [Policy Text Block]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ClinicalTrialExpensePolicyTextBlock" xlink:label="loc_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5" xlink:to="lab_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:to="lab_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_31C6F2205B7C70DF42D3CFE6110F78BA_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_31C6F2205B7C70DF42D3CFE6110F78BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_31C6F2205B7C70DF42D3CFE6110F78BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_31C6F2205B7C70DF42D3CFE6110F78BA" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_31C6F2205B7C70DF42D3CFE6110F78BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_BA05189E1DD9AB67063208017FB95C2E_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_BA05189E1DD9AB67063208017FB95C2E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_BA05189E1DD9AB67063208017FB95C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_BA05189E1DD9AB67063208017FB95C2E" xlink:to="lab_us-gaap_InventoryNet_BA05189E1DD9AB67063208017FB95C2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66" xlink:to="lab_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:type="arc" />
    <link:label id="lab_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1_terseLabel_en-US" xlink:label="lab_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Rights Chenodal</link:label>
    <link:label id="lab_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1_label_en-US" xlink:label="lab_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Rights Chenodal [Member]</link:label>
    <link:label id="lab_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1_documentation_en-US" xlink:label="lab_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Product Rights-Chenodal.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProductRightsChenodalMember" xlink:label="loc_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:to="lab_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:type="arc" />
    <link:label id="lab_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597_terseLabel_en-US" xlink:label="lab_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Product Rights Cholbam</link:label>
    <link:label id="lab_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597_label_en-US" xlink:label="lab_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Product Rights Cholbam [Member]</link:label>
    <link:label id="lab_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597_documentation_en-US" xlink:label="lab_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Acquired product rights.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquiredProductRightsCholbamMember" xlink:label="loc_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:to="lab_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:type="arc" />
    <link:label id="lab_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062_terseLabel_en-US" xlink:label="lab_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Product Rights L-UDCA</link:label>
    <link:label id="lab_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062_label_en-US" xlink:label="lab_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Product Rights L-UDCA [Member]</link:label>
    <link:label id="lab_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062_documentation_en-US" xlink:label="lab_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired Product Rights L-UDCA [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquiredProductRightsLUDCAMember" xlink:label="loc_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:to="lab_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:type="arc" />
    <link:label id="lab_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A_terseLabel_en-US" xlink:label="lab_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A_label_en-US" xlink:label="lab_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A_documentation_en-US" xlink:label="lab_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ChangeinFairValueofContingentConsideration" xlink:label="loc_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:to="lab_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC" xlink:type="arc" />
    <link:label id="lab_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905_verboseLabel_en-US" xlink:label="lab_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of summary of changes in estimated acquisition related contingent consideration</link:label>
    <link:label id="lab_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905_label_en-US" xlink:label="lab_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Changes In Estimated Acquisition-Related Contingent Consideration Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905_documentation_en-US" xlink:label="lab_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of summary of changes in the estimated acquisition-related contingent consideration.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock" xlink:label="loc_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905" xlink:to="lab_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">DERIVATIVE FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B" xlink:type="arc" />
    <link:label id="lab_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A_label_en-US" xlink:label="lab_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:label id="lab_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A_documentation_en-US" xlink:label="lab_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Custom Element.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DocumentAndEntityInformationAbstract" xlink:label="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="lab_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491_label_en-US" xlink:label="lab_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491" xlink:to="lab_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB" xlink:to="lab_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C_label_en-US" xlink:label="lab_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C" xlink:to="lab_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6" xlink:to="lab_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD_label_en-US" xlink:label="lab_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD" xlink:to="lab_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983_terseLabel_en-US" xlink:label="lab_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983_label_en-US" xlink:label="lab_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983" xlink:to="lab_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54" xlink:to="lab_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB_label_en-US" xlink:label="lab_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB" xlink:to="lab_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319" xlink:to="lab_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1" xlink:to="lab_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7" xlink:to="lab_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B" xlink:to="lab_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:to="lab_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:type="arc" />
    <link:label id="lab_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC_terseLabel_en-US" xlink:label="lab_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Censa Pharmaceuticals Inc.</link:label>
    <link:label id="lab_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC_label_en-US" xlink:label="lab_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Censa Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC_documentation_en-US" xlink:label="lab_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Censa Pharmaceuticals Inc. [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CensaPharmaceuticalsInc.Member" xlink:label="loc_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:to="lab_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:type="arc" />
    <link:label id="lab_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966_terseLabel_en-US" xlink:label="lab_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Censa Pharmaceuticals, Inc, Equity Holders</link:label>
    <link:label id="lab_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966_label_en-US" xlink:label="lab_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Censa Pharmaceuticals, Inc, Equity Holders [Member]</link:label>
    <link:label id="lab_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966_documentation_en-US" xlink:label="lab_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Censa Pharmaceuticals, Inc, Equity Holders [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CensaPharmaceuticalsIncEquityHoldersMember" xlink:label="loc_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:to="lab_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A_label_en-US" xlink:label="lab_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:to="lab_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062_label_en-US" xlink:label="lab_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:to="lab_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367_label_en-US" xlink:label="lab_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:to="lab_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:type="arc" />
    <link:label id="lab_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875_terseLabel_en-US" xlink:label="lab_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CNSA-001 Program</link:label>
    <link:label id="lab_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875_label_en-US" xlink:label="lab_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CNSA-001 Program [Member]</link:label>
    <link:label id="lab_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875_documentation_en-US" xlink:label="lab_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CNSA-001 Program [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CNSA001ProgramMember" xlink:label="loc_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:to="lab_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Provision Terms</link:label>
    <link:label id="lab_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2_label_en-US" xlink:label="lab_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Provision Terms [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseProvisionTermsMember" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:to="lab_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement, contract to perform for others, compensation earned</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:type="arc" />
    <link:label id="lab_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209_terseLabel_en-US" xlink:label="lab_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for the option to acquire business</link:label>
    <link:label id="lab_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209_label_en-US" xlink:label="lab_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For The Option To Acquire Business</link:label>
    <link:label id="lab_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209_documentation_en-US" xlink:label="lab_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For The Option To Acquire Business</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_PaymentsForTheOptionToAcquireBusiness" xlink:label="loc_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:to="lab_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:type="arc" />
    <link:label id="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA_terseLabel_en-US" xlink:label="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional required payments for the option to acquire business, successful development milestones</link:label>
    <link:label id="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA_label_en-US" xlink:label="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Required Payments For The Option To Acquire Business, Successful Development Milestones</link:label>
    <link:label id="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA_documentation_en-US" xlink:label="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Required Payments For The Option To Acquire Business, Successful Development Milestones</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones" xlink:label="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:to="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:type="arc" />
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91_terseLabel_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, option agreement, purchase price</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91_label_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Purchase Price</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91_documentation_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Purchase Price</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePrice" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:to="lab_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:type="arc" />
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482_terseLabel_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, option agreement, purchase price, percent transferred in cash</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482_label_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Purchase Price, Percent Transferred In Cash</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482_documentation_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Purchase Price, Percent Transferred In Cash</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:to="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:type="arc" />
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0_terseLabel_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, option agreement, purchase price, percent transferred by issuance of equity</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0_label_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Purchase Price, Percent Transferred By Issuance Of Equity</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0_documentation_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Purchase Price, Percent Transferred By Issuance Of Equity</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:to="lab_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:type="arc" />
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA_terseLabel_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, option agreement, share price (in dollars per share)</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA_label_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Share Price</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA_documentation_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Share Price</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementSharePrice" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:to="lab_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:type="arc" />
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B_terseLabel_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, option agreement, percent of consideration paid in cash if share price falls below share price threshold</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B_label_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B_documentation_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:to="lab_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:type="arc" />
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1_terseLabel_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, option agreement, weighted average ten day share price, which requires all cash payment (in dollars per share)</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1_label_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Weighted Average Ten Day Share Price, Which Requires All Cash Payment</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1_documentation_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Weighted Average Ten Day Share Price, Which Requires All Cash Payment</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:to="lab_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:type="arc" />
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579_terseLabel_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, option agreement, contingent consideration</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579_label_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Contingent Consideration</link:label>
    <link:label id="lab_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579_documentation_en-US" xlink:label="lab_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Option Agreement, Contingent Consideration</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementContingentConsideration" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:to="lab_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:type="arc" />
    <link:label id="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5_terseLabel_en-US" xlink:label="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional required payments for the option to acquire business, successful development funding</link:label>
    <link:label id="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5_label_en-US" xlink:label="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Required Payments For The Option To Acquire Business, Successful Development Funding</link:label>
    <link:label id="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5_documentation_en-US" xlink:label="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Required Payments For The Option To Acquire Business, Successful Development Funding</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding" xlink:label="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:to="lab_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E" xlink:to="lab_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D016FB6F5C7ACABCC9EFCD0E7596335B_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D016FB6F5C7ACABCC9EFCD0E7596335B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D016FB6F5C7ACABCC9EFCD0E7596335B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D016FB6F5C7ACABCC9EFCD0E7596335B" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D016FB6F5C7ACABCC9EFCD0E7596335B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale/maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of debt based marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities Available For Sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3" xlink:type="arc" />
    <link:label id="lab_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC_negatedTerseLabel_en-US" xlink:label="lab_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income from notes receivable</link:label>
    <link:label id="lab_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC_label_en-US" xlink:label="lab_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable from Notes Receivable</link:label>
    <link:label id="lab_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC_documentation_en-US" xlink:label="lab_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Receivable from Notes Receivable</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_InterestReceivablefromNotesReceivable" xlink:label="loc_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC" xlink:to="lab_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC" xlink:type="arc" />
    <link:label id="lab_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63_terseLabel_en-US" xlink:label="lab_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63_label_en-US" xlink:label="lab_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense</link:label>
    <link:label id="lab_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63_documentation_en-US" xlink:label="lab_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NoncashInterestExpense" xlink:label="loc_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63" xlink:to="lab_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premiums on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0" xlink:type="arc" />
    <link:label id="lab_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27_negatedTerseLabel_en-US" xlink:label="lab_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision for Inventory</link:label>
    <link:label id="lab_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27_label_en-US" xlink:label="lab_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision For Inventory</link:label>
    <link:label id="lab_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27_documentation_en-US" xlink:label="lab_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision For Inventory</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProvisionForInventory" xlink:label="loc_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27" xlink:to="lab_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F" xlink:to="lab_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of liability classified warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55553A21A25D32FC70A2CBD76BB2D14B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55553A21A25D32FC70A2CBD76BB2D14B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments related to change in fair value of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55553A21A25D32FC70A2CBD76BB2D14B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55553A21A25D32FC70A2CBD76BB2D14B" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55553A21A25D32FC70A2CBD76BB2D14B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on the extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for Doubtful Accounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency transaction gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net of business acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current and non-current operating assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and non-current operating liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875E39841E8B19FBD3ADCBD76BB70CD1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875E39841E8B19FBD3ADCBD76BB70CD1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875E39841E8B19FBD3ADCBD76BB70CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875E39841E8B19FBD3ADCBD76BB70CD1" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875E39841E8B19FBD3ADCBD76BB70CD1" xlink:type="arc" />
    <link:label id="lab_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20_terseLabel_en-US" xlink:label="lab_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of note receivable</link:label>
    <link:label id="lab_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20_label_en-US" xlink:label="lab_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturity of Note Receivable</link:label>
    <link:label id="lab_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20_documentation_en-US" xlink:label="lab_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Maturity of Note Receivable</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProceedsfromMaturityofNoteReceivable" xlink:label="loc_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20" xlink:to="lab_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for investments - equity</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F" xlink:type="arc" />
    <link:label id="lab_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173_negatedLabel_en-US" xlink:label="lab_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of guaranteed minimum royalty</link:label>
    <link:label id="lab_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173_label_en-US" xlink:label="lab_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Guaranteed Minimum Royalty</link:label>
    <link:label id="lab_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173_documentation_en-US" xlink:label="lab_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow due to guaranteed minimum royalty.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_PaymentOfGuaranteedMinimumRoyalty" xlink:label="loc_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173" xlink:to="lab_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of other liability</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Other Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300" xlink:to="lab_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from 2025 convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Other Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of 2019 convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance and financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DBED27C833EBB2E032ABCBD76BBC22F3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DBED27C833EBB2E032ABCBD76BBC22F3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DBED27C833EBB2E032ABCBD76BBC22F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DBED27C833EBB2E032ABCBD76BBC22F3" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_DBED27C833EBB2E032ABCBD76BBC22F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D27FC002D7053886B1F7CBD76BBCCA6E_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D27FC002D7053886B1F7CBD76BBCCA6E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D27FC002D7053886B1F7CBD76BBCCA6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D27FC002D7053886B1F7CBD76BBCCA6E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D27FC002D7053886B1F7CBD76BBCCA6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:type="arc" />
    <link:label id="lab_country_US_725DF248601C687B7C05BBB9AB378E75_terseLabel_en-US" xlink:label="lab_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_725DF248601C687B7C05BBB9AB378E75_label_en-US" xlink:label="lab_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:to="lab_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:to="lab_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:to="lab_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:type="arc" />
    <link:label id="lab_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66_terseLabel_en-US" xlink:label="lab_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bile acid products</link:label>
    <link:label id="lab_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66_label_en-US" xlink:label="lab_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bile Acid Products [Member]</link:label>
    <link:label id="lab_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66_documentation_en-US" xlink:label="lab_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bile Acid Products</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BileAcidProductsMember" xlink:label="loc_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:to="lab_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:type="arc" />
    <link:label id="lab_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7_terseLabel_en-US" xlink:label="lab_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thiola</link:label>
    <link:label id="lab_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7_label_en-US" xlink:label="lab_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thiola License [Member]</link:label>
    <link:label id="lab_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7_documentation_en-US" xlink:label="lab_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Custom Element.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ThiolaLicenseMember" xlink:label="loc_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:to="lab_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contract with customer, excluding assessed tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:type="arc" />
    <link:label id="lab_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1_terseLabel_en-US" xlink:label="lab_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment And Contingency [Table]</link:label>
    <link:label id="lab_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1_label_en-US" xlink:label="lab_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment And Contingency [Table]</link:label>
    <link:label id="lab_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1_documentation_en-US" xlink:label="lab_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by type of commitment and contingency.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CommitmentAndContingencyTable" xlink:label="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:to="lab_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:to="lab_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:to="lab_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:type="arc" />
    <link:label id="lab_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D_terseLabel_en-US" xlink:label="lab_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retrophin, Inc. v. Shkreli</link:label>
    <link:label id="lab_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D_label_en-US" xlink:label="lab_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retrophin, Inc. v. Shkreli, [Member]</link:label>
    <link:label id="lab_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D_documentation_en-US" xlink:label="lab_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retrophin, Inc. v. Shkreli, [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_RetrophinInc.v.ShkreliMember" xlink:label="loc_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:to="lab_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:type="arc" />
    <link:label id="lab_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298_terseLabel_en-US" xlink:label="lab_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Martin Shkreli</link:label>
    <link:label id="lab_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298_label_en-US" xlink:label="lab_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Martin Shkreli [Member]</link:label>
    <link:label id="lab_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298_documentation_en-US" xlink:label="lab_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Martin Shkreli [Member]</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_MartinShkreliMember" xlink:label="loc_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:to="lab_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:type="arc" />
    <link:label id="lab_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0_terseLabel_en-US" xlink:label="lab_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment And Contingency [Line Items]</link:label>
    <link:label id="lab_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0_label_en-US" xlink:label="lab_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment And Contingency [Line Items]</link:label>
    <link:label id="lab_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0_documentation_en-US" xlink:label="lab_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CommitmentAndContingencyLineItems" xlink:label="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="lab_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:type="arc" />
    <link:label id="lab_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A_terseLabel_en-US" xlink:label="lab_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent future legal fee advance payment</link:label>
    <link:label id="lab_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A_label_en-US" xlink:label="lab_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Future Legal Fee Advance Payment</link:label>
    <link:label id="lab_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A_documentation_en-US" xlink:label="lab_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Future Legal Fee Advance Payment</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ContingentFutureLegalFeeAdvancePayment" xlink:label="loc_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:to="lab_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:type="arc" />
    <link:label id="lab_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7_terseLabel_en-US" xlink:label="lab_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees reimbursed from director and officer insurance carriers</link:label>
    <link:label id="lab_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7_label_en-US" xlink:label="lab_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Fees Reimbursed From Director and Officer Insurance Carriers</link:label>
    <link:label id="lab_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7_documentation_en-US" xlink:label="lab_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal Fees Reimbursed From Director and Officer Insurance Carriers</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers" xlink:label="loc_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:to="lab_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A_label_en-US" xlink:label="lab_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:to="lab_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:to="lab_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Securities of government sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:to="lab_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340_verboseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340" xlink:to="lab_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="lab_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4F041400FC40449A219CD10E8ED00FC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4F041400FC40449A219CD10E8ED00FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4F041400FC40449A219CD10E8ED00FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4F041400FC40449A219CD10E8ED00FC" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4F041400FC40449A219CD10E8ED00FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:to="lab_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fee settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358" xlink:to="lab_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358" xlink:type="arc" />
    <link:label id="lab_rtrx_ChangeinFairValueofContingentConsideration_DCFAE984B01D4A82C588CD10E8EF6496_verboseLabel_en-US" xlink:label="lab_rtrx_ChangeinFairValueofContingentConsideration_DCFAE984B01D4A82C588CD10E8EF6496" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ChangeinFairValueofContingentConsideration" xlink:label="loc_rtrx_ChangeinFairValueofContingentConsideration_DCFAE984B01D4A82C588CD10E8EF6496" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_ChangeinFairValueofContingentConsideration_DCFAE984B01D4A82C588CD10E8EF6496" xlink:to="lab_rtrx_ChangeinFairValueofContingentConsideration_DCFAE984B01D4A82C588CD10E8EF6496" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956" xlink:to="lab_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA" xlink:to="lab_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16" xlink:to="lab_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expenses), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_BE293CFA8ED1BEDF861BCD10E8F0EF0A_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_BE293CFA8ED1BEDF861BCD10E8F0EF0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BE293CFA8ED1BEDF861BCD10E8F0EF0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BE293CFA8ED1BEDF861BCD10E8F0EF0A" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_BE293CFA8ED1BEDF861BCD10E8F0EF0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_5696432595622CD650BDCD10E8F0FD30_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_5696432595622CD650BDCD10E8F0FD30" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5696432595622CD650BDCD10E8F0FD30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_5696432595622CD650BDCD10E8F0FD30" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_5696432595622CD650BDCD10E8F0FD30" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_831AA03BA2A95B0B5FC4CD10E8F1D664_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_831AA03BA2A95B0B5FC4CD10E8F1D664" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_831AA03BA2A95B0B5FC4CD10E8F1D664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_831AA03BA2A95B0B5FC4CD10E8F1D664" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_831AA03BA2A95B0B5FC4CD10E8F1D664" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_00EC32AA4C71FA8745C6CD10E8F27211_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_00EC32AA4C71FA8745C6CD10E8F27211" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_00EC32AA4C71FA8745C6CD10E8F27211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_00EC32AA4C71FA8745C6CD10E8F27211" xlink:to="lab_us-gaap_NetIncomeLoss_00EC32AA4C71FA8745C6CD10E8F27211" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D54458B3A2651781A92BCD10E8F2EA4D_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D54458B3A2651781A92BCD10E8F2EA4D" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D54458B3A2651781A92BCD10E8F2EA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D54458B3A2651781A92BCD10E8F2EA4D" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D54458B3A2651781A92BCD10E8F2EA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Realized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61" xlink:to="lab_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares Underlying Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D262D3EE6C30FA6C44D08017E84A9FF_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D262D3EE6C30FA6C44D08017E84A9FF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D262D3EE6C30FA6C44D08017E84A9FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D262D3EE6C30FA6C44D08017E84A9FF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D262D3EE6C30FA6C44D08017E84A9FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1705846F438EDB6A57CA08017E861A56_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1705846F438EDB6A57CA08017E861A56" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1705846F438EDB6A57CA08017E861A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1705846F438EDB6A57CA08017E861A56" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1705846F438EDB6A57CA08017E861A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54_totalLabel_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, amortized cost basis, current</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54_label_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost Basis, Current</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54_documentation_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost Basis, Current</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:to="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695_terseLabel_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities available for sale, unrealized gain, current</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695_label_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Available For Sale, Unrealized Gain, Current</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695_documentation_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Available For Sale, Unrealized Gain, Current</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:to="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607_negatedTerseLabel_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt securities available for sale unrealized loss, current</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607_label_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Available For Sale Unrealized Loss, Current</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607_documentation_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available For Sale, Unrealized Loss, Current</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:to="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917_totalLabel_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, amortized cost basis, noncurrent</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917_label_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost Basis, Noncurrent</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917_documentation_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost Basis, Noncurrent</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:to="lab_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992_terseLabel_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available for sale unrealized gain, noncurrent</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992_label_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available For Sale Unrealized Gain, Noncurrent</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992_documentation_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available For Sale Unrealized Gain, Noncurrent</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:to="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:type="arc" />
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B_negatedTerseLabel_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt securities available for sale unrealized gain loss, noncurrent</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B_label_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Available For Sale Unrealized Loss, Noncurrent</link:label>
    <link:label id="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B_documentation_en-US" xlink:label="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Available For Sale Unrealized Loss, Noncurrent</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:to="lab_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, noncurrent</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available for sale, unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Aggregate Estimated Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of amortization expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7" xlink:to="lab_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7" xlink:type="arc" />
    <link:label id="lab_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8_terseLabel_en-US" xlink:label="lab_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8_label_en-US" xlink:label="lab_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Tranches</link:label>
    <link:label id="lab_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8_documentation_en-US" xlink:label="lab_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Tranches</link:label>
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NumberofTranches" xlink:label="loc_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:to="lab_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>rtrx-20180930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.retrophin.com/role/AccountsReceivable" xlink:href="rtrx-20180930.xsd#AccountsReceivable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccountsReceivableDetails" xlink:href="rtrx-20180930.xsd#AccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpenses" xlink:href="rtrx-20180930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpensesDetails" xlink:href="rtrx-20180930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/AccruedExpensesTables" xlink:href="rtrx-20180930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="rtrx-20180930.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingencies" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CommitmentsAndContingenciesTables" xlink:href="rtrx-20180930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheets" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rtrx-20180930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayable" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableCompositionOfNotesDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableCompositionOfNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:href="rtrx-20180930.xsd#ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstruments" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsDetails" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:href="rtrx-20180930.xsd#DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DescriptionOfBusiness" xlink:href="rtrx-20180930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DescriptionOfBusinessNarrativeDetails" xlink:href="rtrx-20180930.xsd#DescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/DocumentAndEntityInformation" xlink:href="rtrx-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurements" xlink:href="rtrx-20180930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FairValueMeasurementsTables" xlink:href="rtrx-20180930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:href="rtrx-20180930.xsd#FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:href="rtrx-20180930.xsd#FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxes" xlink:href="rtrx-20180930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:href="rtrx-20180930.xsd#IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IncomeTaxesTables" xlink:href="rtrx-20180930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssets" xlink:href="rtrx-20180930.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsAmortizationDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsAmortizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsDetails" xlink:href="rtrx-20180930.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/IntangibleAssetsTables" xlink:href="rtrx-20180930.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/Inventory" xlink:href="rtrx-20180930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/InventoryDetails" xlink:href="rtrx-20180930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/InventoryTables" xlink:href="rtrx-20180930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShare" xlink:href="rtrx-20180930.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareAntidilutiveSharesDetails" xlink:href="rtrx-20180930.xsd#LossPerCommonShareAntidilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareEpsReconciliationDetails" xlink:href="rtrx-20180930.xsd#LossPerCommonShareEpsReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/LossPerCommonShareTables" xlink:href="rtrx-20180930.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecurities" xlink:href="rtrx-20180930.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesMarketableSecuritiesDetails" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesMarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/MarketableSecuritiesTables" xlink:href="rtrx-20180930.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognition" xlink:href="rtrx-20180930.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognitionDetails" xlink:href="rtrx-20180930.xsd#RevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/RevenueRecognitionTables" xlink:href="rtrx-20180930.xsd#RevenueRecognitionTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensation" xlink:href="rtrx-20180930.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationExerciseOfWarrantsDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationExerciseOfWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationRestrictedStockActivityDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.retrophin.com/role/ShareBasedCompensationTables" xlink:href="rtrx-20180930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.retrophin.com/role/AccountsReceivable" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_8C964A44B740415949B708017E3599D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_8C964A44B740415949B708017E3599D9" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock_36AF02E84F677736872408017E352D1E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/AccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_1F29BC9728DE64529740CFE6110A962E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_31C6F2205B7C70DF42D3CFE6110F78BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_1F29BC9728DE64529740CFE6110A962E" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_31C6F2205B7C70DF42D3CFE6110F78BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_210A239C83F61E3AD7EE08017FBD201D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_210A239C83F61E3AD7EE08017FBD201D" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BA443DD9B2D078C6398808017FBD61A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:type="locator" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_GovernmentRebatesPayable" xlink:label="loc_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:to="loc_rtrx_GovernmentRebatesPayable_70DA7E4D8BE2E48E331508017DF6FE29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:to="loc_us-gaap_AccruedSalariesCurrent_2F7278269CAF9D9AA22508017DF756A8" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedRoyaltyandContingentConsideration" xlink:label="loc_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:to="loc_rtrx_AccruedRoyaltyandContingentConsideration_BCEB437B8B961E6E101A08017DF74A31" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent" xlink:label="loc_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:to="loc_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent_732B19C3733CCF6E218D08017DF74F50" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent" xlink:label="loc_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:to="loc_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent_0D3D20244B6FA391A0D508017DF7EBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:to="loc_us-gaap_RestructuringReserve_36747DD123B7D8BDA93F08017DF8FC82" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedLiabilitiesMiscellaneous" xlink:label="loc_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:to="loc_rtrx_AccruedLiabilitiesMiscellaneous_BF8B69DB057E02092CB408017DF8C8C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1BD4ED243218C1656BD508017DF64723" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_71DBA70F4AE892EDA9B308017DF83C63" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_511E11E5E5BF56AC265C08017E5EA3B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_511E11E5E5BF56AC265C08017E5EA3B1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_C9BE18FAB21020E74C3408017E5E7EA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A71BF05A7697B1BF1C56CD0AD66D5934" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F9245ABFFE5913A0FA2CD0AD670D3AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A71BF05A7697B1BF1C56CD0AD66D5934" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2F9245ABFFE5913A0FA2CD0AD670D3AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2689C94189A01E3CA76FCC20BECE3535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6C90E1DC9D7BB9917D05CC20BED0DD2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_348D13C5AA60162DAEC7CC20BECF7A4D" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ClinicalTrialExpensePolicyTextBlock" xlink:label="loc_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_rtrx_ClinicalTrialExpensePolicyTextBlock_04A6F359ED2A36DC1AF1CC20BED047C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8CBF32E015D04DC69A9DCC20F8DB49B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_638C0A7D60C1626C27FFCC20BED05D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_F1C3FF89A5FA6A140012CC20BED09869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9CFDDB1338DC98DBDAD4CC20BED0E30B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5E7CDE6CE1D0A2F4BA01CC20BECABA63" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_B04F5EA5E9F054AA856FCC20BED11E61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BB6E9297F52412B50036B644DAD332FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BB6E9297F52412B50036B644DAD332FB" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_93A3CD3597B681340322B644DAD59F51" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_214CEF2BEF97B410925208017E93C96F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_214CEF2BEF97B410925208017E93C96F" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3BEED6E1E5013651BA1A08017E9382F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDB3ADB30549941A2E9BBC63D7C52EE0" xlink:type="locator" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CommitmentAndContingencyTable" xlink:label="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FDB3ADB30549941A2E9BBC63D7C52EE0" xlink:to="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:to="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_30B5E6B05EDB4BA19FCFBC63D7C6944D" xlink:to="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_RetrophinInc.v.ShkreliMember" xlink:label="loc_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_DF5DB25BA6B83A764F1EBC63D7C6CC98" xlink:to="loc_rtrx_RetrophinInc.v.ShkreliMember_A9D4684635C254BF82C4BC63D7C7EA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_04E44F0C14233D341662BC63D7C8DFCA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:to="loc_srt_CounterpartyNameAxis_04E44F0C14233D341662BC63D7C8DFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24EE785F1C6980B236EFBC63D7C87A99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_04E44F0C14233D341662BC63D7C8DFCA" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24EE785F1C6980B236EFBC63D7C87A99" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_MartinShkreliMember" xlink:label="loc_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_24EE785F1C6980B236EFBC63D7C87A99" xlink:to="loc_rtrx_MartinShkreliMember_8A80C89CE349C1FDB1BEBC63D7C86298" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CommitmentAndContingencyLineItems" xlink:label="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_CommitmentAndContingencyTable_F4E30B5885A59A47DC73BC63D7C602C1" xlink:to="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ContingentFutureLegalFeeAdvancePayment" xlink:label="loc_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_rtrx_ContingentFutureLegalFeeAdvancePayment_E4B44CBCC8ED70967D8BBC63D7C9BF9A" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers" xlink:label="loc_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers_C066BFC7752BFD7FE187BC63D7C9E9F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_us-gaap_LegalFees_25AE269A0D6D119E9585BC63D7C9071A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_572A2EC6C88060A35A72BC63D7CAA177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_CommitmentAndContingencyLineItems_D914502FDF6AD7427FFDBC63D7C8B5C0" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_BF6F8CB3DC18B3E7EE76BC63D7CA4C50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F22859E621D990C039E911198AA29740" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F22859E621D990C039E911198AA29740" xlink:to="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementAxis" xlink:label="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:to="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementDomain" xlink:label="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_AgreementAxis_62D941C6A5136A11C2B111198AA2B427" xlink:to="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_LeaseAgreementMember" xlink:label="loc_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_AgreementDomain_EFD00148A1E6CF45384111198AA2AE33" xlink:to="loc_rtrx_LeaseAgreementMember_C51D80DF287B1935484111198AA35073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:to="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_60A0A2EF60D69012153611198AA3C1BF" xlink:to="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SanDiegoCACorporateMember" xlink:label="loc_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:to="loc_rtrx_SanDiegoCACorporateMember_697B76D6DA2239BFE0DE11198AA36452" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="loc_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_62B906B9AB3839C5DFDE11198AA31D04" xlink:to="loc_stpr_NY_D109F41C2279321DC4CF11198AA4D02A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8A5019C42F60F74DE32511198AA25603" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_790FB6878E61F92B9D2211198AA47E96" xlink:to="loc_us-gaap_LeaseAndRentalExpense_3B446C5685E9F225EBA411198AA45C40" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0501B75D12AFB9C166D808017E140BD5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock" xlink:label="loc_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0501B75D12AFB9C166D808017E140BD5" xlink:to="loc_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock_2BA25FFF08F643A8683708017E14AC67" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1D46C8B216F8E6A8B314CBF96914B488" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D46C8B216F8E6A8B314CBF96914B488" xlink:to="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1CFA8F596A383B20E7AACBF969159B48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61652B5BF61A9FE62542CC28509AD490" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61652B5BF61A9FE62542CC28509AD490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8BF74E95BF0CC5673A78CBF969169569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:to="loc_us-gaap_InventoryNet_6656F5EF7A5C3B6A9765CBF969165A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_E0E56D83EBF3EB08D9D4CBF96916360B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:to="loc_us-gaap_PrepaidTaxes_F9B012D97DBD2564A423CBF96917FAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9E983355040AA28A3A74CBF96915F7C7" xlink:to="loc_us-gaap_AssetsCurrent_0879C985063D218A2C38CBF969170CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3E5FCD14016C82A5EEF9CBF96917CB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_36A09A51E6D9887C1C70CBF96918AD88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:to="loc_us-gaap_EquityMethodInvestments_6CE4A950537DCF772AF1CBF9691896B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7D69DE72A7FD4D2CAD9BCBF969185EBD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7D69DE72A7FD4D2CAD9BCBF969185EBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:to="loc_us-gaap_Goodwill_62813CAD89C2A2BC29E4CBF96919FAD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22578C34B62317A6D6DACBF96914C8C4" xlink:to="loc_us-gaap_Assets_5FC770F177ABC85EA67FCBF969197B28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1D46C8B216F8E6A8B314CBF96914B488" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="loc_us-gaap_AccountsPayableCurrent_D908F033715A67B708DACBF9691AA28C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_F77695FDA3DA0B107D85CBF9691A6F8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_F77695FDA3DA0B107D85CBF9691A6F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_6D3C0812ABAE5F20E145CBF9691B1074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7D4DED6078F59792074ECBF9691BB3E4" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquisitionRelatedContingentConsideration" xlink:label="loc_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="loc_rtrx_AcquisitionRelatedContingentConsideration_473B166CECDD4A085964CBF9691C69EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_88B0DF1C4D77668F3B0DCBF9691C48A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_42A443E379A1F471910ACBF9691C3BFE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_42A443E379A1F471910ACBF9691C3BFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DA7F50975D6C81C14498CBF9691A9C63" xlink:to="loc_us-gaap_LiabilitiesCurrent_6C577896AFD349C697F4CBF9691D994D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_351AF98CA09FB9B18794CBF9691D15DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8490BB80DB24D97361A5CBF9691DE4C2" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AccruedRoyaltiesNoncurrent" xlink:label="loc_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="loc_rtrx_AccruedRoyaltiesNoncurrent_90EDFDB71D5181E11072CBF9691E1D37" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquisitionRelatedContingentConsiderationNoncurrent" xlink:label="loc_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="loc_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent_A28D0BE3038BCC932FBBCBF9691E5A52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="loc_us-gaap_Liabilities_F24CEF37E1415CAA90E5CBF9691E9587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:to="loc_us-gaap_PreferredStockValue_23C5040310AE825D00A8CBF9691EB5ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:to="loc_us-gaap_CommonStockValue_84824E0069E94D6C17BECBF9691F4848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1C6E85182666621238FBCBF9691F9A31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22062C60417362ADD2EECBF969201228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20A9C49C374E5212A8C5CBF96920EFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23337F16B999D494C57BCBF9691E4289" xlink:to="loc_us-gaap_StockholdersEquity_96B876224EEFD2888A7BCBF96921B6DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26284B2D700E4A5F6C4CCBF96919FABE" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_BF734D901EFC103C020DCBF96921FACF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34F1448A21E4896664B5B644DB6DF149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B3896FC4203C2304CA25B644DB6EBCA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="loc_us-gaap_PreferredStockSharesIssued_AD3951F6976BB66269B6B644DB6E8A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0C82B5ED5E2BB98A3A0EB644DB6EA759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ECE262982A810BB9AF43B644DB6F6DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_81D2B520D28578625BEBB644DB6FD40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="loc_us-gaap_CommonStockSharesIssued_287062661FB98A641A4EB644DB6FC8CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0FAA232A0F11A4520F3DB644DB6DF934" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_84EC78398D32B5A8D439B644DB705E29" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2FE9883F9BAD293B41E8CBD76BAE4FD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:to="loc_us-gaap_NetIncomeLoss_2FE9883F9BAD293B41E8CBD76BAE4FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6AD0F7EADEF8BD1B96BDCBD76BAFC901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C12B49DA64C7FF05F76FCBD76BB04DB3" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_InterestReceivablefromNotesReceivable" xlink:label="loc_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_rtrx_InterestReceivablefromNotesReceivable_F5EF857B883E00978827CBD76BB057CC" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NoncashInterestExpense" xlink:label="loc_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_rtrx_NoncashInterestExpense_AEF977FA708B4C849311CBD76BB00F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_F3200109F2EC06E18CB8CBD76BB08FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_F32EAFF51C489D033D88CBD76BB1DDF0" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProvisionForInventory" xlink:label="loc_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_rtrx_ProvisionForInventory_41C074CD4B1495BD5567CBD76BB14B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_ShareBasedCompensation_BA634FCE891D805791AECBD76BB1E92F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_11128C74AF69F95864B1CBD76BB2BDC8" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ChangeinFairValueofContingentConsideration" xlink:label="loc_rtrx_ChangeinFairValueofContingentConsideration_374AF7941C8F3E874B73CBD76BB2770D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_rtrx_ChangeinFairValueofContingentConsideration_374AF7941C8F3E874B73CBD76BB2770D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55553A21A25D32FC70A2CBD76BB2D14B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_55553A21A25D32FC70A2CBD76BB2D14B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_10C8C916441B4996D4FBCBD76BB23433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_21619E95EA629F9F0A17CBD76BB3D35B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5A85723D48C0B968F45DCBD76BB333CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_28DDFE6C2B8EEB89219ACBD76BAEA5E2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B0205C32E9F88514FBE4CBD76BB424C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5BDCAD2C3F06AC5FA6BBCBD76BB4E634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_CD238E2951AF209D183FCBD76BB44DC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_80DBE36556B6CADF228ACBD76BB52168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3D3E72A4555CF2CA1338CBD76BB35097" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CF833434BDE4F24B7B1FCBD76BB59926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ABC6FEBB8F5E5C6F2844CBD76BAD999F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_648EF5CA51F94EF5D834CBD76BB52EF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7472A14F02278AE98AA4CBD76BB62AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D4A13FD535ABEEEA4E00CBD76BB6D713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_16EACF3A20A02C6CC8FACBD76BB6F43E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_16EACF3A20A02C6CC8FACBD76BB6F43E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875E39841E8B19FBD3ADCBD76BB70CD1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_875E39841E8B19FBD3ADCBD76BB70CD1" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProceedsfromMaturityofNoteReceivable" xlink:label="loc_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:to="loc_rtrx_ProceedsfromMaturityofNoteReceivable_038A50AFBBB26CA6DE2DCBD76BB79B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2BDE6D7F010E154D2653CBD76BB7F2D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_23449B89261A2C0B8238CBD76BB63AD3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4C988A0857FAB06D1A6ECBD76BB7B403" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_A74A5EF3D61418E4144ECBD76BB8D11F" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_PaymentOfGuaranteedMinimumRoyalty" xlink:label="loc_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_rtrx_PaymentOfGuaranteedMinimumRoyalty_138012ED906DC3B6BF67CBD76BB8D173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_RepaymentsOfOtherDebt_E973BE229BFA8D398144CBD76BB9B300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_616FF9554E169E22522ACBD76BB91407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_E7F2453F9B6FF98A7593CBD76BB9B4AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_44D21E3F50D7648B3A50CBD76BBAF67D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9BA3755E14E06EFAEDA2CBD76BBA591D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_380FBC1E83B26A11A11FCBD76BBA3AB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_B8919FED1A74570D7635CBD76BBA9B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5C4AB6B8BDBE5D0983A8CBD76BB8605E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5AEA4CA79828BA571015CBD76BBA4234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9EA58053BED47443DEF8CBD76BBBD5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_995902D4C4B9C2FFEF2FCBD76BBBEABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DBED27C833EBB2E032ABCBD76BBC22F3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_DBED27C833EBB2E032ABCBD76BBC22F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D27FC002D7053886B1F7CBD76BBCCA6E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C9F12E776ED356DF95F0CBD76BAD1860" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D27FC002D7053886B1F7CBD76BBCCA6E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4F041400FC40449A219CD10E8ED00FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4F041400FC40449A219CD10E8ED00FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_C960F18B7A37B41A48BACD10E8EE8693" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_200E6F5C59CBC4695C81CD10E8EEC788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_F95DC1103184A72F0719CD10E8EEF686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:to="loc_us-gaap_LitigationSettlementExpense_04C60DDB60BB5CC08EE0CD10E8EF1358" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ChangeinFairValueofContingentConsideration" xlink:label="loc_rtrx_ChangeinFairValueofContingentConsideration_DCFAE984B01D4A82C588CD10E8EF6496" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:to="loc_rtrx_ChangeinFairValueofContingentConsideration_DCFAE984B01D4A82C588CD10E8EF6496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:to="loc_us-gaap_RestructuringCharges_11D128713B49D24A985DCD10E8EF5956" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_F336F65C45F582899726CD10E8EE010C" xlink:to="loc_us-gaap_OperatingExpenses_B19893E0AB5AD6127155CD10E8EFE9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_OperatingIncomeLoss_B6D280FC06D945B4D875CD10E8EF2E16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_BFEDA33F30376134646DCD10E8EFE13B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_6D527E660B79D119623DCD10E8F0D46E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_817AE4CFBCEBD22CC674CD10E8F03286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BE293CFA8ED1BEDF861BCD10E8F0EF0A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_BE293CFA8ED1BEDF861BCD10E8F0EF0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5696432595622CD650BDCD10E8F0FD30" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5696432595622CD650BDCD10E8F0FD30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0C53FA1F3DD8E4BC68E9CD10E8EF264B" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_A6132394211DD7467FFBCD10E8F1A6A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B8DAEBF39F5FEAF8F7A3CD10E8F15075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_831AA03BA2A95B0B5FC4CD10E8F1D664" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_831AA03BA2A95B0B5FC4CD10E8F1D664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_00EC32AA4C71FA8745C6CD10E8F27211" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_NetIncomeLoss_00EC32AA4C71FA8745C6CD10E8F27211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_65A8027C235252BE7A26CD10E8F26172" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_E144F65008728BA1F5B4CD10E8F20E81" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_65A8027C235252BE7A26CD10E8F26172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D54458B3A2651781A92BCD10E8F2EA4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_30114D610AB097B5C17FCD10E8F2F4DA" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_D54458B3A2651781A92BCD10E8F2EA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9481FB182DA00CA06FEFCD10E8EDC5FA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_051D55ECBE733CB2AF19CD10E8F39104" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:to="loc_us-gaap_NetIncomeLoss_051D55ECBE733CB2AF19CD10E8F39104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_F309D85CFA8533F12C30CD10E8F342D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40D8E077771F9CD20D28CD10E8F3390C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_B8B647C3131D2CD23A1ECD10E8F3FE67" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4A499A9E84C3C95F5914CD10E8F4D83B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayable" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_71A25F0C8AA15696BD2708017F05502A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_71A25F0C8AA15696BD2708017F05502A" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6577A33B16D531F6765A08017F052614" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableCompositionOfNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A93DE666541D5C7B2551C7178B42A974" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A93DE666541D5C7B2551C7178B42A974" xlink:to="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2F5792B65688335CD318C7178B43FB61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2F5792B65688335CD318C7178B43FB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_14FE4DF68C87DD04494BC7178B445BA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2F5792B65688335CD318C7178B43FB61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_14FE4DF68C87DD04494BC7178B445BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_6E208E56D6ECAB805CF4C7178B442D45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_14FE4DF68C87DD04494BC7178B445BA1" xlink:to="loc_us-gaap_SeniorNotesMember_6E208E56D6ECAB805CF4C7178B442D45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0D0018FA349631AE951CC7178B44B011" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:to="loc_us-gaap_DebtInstrumentAxis_0D0018FA349631AE951CC7178B44B011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0D0018FA349631AE951CC7178B44B011" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_79AB2D42B8536E1BBCF5C7178B451FE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E" xlink:to="loc_rtrx_SeniorNotesDue2025Member_79AB2D42B8536E1BBCF5C7178B451FE3" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ConvertibleNotesDue2019Member" xlink:label="loc_rtrx_ConvertibleNotesDue2019Member_3A865AB4D88C4B7F2EADC7178B45E5C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F0D8E2B0E76C4F4CEEE0C7178B457F5E" xlink:to="loc_rtrx_ConvertibleNotesDue2019Member_3A865AB4D88C4B7F2EADC7178B45E5C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B9C4F510F05110E2F7A1C7178B43BDD6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D3076342BBE9AA1FF106C71D0B300E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_86D51FA8375E99A20222C7178B466071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6432D3FC1B24EEE5D9C6C7178B462BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6B29EC55E20CCAFA675BC7178B46F18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_08EB0F79F2082F771985C7178B4537D4" xlink:to="loc_us-gaap_LongTermDebt_5E01BE3D723D41A1AB9EC7178B46E113" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableConvertibleNotesPayableTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_97D910988CDF43B38F86BC63D81E80D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_97D910988CDF43B38F86BC63D81E80D3" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_FA5588B1A9E174B8B0CCBC63D81EF21D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A4C77376B99504FE3210C7178B4E162C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A4C77376B99504FE3210C7178B4E162C" xlink:to="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8E642C076ED43F5FC0BCC7178B4F551F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8EA88964B61936241998C7178B4FE066" xlink:to="loc_us-gaap_SeniorNotesMember_1EBFBE732A4C20031BD9C7178B50CD3C" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementAxis" xlink:label="loc_rtrx_AgreementAxis_C673FCD93336518D9FFCC7178B50A3E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:to="loc_rtrx_AgreementAxis_C673FCD93336518D9FFCC7178B50A3E8" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AgreementDomain" xlink:label="loc_rtrx_AgreementDomain_004E932AA13E47D20380C7178B503651" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_AgreementAxis_C673FCD93336518D9FFCC7178B50A3E8" xlink:to="loc_rtrx_AgreementDomain_004E932AA13E47D20380C7178B503651" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NotePurchaseAgreementMember" xlink:label="loc_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_AgreementDomain_004E932AA13E47D20380C7178B503651" xlink:to="loc_rtrx_NotePurchaseAgreementMember_FF1F107BAB9CEA455ADCC7178B50E88C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:to="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F211154C7E1177ACBAC4C7178B51BFC7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:to="loc_rtrx_SeniorNotesDue2025Member_539C071ECFC8751E05BDC7178B514E4B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ConvertibleNotesDue2019Member" xlink:label="loc_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:to="loc_rtrx_ConvertibleNotesDue2019Member_F01958BE0137985176F5C7178B51C88D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_B1AD53CA25854C9B4AB3C7178B512E4C" xlink:to="loc_us-gaap_ConvertibleDebtMember_687B22241217C9CCF99FC7178B51EDA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_417ED70880D1C2FEC60AC7178B4EF78C" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_03CC8AFD7592BC277D29C7178B52331B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5415CF1985889DA551A1C7178B549DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_885B6FB2AD170C20222BC7178B5465D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_07B73180ED6B8F00125EC7178B542B2B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtConversionLiability" xlink:label="loc_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_DebtConversionLiability_02A84853EA2EF7F2F1A2C7178B558C59" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtConversionEquity" xlink:label="loc_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_DebtConversionEquity_D01CFF76D6D1AA0340C8C7178B55ACEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_1AA4C1542D53DB0B04F7C7178B55FAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_C6F284561BD16DC0588FC7178B55F97F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_A96639AFD8054C3D3DBEC7178B550309" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod" xlink:label="loc_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod_319E388FFB9AEBF592FFC7178B565B04" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_TradingPricePerPrincipalPercentage" xlink:label="loc_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_TradingPricePerPrincipalPercentage_C62955CE22226A203A01C7178B56F177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_F402FBD07DD4607F5E9CC728FD75F37A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_01428A6FF67309E8B8D7C7178B56A24A" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000" xlink:label="loc_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000_46816E1E29C311548DA7C7178B56A1D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_A3EBF481893931C77EE2C7178B56B278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_F0CF8D928961F8AF46D7C7178B57322A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0820D10B6ACA95546389C7178B57CFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24EA39CB60C033588610C7178B5702E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1A1562EF0FAA6F8F90C6C7178B529ECE" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_053027F29690D0C39271C7178B573270" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ConvertibleNotesPayableScheduleOfInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_74F2BE4B789F0C59982CBC63D8019F7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_74F2BE4B789F0C59982CBC63D8019F7B" xlink:to="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2494CDFE8DF658C7D22BBC63D802406A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2494CDFE8DF658C7D22BBC63D802406A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_604A3E97BD72F84362A4BC63D802B1EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2494CDFE8DF658C7D22BBC63D802406A" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_604A3E97BD72F84362A4BC63D802B1EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_2E2F6EB1A7EC4E090D9BBC63D8035815" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_604A3E97BD72F84362A4BC63D802B1EB" xlink:to="loc_us-gaap_SeniorNotesMember_2E2F6EB1A7EC4E090D9BBC63D8035815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_FBF20F4D4F6F79EAD046BC63D8035CAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:to="loc_us-gaap_DebtInstrumentAxis_FBF20F4D4F6F79EAD046BC63D8035CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9D94854D82AC1A927458BC63D804FCD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_FBF20F4D4F6F79EAD046BC63D8035CAC" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9D94854D82AC1A927458BC63D804FCD0" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_DD77E73E76A63B960CC0BC63D804BFEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9D94854D82AC1A927458BC63D804FCD0" xlink:to="loc_rtrx_SeniorNotesDue2025Member_DD77E73E76A63B960CC0BC63D804BFEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F6D37193F5F88A704B74BC63D8021A2F" xlink:to="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:to="loc_us-gaap_InterestExpenseDebt_DF165309DBEA43A57CE9BC63D805047F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7556A31CB62AC365429FBC63D805EEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77F6CA0AA2E87C9C4EEBBC63D804A819" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_AA9BAACAB7A29F36E967BC63D805220D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3134738246BE9F8D0B3308017FCE6962" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3134738246BE9F8D0B3308017FCE6962" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_29C51A45EEC7CB9EEA8808017FCEAA1B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28270DF7B671235C412DBC63D8631A84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_CD3D7A47BE8F01FF5242BC63D863C023" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28270DF7B671235C412DBC63D8631A84" xlink:to="loc_us-gaap_DerivativeTable_CD3D7A47BE8F01FF5242BC63D863C023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_751512BA6BFECA6DDAA1BC63D8638700" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_CD3D7A47BE8F01FF5242BC63D863C023" xlink:to="loc_us-gaap_FinancialInstrumentAxis_751512BA6BFECA6DDAA1BC63D8638700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71046887D75C770B6F4ABC63D86408C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_751512BA6BFECA6DDAA1BC63D8638700" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71046887D75C770B6F4ABC63D86408C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71046887D75C770B6F4ABC63D86408C0" xlink:to="loc_us-gaap_WarrantMember_0D4B2E448387DD515CBBBC63D86466C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_CD3D7A47BE8F01FF5242BC63D863C023" xlink:to="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NumberofTranches" xlink:label="loc_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:to="loc_rtrx_NumberofTranches_CEFBC055E70A4595A054BC63D8656BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5F485F88EC5E24FA8E19BC63D86576FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5F485F88EC5E24FA8E19BC63D86576FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_3DF098E02E6D47880EF3BC63D8656362" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_E8607150429C6419986FBC63D864A509" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_3DF098E02E6D47880EF3BC63D8656362" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0084C17E5C36A88189F08017FCAE3A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0084C17E5C36A88189F08017FCAE3A1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5F9C7EF66807C247058908017FCAEDE3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/DerivativeFinancialInstrumentsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1231750991D9AED77F56C6E7CF1DB0D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1231750991D9AED77F56C6E7CF1DB0D3" xlink:to="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4E9553258997E6A88299C6E7CF1E4746" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_494501DDBCE89AB12FD1C6E7CF1FDFD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_218DD53311A7A8C1C4B3C6E7CF1F7121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2942478CB8EFEFE1C403C6E7CF1F6BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_A9BFE83C5D9163195593C6E7CF1EF9F8" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8D1E09341EA6DE935E24C6E7CF1FBC8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22C01688D2A5384A16BEC6E7CF1F0F8D" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1813668A2984C09CAA9AC6E7CF208B7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ACCC8101C5A0B8C8B647C6E7CF202E10" xlink:to="loc_us-gaap_WarrantMember_1813668A2984C09CAA9AC6E7CF208B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:to="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_DD78E808C5AD7144E1C3C6E7CF205D26" xlink:to="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:to="loc_srt_MinimumMember_0F9067504C70666BA413C6E7CF214EDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_59D11CC16CC21CA1258EC6E7CF20FF89" xlink:to="loc_srt_MaximumMember_3C52180CD2BCFCCAE724C6E7CF213C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_476BCDAF592D6C077401C6E7CF1E7BD3" xlink:to="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:to="loc_us-gaap_SharePrice_581D3242DFF3F6790E1AC6E7CF22B6E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_824A64E4EDADA38A6265C6E7CF21462E" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_ED1C745F29104D7B6B0DC6E7CF223357" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D540B540655958A3228908017F02D1C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D540B540655958A3228908017F02D1C8" xlink:to="loc_us-gaap_NatureOfOperations_2A3B2915EDAE99DE39DB08017F02C340" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/DescriptionOfBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E5D24D233AADCF7C44508017DD4AA1A" xlink:type="locator" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_NumberOfProductsSold" xlink:label="loc_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E5D24D233AADCF7C44508017DD4AA1A" xlink:to="loc_rtrx_NumberOfProductsSold_E870FA8AA18903B45AC908017DD510A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DocumentAndEntityInformationAbstract" xlink:label="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_EntityRegistrantName_F078E65D2A0AF78CE3D9C21E99C71491" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_EntityCentralIndexKey_17694FFC077514B31A27C21E99CA8CDB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_TradingSymbol_2911C05B5C930EAB2F1AC21E99CBB31C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_CurrentFiscalYearEndDate_EA38168EA8AEF770C7C5C21E99CB75F6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_EntityFilerCategory_E6790A83F763F7B9026EC21E99CB20AD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_D86F88783FBC1677700DC21E99CC25A7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_DocumentType_DE7A1CD124CA037A39D3C21E99CC0983" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_DocumentPeriodEndDate_5A9300AAB4B13A582D16C21E99CC0E54" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_AmendmentFlag_D275A2C69A6ED40DD922C21E99CCB7BB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_DocumentFiscalYearFocus_AA435F0065CF3A6F0A35C21E99CDE319" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6B06B75B854E9A8300FFC21E99CD0BF1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_EntityEmergingGrowthCompany_A6902F0EB97C2BD13431C230889910A7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtrx_DocumentAndEntityInformationAbstract_F7D7D616CBA81F4363C8C21E99BB670A" xlink:to="loc_dei_EntitySmallBusiness_4A6E42F737622AD36121C2345E4A2B7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_41F9B31A50A6E3E223ED08017E0BC816" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_41F9B31A50A6E3E223ED08017E0BC816" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_CF711F69D70FB1475D5308017E0B9069" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5691476966D7454EBB570CBA72438C35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5691476966D7454EBB570CBA72438C35" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29CDDCB9F429E70D1F8F0CBA7244036D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29CDDCB9F429E70D1F8F0CBA7244036D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_76FBF3D285B430119F800CBA7244C8B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29CDDCB9F429E70D1F8F0CBA7244036D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_76FBF3D285B430119F800CBA7244C8B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_82F3B05668A1652B61100CBA7245029C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_76FBF3D285B430119F800CBA7244C8B9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_82F3B05668A1652B61100CBA7245029C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DB2E1C9DB5BDC6770C900CBA72452B69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DB2E1C9DB5BDC6770C900CBA72452B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4A4CD0075FE16B5C8ACE0CBA7245E240" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DB2E1C9DB5BDC6770C900CBA72452B69" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4A4CD0075FE16B5C8ACE0CBA7245E240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4A4CD0075FE16B5C8ACE0CBA7245E240" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8BB5C388ABA6D1DCAE330CBA724BBCFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F46F8ED93126BCD261840CBA724BADB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F30BD8C9702DE0B982420CBA724403EE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F46F8ED93126BCD261840CBA724BADB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F46F8ED93126BCD261840CBA724BADB2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3AC96EC75810BD3E4FFC0CBA724BD5AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_49F955F97C5AEDA0FE680CBA724CDA80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4D623D8F67CAAAA166FB0CBA724CA0FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_B060367B809F3C8020490CBA724CAF7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F944A41145A23F7A5DDC0CBA724C02F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_25F695D78897439989670CBA724BDC74" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F944A41145A23F7A5DDC0CBA724C02F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4AC1914CAD1E5AD28B35CBD76AAFDD3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4AC1914CAD1E5AD28B35CBD76AAFDD3F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DAB3256B7799DB51CB07CBD76AB01D98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DAB3256B7799DB51CB07CBD76AB01D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B5C3540732941D594405CBD76AB09F74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DAB3256B7799DB51CB07CBD76AB01D98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B5C3540732941D594405CBD76AB09F74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_53E12616E0E38FA0B78CCBD76AB14351" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B5C3540732941D594405CBD76AB09F74" xlink:to="loc_us-gaap_SeniorNotesMember_53E12616E0E38FA0B78CCBD76AB14351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9FBD6416327AAA041BD1CBD76AB14073" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:to="loc_us-gaap_DebtInstrumentAxis_9FBD6416327AAA041BD1CBD76AB14073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9FBD6416327AAA041BD1CBD76AB14073" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ConvertibleNotesDue2019Member" xlink:label="loc_rtrx_ConvertibleNotesDue2019Member_58928872F8F951B44F1ECBD76AB24B3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3" xlink:to="loc_rtrx_ConvertibleNotesDue2019Member_58928872F8F951B44F1ECBD76AB24B3D" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_SeniorNotesDue2025Member" xlink:label="loc_rtrx_SeniorNotesDue2025Member_058E54CA91F922B1FC03CBD76AB2D054" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1F85E86857F0D5B18828CBD76AB2BFA3" xlink:to="loc_rtrx_SeniorNotesDue2025Member_058E54CA91F922B1FC03CBD76AB2D054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_AB05F56B52D25B13205ECBD76AB302C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ProductRightsChenodalMember" xlink:label="loc_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:to="loc_rtrx_ProductRightsChenodalMember_DD6D306CA70E1100B0E8CBD76AB497C1" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquiredProductRightsCholbamMember" xlink:label="loc_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:to="loc_rtrx_AcquiredProductRightsCholbamMember_1AC73924CD2427DA551DCBD76AB47597" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AcquiredProductRightsLUDCAMember" xlink:label="loc_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06302C66392E27AB156FCBD76AB3F18A" xlink:to="loc_rtrx_AcquiredProductRightsLUDCAMember_EF5610B979204E398911CBD76AB4B062" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54C245A1CD687D5EABD5CBD76AAF0C5D" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6C40B64ADC7292F7616ACBD76AB5FAD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6C40B64ADC7292F7616ACBD76AB5FAD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_191D232C701D9F86F036CBD76AB622E7" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ChangeinFairValueofContingentConsideration" xlink:label="loc_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_rtrx_ChangeinFairValueofContingentConsideration_55EB8754037640F8EDA1CBD76AB6685A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1B8734FC141C3F77BA3FCBD76AB61260" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7A80814E49F9BEA2AEFFCBD76AB5E962" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1B8734FC141C3F77BA3FCBD76AB61260" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_93F3B3F980A3C8FC4B75BC63D8444E72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93F3B3F980A3C8FC4B75BC63D8444E72" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F6C5D0D05C2B7AECCEBBC63D8454274" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBC3CE8855687A283F6ABC63D8451FF3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_B0DD60D4407DD8F5EE56BC63D8454C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3FB02617B22254D1EC9BBC63D8465D7A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_858EC5C48CA41320332ABC63D8468D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DDB9436960482F81707FBC63D8471DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6078D2DA69083FC04D54BC63D8467A0F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4265FDE2AB9C364D1660BC63D84717EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_23C04327F90B97F7D78CBC63D844E667" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F3988072AB6DA5111F5BC63D848904D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8EB4D746A74FB8D37253BC63D847D469" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0E985F7EB5F1D4B68DDEBC63D84863D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3C806130DB11B7A90FADBC63D847D9EE" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_24A5F2D2E2F1C733FD9EBC63D848D6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_374ED64F824D9A36571CBC63D849A329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_19C2BD2A074D3A4CBE40BC63D848A6AC" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_C95EE7CD2DC5ACFB8F3CBC63D849FB54" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9164E7311236B21DF39308017DFB90BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9164E7311236B21DF39308017DFB90BD" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5EA44702633E5343538C08017DFC03EC" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock" xlink:label="loc_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9164E7311236B21DF39308017DFB90BD" xlink:to="loc_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock_6D58BCC3D0821642C36108017DFC6905" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2843BB3F5B758D75846708017F9D1C95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2843BB3F5B758D75846708017F9D1C95" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_66CA538010F9541FA33B08017F9D85E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreementDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4AE754C84B4455D3F53DC7178C03CEF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4AE754C84B4455D3F53DC7178C03CEF8" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2B5A8C6C767959AD2C64C7178C044D8F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CensaPharmaceuticalsInc.Member" xlink:label="loc_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:to="loc_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CensaPharmaceuticalsIncEquityHoldersMember" xlink:label="loc_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_CCAA832B3E6920309522C7178C04A013" xlink:to="loc_rtrx_CensaPharmaceuticalsIncEquityHoldersMember_52951F7D744C09F83D15C7178C05F966" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_CB4BA62F8837C17C7DA0C7178C05D65A" xlink:to="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_50BC18C5E0ED26D637F2C7178C056062" xlink:to="loc_rtrx_CensaPharmaceuticalsInc.Member_A68D3800AB24DFDBF65FC7178C049FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_FE11907EE0910CAF17EBC7178C05C851" xlink:to="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_CNSA001ProgramMember" xlink:label="loc_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_96E81D5B4A9B3DF30555C7178C068367" xlink:to="loc_rtrx_CNSA001ProgramMember_2B8C6586BE859C405C5EC7178C06F875" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_78DD735EBB50CE3791D4C7178C0614D0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseProvisionTermsMember" xlink:label="loc_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6189E9687738E2D10CB6C7178C061A8E" xlink:to="loc_us-gaap_PurchaseProvisionTermsMember_3A35A6361B86A405F576C7178C074FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_F9C6A261AEE505751E08C7178C037D74" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_FD65C9B8ACD6FEF694DBC7178C073E8B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_PaymentsForTheOptionToAcquireBusiness" xlink:label="loc_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_PaymentsForTheOptionToAcquireBusiness_409B3CA36AE9B75EE7CCC7178C07A209" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones" xlink:label="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones_FA9666C69DBC1255F213C7178C08AAFA" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePrice" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementPurchasePrice_4A0B65729D698C9C2F56C7178C084E91" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash_008EFF3D45A09B179112C7178C083482" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity_1497BA772B98AD1B69CCC7178C080EE0" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementSharePrice" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementSharePrice_1447E1D65A3DFEDBC31FC7178C0841CA" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold_DC519D0670B7E7E81173C7178C09542B" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment_116EB711D22E488F5187C7178C0910A1" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BusinessCombinationOptionAgreementContingentConsideration" xlink:label="loc_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_BusinessCombinationOptionAgreementContingentConsideration_620C8AA7A3D2B0732023C7178C09F579" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding" xlink:label="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding_7A8AD853B65FD3B54A20C7178C0924F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_35EA4E7E947006ACF0CBC7178C078BD6" xlink:to="loc_us-gaap_EquityMethodInvestments_90C4FE4CA55315F7A515C7178C09C81E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C588FF6470EF0AED374208017E6A3E26" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C588FF6470EF0AED374208017E6A3E26" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_8D45C208F84509A097C908017E6BE19B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C4F4B9158F55ECAD35CECFF600AF9226" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_079BA15719B2DF04129ACFF600B06749" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4F4B9158F55ECAD35CECFF600AF9226" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_079BA15719B2DF04129ACFF600B06749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FC899E5956CC566D813DCFF600AF811C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4F4B9158F55ECAD35CECFF600AF9226" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_FC899E5956CC566D813DCFF600AF811C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4F4B9158F55ECAD35CECFF600AF9226" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1310D0B0FF7615289809CFF600B04FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4F4B9158F55ECAD35CECFF600AF9226" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_8541F1A1B4496791F634CFF600B01C51" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AF6D5A7E8C9665D18172CD869858BBC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AF6D5A7E8C9665D18172CD869858BBC4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0DC63AD9DE4CF251A078CD8698585980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AF6D5A7E8C9665D18172CD869858BBC4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01A64BBE024093D21600CD86985964C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_97B6D22C11B87AE729C408017F4C0909" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_97B6D22C11B87AE729C408017F4C0909" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_19EBF30C1118C02A0EEB08017F4C50EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37EAA1BA68D26412E6708017FA7F7EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_B37EAA1BA68D26412E6708017FA7F7EE" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_592B65D9D047A5DB9A6B08017FA8764C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsAmortizableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75D3F07D23BE45E8FFD908017E1AAFF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75D3F07D23BE45E8FFD908017E1AAFF8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3B64FA9935348B9C4CFA08017E1AC16D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75D3F07D23BE45E8FFD908017E1AAFF8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ABC3D733A2CC37BC14D808017E1AB9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_177ACAB4462BFAB8226C08017E1A3EA5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75D3F07D23BE45E8FFD908017E1AAFF8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_177ACAB4462BFAB8226C08017E1A3EA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsAmortizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C8B01BF63715CF414E7A08017FC4AED3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C8B01BF63715CF414E7A08017FC4AED3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B41744D4D96792BBAB8C08017FC57F8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B41744D4D96792BBAB8C08017FC57F8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B41744D4D96792BBAB8C08017FC57F8C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_A44EA52E601629F521DF08017FC553B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F21938E9CB540AEA178508017FC508B0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9576EAEF6A6C7447AC8508017FC683B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_F604D4E84E4F4609F3FD08017FC42044" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FA10AD7A72FF086F296608017FC6271D" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7A8F2A7ACD0A7902792C08017FC6236C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BAC70A18D3A292DBA78CD0F5B370806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4BAC70A18D3A292DBA78CD0F5B370806" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8E034CEEEB7CB24F76A8CD0F5B374EC4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E13E862330E916E40DD908017F312F72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E13E862330E916E40DD908017F312F72" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_18C42E716542FF0D98AD08017F32FCB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E13E862330E916E40DD908017F312F72" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CF838EF1D9A85BF6E5B808017F32939C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_FE9352AA2CB95409D47C08017F8DF042" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_FE9352AA2CB95409D47C08017F8DF042" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_51D909621F964CF8175208017F8D44B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0DEC7B66E1BDB45E524008017FB89F00" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0DEC7B66E1BDB45E524008017FB89F00" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22F0C6F69091FCD3950908017FB890EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0DEC7B66E1BDB45E524008017FB89F00" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_B135F01F201DB35B5B6408017FB82FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_BA05189E1DD9AB67063208017FB95C2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0DEC7B66E1BDB45E524008017FB89F00" xlink:to="loc_us-gaap_InventoryNet_BA05189E1DD9AB67063208017FB95C2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0DEC7B66E1BDB45E524008017FB89F00" xlink:to="loc_us-gaap_InventoryValuationReserves_B76E4CF875D394340D3C08017FB91B66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_C41B76C64698FFC2AC1F08017F97FC71" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_C41B76C64698FFC2AC1F08017F97FC71" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4D8AF23AA9518F9933DB08017F97702E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0A2DD3D2D133571EBF2708017E1DC7C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0A2DD3D2D133571EBF2708017E1DC7C8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_FB506DEFD4F7B7F3ED6508017E1DA244" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_78ACD1E9C0F421A6EEED08017DD82863" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_78ACD1E9C0F421A6EEED08017DD82863" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FDD4A140F1DC3C5CABC808017DD958CC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="loc_us-gaap_RestrictedStockMember_AD294F7A69B533CFC41408017DD9D197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_F88EA74F77634BE96C3008017DD98363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F31A8656A5F6DA6B091308017DDA345E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C421639EE4B9B7A1937108017DD9C9A3" xlink:to="loc_us-gaap_WarrantMember_A3D73AA3458FAA3B4A0D08017DDA85B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63F5968E9A85D5B44A4B08017DD8EF97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43D28081891ABA5AEBD708017DDA0A1D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5C9EBDED37CDC997D4AA08017DDA3061" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareEpsReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5C5290ACD8AB29BEA377B644D8791648" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5C5290ACD8AB29BEA377B644D8791648" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_FEF499569F260153408BB644D87ACA31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:to="loc_us-gaap_NetIncomeLoss_BEE4335B5EA965F92E68B644D87C8B2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_7D433B7DE94EBD020BB4B644D87A93EB" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5C5290ACD8AB29BEA377B644D8791648" xlink:to="loc_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_394A8FB4BE3408174638B644D87C50C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_394A8FB4BE3408174638B644D87C50C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0BBDE999AA98C9BE6959B644D87D202D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:to="loc_us-gaap_NetIncomeLoss_0BBDE999AA98C9BE6959B644D87D202D" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_63EE5D5EE33E186C5829B644D87CC4BB" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_7265EAE5D8C98FF50008B644D87C0FBD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6B378F8C77F658147F3608017E22B5C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6B378F8C77F658147F3608017E22B5C8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8CC6B7136198AEE895D508017E22B468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6B378F8C77F658147F3608017E22B5C8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8E647759BF77522D8AB308017E221D0B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_280898015357F70B0C6808017E129F17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_280898015357F70B0C6808017E129F17" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F1DFF63E9117469DFB9608017E127C99" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D016FB6F5C7ACABCC9EFCD0E7596335B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D016FB6F5C7ACABCC9EFCD0E7596335B" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_52C0F5C5A00205EB7A4CCD0E75960A36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D016FB6F5C7ACABCC9EFCD0E7596335B" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_FF1582D5C5F844887B6BCD0E75965034" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CFDAAD34140454E5E9E8CBE1B0D6FFE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C3C450C9DCFD99F1C883CBE1B0D6ADD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CFDAAD34140454E5E9E8CBE1B0D6FFE2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C3C450C9DCFD99F1C883CBE1B0D6ADD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_746D76B2B7EA2EA4D0D0CBE1B0D677DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C3C450C9DCFD99F1C883CBE1B0D6ADD2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_746D76B2B7EA2EA4D0D0CBE1B0D677DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_746D76B2B7EA2EA4D0D0CBE1B0D677DC" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DE3FDCE1ED39A1EBA0D8CBE1B0D715A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:to="loc_us-gaap_CommercialPaperMember_DE3FDCE1ED39A1EBA0D8CBE1B0D715A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0A8F0188095D8DFBA6DBCBE1B0D70C78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0A8F0188095D8DFBA6DBCBE1B0D70C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0008380C297329458A0CCBE1B0D8D08B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2E88551F5FD3D7807F91CBE1B0D76265" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0008380C297329458A0CCBE1B0D8D08B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C3C450C9DCFD99F1C883CBE1B0D6ADD2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent_39C66DA6C6645E63EA74CBE1B0D82B54" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent_4195921C8DF843F3DAA5CBE1B0D83695" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent_02EA6BBC6910DB37179DCBE1B0D82607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC23B565BCCDA9B1CB38CBE1B0D8AEC3" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent_E361E4FEB69D514E234ACBE1B0D94917" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent_B236AF7DE8431A04147ECBE1B0D98992" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent" xlink:label="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent_B0F69BA33529968D01E0CBE1B0D9EF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5E0C6A43E6CAD1637F56CBE1B0D92251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_183E3455787B7B165904CBE1B0D92DDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A3688F55E16F9017404FCBE1B0D9B2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3EA434F21915011E43B2CBE1B0DA3FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8BB4A6963FE9FBA55616CBE1B0D8F181" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_327BB8C81B01C20251BFCBE1B0DA092F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58D4EA132F00552C6EC40C3B5BC88594" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58D4EA132F00552C6EC40C3B5BC88594" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_09B862413B84659D48CC0C41B09F1F77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:to="loc_us-gaap_FinancialInstrumentAxis_09B862413B84659D48CC0C41B09F1F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_09B862413B84659D48CC0C41B09F1F77" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:to="loc_us-gaap_CommercialPaperMember_B9375C2B20BC73E778190C41B0B32399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_143F2B42184772AA197A0C41B0BDEAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47D47C66D336D965F0A90C41B0A1E945" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8E13007172A21547924E0C41B0C73025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B2DC1FD26C7899A741660C3B5BC9517E" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87EF2C877AC47A7A1FCD0C3B5BCBA840" xlink:to="loc_us-gaap_MarketableSecurities_364403217C3EF662C4210C412A053FAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A67A1D2E8C33F0DFA87A08017F4FEA38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A67A1D2E8C33F0DFA87A08017F4FEA38" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_AE389C28D0B5C2A3D46108017F4FD670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A67A1D2E8C33F0DFA87A08017F4FEA38" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DA778F0FF1EAD6B4CF9E08017F501296" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A2F40D3CD2F4F2B5F75208017F94377F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A2F40D3CD2F4F2B5F75208017F94377F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2F97162FB7882C32BC0408017F9487B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/RevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E780A7D2B73D8CC51C13BBB9AB2E4D2E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E780A7D2B73D8CC51C13BBB9AB2E4D2E" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_CA5F6D5D4A10C7D4E4C6BBB9AB348AE9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8CCA22E735D7647F45B3BBB9AB3550A0" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_96F0288510556B14C5A6BBB9AB35C9CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_81DECF106CEBA105E26ABBB9AB35B42B" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE100E2A2B23BF4748B2BBB9AB36F082" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_B77BEEB084599A92A6ECBBB9AB36872A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_A264FF48BCEA0F9E1441BBB9AB36E459" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_srt_StatementGeographicalAxis_A264FF48BCEA0F9E1441BBB9AB36E459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_FDF68B5FCEE8D120D4C4BBB9AB37050F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_A264FF48BCEA0F9E1441BBB9AB36E459" xlink:to="loc_srt_SegmentGeographicalDomain_FDF68B5FCEE8D120D4C4BBB9AB37050F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_FDF68B5FCEE8D120D4C4BBB9AB37050F" xlink:to="loc_country_US_725DF248601C687B7C05BBB9AB378E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_D9FB4F89D788647AE310BBB9AB3807D1" xlink:to="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_BileAcidProductsMember" xlink:label="loc_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:to="loc_rtrx_BileAcidProductsMember_A2CA499EE64DB1138D32BBB9AB386C66" xlink:type="arc" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ThiolaLicenseMember" xlink:label="loc_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A9FF42F5CB39D68E9AC9BBB9AB386044" xlink:to="loc_rtrx_ThiolaLicenseMember_6F59A50BE4CA4FFA1428BBB9AB39F5E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_D67D76EF8EF02093ADAABBB9AB2F0F81" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4A4797935160ACAA5886BBB9AB39144C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9301C9080E2CC6EB0F9BBBB9AB39E353" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06509AC34EA75C9D9B1DBBB9AB3ACB96" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33EBDF2382E8A458D81008017E997A2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33EBDF2382E8A458D81008017E997A2F" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_20784820F5260477269608017E995FB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0AF562CA63F85EAD7A6908017DFED504" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0AF562CA63F85EAD7A6908017DFED504" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5010F5C6EB82D16022E408017DFE10E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationExerciseOfWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_701329027C78ADA1C8C208017E4D9C6A" xlink:type="locator" />
    <link:loc xlink:href="rtrx-20180930.xsd#rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants" xlink:label="loc_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_701329027C78ADA1C8C208017E4D9C6A" xlink:to="loc_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants_283013DF01B28EE7505C08017E4D9B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_701329027C78ADA1C8C208017E4D9C6A" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_E4E6E89EC577B036098F08017E4D91F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_701329027C78ADA1C8C208017E4D9C6A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_E6217D4EAA843D81F08408017E4E0E53" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C8891C25A11B06286F9BC60BBAFECB5B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E35619597665B1AB3A97C60BBAFE6287" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C8891C25A11B06286F9BC60BBAFECB5B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E35619597665B1AB3A97C60BBAFE6287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E35619597665B1AB3A97C60BBAFE6287" xlink:to="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E85060C6029562FE1B9AC60BBB01EBDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0A8963D4D1886B2D41F0C60BBB0448B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_331D4296D711D6A8F8DCC60BBB01921C" xlink:to="loc_us-gaap_PerformanceSharesMember_DEB7BC86E68DCFFF219AC60BBB062066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E35619597665B1AB3A97C60BBAFE6287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9939D86FFEC90AFE842AC60BBB0B2545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5D461AB74BC936E6D6DEC60BBB0D1476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F34EAE7FC9979E4A7CFEC60BBB0D9D07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A39BF32A5800405B9A27C60BBB0D03E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_FB964570FCDF609F6BC9C60BBB0D042E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_870FF5111AB0BD59F10BC60BBB098E8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_FB964570FCDF609F6BC9C60BBB0D042E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B4E6AB758768249C2406C60BBB0E6D6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C79B0E9CCA4BAF26B514C60BBB108918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_599A9294850F502FAE09C60BBB10D950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_532E6F9CFB5B9A2DA008C60BBB119728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2E20FF6E252E76E6FDFFC60BBB11E77F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_D3E634B5A7E6BCF072C2C60BBB0EC492" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2E20FF6E252E76E6FDFFC60BBB11E77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_C4CB0B6FD3E977D93EE4C60BBB1118EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E602021367CF783ACEF3C60BBB0785CF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_E2E285FEABA163A57E9DC60BBB135E3D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EE0C04411E540CF22D6408017F09032B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_EE0C04411E540CF22D6408017F09032B" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9CB5B01A5707232FD8208017F0ACB5B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43632576B481A0B40C3108017F0B1FEC" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B5145AF358210BDFCCA608017F0C86F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3B50D23CF8B0CA2E9CD308017F0C3755" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6E1D79CF2EDCEE9F533B08017F0C5A12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B0B4873C268C9370FBFB08017F0A12C4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8D58BEF79D88923FEA3D08017F0CDC91" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D54A2B376F8EF5D4E0CE08017F0DA126" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_8B1DEAAFA4124FDBE9E808017E7C893B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F28F9D87DB0E8CEC8CE008017E7D9CB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8B1DEAAFA4124FDBE9E808017E7C893B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F28F9D87DB0E8CEC8CE008017E7D9CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F2143B873C15A41E5BD308017E7DAB43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F28F9D87DB0E8CEC8CE008017E7D9CB5" xlink:to="loc_us-gaap_AwardTypeAxis_F2143B873C15A41E5BD308017E7DAB43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72DCBD5CF5207AA9A5BB08017E7F9044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_F2143B873C15A41E5BD308017E7DAB43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72DCBD5CF5207AA9A5BB08017E7F9044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72DCBD5CF5207AA9A5BB08017E7F9044" xlink:to="loc_us-gaap_EmployeeStockOptionMember_32A7397CDE09CCFE939E08017E80CA61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_F28F9D87DB0E8CEC8CE008017E7D9CB5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40C7C0C5F2596CF378EF08017E814B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F5E1BF42D78FA591A17F08017E82C5E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60C3E463158345D0844008017E826C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4166291542F09B8D93E608017E836ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D262D3EE6C30FA6C44D08017E84A9FF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ADB26E63BC209138178608017E80D3FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D262D3EE6C30FA6C44D08017E84A9FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_131B44F21D078DBE2B5908017E8488B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_DD3105B79B91774600EB08017E85ACC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_DB0701E39B35605672F708017E8563F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F62AA1D8F6A7558E850708017E861B4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1705846F438EDB6A57CA08017E861A56" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_341F0464542C0AC338E908017E84B72F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1705846F438EDB6A57CA08017E861A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8290CDC5E2932E51F05308017E873595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_AB7C8CC912FC1E49305108017E8A6645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_A67B5C58489F2A59F46708017E8B6C5A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_A67B5C58489F2A59F46708017E8B6C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_08056C246F1A4502B20A08017E8BD440" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_08056C246F1A4502B20A08017E8BD440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_340F88F3B7FF4C35217B08017E8C45DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_824B3321C63FB10AABE208017E805A62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_F14C2A642865CEF2FE1008017E8C1767" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.retrophin.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_CAB27613F38DA9A5614908017E259754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_75B09BFCAE873821F25B08017E257D9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0AD850CA3309331C477F08017E25C992" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8AAA70A1883BA9F2F27C08017E266135" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pipelineq318a02.jpg
<TEXT>
begin 644 pipelineq318a02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A=FED($UC
M3&5N;F%N    !9 #  (    4   0J) $  (    4   0O)*1  (    #-S0
M )*2  (    #-S0  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,3@Z,3 Z,S$@,3 Z,3 Z,C8 ,C Q.#HQ
M,#HS,2 Q,#HQ,#HR-@   $0 80!V &D 9  @ $T 8P!, &4 ;@!N &$ ;@
M /_A"R%H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B
M96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A
M9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#$X+3$P+3,Q5#$P.C$P
M.C(V+C<S.3PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^/')D9CIL:3Y$879I9"!-8TQE;FYA;CPO<F1F.FQI/CPO<F1F
M.E-E<3X-"@D)"3PO9&,Z8W)E871O<CX\+W)D9CI$97-C<FEP=&EO;CX\+W)D
M9CI21$8^/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_
M>'!A8VME="!E;F0])W<G/S[_VP!#  <%!08%! <&!08(!P<("A$+"@D)"A4/
M$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_VP!#
M 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" )H TP# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MZ^UK<6]KJ+7&?+BW+EP?E<'JH)&>Y%)U*:5VN_;H-4JC?+?7YGF?_":>*/\
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MO_X'R_\ Q58M%'+'L'-+N;7_  FGBC_H9-7_ / ^7_XJC_A-/%'_ $,FK_\
M@?+_ /%5BT4<L>P<TNYT%QXH\96BQ&ZUS78!/&)8C)=S+YB'HRY/(XZBH?\
MA-/%'_0R:O\ ^!\O_P 57?SZ;I>H1Z5)K=J]U!9>#ENECCE,;%DD[$>Q(Y!'
M/0U6;PUX8;4!K*Z3,--70!JATE;ICN?>4V^9][:.N?Z<5ASP6Z[_ (7_ ,C?
MDF]GV_&W^:.577?'3(KKJOB$JT)N%87$^#$."_7[H]>E4_\ A-/%'_0R:O\
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MFM:3-J3R>)Y=.4&]D0A" 06;)+$')]23R:.>-_A_K3_,;A)+?^O>_P CC/\
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M[P%,*Q$-M!R",#)Y-,^'VMZEINE"YDN!IN@:7=_:KJ>+<)+V4KA;?KA\X'&
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M?E7]7L1)2C;F?]6N9I\9^*02#XDU@$=1]NE_^*I/^$T\4?\ 0R:O_P"!\O\
M\54OCJ&6W\?:VDYC+_;)&/E#"\G(X^AK JH*,HJ5MQ3YHR<;[&U_PFGBC_H9
M-7_\#Y?_ (JC_A-/%'_0R:O_ .!\O_Q58M%5RQ[$<TNYM?\ ":>*/^ADU?\
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MQC Z=<<YJS8_$?Q7IOVK[%J[Q?:[@W,V(8SND)!)Y7C..@P/:OJ/[?%_=?\
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M+_T&T_[\'_&C_A1DO_0;3_OP?\:]@HH]O4[A[&'8\?\ ^%&2_P#0;3_OP?\
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ML>10_ B664)_;B#/?[.?\:6?X#2P2!?[=0Y&?^/<_P"->Q6?_'TGX_RJ2_\
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M]OB_NO\ D*7,^P^5=S/HK0^WQ?W7_(4?;XO[K_D*.9]@Y5W,^BM#[?%_=?\
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M^Q1]KM_^>\7_ 'V*+,":BH?M=O\ \]XO^^Q1]KM_^>\7_?8HLP)J*A^UV_\
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M;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:*
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MM_Z!+_\ ?Q/\:/\ A67BW_H$O_W\3_&OH^BCZS+L'U>)\X?\*R\6_P#0)?\
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M6GX?UJK-_P ?$G^\?YU:T[_EI^']:JS?\?$G^\?YU"^)EOX4,HHHJR HHHH
M**** "BBB@ HHHH **** +NG?\M/P_K56;_CXD_WC_.K6G?\M/P_K4K7T:.5
M*MD''05G=J3-+)Q5S-HK0^WQ?W7_ "%'V^+^Z_Y"GS/L+E7<SZ*T/M\7]U_R
M%'V^+^Z_Y"CF?8.5=S/HK0^WQ?W7_(4?;XO[K_D*.9]@Y5W,^BM#[?%_=?\
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MV5%<;_PM;PE_T$'_ ._+_P"%'_"UO"7_ $$'_P"_+_X4>SGV#GCW.RHKC?\
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M_'O'_NC^59U-C2GN9<W_ !\2?[Q_G3*?-_Q\2?[Q_G3*T6QF]PHHHH ****
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M'MZG</8P['D<'P&EGD*_VZ@P,_\ 'N?\:2;X$2Q2E/[<0X[_ &<_XU[/8?\
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M.2VLYISK2L(HV?;Y'7 SZU[+535 6T>\"C),#@ =_E--5ZE]Q>QAV/E%49Y
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M 7_&FS_'#099F<6%\ ?4+Z?6I]A4YKV*]K#EM<]%HKS;_A=NA?\ /C??DO\
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M'0M,M[[[9!911W'F22^8HP2SX#G\<#\JT*R;5E8U5[NX4445)04444 %%%%
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MU/Q#X=\7Z;I'B+4HM6M]5C;RIUMUA:&11DKA>"IXY/KVQRO9OI_6EP]HNO\
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MGX_RJ2__ ./A?]W^IJ.S_P"/I/Q_E4E__P ?"_[O]34?:+^R5:***L@****
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MC_WA_.K6H_\ +/\ '^E0_B1:^%E*BBBK("BBB@ HHHH **** "BBB@ K0O\
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M /DJCV@>S+5%5?\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\
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MH/\ A,?#G_0;L?\ O\*/^$Q\.?\ 0;L?^_PKY?HH^K1[A]8?8^H/^$Q\.?\
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MJ3V.<9YE/^%))\$_$D4A1I['(])3_A1[6'<?LI]CSJBO0O\ A2_B/_GO8_\
M?P_X4?\ "E_$?_/>Q_[^'_"CVD.XO93['GM%>A?\*7\1_P#/>Q_[^'_"C_A2
M_B/_ )[V/_?P_P"%'M(=P]E/L>>T5Z%_PI?Q'_SWL?\ OX?\*/\ A2_B/_GO
M8_\ ?P_X4>TAW#V4^QY[17H7_"E_$?\ SWL?^_A_PH_X4OXC_P">]C_W\/\
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M48?$%Q++9VD)S$%.&G/I_N]CZ]/7'OE__P >Z_[W]#6;'&D,2QQ(J(@"JJC
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M_P#R95WSI?\ GH__ 'T:/.E_YZ/_ -]&CV;#VB*7V'QO_P!##X?_ /!#/_\
M)E'V'QO_ -##X?\ _!#/_P#)E7?.E_YZ/_WT:/.E_P">C_\ ?1H]FP]HBE]A
M\;_]##X?_P#!#/\ _)E'V'QO_P!##X?_ /!#/_\ )E7?.E_YZ/\ ]]&CSI?^
M>C_]]&CV;#VB*7V'QO\ ]##X?_\ !#/_ /)E'V'QO_T,/A__ ,$,_P#\F5=\
MZ7_GH_\ WT:/.E_YZ/\ ]]&CV;#VB*7V'QO_ -##X?\ _!#/_P#)E'V'QO\
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MG[-B]HBE]A\;_P#0P^'_ /P0S_\ R91]A\;_ /0P^'__  0S_P#R95WSI?\
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M&_\ T,/A_P#\$,__ ,F5=\Z7_GH__?1H\Z7_ )Z/_P!]&G[-B]HBE]A\;_\
M0P^'_P#P0S__ "91]A\;_P#0P^'_ /P0S_\ R95WSI?^>C_]]&CSI?\ GH__
M 'T:/9L/:(I?8?&__0P^'_\ P0S_ /R91]A\;_\ 0P^'_P#P0S__ "95WSI?
M^>C_ /?1H\Z7_GH__?1H]FP]HBE]A\;_ /0P^'__  0S_P#R91]A\;_]##X?
M_P#!#/\ _)E7?.E_YZ/_ -]&CSI?^>C_ /?1H]FP]HBE]A\;_P#0P^'_ /P0
MS_\ R91]A\;_ /0P^'__  0S_P#R95F*^\_?Y-SO\MRC[7SM8=0?0U)YTO\
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MG>5)_<;\J/*D_N-^5 #:*=Y4G]QORH\J3^XWY4 -HIWE2?W&_*CRI/[C?E0
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M!>.PO]G1E%5G=@@ 3)'R@?SH.FQD8WN/ICWYZ<=:3^T?^F7_ (]_]:C^T?\
MIE_X]_\ 6IVF'N$TEJ))$8NWR=!U'U^M,^Q ,&$LF]1A6XX'ITYIG]H_],O_
M ![_ .M1_:/_ $R_\>_^M2Y9!>)*;2,QA#N("E<YYYZU'+8L\A:.4H&(9AZD
M'(I/[1_Z9?\ CW_UJ/[1_P"F7_CW_P!:CED#<&6HHQ%$J#HHQ3ZI?VC_ -,O
M_'O_ *U']H_],O\ Q[_ZU+ED5S1+M%4O[1_Z9?\ CW_UJ/[1_P"F7_CW_P!:
MCDD'-$NUBU=_M'_IE_X]_P#6JE6D$UN9S:>P44459 4444 %%%% !1110 44
M44 %%%% %W3O^6GX?UJC<V\+W4C/#&S%CDE035[3O^6GX?UJK-_Q\2?[Q_G4
M+XF6_A16^R6__/"+_O@4?9+?_GA%_P!\"IJ*TNR"'[);_P#/"+_O@4?9+?\
MYX1?]\"IJ*+L"'[);_\ /"+_ +X%'V2W_P">$7_? J:BB[ A^R6__/"+_O@4
M?9+?_GA%_P!\"IJ*+L"'[);_ //"+_O@4?9+?_GA%_WP*FHHNP)+"TMC.V;>
M+[O]P>HIEW:6XNGQ;Q=OX!Z59L/^/AO]W^HJ.\_X^G_#^51=\Q7V2G]DM_\
MGA%_WP*/LEO_ ,\(O^^!4U%7=DD/V2W_ .>$7_? H^R6_P#SPB_[X%34478$
M/V2W_P">$7_? H^R6_\ SPB_[X%34478$/V2W_YX1?\ ? H^R6__ #PB_P"^
M!4U%%V!#]DM_^>$7_? H^R6__/"+_O@5-11=@+:6EN;I,V\7?^ >E/O[2V$Z
MXMXON_W!ZFG6?_'TGX_RJ2__ ./A?]W^IJ+OF*^R9_V2W_YX1?\ ? H^R6__
M #PB_P"^!4U%7=DD/V2W_P">$7_? H^R6_\ SPB_[X%34478$/V2W_YX1?\
M? H^R6__ #PB_P"^!4U%%V!#]DM_^>$7_? H^R6__/"+_O@5-11=@0_9+?\
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M_OHT6EW"\>Q:_L[_ *:_^.__ %Z/[._Z:_\ CO\ ]>JOG2_\]'_[Z-'G2_\
M/1_^^C1:7<+Q[%K^SO\ IK_X[_\ 7H_L[_IK_P"._P#UZJ^=+_ST?_OHT>=+
M_P ]'_[Z-%I=PO'L6O[._P"FO_CO_P!>C^SO^FO_ ([_ /7JKYTO_/1_^^C2
MB:7</WC_ /?1HM+N%X]BS_9W_37_ ,=_^O1_9W_37_QW_P"O47F2?WW_ #K-
MO/$$=M<&UM_/O;OO!;\E?]X]%_&LI5.57;+Y8HU_[._Z:_\ CO\ ]>C^SO\
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M^SO^FO\ X[_]>JOG2_\ /1_^^C1YTO\ ST?_ +Z-%I=PO'L6O[._Z:_^._\
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MWQ;_ -!9_P#OVG^%'_"S?%O_ $%G_P"_:?X57U:7<GZQ$^CZ*^</^%F^+?\
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M4G]QORH\J3_GFW_?- #:*=Y4G]QORH\J3^XWY4 -HIWE2?W&_*CRI/[C?E0
MVBG>5)_<;\J/*D_N-^5 #:*=Y4G]QORH\J3^XWY4 -HH((.#P:UO#GAR_P#$
M^K)8Z='DGF20_=C7NQ-#TW!)MV1V'PCUW6H-<&EV<+W=A*=TR$X$ _O@]OIW
MZ=<5]%P_\>\?^Z/Y5Q_ACPQ8>%=)6RL%RQP9IF'S2MZGV]!V_6NPA_X]X_\
M='\J\C$S4Y71ZN'BXJS,N;_CXD_WC_.F4^;_ (^)/]X_SIE); ]PHHHH ***
M* "BBB@ HHHH **** "G1?ZU/]X4VGQ?ZY/]X4/8%N7\48I^*,5S'2<QXJ'_
M !--#_Z[3?\ HEJI^#1_I\7_ &"+?_T)JU?$=C<W6HZ0]M"\B0RRF0K_  @Q
M,!G\3BJ7AK3+ZUF!GMWA/]E10@L.D@+9'U&1659-SIV\QS^S_74@NO" ^U3Z
MKX;UF72A-N:81KNC;!.2!Q[^OM5W0O"-OIR7%U)=R7]]>QE7NY1SM8=A4%M:
MS26:_P"BW4LA@18'CDPD:B,!E/.,[MV01SD?A+_9D]K) AM[J2Q\N(W$22$L
MS[7![Y.#LR![5TNI)JURW5FU:Y9T+2;;1-'_ +#2\\YQO^8I@_,">GTS5)?
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M)II!,X$C !C_ !'UIGG2_P#/1_\ OHT[2[BO'L6O[._Z:_\ CO\ ]>C^SO\
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M)_PGUU_SY+^%V#0JT'LP^MT>_P"#/05C55"J H P !@"EVUY[_PL"Z_Y\/\
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MT:+2[A>/8M?V=_TU_P#'?_KT?V=_TU_\=_\ KU5\Z7_GH_\ WT:/.E_YZ/\
M]]&BTNX7CV+7]G?]-?\ QW_Z]']G?]-?_'?_ *]5?.E_YZ/_ -]&CSI?^>C_
M /?1HM+N%X]BU_9W_37_ ,=_^O1_9W_37_QW_P"O57SI?^>C_P#?1H\Z7_GH
M_P#WT:+2[A>/8T;>W^S[OFW;L=L5$]AOD9O,QN).-M%@[/YF]F;&,9.?6JTT
MT@F<"1@ Q_B/K4I.Y3:L3_V=_P!-?_'?_KT?V=_TU_\ '?\ Z]5?.E_YZ/\
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M_P#KU5\Z7_GH_P#WT:/.E_YZ/_WT:+2[A>/8M?V=_P!-?_'?_KT?V=_TU_\
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MP/>**\'_ .%T>(_^>%C_ -^S_C1_PNCQ'_SPL?\ OV?\:/J\P]O ]XHKP?\
MX71XC_YX6/\ W[/^-'_"Z/$?_/"Q_P"_9_QH^KS#V\#WBM"__P"/=?\ >_H:
M^=_^%T>(_P#GA8_]^S_C4TOQQ\33(%>"PQG/$1_QI/#3;12Q$$F>Y45X/_PN
MCQ'_ ,\+'_OV?\:/^%T>(_\ GA8_]^S_ (T_J\R?;P/>**\'_P"%T>(_^>%C
M_P!^S_C1_P +H\1_\\+'_OV?\:/J\P]O ]XHKP?_ (71XC_YX6/_ '[/^-'_
M  NCQ'_SPL?^_9_QH^KS#V\#WBBO!_\ A='B/_GA8_\ ?L_XT?\ "Z/$?_/"
MQ_[]G_&CZO,/;P-#PC\16T+Q!=Z3K#L^FM=2".0\FW)8_P#COM^(]_9HY$EC
M62)U=' 964Y# ]"#7R7<SM=7<MQ( &E<NP'J3FO0OAS\1GT.1-*UJ1GTYSB.
M0\F G_V7U'XCWWK4>;WH[F=.MK9GNE:\/_'O'_NC^58T<B2QK)$ZNC@,K*<A
M@>A!K9A_X]X_]T?RKS*AWT]S+F_X^)/]X_SIE/F_X^)/]X_SIE:+8S>X4444
M %%%% !1110 4444 %%%% !2I]]?K24Y/]8OU%#V!;EG%>5^+_\ D:[WZK_Z
M"*]6Q7FWBG2-1N?$UW+;V-Q+&Q7:Z1D@_**\K%IN"MW,L<FZ:MW.B\!C_BFS
M_P!=W_I6?\1?N:?]9/Z5K^"K6>T\/F*[ADAD\YCM=<''%4/'EA=WJ6/V.VEG
MV%]WEH6QTI23^K6]"9Q?U2WDBA\.Q_IM\<<^6O/XFJGCX?\ %1)_U[K_ #-:
MO@/3KRRNKTWEK- &C4*9$*YY-5?&VEWUYKR26EG-,@@4;HT)&<GBLG%_5DK&
M#C+ZHE;J4[/_ ))SJ'_7TO\ [+53P?\ \C79_5O_ $$UK6FEWZ^ ;ZV:SG$[
MW*LL90[B/EYQ5;PKI&HVWB6UFN+&XBC4MEWC( ^4UGRRYX:=OS,^67/3T[?F
M<]?.TFH7+R<NTKDY]<FO5]+C3_A&;5,#8;501]5YKD_$_@^[^WRWNEQ>?%,V
M]HE^\C'K@=Q4$&M^(;;1_P"S%TV4E4,:R&%]RK_*KI7HSESHTHWP]27.CE02
MIRO!!X-;OC!F;7]S_>-O$3]=M6M!\&WMU=QRZC"UM:H0S*_#/[ =JE\8Z5?W
M7B.26ULIY8_+0!DC)'2LO9S5)MKJC!4IJBVUNU^I;T&^L-/\$F75(UFC-PP6
M(J&WM[ _SJG9^()[C4MOAW0K2*=E(R%RVWW/  I1X<U&[\'PJEO(MQ;W$CF!
MQM9E('(S]*HZ&^L:%J320Z7/*SKL:-XF&1G/7%:<TURIZ+T->:I'DB]%9:V$
M\5'5C=VYUM85D,9V"+L,]ZW?AU_QZW_^^G\C6=X@TS7]3:*_O+-M[Y1;>%2Q
MB4<\_7)K9\!V5U90WJWEM+ 69"OF(5SP:JG%_6+Z_/T*I1E]9O9V\_0Z"BBB
MO;.X**** "BBB@ HHHH **** "BBB@ HHHH NZ=_RT_#^M?*?C;_ )'[7_\
ML)7'_HQJ^K-._P"6GX?UKY3\;?\ (_:__P!A*X_]&-71A?CD8XG^&C$HHHKT
M#SPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+N'*C%_X0[PY_P! 2Q_[\BC_ (0[PY_T!+'_ +\BMJBCGEW#E1B_\(=X<_Z
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M_P!-?_'?_KT?V=_TU_\ '?\ Z]%%'-(.2(?V=_TU_P#'?_KT?V=_TU_\=_\
MKT44<T@Y(A_9W_37_P =_P#KT?V=_P!-?_'?_KT44<T@Y(A_9W_37_QW_P"O
M1_9W_37_ ,=_^O111S2#DB']G?\ 37_QW_Z]']G?]-?_ !W_ .O111S2#DB.
M2PV2*WF9VD'&VI;BW^T;?FV[<]LT44<SO<.56L0?V=_TU_\ '?\ Z]']G?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770962688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Nov. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Retrophin, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001438533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">rtrx<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,247,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771587168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 154,820<span></span>
</td>
<td class="nump">$ 99,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">323,993<span></span>
</td>
<td class="nump">201,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">13,450<span></span>
</td>
<td class="nump">13,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">5,129<span></span>
</td>
<td class="nump">5,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">3,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">502,989<span></span>
</td>
<td class="nump">325,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,323<span></span>
</td>
<td class="nump">3,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">7,393<span></span>
</td>
<td class="nump">5,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment-equity</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">186,545<span></span>
</td>
<td class="nump">184,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">716,186<span></span>
</td>
<td class="nump">520,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,314<span></span>
</td>
<td class="nump">18,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">43,348<span></span>
</td>
<td class="nump">36,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Guaranteed minimum royalty</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">3,833<span></span>
</td>
<td class="nump">3,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AcquisitionRelatedContingentConsideration', window );">Business combination-related contingent consideration</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Debt</a></td>
<td class="nump">22,377<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative financial instruments, warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">99,872<span></span>
</td>
<td class="nump">85,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt</a></td>
<td class="nump">192,753<span></span>
</td>
<td class="nump">45,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">4,885<span></span>
</td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AccruedRoyaltiesNoncurrent', window );">Guaranteed minimum royalty, less current portion</a></td>
<td class="nump">12,611<span></span>
</td>
<td class="nump">13,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent', window );">Business combination-related contingent consideration, less current portion</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="nump">80,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">397,121<span></span>
</td>
<td class="nump">227,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock $0.0001 par value; 20,000,000 shares authorized; 0 issued and outstanding as of September 30, 2018 and December 31, 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.0001 par value; 100,000,000 shares authorized; 41,167,942 and 39,373,745 issued and outstanding as of September 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">582,706<span></span>
</td>
<td class="nump">471,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(262,562)<span></span>
</td>
<td class="num">(177,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="num">(1,015)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">319,065<span></span>
</td>
<td class="nump">293,134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 716,186<span></span>
</td>
<td class="nump">$ 520,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AccruedRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalties, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AccruedRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AcquisitionRelatedContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of acquisition-related contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AcquisitionRelatedContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AcquisitionRelatedContingentConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of acquisition-related contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AcquisitionRelatedContingentConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763679856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">41,167,942<span></span>
</td>
<td class="nump">39,373,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">41,167,942<span></span>
</td>
<td class="nump">39,373,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770930192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 40,706<span></span>
</td>
<td class="nump">$ 40,340<span></span>
</td>
<td class="nump">$ 120,475<span></span>
</td>
<td class="nump">$ 112,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="nump">3,924<span></span>
</td>
<td class="nump">2,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">32,448<span></span>
</td>
<td class="nump">19,610<span></span>
</td>
<td class="nump">91,762<span></span>
</td>
<td class="nump">58,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">26,107<span></span>
</td>
<td class="nump">24,852<span></span>
</td>
<td class="nump">77,699<span></span>
</td>
<td class="nump">74,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Legal fee settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ChangeinFairValueofContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">16,601<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
<td class="nump">22,387<span></span>
</td>
<td class="nump">11,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
<td class="num">(242)<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">76,289<span></span>
</td>
<td class="nump">50,948<span></span>
</td>
<td class="nump">195,530<span></span>
</td>
<td class="nump">151,374<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(35,583)<span></span>
</td>
<td class="num">(10,608)<span></span>
</td>
<td class="num">(75,055)<span></span>
</td>
<td class="num">(38,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(90)<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="num">(372)<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="num">(2,533)<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">(4,848)<span></span>
</td>
<td class="num">(3,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="num">(17,042)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,042)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,901)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,921)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(18,518)<span></span>
</td>
<td class="num">(8,409)<span></span>
</td>
<td class="num">(19,357)<span></span>
</td>
<td class="num">(8,711)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(54,101)<span></span>
</td>
<td class="num">(19,017)<span></span>
</td>
<td class="num">(94,412)<span></span>
</td>
<td class="num">(47,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(415)<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
<td class="num">(811)<span></span>
</td>
<td class="nump">5,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,516)<span></span>
</td>
<td class="num">$ (17,794)<span></span>
</td>
<td class="num">$ (95,223)<span></span>
</td>
<td class="num">$ (42,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted (in dollars/share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and Diluted (in shares)</a></td>
<td class="nump">40,717,440<span></span>
</td>
<td class="nump">38,654,086<span></span>
</td>
<td class="nump">40,149,184<span></span>
</td>
<td class="nump">38,301,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,516)<span></span>
</td>
<td class="num">$ (17,794)<span></span>
</td>
<td class="num">$ (95,223)<span></span>
</td>
<td class="num">$ (42,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency translation</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (54,447)<span></span>
</td>
<td class="num">$ (17,813)<span></span>
</td>
<td class="num">$ (95,291)<span></span>
</td>
<td class="num">$ (42,218)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ChangeinFairValueofContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Fair Value of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ChangeinFairValueofContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771561008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (95,223)<span></span>
</td>
<td class="num">$ (42,113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">13,789<span></span>
</td>
<td class="nump">13,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_InterestReceivablefromNotesReceivable', window );">Interest income from notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on marketable securities</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ProvisionForInventory', window );">Provision for Inventory</a></td>
<td class="nump">1,625<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">15,114<span></span>
</td>
<td class="nump">21,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of liability classified warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ChangeinFairValueofContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">22,387<span></span>
</td>
<td class="nump">11,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Payments related to change in fair value of contingent consideration</a></td>
<td class="num">(6,852)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Loss on the extinguishment of debt</a></td>
<td class="nump">17,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized foreign currency transaction gain (loss)</a></td>
<td class="nump">270<span></span>
</td>
<td class="num">(1,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of business acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">4,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,428)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current and non-current operating assets</a></td>
<td class="num">(2,183)<span></span>
</td>
<td class="num">(3,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,797<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and non-current operating liabilities</a></td>
<td class="nump">3,094<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(21,393)<span></span>
</td>
<td class="nump">8,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(727)<span></span>
</td>
<td class="num">(1,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash paid for intangible assets</a></td>
<td class="num">(15,108)<span></span>
</td>
<td class="num">(9,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from the sale/maturity of marketable securities</a></td>
<td class="nump">96,166<span></span>
</td>
<td class="nump">76,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(219,820)<span></span>
</td>
<td class="num">(67,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ProceedsfromMaturityofNoteReceivable', window );">Proceeds from maturity of note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash paid for investments - equity</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) provided by investing activities</a></td>
<td class="num">(154,489)<span></span>
</td>
<td class="nump">45,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of acquisition-related contingent consideration</a></td>
<td class="num">(8,842)<span></span>
</td>
<td class="num">(5,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_PaymentOfGuaranteedMinimumRoyalty', window );">Payment of guaranteed minimum royalty</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Payment of other liability</a></td>
<td class="num">(750)<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">4,274<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">10,379<span></span>
</td>
<td class="nump">7,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from 2025 convertible senior notes</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of 2019 convertible senior notes</a></td>
<td class="num">(40,203)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of debt issuance and financing costs</a></td>
<td class="num">(8,820)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">231,338<span></span>
</td>
<td class="nump">4,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">55,426<span></span>
</td>
<td class="nump">57,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">99,394<span></span>
</td>
<td class="nump">41,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 154,820<span></span>
</td>
<td class="nump">$ 98,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ChangeinFairValueofContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Fair Value of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ChangeinFairValueofContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_InterestReceivablefromNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Receivable from Notes Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_InterestReceivablefromNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_PaymentOfGuaranteedMinimumRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow due to guaranteed minimum royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_PaymentOfGuaranteedMinimumRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ProceedsfromMaturityofNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Maturity of Note Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ProceedsfromMaturityofNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ProvisionForInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ProvisionForInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130534-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762232944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (&#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;Retrophin&#8221; and the &#8220;Company&#8221;) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration (&#8220;PKAN&#8221;). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. There are currently no viable treatment options for patients with PKAN. Fosmetpantotenate is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan (RE-021) is an investigational product candidate which acts as both a potent </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">angiotensin receptor blocker (&#8220;ARB&#8221;), as well as a selective endothelin receptor antagonist (&#8220;ERA&#8221;), with in vitro selectivity toward endothelin receptor type A. The Company secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Focal segmental glomerulosclerosis ("FSGS")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is a leading cause of end-stage renal disease and nephrotic syndrome (&#8220;NS&#8221;). There are no U.S. Food and Drug Administration ("FDA") approved pharmacologic treatments for FSGS and off-label resources are limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Immunoglobulin A nephropathy ("IgAN")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is characterized by hematuria, proteinuria, and variable rates of progressive renal failure. There is no FDA approved treatment for IgAN.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a party to a&#160;joint development agreement with&#160;Censa Pharmaceuticals Inc. ("Censa"), a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria ("PKU"). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin ("BH4") with the potential to provide improved phenylalanine ("Phe") reduction in patients with PKU when compared to BH4.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">PKU is a rare, genetic metabolic condition in which the body cannot breakdown Phe due to a missing or defective phenylalanine hydroxylase ("PAH") enzyme. High Phe levels can lead to developmental and physical growth delay, executive function impairment, seizures, and microcephaly caused by toxic Phe accumulation in the brain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is party to a three-way Cooperative Research and Development Agreement ("CRADA")&#160;with the National Institutes of Health&#8217;s National Center for Advancing Translational Sciences and patient advocacy foundation NGLY1.org&#160;to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for N-glycanase deficiency ("NGLY1").</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">NGLY1 is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition has been characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). The Company obtained the rights to L-UDCA in 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"> products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal&#174; (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam&#174; (cholic acid capsules) is approved in the United States (approved and marketed in Europe for select indications as Kolbam) for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola&#174; (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757686224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the 2017 10-K filed with the SEC on February 27, 2018. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information, the instructions for Form&#160;10-Q and the rules and regulations of the SEC. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for annual financial statements, but reflect all adjustments consisting of normal, recurring adjustments, that are necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for any future periods.&#160;The </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> balance sheet information was derived from the audited financial statements as of that date.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain reclassifications have been made to the prior period consolidated financial statements to&#160;conform&#160;to&#160;the current period presentation.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">A summary of the significant accounting policies applied in the preparation of the accompanying condensed consolidated financial statements follows:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The unaudited condensed consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Effective January 1, 2018, the Company adopted Accounting Standards Codification (" ASC"), Topic 606,&#160;Revenue from Contracts with Customers, using the full retrospective transition method. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. See Note 3 for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Research and development expenses are comprised of salaries and bonuses, benefits, non-cash share-based compensation, license fees, costs paid to third-party contractors to perform research, conduct clinical trials and pre/non-clinical trials, develop drug materials, and associated overhead expenses and facilities. We also incur indirect costs that are not allocated to specific programs because such costs benefit multiple development programs and allow us to increase our pharmaceutical development capabilities. These consist of internal shared resources related to the development and maintenance of systems and processes applicable to all of our programs.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Clinical Trial Expenses</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We record expenses in connection with our clinical trials under contracts with contract research organizations (CROs) that support conducting and managing clinical trials. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up, initiation activities, enrollment, treatment of patients, or the completion of other clinical trial activities.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We currently have three Phase 3 clinical trials in process that are in varying stages of activity, with ongoing non-clinical support trials. As such, clinical trial expenses will vary depending on the all the factors set forth above and may fluctuate significantly from quarter to quarter.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. See Note 6 for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In January 2017, the FASB issued&#160;ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. The new guidance dictates that, when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, it should be treated as an acquisition or disposal of an asset. The guidance was adopted as of January 1, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In February 2016, the FASB issued ASU No. 2016-02, Leases.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach or a </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> are both options for transition. The Company is in the process of identifying and quantifying all leases.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As of September 30, 2018, the Company held </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$324.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in available for sale debt securities. If adopted as of September 30, 2018, this ASU update would not have a material impact on the Company's financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762223440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">REVENUE RECOGNITION</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Product Revenue, Net</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company sells Chenodal and Cholbam (Kolbam), which are </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">aggregated as bile acid products,</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and Thiola through direct-to-patient distributors.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> The Company sells its products worldwide, with more than </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">95%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> of the revenue generated in North America.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Revenues from product sales are recognized when the customer obtains control of the Company&#8217;s product, which occurs upon delivery to the customer.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Deductions from Revenue</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Revenues from product sales are recorded at the net sales price, which includes provisions resulting from discounts, rebates and co-pay assistance that is offered to its customers, health care providers, payors and other indirect customers relating to the Company&#8217;s sales of its products. These provisions are based on the amounts earned or to be claimed on the related sales and are classified as a reduction of accounts receivable (if the amount is payable to the customer) or as a current liability (if the amount is payable to a party other than a customer). Where appropriate, these reserves take into consideration the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. If actual results in the future vary from the Company&#8217;s provisions, the Company will adjust the provision, which would affect net product revenue and earnings in the period such variances become known. Our historical experience is that such adjustments have been immaterial.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Government Rebates:</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> We calculate the rebates that we will be obligated to provide to government programs and deduct these estimated amounts from our gross product sales at the time the revenues are recognized. Allowances for government rebates and discounts are established based on actual payer information, which is reasonably estimated at the time of delivery, and the government-mandated discounts applicable to government-funded programs.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Commercial Rebates: </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">calculate the rebates that we incur due to contracts with certain commercial payors and deduct these amounts from our gross product sales at the time the revenues are recognized. Allowances for commercial rebates are established based on actual payer information, which is reasonably estimated at the time of delivery.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Prompt Pay Discounts: </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> offer discounts to certain customers for prompt payments. We accrue for the calculated prompt pay discount based on the gross amount of each invoice for those customers at the time of sale.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Product Returns:</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> Consistent with industry practice, we offer our customers a limited right to return product purchased directly from the Company, which is principally based upon the product&#8217;s expiration date. Generally, shipments are only made upon a patient prescription thus returns are minimal.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Co-pay Assistance:&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> offer a co-pay assistance program, which is intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an identification of claims and the cost per claim associated with product that has been recognized as revenue.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes net product revenues for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Bile acid products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">55,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">52,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Thiola</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21,501</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">65,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">60,098</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total net product revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">112,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757726640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">MARKETABLE SECURITIES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company's marketable securities as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> were comprised of available-for-sale marketable securities which are carried at fair value, with the unrealized gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. Interest and dividends on securities classified as available-for-sale are included in interest income. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income. During the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, investment activity for the Company included </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$96.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in maturities and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$219.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in purchases, all relating to debt based marketable securities. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Marketable securities&#160;consisted of the following (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable Securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">266,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">164,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government sponsored entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total marketable securities:</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following is a summary of short-term&#160;marketable securities classified as available-for-sale as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Remaining Contractual Maturity<br clear="none"/>(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Aggregate Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">138,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">138,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government-sponsored entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity less than 1 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">196,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">196,064</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1 to 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">128,174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(249</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">127,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity 1 to 2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">128,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">127,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">324,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following is a summary of short-term&#160;marketable securities classified as available-for-sale as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Remaining Contractual Maturity</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Aggregate Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">86,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">86,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government-sponsored entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(90</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity less than 1 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">123,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">123,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1 to 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">78,388</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(424</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">77,964</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity 1 to 2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">78,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">77,964</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The primary objective of the Company&#8217;s investment portfolio is to enhance overall returns while preserving capital and liquidity. The Company&#8217;s investment policy limits interest-bearing security&#160;investments&#160;to certain types of instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.  All available for sale securities are held in current assets regardless of contractual maturities exceeding one year, as the Company could sell them within the next twelve months.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company reviews the available-for-sale&#160;investments&#160;for other-than-temporary declines in fair value below cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security, and the intent to sell, or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security. As of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company believed the cost basis for available-for-sale&#160;investments&#160;was recoverable in all material respects.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762271760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Censa Pharmaceuticals Inc.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In December 2017, the Company entered into a Future Acquisition Right and Joint Development Agreement (the &#8220;Option Agreement&#8221;) with Censa, which became effective in January 2018.  The Company has agreed to fund certain development activities of Censa&#8217;s&#160;CNSA-001&#160;program, in an aggregate amount expected to be approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$17 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> through proof of concept, and has the right, but not the obligation, to acquire Censa (the &#8220;Option&#8221;) on the terms and subject to the conditions set forth in a separate Agreement and Plan of Merger. In exchange for the Option, the Company paid </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, and an additional </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> upon Censa&#8217;s completion of a specified development milestone set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">If the Company exercises the Option, the Company will acquire Censa for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$65 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in upfront consideration, subject to certain adjustments, paid as a combination of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">20%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in cash and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">80%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in shares of the Company&#8217;s common stock, valued at a fixed price of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$21.40</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> per share; provided, however, that Censa may elect on behalf of its equity holders to receive the upfront consideration in </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">100%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> cash if the average price per share of the Company&#8217;s common stock for the ten trading days ending on the date the Company provides a notice of interest to exercise the Option is less than </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$19.26</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. In addition, if the Company exercises the Option and acquires Censa, the Company would be required to make further cash payments to Censa&#8217;s equity holders of up to an aggregate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$25 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> if the&#160;CNSA-001 program achieves specified development and commercial milestones.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company determined that Censa is a variable interest entity ("VIE") and concluded that the Company is not the primary beneficiary of the VIE. As such, the Company did not consolidate Censa&#8217;s results into its consolidated financial statements. The Company will continue to monitor facts and circumstances for changes that could potentially result in the Company becoming the primary beneficiary.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Through&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company has paid Censa </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> as an upfront payment, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$15.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in development funding, and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$5.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> related to a development milestone. The Company capitalized the upfront and milestone payments, and expensed the development funding paid. The Company is treating the upfront payment and milestone payment, both of which are compensation for the Option, as a cost-method investment with a total carrying value of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$15.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762235952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">DERIVATIVE FINANCIAL INSTRUMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DERIVATIVE FINANCIAL INSTRUMENTS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Since 2013, the Company has issued </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">five</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> tranches of common stock purchase warrants to secure financing, remediate covenant violations and provide consideration for amendments with respect to a credit facility extinguished in 2015.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Historically, the Company accounted for these instruments, which do not have fixed settlement provisions, as derivative instruments in accordance with FASB ASC 815-40, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Derivative and Hedging &#8211; Contracts in Entity&#8217;s Own Equity. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">This was due to an anti-dilution provision for the warrants that provides for a reduction to the exercise price if the Company issues equity or equity linked instruments in the future at an effective price per share less than the exercise price then in effect for the warrant ("down round provision"). As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value were recorded as non-cash adjustments within other income (expenses), net, in the Company&#8217;s accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.&#160;&#160;The Company recorded a loss on the change in the estimated fair value of warrants of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$8.9 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> for each of the three and nine months ended September 30, 2017.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of January 1, 2018 the Company early adopted ASU 2017-11, which </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">revised the guidance for instruments with down round provisions. As such the Company treats outstanding warrants as free-standing equity linked instruments that will be recorded to equity in the Consolidated Balance Sheet. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The fair value of the derivative liability balance as of December 31, 2017 of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$15.7 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> was reclassified by </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">means of a cumulative-effect adjustment to equity as of January 1, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company calculated the fair value of the warrants using the Black-Scholes Model as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Fair value of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Remaining life of the warrants (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">0.1 - 2.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Risk-free interest rate*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1.39 - 1.89%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Expected volatility**</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">33 - 43%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">*The risk-free interest rate is based on the U.S. Treasury security rates for the remaining term of the warrants at the measurement date.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">**Expected volatility is based on an analysis of the Company&#8217;s historical volatility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757723664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Financial Instruments and Fair Value</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company accounts for financial instruments in accordance with ASC 820, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (&#8220;ASC 820&#8221;).  ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.&#160;&#160;The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).&#160;&#160;The three levels of the fair value hierarchy under ASC 820 are described below:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 1</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> &#8211; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 2</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> &#8211; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 3</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> &#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The valuation techniques used to measure the fair value of the Company&#8217;s marketable securities and all other financial instruments, all of which have counter-parties with high credit ratings, were valued based on quoted market prices or model driven valuations using significant inputs derived from or corroborated by observable market data. Based on the fair value hierarchy, the Company classified marketable securities within Level 2.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In estimating the fair value of the Company&#8217;s derivative liabilities as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company used the Black Scholes Model.  Based on the fair value hierarchy, the Company classified the derivative liability within Level 3. The Company adopted ASU 2017-11 as of January 1, 2018 and is no longer required to treat outstanding warrants as derivative liabilities measured at fair value. See Note 6 for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In estimating the fair value of the Company&#8217;s contingent consideration, the Company used the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Monte Carlo Simulation model as of September 30,  2018 and a probability-based expected method for royalty payments based on projected revenues as of December 31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. Based on the fair value hierarchy, the Company classified the fair value measurement of contingent consideration within Level 3.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, and accounts payable, due to their short term nature. As of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the estimated fair value of the Company's </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> Senior Convertible Notes due 2019 was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$38.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and the estimated fair value of the  Company's </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> Convertible Senior Notes due 2025 was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$283.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, considering factors such as market conditions, prepayment and make-whole provisions, variability in pricing from multiple lenders and the term of the debt.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">As of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total carrying and estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Quoted prices in active markets<br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant other observable inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant unobservable inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities, available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Business combination-related contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total carrying and estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Quoted prices in active markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant other observable inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant unobservable inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities, available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Derivative liability related to warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Business combination-related contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">105,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">105,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth a summary of changes in the estimated fair value of the Company's business combination-related contingent consideration for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Fair Value Measurements of Acquisition-Related Contingent Consideration<br clear="none"/>(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Increase from revaluation of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,387</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual payments included in accrued liabilities at September 30, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(4,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Balance at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The key assumptions included in the calculations for contingent consideration were the future number of patients in treatment, projected revenues, discount rate, and the timing of payments. The present value of the expected payments considers the time at which the obligations are expected to be settled and a discount rate that reflects the risk associated with the performance payments. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">During the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company incurred charges of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$16.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$22.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, in operating expenses on the Condensed Consolidated Statements of Operations and Comprehensive Loss for the revaluation of the contingent consideration liabilities.  For the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> of the charges were related to the increase in contingent consideration liabilities for the products Chenodal and Cholbam and product candidate L-UDCA, respectively. In each case, the value increased due to </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">changes in the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">discount factors, estimated timing of payments, and changes in projections</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">During the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company incurred charges of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$4.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$11.1 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, in operating expenses on the Condensed Consolidated Statement of Operations and Comprehensive Loss for the change in fair value of the contingent consideration liabilities. For the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine months ended September 30, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$5.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> of the charges were related to the increase in contingent consideration liabilities for the products Chenodal and Cholbam and product candidate L-UDCA, respectively. In each case, the value increased due to </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">changes in the discount factor, estimated timing of payments and expected payments.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762235952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INTANGIBLE ASSETS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the net book value of amortizable intangible assets was approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$186.5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth amortizable intangible assets as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Finite-lived intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">250,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">235,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less: accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(64,279</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(51,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net carrying value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">186,545</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">184,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes amortization expense for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,752</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total amortization expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">13,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757688336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES PAYABLE</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONVERTIBLE NOTES PAYABLE</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Convertible Senior Notes Due 2025</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On September 10, 2018, the Company completed its registered underwritten public offering of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$276 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> aggregate principal amount of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.50%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> Convertible Senior Notes due 2025 ("2025 Notes"), and entered into a base indenture and supplemental indenture agreement ("2025 Indenture") with respect to the 2025 Notes. The 2025 Notes will mature on September 15, 2025 ("Maturity Date&#8221;), unless earlier repurchased, redeemed, or converted. The 2025 Notes are senior unsecured obligations of the Company and bear interest at an annual rate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.50%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2019.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The composition of the Company&#8217;s 2025 Notes are as follows (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:437px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:3px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:3px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2.50% convertible senior notes due 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">276,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(76,951</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(6,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total 2025 Notes, net of unamortized debt discount and debt issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">192,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The net proceeds from the issuance of the 2025 Notes were approximately&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$267.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, after deducting commissions and the offering expenses payable by the Company. A portion of the net proceeds from the 2025 Notes were used by the Company to repurchase </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$23.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> aggregate principal amount of its then-outstanding </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> senior convertible notes due in 2019 in privately-negotiated transactions. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Holders may convert their 2025 Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2018 (and only during such calendar quarter), if the last reported sale price per share of the Company&#8217;s common stock for each of at least </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">20</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> trading days, whether or not consecutive, during the period of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">30</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">130%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> of the conversion price on the applicable trading day; (2) during the five consecutive business days immediately after any </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">10</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> consecutive trading day period (&#8220;measurement period&#8221;) if the trading price per $1,000 principal amount of 2025 Notes for each trading day of the measurement period was less than </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">98%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> of the product of the last reported sale price per share of the Company&#8217;s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company&#8217;s common stock; (4) if the Company calls the 2025 Notes for redemption; and (5) at any time from, and including, May 15, 2025 until the close of business on the scheduled trading day immediately before the Maturity Date. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company&#8217;s common stock, or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s election, based on the applicable conversion rate.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The initial conversion rate for the 2025 Notes is </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">25.7739</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> shares of the Company&#8217;s common stock per $1,000 principal amount of 2025 Notes, which represents an initial conversion price of approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$38.80</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> per share. If a &#8220;make-whole fundamental change&#8221; (as defined in the 2025 Indenture) occurs, then the company will, in certain circumstances, increase the conversion rate for a specified period of time.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after September 15, 2022 and, in the case of any partial redemption, on or before the 40th scheduled trading day before the Maturity Date, at a cash redemption price equal to the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company&#8217;s common stock exceeds </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">130%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> of the conversion price on each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice. If a fundamental change (as defined in the 2025 Indenture) occurs, then, subject to certain exceptions, holders may require the Company to repurchase their 2025 Notes at a cash repurchase price equal to the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As of&#160;September 30, 2018, the 2025 Notes had a market price of&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$1,027</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;per&#160;$1,000&#160;principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$276.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;in principal value and any conversion premium in any combination of cash and shares of its common stock at the Company&#8217;s option. In addition, calling the 2025 Notes for redemption will constitute a &#8220;make whole fundamental change &#8221;.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes are the Company&#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2025 Notes, and equal in right of payment to the Company&#8217;s unsecured indebtedness. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes are currently classified on the Company&#8217;s consolidated balance sheet at&#160;September 30, 2018&#160;as long-term debt.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Under ASC 470-20,&#160;Debt with Conversion and Other Options, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2025 Notes) that may be settled entirely or partially in cash upon conversion, in a manner that reflects the issuer&#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component was&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$198.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.&#160;The equity component of&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$77.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2025 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2025 Notes, which is amortized over the seven year term of the 2025 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.&#160;The Company allocated the total transaction costs of approximately </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$8.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> related to the issuance of the 2025 Notes to the liability and equity components of the 2025 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the seven-year term of the 2025 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The effective interest rate on the liability components of the 2025 Notes for the period from the date of issuance through September 30, 2018 was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">7.7%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. The following table sets forth total interest expense recognized related to the 2025 Notes (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Three and Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total interest expense for the 2025 Notes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">901</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The 2025 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2025 Indenture contains customary events of default with respect to the 2025 Notes, including that upon certain events of default,&#160;100%&#160;of the principal and accrued and unpaid interest on the 2025 Notes will automatically become due and payable.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Senior Convertible Notes Due 2019</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On May 29, 2014, the Company entered into a Note Purchase Agreement relating to a private placement by the Company of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$46.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> aggregate principal senior convertible notes due in 2019 (the &#8220;2019 Notes&#8221;) which are convertible into shares of the Company&#8217;s common stock at an initial conversion price of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$17.41</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> per share. The conversion price is subject to customary anti-dilution protection. The 2019 Notes bear interest at a rate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.5%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> per annum, payable semiannually in arrears on May 15 and November 15 of each year. The 2019 Notes mature on May 30, 2019 unless earlier converted or repurchased in accordance with their terms, and there are no contractual payments due prior to that date. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In September 2018, the Company used part of the net proceeds from the issuance of the 2025 Notes discussed above to repurchase </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$23.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;aggregate principal value of the 2019 Notes in privately-negotiated transactions for approximately&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$40.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;in cash. The partial repurchase of the 2019 Notes resulted in a&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$17.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;loss on early extinguishment of debt.  At&#160;September 30, 2018, approximately&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$22.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">&#160;of principal remained outstanding on the 2019 Notes.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The composition of the Company&#8217;s 2019 Notes are as follows (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:437px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:3px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:3px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.50% senior convertible notes due 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total 2019 Notes, net of unamortized debt discount and debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,377</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">45,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762236496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> ACCRUED EXPENSES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Accrued expenses at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> consisted of the following (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Government rebates payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">10,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Compensation related costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">9,292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accrued royalties and contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,989</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Restructuring expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Miscellaneous accrued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">43,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">36,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762229072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">LOSS PER COMMON SHARE</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Basic and diluted net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The Company&#8217;s potentially dilutive shares, which include outstanding stock options, restricted stock units, warrants, and shares issuable upon conversion of the 2019 and 2025 Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Basic and diluted net loss per share is calculated as follows </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">(net loss amounts are stated in thousands)</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40,717,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(54,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">38,654,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(17,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(0.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40,149,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(95,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(2.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">38,301,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(42,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(1.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following common stock equivalents have been excluded because they were anti-dilutive (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Convertible debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">8,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">2,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">8,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">2,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">6,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">1,159</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">377</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">1,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Total anti-dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">16,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">11,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">16,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">10,936</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757748400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Leases and Sublease Agreements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:44%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Facilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Annual Base Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Lease Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Comments</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;">Occupied Locations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Corporate Headquarters</font></div><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">San Diego, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$2.1 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">July 2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;">Vacated Locations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">New York, NY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$0.5 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">November 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Sublet through expiration</font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Research Collaboration and Licensing Agreements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreements with unrelated companies, scientific collaborators, universities, and consultants. These agreements contain varying terms and provisions which include fees and milestones to be paid by the Company, services to be provided, and ownership rights to certain proprietary technology developed under the agreements. Some of these agreements contain provisions which require the Company to pay royalties, in the event the Company sells or licenses any proprietary products developed under the respective agreements.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In August 2017, Martin Shkreli, the Company&#8217;s former Chief Executive Officer, was convicted on securities fraud charges following investigations by the U.S. Attorney for the Eastern District of New York and the U.S Securities and Exchange Commission. The Company was not a target of these investigations and cooperated with them fully.  </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Mr. Shkreli has appealed his conviction to the United States Court of Appeals for the Second Circuit, and the appeal will likely not be decided until 2019.  In connection with the trial and pending appeal proceedings, Mr. Shkreli sought advancement of his legal fees from the Company, and the Company has advanced a total of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$5.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in legal fees, of which </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> has been reimbursed by its directors&#8217; and officers&#8217; insurance carriers. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Pending the outcome of Mr. Shkreli's appeal, the insurance carriers have reserved their rights to assert that certain of the advanced funds pertain to claims excluded from coverage under the relevant insurance policy and are therefore recoverable by the carriers. As a result, the final amount of the reimbursement from the insurance carriers is not currently estimable. In addition, a portion of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">these and the other</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> legal fees the Company has advanced to Mr. Shkreli will be subject to reimbursement by Mr. Shkreli under Delaware law in the event it is ultimately determined that Mr. Shkreli is not entitled to be indemnified by the Company in these proceedings.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In August 2015, the Company filed a lawsuit in federal district court for the Southern District of New York against Mr. Shkreli, asserting that he breached his fiduciary duty of loyalty during his tenure as the Company&#8217;s Chief Executive Officer and a member of its Board of Directors. Mr. Shkreli served a demand for JAMS arbitration on Retrophin, claiming that Retrophin had breached his December 2013 employment agreement. In response to Mr. Shkreli&#8217;s arbitration demand, the Company asserted counterclaims in the arbitration that are substantially similar to the claims it previously asserted in the federal lawsuit against Mr. Shkreli.  The federal Court granted a stay of the federal lawsuit pending a determination by the arbitration panel whether the Company&#8217;s counterclaims would be litigated in the arbitration, as the Company is seeking. In April 2016, the arbitration panel granted the parties&#8217; request for a stay of the proceedings pending settlement discussions. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Earlier this year, the parties asked the panel to lift the stay</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. On June 29, 2018, Mr. Shkreli applied to the federal court to enjoin the arbitration panel from hearing the Company&#8217;s counterclaims. On July 2, 2018, the federal court denied Mr. Shkreli&#8217;s application</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> Mr. Shkreli at first filed a notice of appeal indicating his intent to appeal the federal court&#8217;s decision, but then agreed to voluntarily dismiss the appeal. On September 13, 2018, the Clerk of the United States Court of Appeals for the Second Circuit ordered the appeal dismissed</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.  On October 2, 2018, the arbitration panel determined that Retrophin's counterclaims were arbitrable. On October 5, 2018, Retrophin voluntarily dismissed the federal action without prejudice. Mr. Shkreli's claims and the Company's counterclaims in the arbitration are scheduled to be heard by the arbitration panel in June 2019. In connection with these proceedings, Mr. Shkreli sought advancement of his legal fees from the Company relating to his defense of the Company&#8217;s claims against him. The Company has advanced, and expects to continue to advance, certain of these legal fees to Mr. Shkreli.          </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and nine months ended September 30, 2018, the Company recorded and paid zero in expenses under the settlement agreement. For the three and nine months ended September 30, 2017, the Company recorded </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">zero</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in expenses, respectively, and paid </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">zero</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, under the settlement agreement.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">During the nine months ended September 30, 2018 and 2017, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$0.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> of reimbursements from the Company's directors&#8217; and officers&#8217; insurance carriers were received. Of the total </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> reimbursed by the insurance carriers, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$3.2 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> is recorded as a liability on the Consolidated Balance Sheet pending the outcome of Mr. Shkreli's appeal.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">From time to time the Company is involved in legal proceedings arising in the ordinary course of business.&#160; On October 23, 2018, Spring Pharmaceuticals, LLC (Spring) filed a lawsuit against the Company, Martin Shkreli, Mission Pharmacal Company and Alamo Pharma Services, Inc. in the United States District Court for the Eastern District of Pennsylvania alleging that the Company violated various federal and state antitrust and unfair competition laws (and that Defendants were unjustly enriched) by implementing a distribution system that prevented Plaintiff from obtaining sufficient samples of Thiola to conduct bioequivalence testing.&#160; Spring&#8217;s complaint seeks injunctive relief compelling Defendants to sell Thiola to it and damages. The Company intends to vigorously defend against Spring&#8217;s claims.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is not aware of any other  proceedings or claims that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770982976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE BASED COMPENSATION</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SHARE BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Restricted Shares</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Service and Performance Based Restricted Stock Units</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes the Company&#8217;s restricted stock unit activity during the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Number of Restricted Stock Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unvested December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">345,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">20.51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">449,811</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">25.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(56,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">20.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Forfeited/canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(30,216</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">24.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unvested September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">708,426</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">23.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, unamortized stock compensation for restricted stock units was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$10.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, with a weighted-average recognition period of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.2</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> years. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Performance Based Restricted Stock Units</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company granted </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">10,000</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">66,500</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> performance based restricted stock units during the three and nine months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Stock Options</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes stock option activity during the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,153,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">17.16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">6.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">39,010</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,242,550</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">25.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(737,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Forfeited/canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(427,587</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">24.56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Outstanding at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,230,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">76,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, unamortized stock compensation for stock options was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$32.5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, with a weighted-average recognition period of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2.8 years</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, outstanding options to purchase </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">4.6 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> shares of common stock were exercisable with a weighted-average exercise price per share of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$16.72</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Share Based Compensation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth total stock-based compensation for the three and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general &amp; administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,282</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,962</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">10,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14,179</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Exercise of Warrants</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company issued </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">532,830</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">956,887</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> shares of common stock upon the exercise of outstanding warrants during the three and nine months ended September 30, 2018, respectively, for cash received by the Company in the amount of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$2.1 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$4.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively. See Note 6 for changes in warrant accounting.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, warrants to purchase </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">79,167</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">1,159,424</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> shares of common stock, respectively, were outstanding.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757688336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes our effective tax rate and income tax benefit (expense) for the three and nine months ended September 30, 2018 and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">dollars</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in millions</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and six nine ended September 30, 2018, we recognized an income tax expense of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$0.4 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$0.8 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, representing an effective tax rate of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(0.8)%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">(0.9)%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">,</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> respectively. Under GAAP, quarterly effective tax rates may vary significantly depending on the actual operating results in the various tax jurisdictions, and significant transactions, as well as changes in the valuation allowance related to the expected recovery of deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">For the three and nine months ended September 30, 2018, when compared to the same periods in 2017, the change in the tax benefit and decrease in the effective income tax rate was primarily attributable to the increase of the U.S. federal valuation allowance in 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The difference between the expected statutory federal tax benefit of 21% and the effective tax expense for three and nine months ended September&#160;30, 2018, was primarily attributable to the valuation allowance against our deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At&#160;September 30, 2018, we had </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">no</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> unrecognized tax benefits. We did not recognize any interest or penalties related to unrecognized tax benefits during the three and nine months ended September 30, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">On&#160;December 22,&#160;2017, the President of the United States signed into law the Tax Cuts and Jobs Act. The Tax Cuts and Jobs Act reduces the US federal corporate tax rate from 35% to 21%, as well as making several other significant changes to the tax law, effective January 1, 2018. Pursuant to the Securities and Exchange Commission Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), given the amount and complexity of the changes in tax law resulting from the Tax Cuts and Jobs Act, the Company has not finalized the accounting for the income tax effects of the Tax Cuts and Jobs Act. This includes the provisional amounts recorded related to the re-measurement of the deferred taxes and the change to our valuation allowance. The impact of the Tax Cuts and Jobs Act may differ from this estimate during the one-year measurement period due to, among other things, further refinement of the Company's calculation, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the Tax Cuts and Jobs Act.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">At September 30, 2018, the Company is still analyzing certain aspects of the Tax Cuts and Jobs Act and refining its calculations, which could potentially affect the analysis of the Company&#8217;s deferred tax assets and liabilities and its valuation allowance.&#160; Any subsequent adjustment is not expected to be material to the Company&#8217;s financial position or results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757718240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INVENTORY</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Inventory, net of reserves, consisted of the following at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The inventory reserve was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$1.3 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$0.7 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757743648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock', window );">ACCOUNTS RECEIVABLE</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ACCOUNTS RECEIVABLE</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$13.5 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$13.9 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively. The total reserves for both periods were immaterial.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a company, excluding disclosure for allowance for credit losses. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Also excludes disclosure for financing receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesExcludingAllowanceForCreditLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771580976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The unaudited condensed consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Effective January 1, 2018, the Company adopted Accounting Standards Codification (" ASC"), Topic 606,&#160;Revenue from Contracts with Customers, using the full retrospective transition method. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. See Note 6 for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In January 2017, the FASB issued&#160;ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. The new guidance dictates that, when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, it should be treated as an acquisition or disposal of an asset. The guidance was adopted as of January 1, 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In February 2016, the FASB issued ASU No. 2016-02, Leases.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach or a </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> are both options for transition. The Company is in the process of identifying and quantifying all leases.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. This update is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As of September 30, 2018, the Company held </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">$324.0 million</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in available for sale debt securities. If adopted as of September 30, 2018, this ASU update would not have a material impact on the Company's financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Research and development expenses are comprised of salaries and bonuses, benefits, non-cash share-based compensation, license fees, costs paid to third-party contractors to perform research, conduct clinical trials and pre/non-clinical trials, develop drug materials, and associated overhead expenses and facilities. We also incur indirect costs that are not allocated to specific programs because such costs benefit multiple development programs and allow us to increase our pharmaceutical development capabilities. These consist of internal shared resources related to the development and maintenance of systems and processes applicable to all of our programs.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ClinicalTrialExpensePolicyTextBlock', window );">Clinical Trial Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Clinical Trial Expenses</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We record expenses in connection with our clinical trials under contracts with contract research organizations (CROs) that support conducting and managing clinical trials. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up, initiation activities, enrollment, treatment of patients, or the completion of other clinical trial activities.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Expenses related to clinical trials are accrued based on our estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts we are obligated to pay under our clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we adjust our accruals accordingly on a prospective basis. Revisions to our contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We currently have three Phase 3 clinical trials in process that are in varying stages of activity, with ongoing non-clinical support trials. As such, clinical trial expenses will vary depending on the all the factors set forth above and may fluctuate significantly from quarter to quarter.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Deductions from Revenue</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Revenues from product sales are recorded at the net sales price, which includes provisions resulting from discounts, rebates and co-pay assistance that is offered to its customers, health care providers, payors and other indirect customers relating to the Company&#8217;s sales of its products. These provisions are based on the amounts earned or to be claimed on the related sales and are classified as a reduction of accounts receivable (if the amount is payable to the customer) or as a current liability (if the amount is payable to a party other than a customer). Where appropriate, these reserves take into consideration the Company&#8217;s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. If actual results in the future vary from the Company&#8217;s provisions, the Company will adjust the provision, which would affect net product revenue and earnings in the period such variances become known. Our historical experience is that such adjustments have been immaterial.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Government Rebates:</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> We calculate the rebates that we will be obligated to provide to government programs and deduct these estimated amounts from our gross product sales at the time the revenues are recognized. Allowances for government rebates and discounts are established based on actual payer information, which is reasonably estimated at the time of delivery, and the government-mandated discounts applicable to government-funded programs.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Commercial Rebates: </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">calculate the rebates that we incur due to contracts with certain commercial payors and deduct these amounts from our gross product sales at the time the revenues are recognized. Allowances for commercial rebates are established based on actual payer information, which is reasonably estimated at the time of delivery.  Rebate discounts are included in other current liabilities in the accompanying consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Prompt Pay Discounts: </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> offer discounts to certain customers for prompt payments. We accrue for the calculated prompt pay discount based on the gross amount of each invoice for those customers at the time of sale.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-weight:bold;">Product Returns:</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> Consistent with industry practice, we offer our customers a limited right to return product purchased directly from the Company, which is principally based upon the product&#8217;s expiration date. Generally, shipments are only made upon a patient prescription thus returns are minimal.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:12px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">Co-pay Assistance:&#160;</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">We</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> offer a co-pay assistance program, which is intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an identification of claims and the cost per claim associated with product that has been recognized as revenue.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The primary objective of the Company&#8217;s investment portfolio is to enhance overall returns while preserving capital and liquidity. The Company&#8217;s investment policy limits interest-bearing security&#160;investments&#160;to certain types of instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.  All available for sale securities are held in current assets regardless of contractual maturities exceeding one year, as the Company could sell them within the next twelve months.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company reviews the available-for-sale&#160;investments&#160;for other-than-temporary declines in fair value below cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security, and the intent to sell, or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Historically, the Company accounted for these instruments, which do not have fixed settlement provisions, as derivative instruments in accordance with FASB ASC 815-40, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Derivative and Hedging &#8211; Contracts in Entity&#8217;s Own Equity. </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">This was due to an anti-dilution provision for the warrants that provides for a reduction to the exercise price if the Company issues equity or equity linked instruments in the future at an effective price per share less than the exercise price then in effect for the warrant ("down round provision"). As such, the warrants were re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value were recorded as non-cash adjustments within other income (expenses), net, in the Company&#8217;s accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.&#160;</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Financial Instruments and Fair Value</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company accounts for financial instruments in accordance with ASC 820, </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (&#8220;ASC 820&#8221;).  ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.&#160;&#160;The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).&#160;&#160;The three levels of the fair value hierarchy under ASC 820 are described below:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 1</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> &#8211; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 2</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> &#8211; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">Level 3</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> &#8211; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The valuation techniques used to measure the fair value of the Company&#8217;s marketable securities and all other financial instruments, all of which have counter-parties with high credit ratings, were valued based on quoted market prices or model driven valuations using significant inputs derived from or corroborated by observable market data. Based on the fair value hierarchy, the Company classified marketable securities within Level 2.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In estimating the fair value of the Company&#8217;s derivative liabilities as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, the Company used the Black Scholes Model.  Based on the fair value hierarchy, the Company classified the derivative liability within Level 3. The Company adopted ASU 2017-11 as of January 1, 2018 and is no longer required to treat outstanding warrants as derivative liabilities measured at fair value. See Note 6 for further discussion.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In estimating the fair value of the Company&#8217;s contingent consideration, the Company used the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Monte Carlo Simulation model as of September 30,  2018 and a probability-based expected method for royalty payments based on projected revenues as of December 31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. Based on the fair value hierarchy, the Company classified the fair value measurement of contingent consideration within Level 3.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Financial instruments with carrying values approximating fair value include cash and cash equivalents, accounts receivable, and accounts payable, due to their short term nature.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Basic and diluted net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The Company&#8217;s potentially dilutive shares, which include outstanding stock options, restricted stock units, warrants, and shares issuable upon conversion of the 2019 and 2025 Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ClinicalTrialExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Expense [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ClinicalTrialExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762157728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Net Product Revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes net product revenues for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Bile acid products</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">55,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">52,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Thiola</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21,501</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">65,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">60,098</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total net product revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">40,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">112,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762208576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of marketable securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Marketable securities&#160;consisted of the following (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable Securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">266,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">164,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government sponsored entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total marketable securities:</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities Available For Sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following is a summary of short-term&#160;marketable securities classified as available-for-sale as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Remaining Contractual Maturity<br clear="none"/>(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Aggregate Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">54,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">138,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">138,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government-sponsored entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity less than 1 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">196,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">196,064</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1 to 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">128,174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(249</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">127,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity 1 to 2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">128,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">127,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">324,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following is a summary of short-term&#160;marketable securities classified as available-for-sale as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Remaining Contractual Maturity</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Aggregate Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">86,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">86,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Securities of government-sponsored entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(90</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">30,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity less than 1 year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">123,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">123,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1 to 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">78,388</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(424</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">77,964</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total maturity 1 to 2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">78,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">77,964</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(726</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762134080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions for valuation of warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company calculated the fair value of the warrants using the Black-Scholes Model as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Fair value of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Remaining life of the warrants (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">0.1 - 2.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Risk-free interest rate*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1.39 - 1.89%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Expected volatility**</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">33 - 43%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">*The risk-free interest rate is based on the U.S. Treasury security rates for the remaining term of the warrants at the measurement date.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">**Expected volatility is based on an analysis of the Company&#8217;s historical volatility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904843760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value on a recurring basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">As of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total carrying and estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Quoted prices in active markets<br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant other observable inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant unobservable inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities, available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">323,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Business combination-related contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total carrying and estimated fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Quoted prices in active markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant other observable inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Significant unobservable inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Marketable securities, available-for-sale</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">201,236</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Derivative liability related to warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">15,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Business combination-related contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">105,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">105,710</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock', window );">Schedule of summary of changes in estimated acquisition related contingent consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth a summary of changes in the estimated fair value of the Company's business combination-related contingent consideration for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Fair Value Measurements of Acquisition-Related Contingent Consideration<br clear="none"/>(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">90,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Increase from revaluation of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,387</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual payments included in accrued liabilities at September 30, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(2,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(4,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Balance at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">106,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of summary of changes in the estimated acquisition-related contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ScheduleofChangesInEstimatedAcquisitionRelatedContingentConsiderationUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904652560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived amortizable intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth amortizable intangible assets as of </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Finite-lived intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">250,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">235,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Less: accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(64,279</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(51,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Net carrying value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">186,545</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">184,817</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of amortization expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes amortization expense for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">three and nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,752</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total amortization expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">13,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">12,996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757740528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE CONVERTIBLE NOTES PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The effective interest rate on the liability components of the 2025 Notes for the period from the date of issuance through September 30, 2018 was </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">7.7%</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">. The following table sets forth total interest expense recognized related to the 2025 Notes (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Three and Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Contractual interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total interest expense for the 2025 Notes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">901</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The composition of the Company&#8217;s 2025 Notes are as follows (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:437px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:3px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:3px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2.50% convertible senior notes due 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">276,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(76,951</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(6,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total 2025 Notes, net of unamortized debt discount and debt issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">192,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The composition of the Company&#8217;s 2019 Notes are as follows (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:437px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:3px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:3px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4.50% senior convertible notes due 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total 2019 Notes, net of unamortized debt discount and debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">22,377</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">45,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757656112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Accrued expenses at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> consisted of the following (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Government rebates payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">10,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Compensation related costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">9,292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Accrued royalties and contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,989</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Restructuring expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Miscellaneous accrued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">2,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">43,348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">36,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6910229136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net income (loss) per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Basic and diluted net loss per share is calculated as follows </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">(net loss amounts are stated in thousands)</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40,717,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(54,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">38,654,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(17,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(0.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="22" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="21" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">EPS</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40,149,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(95,223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(2.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">38,301,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(42,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">(1.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of common stock options, convertible debt and restricted stock units anti-dilutive</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following common stock equivalents have been excluded because they were anti-dilutive (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Convertible debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">8,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">2,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">8,411</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">2,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">7,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">6,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">1,159</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">377</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">1,159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Total anti-dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">16,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">11,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">16,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">10,936</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771213104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock', window );">Schedule of property subject to or available for operating lease</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">Leases and Sublease Agreements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:44%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Facilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Annual Base Rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Lease Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Comments</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;">Occupied Locations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Corporate Headquarters</font></div><div style="font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">San Diego, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$2.1 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">July 2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;text-decoration:underline;">Vacated Locations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">New York, NY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">$0.5 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">November 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">Sublet through expiration</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessor's property under leasing agreements and property available for lease (not currently under lease) by property class, the gross amount, accumulated depreciation and net amount of  as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164653&amp;loc=d3e41551-112718<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757714016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of restricted stock activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes the Company&#8217;s restricted stock unit activity during the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Number of Restricted Stock Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unvested December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">345,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">20.51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">449,811</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">25.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(56,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">20.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Forfeited/canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(30,216</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">24.08</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Unvested September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">708,426</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">23.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option issuances and balances outstanding</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes stock option activity during the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,153,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">17.16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">6.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;">39,010</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,242,550</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">25.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(737,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Forfeited/canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(427,587</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">24.56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Outstanding at September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,230,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">18.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">76,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share based compensation expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table sets forth total stock-based compensation for the three and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">nine</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> months ended </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">7,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Selling, general &amp; administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,282</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,962</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">10,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14,179</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">4,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">14,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">21,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762205136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax (Expense) Benefit</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The following table summarizes our effective tax rate and income tax benefit (expense) for the three and nine months ended September 30, 2018 and 2017 (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">dollars</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in millions</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">6.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial Narrow;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">11.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762228096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Inventory, net of reserves, consisted of the following at </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">September&#160;30, 2018</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">in thousands</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">3,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">1,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial Narrow;font-size:9pt;">5,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6629558416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_NumberOfProductsSold', window );">Number of products sold</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_NumberOfProductsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Products Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_NumberOfProductsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904757648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 323,993<span></span>
</td>
<td class="nump">$ 201,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763822368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">$ 40,706<span></span>
</td>
<td class="nump">$ 40,340<span></span>
</td>
<td class="nump">$ 120,475<span></span>
</td>
<td class="nump">$ 112,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rtrx_BileAcidProductsMember', window );">Bile acid products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">18,052<span></span>
</td>
<td class="nump">18,839<span></span>
</td>
<td class="nump">55,153<span></span>
</td>
<td class="nump">52,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rtrx_ThiolaLicenseMember', window );">Thiola</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">$ 22,654<span></span>
</td>
<td class="nump">$ 21,501<span></span>
</td>
<td class="nump">$ 65,322<span></span>
</td>
<td class="nump">$ 60,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk | Revenue from Contract with Customer | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rtrx_BileAcidProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rtrx_BileAcidProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rtrx_ThiolaLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rtrx_ThiolaLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757688336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from the sale/maturity of marketable securities</a></td>
<td class="nump">$ 96,166<span></span>
</td>
<td class="nump">$ 76,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt based marketable securities</a></td>
<td class="nump">$ 219,820<span></span>
</td>
<td class="nump">$ 67,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760329360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES - Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 323,993<span></span>
</td>
<td class="nump">$ 201,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">54,611<span></span>
</td>
<td class="nump">6,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">266,132<span></span>
</td>
<td class="nump">164,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="nump">$ 30,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772183232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES - Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent', window );">Debt securities, available-for-sale, amortized cost basis, current</a></td>
<td class="nump">$ 196,623<span></span>
</td>
<td class="nump">$ 123,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent', window );">Debt securities available for sale, unrealized gain, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent', window );">Debt securities available for sale unrealized loss, current</a></td>
<td class="num">(559)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, available-for-sale, current</a></td>
<td class="nump">196,064<span></span>
</td>
<td class="nump">123,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent', window );">Debt securities, available-for-sale, amortized cost basis, noncurrent</a></td>
<td class="nump">128,174<span></span>
</td>
<td class="nump">78,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent', window );">Debt securities, available for sale unrealized gain, noncurrent</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent', window );">Debt securities available for sale unrealized gain loss, noncurrent</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Debt securities, available-for-sale, noncurrent</a></td>
<td class="nump">127,929<span></span>
</td>
<td class="nump">77,964<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, available-for-sale, amortized cost</a></td>
<td class="nump">324,797<span></span>
</td>
<td class="nump">201,962<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, available for sale, unrealized gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, available-for-sale, unrealized gain (loss)</a></td>
<td class="num">(808)<span></span>
</td>
<td class="num">(726)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Estimated Fair Value</a></td>
<td class="nump">323,993<span></span>
</td>
<td class="nump">201,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent', window );">Debt securities, available-for-sale, amortized cost basis, current</a></td>
<td class="nump">54,649<span></span>
</td>
<td class="nump">6,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent', window );">Debt securities available for sale, unrealized gain, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent', window );">Debt securities available for sale unrealized loss, current</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, available-for-sale, current</a></td>
<td class="nump">54,611<span></span>
</td>
<td class="nump">6,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent', window );">Debt securities, available-for-sale, amortized cost basis, current</a></td>
<td class="nump">138,724<span></span>
</td>
<td class="nump">86,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent', window );">Debt securities available for sale, unrealized gain, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent', window );">Debt securities available for sale unrealized loss, current</a></td>
<td class="num">(521)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, available-for-sale, current</a></td>
<td class="nump">138,203<span></span>
</td>
<td class="nump">86,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent', window );">Debt securities, available-for-sale, amortized cost basis, noncurrent</a></td>
<td class="nump">128,174<span></span>
</td>
<td class="nump">78,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent', window );">Debt securities, available for sale unrealized gain, noncurrent</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent', window );">Debt securities available for sale unrealized gain loss, noncurrent</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Debt securities, available-for-sale, noncurrent</a></td>
<td class="nump">127,929<span></span>
</td>
<td class="nump">77,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent', window );">Debt securities, available-for-sale, amortized cost basis, current</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">30,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent', window );">Debt securities available for sale, unrealized gain, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent', window );">Debt securities available for sale unrealized loss, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, available-for-sale, current</a></td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="nump">$ 30,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Available For Sale, Unrealized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale Unrealized Gain, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Unrealized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Available For Sale Unrealized Loss, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Amortized Cost Basis, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Amortized Cost Basis, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771517760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_BusinessCombinationOptionAgreementPurchasePrice', window );">Business combination, option agreement, purchase price</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash', window );">Business combination, option agreement, purchase price, percent transferred in cash</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity', window );">Business combination, option agreement, purchase price, percent transferred by issuance of equity</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_BusinessCombinationOptionAgreementSharePrice', window );">Business combination, option agreement, share price (in dollars per share)</a></td>
<td class="nump">$ 21.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold', window );">Business combination, option agreement, percent of consideration paid in cash if share price falls below share price threshold</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment', window );">Business combination, option agreement, weighted average ten day share price, which requires all cash payment (in dollars per share)</a></td>
<td class="nump">$ 19.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_BusinessCombinationOptionAgreementContingentConsideration', window );">Business combination, option agreement, contingent consideration</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rtrx_CensaPharmaceuticalsInc.Member', window );">Censa Pharmaceuticals Inc. | CNSA-001 Program | Purchase Provision Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development arrangement, contract to perform for others, compensation earned</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rtrx_CensaPharmaceuticalsInc.Member', window );">Censa Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_PaymentsForTheOptionToAcquireBusiness', window );">Payments for the option to acquire business</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rtrx_CensaPharmaceuticalsIncEquityHoldersMember', window );">Censa Pharmaceuticals, Inc, Equity Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones', window );">Additional required payments for the option to acquire business, successful development milestones</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding', window );">Additional required payments for the option to acquire business, successful development funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Required Payments For The Option To Acquire Business, Successful Development Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Required Payments For The Option To Acquire Business, Successful Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AdditionalRequiredPaymentsForTheOptionToAcquireBusinessSuccessfulDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_BusinessCombinationOptionAgreementContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Option Agreement, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_BusinessCombinationOptionAgreementContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Option Agreement, Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_BusinessCombinationOptionAgreementPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Option Agreement, Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_BusinessCombinationOptionAgreementPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Option Agreement, Purchase Price, Percent Transferred By Issuance Of Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Option Agreement, Purchase Price, Percent Transferred In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_BusinessCombinationOptionAgreementSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Option Agreement, Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_BusinessCombinationOptionAgreementSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Option Agreement, Weighted Average Ten Day Share Price, Which Requires All Cash Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_PaymentsForTheOptionToAcquireBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For The Option To Acquire Business</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_PaymentsForTheOptionToAcquireBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rtrx_CensaPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rtrx_CensaPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=rtrx_CNSA001ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=rtrx_CNSA001ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_PurchaseProvisionTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_PurchaseProvisionTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rtrx_CensaPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rtrx_CensaPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rtrx_CensaPharmaceuticalsIncEquityHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rtrx_CensaPharmaceuticalsIncEquityHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771466640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of liability classified warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,901<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability related to warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_NumberofTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_NumberofTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_NumberofTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760333584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Valuation Assumptions (Details) - Warrants<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>Year </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 21.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining life of the warrants (in years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Remaining life of the warrants (in years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772398000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 10, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ChangeinFairValueofContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">$ 16,601<span></span>
</td>
<td class="nump">$ 4,429<span></span>
</td>
<td class="nump">$ 22,387<span></span>
</td>
<td class="nump">$ 11,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase from revaluation of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,852)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rtrx_ProductRightsChenodalMember', window );">Product Rights Chenodal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase from revaluation of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rtrx_AcquiredProductRightsCholbamMember', window );">Acquired Product Rights Cholbam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase from revaluation of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rtrx_AcquiredProductRightsLUDCAMember', window );">Acquired Product Rights L-UDCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase from revaluation of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Convertible Notes Due 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="nump">$ 38,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="nump">$ 283,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ChangeinFairValueofContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Fair Value of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ChangeinFairValueofContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rtrx_ProductRightsChenodalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rtrx_ProductRightsChenodalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rtrx_AcquiredProductRightsCholbamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rtrx_AcquiredProductRightsCholbamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rtrx_AcquiredProductRightsLUDCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rtrx_AcquiredProductRightsLUDCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rtrx_ConvertibleNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rtrx_ConvertibleNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rtrx_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rtrx_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772255200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">$ 323,993<span></span>
</td>
<td class="nump">$ 201,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability related to warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">323,993<span></span>
</td>
<td class="nump">201,236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">323,993<span></span>
</td>
<td class="nump">201,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability related to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination-related contingent consideration</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">105,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted prices in active markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability related to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant other observable inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">323,993<span></span>
</td>
<td class="nump">201,236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">323,993<span></span>
</td>
<td class="nump">201,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability related to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability related to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination-related contingent consideration</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="nump">$ 105,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772227024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Acquisition-related Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase from revaluation of contingent consideration</a></td>
<td class="num">$ (6,852)<span></span>
</td>
<td class="num">$ (885)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at January 1, 2018</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase from revaluation of contingent consideration</a></td>
<td class="nump">22,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contractual payments included in accrued liabilities at September 30, 2018</a></td>
<td class="num">(2,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Contractual payments</a></td>
<td class="num">(4,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at September 30, 2018</a></td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757675568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net book value of amortizable intangible assets</a></td>
<td class="nump">$ 186,545<span></span>
</td>
<td class="nump">$ 184,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6914000224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 250,824<span></span>
</td>
<td class="nump">$ 235,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(64,279)<span></span>
</td>
<td class="num">(51,046)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying value</a></td>
<td class="nump">$ 186,545<span></span>
</td>
<td class="nump">$ 184,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760693360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization expense</a></td>
<td class="nump">$ 4,625<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="nump">$ 13,319<span></span>
</td>
<td class="nump">$ 12,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization expense</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total amortization expense</a></td>
<td class="nump">$ 4,333<span></span>
</td>
<td class="nump">$ 4,424<span></span>
</td>
<td class="nump">$ 12,635<span></span>
</td>
<td class="nump">$ 12,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773309472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE  - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 29, 2014 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtConversionLiability', window );">Debt conversion, liability</a></td>
<td class="nump">$ 198,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtConversionEquity', window );">Debt conversion, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="nump">23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000', window );">Debt instrument, convertible note, market price</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (17,042,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (17,042,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt and capital lease obligations</a></td>
<td class="nump">22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AgreementAxis=rtrx_NotePurchaseAgreementMember', window );">Note Purchase Agreement | Senior convertible notes due 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Credit agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, excluding current maturities</a></td>
<td class="nump">$ 276,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 38.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">$ 6,296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Convertible Notes Due 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod', window );">Debt instrument, convertible, threshold consecutive days measuring period | day</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_TradingPricePerPrincipalPercentage', window );">Trading price per principal, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtConversionEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtConversionEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtConversionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtConversionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Note, Market Price, Per $1,000</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtInstrumentConvertibleNoteMarketPricePer1000</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Threshold Consecutive Days Measuring Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_DebtInstrumentConvertibleThresholdConsecutiveDaysMeasuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_TradingPricePerPrincipalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading Price Per Principal, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_TradingPricePerPrincipalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AgreementAxis=rtrx_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AgreementAxis=rtrx_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rtrx_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rtrx_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rtrx_ConvertibleNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rtrx_ConvertibleNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773371600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE - Composition of Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 10, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">$ (8,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(76,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(6,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 192,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Convertible Notes Due 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 22,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 22,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rtrx_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rtrx_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rtrx_ConvertibleNotesDue2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rtrx_ConvertibleNotesDue2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760879120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE - Schedule of Interest Expense (Details) - Senior Notes Due 2025 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rtrx_SeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rtrx_SeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759807376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_GovernmentRebatesPayable', window );">Government rebates payable</a></td>
<td class="nump">$ 10,377<span></span>
</td>
<td class="nump">$ 5,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Compensation related costs</a></td>
<td class="nump">9,292<span></span>
</td>
<td class="nump">7,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AccruedRoyaltyandContingentConsideration', window );">Accrued royalties and contingent consideration</a></td>
<td class="nump">6,332<span></span>
</td>
<td class="nump">6,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">11,969<span></span>
</td>
<td class="nump">6,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent', window );">Selling, general and administrative</a></td>
<td class="nump">2,913<span></span>
</td>
<td class="nump">3,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AccruedLiabilitiesMiscellaneous', window );">Miscellaneous accrued</a></td>
<td class="nump">2,465<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 43,348<span></span>
</td>
<td class="nump">$ 36,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AccruedLiabilitiesMiscellaneous">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Miscellaneous</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AccruedLiabilitiesMiscellaneous</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Research and Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AccruedLiabilitiesResearchandDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Selling, General, and Administrative, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AccruedLiabilitiesSellingGeneralandAdministrativeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AccruedRoyaltyandContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalty and Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AccruedRoyaltyandContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_GovernmentRebatesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government Rebates Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_GovernmentRebatesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760891312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE - EPS Reconciliation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding, basic and diluted</a></td>
<td class="nump">40,717,440<span></span>
</td>
<td class="nump">38,654,086<span></span>
</td>
<td class="nump">40,149,184<span></span>
</td>
<td class="nump">38,301,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,516)<span></span>
</td>
<td class="num">$ (17,794)<span></span>
</td>
<td class="num">$ (95,223)<span></span>
</td>
<td class="num">$ (42,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted (in dollars/share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding, basic and diluted</a></td>
<td class="nump">40,717,440<span></span>
</td>
<td class="nump">38,654,086<span></span>
</td>
<td class="nump">40,149,184<span></span>
</td>
<td class="nump">38,301,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,516)<span></span>
</td>
<td class="num">$ (17,794)<span></span>
</td>
<td class="num">$ (95,223)<span></span>
</td>
<td class="num">$ (42,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted (in dollars/share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771500400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE - Antidilutive Shares (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation</a></td>
<td class="nump">16,318<span></span>
</td>
<td class="nump">11,461<span></span>
</td>
<td class="nump">16,325<span></span>
</td>
<td class="nump">10,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation</a></td>
<td class="nump">8,411<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
<td class="nump">8,411<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation</a></td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">7,515<span></span>
</td>
<td class="nump">7,202<span></span>
</td>
<td class="nump">6,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from the calculation</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908780560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Leases and Subleases Commitment (Details) - Lease Agreement<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AgreementAxis=rtrx_LeaseAgreementMember', window );">San Diego CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual Base Rent</a></td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_AgreementAxis=rtrx_LeaseAgreementMember', window );">New York, NY</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Annual Base Rent</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_AgreementAxis=rtrx_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_AgreementAxis=rtrx_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rtrx_SanDiegoCACorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rtrx_SanDiegoCACorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760873280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_CommitmentAndContingencyLineItems', window );"><strong>Commitment And Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rtrx_MartinShkreliMember', window );">Martin Shkreli</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_CommitmentAndContingencyLineItems', window );"><strong>Commitment And Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ContingentFutureLegalFeeAdvancePayment', window );">Contingent future legal fee advance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers', window );">Legal fees reimbursed from director and officer insurance carriers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=rtrx_RetrophinInc.v.ShkreliMember', window );">Retrophin, Inc. v. Shkreli</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_CommitmentAndContingencyLineItems', window );"><strong>Commitment And Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_CommitmentAndContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_CommitmentAndContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ContingentFutureLegalFeeAdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Future Legal Fee Advance Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ContingentFutureLegalFeeAdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal Fees Reimbursed From Director and Officer Insurance Carriers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_LegalFeesReimbursedFromDirectorandOfficerInsuranceCarriers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rtrx_MartinShkreliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rtrx_MartinShkreliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=rtrx_RetrophinInc.v.ShkreliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=rtrx_RetrophinInc.v.ShkreliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772179808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION - Restricted Stock Activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Ending Balance (in share)</a></td>
<td class="nump">708,426<span></span>
</td>
<td class="nump">708,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/canceled (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.54<span></span>
</td>
<td class="nump">$ 23.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized stock compensation expense | $</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771467312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares exercisable (in shares)</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 16.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Underlying Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">7,153,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,242,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(737,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/canceled (in shares)</a></td>
<td class="num">(427,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">7,230,983<span></span>
</td>
<td class="nump">7,153,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 17.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">25.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">14.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Forfeited/canceled (in dollars per share)</a></td>
<td class="nump">24.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 18.49<span></span>
</td>
<td class="nump">$ 17.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 1 month 17 days<span></span>
</td>
<td class="text">6 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value (in thousands)</a></td>
<td class="nump">$ 76,529<span></span>
</td>
<td class="nump">$ 39,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized stock compensation expense</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period (in years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761285392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION - Stock based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,885<span></span>
</td>
<td class="nump">$ 6,960<span></span>
</td>
<td class="nump">$ 14,920<span></span>
</td>
<td class="nump">$ 21,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
<td class="nump">7,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general &amp; administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,282<span></span>
</td>
<td class="nump">$ 4,962<span></span>
</td>
<td class="nump">$ 10,328<span></span>
</td>
<td class="nump">$ 14,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757694384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION - Exercise of Warrants (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants', window );">Warrants exercised (in shares)</a></td>
<td class="nump">532,830<span></span>
</td>
<td class="nump">956,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">79,167<span></span>
</td>
<td class="nump">79,167<span></span>
</td>
<td class="nump">1,159,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Common Stock Issued Upon Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rtrx_ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rtrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905534496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Effective Tax Rate and Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">$ (415)<span></span>
</td>
<td class="nump">$ 1,223<span></span>
</td>
<td class="num">$ (811)<span></span>
</td>
<td class="nump">$ 5,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770880320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 415,000<span></span>
</td>
<td class="num">$ (1,223,000)<span></span>
</td>
<td class="nump">$ 811,000<span></span>
</td>
<td class="num">$ (5,212,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate reconciliation, percent</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized tax benefits, income tax penalties expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757654432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,272<span></span>
</td>
<td class="nump">$ 3,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">5,129<span></span>
</td>
<td class="nump">5,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Reserve</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757671200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of reserves</a></td>
<td class="nump">$ 13,450<span></span>
</td>
<td class="nump">$ 13,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  ^&84T?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ #X9A32?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^5V'7&[NS_]CX(B@;^'47\@M02P,$%     @ #X9A39E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M*@>*RKCF<I/0/4# T&/40L",:)9D @AMWVM36=@T%S:@[?BL Y%L-.P$(.'
MI<#(";B8C;0]SR2<002Z>X\OWJCO0OG:?MZH!LOB;5\WM7KQ]/P)Y;']@D*>
MS^!^#L+S!=QGIP\D/]V?OM?\D9>OFWTU>"[JNMBU;^M?BJ(.<?KJ+B[,.N2K
M\\TVO-3-I8O7Y>D[R>FF+@[=-Z#Q^4/4]']02P,$%     @ #X9A38<YI<)R
M!0  4AP  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R%F6%OVS80AO^*
MX>^NQ;N3* 5)@%K#L $;4'3H]EE-F,2H;7F2DG3_?I3LN/;=R_1++"DOR?=$
M\N%1O'YMNV_]4PC#[/MVL^MOYD_#L+]:+ON[I[!M^@_M/NSB?Q[:;ML,\;9[
M7/;[+C3W4Z'M9DE95BRWS7HWO[V>GGWJ;J_;YV&SWH5/W:Q_WFZ;[K]5V+2O
M-W,W?WOP>?WX-(P/EK?7^^8Q_!6&+_M/7;Q;GFJY7V_#KE^WNUD7'F[F']U5
M+=588%+\O0ZO_=GU; SE:]M^&V]^O[^99Z.CL EWPUA%$W]>0ATVF[&FZ./?
M8Z7S4YMCP?/KM]I_G8*/P7QM^E"WFW_6]\/3S;R<S^[#0_.\&3ZWK[^%8T#Y
M?':,_H_P$C91/CJ);=RUFW[Z.[M[[H=V>ZPE6MDVWP^_Z]WT^WJL_ZT8+D#'
M G0J$-M^KP ?"_"/ C(%?W VA?I+,S2WUUW[.NL.O;5OQD'AKCB^S+OQX?3N
MIO_%:/OX].769<7U\F6LZ*A9'31TKCDIEK'V4Q.$FEB1*4Z7#=16X0O< L,@
M>"K/%T%X7(' "F2J0,XJJ+QZ"0>)GR2[2;*H<B)6H0"9D'.,W>3030["*7$%
M!:R@,.&XK%+Q'#3YF5''OE2J&JF8$YWCH1EOS;A,F?&F&:6HK6+A2Y<8AR4T
M4@(C3ADI?VK$*A9%GO!101\5\*%FQ*JR[]VY7%D!(LX3(\UE>/IGP SK^9^9
MAKSHD0)$E:>$F02+'# CVHRS[92ZDX!(BBQA!E+KHR-@)M=FR'9!0;J?@(KR
MU*O!A',,W!A.LW63FS=8 QDYJE*&,#&=1:9SFIE'T7O3"4C*BA+SR6%>NMQX
M*<VPR6W0Q*77=JPLTBI/+"8.X]<!_KI2&[)H711EKI=&)"O+/.$'$]@A!.OU
MP%G".I^)\?,>JB_-8 H[@&'2ZX&SE"5OA@Y <5SW)6$'P]@!&I->%9PE[<+0
M&(A<D3!#F,:4V96?$O.2,$,),%0G*2NR>'0L"B<U4$F6C A3E !%2<]-LGQ<
M.*%2^P$R/AO'EWXP1PEP5/-Z11:0"W*E3O60C+TD6$&8HP0X2AKL9"%9>)VA
MUD EE" %89*2):DC376RC.2LTJL,4%%>I#8.&*0$0*J'Q8H (<EQ9;K+ZDI*
MD9TP2<F#"9H:@9A_!/C'FG\$T.9U1]1(Y813(6$ $@ @:P 2!.#YKN3H".BJ
M@A,(8TQ!!CDIZP290;I9N$(S#,A\45)J=XF9RH"IK)G*EI9Q&%:E7MMJ)"Q\
MGDH(&8.5 5A9@Y4M,8T;*Q&?9XDUG1/[;T!5UE1E@$L76S*.K"[E!B.5 5)9
M(Y4M+*,;$;,#!D+)?9;@*F.N,MC2I^8I8Q8R8"%K%C+,%DT2AV2Q)U*S K.0
M05;).JMDL&]WN>WSG\DN#6&R,B"K:+(R(FMN_/Q$=6D'@Y4!6$6#E2TPA;Q>
M2X&*"TD,0<%4%4!5/3!68G'I,O9Z3@"9+ZJ4'PQ5 5 5#56QK"1?6&8 7:*S
M!.-4 $Y%XU1  BH99>8;X'O8O72#>2J IZ)Y*H"GI5UN@"QE)O%M%.!4[Q56
M K;QMI?>^QQP:05C5$!Z*N9#+4@\.:[7.E<!.LG*Q/9&,)0%0%DTE 705F=\
M-1*EDE/!0!8 9/V9;B66M'DN>L=1(YFORD2J*QC( H"L4;L2B]JJ8K.= #)Q
M699(F@0C60"2<XWDH^C\$WY,#,#$LKKX@BJ]PUF>G<1L0_<X'5KUL[OV>3>,
M9QYG3T\'8Q]I/,E1SU?NJCX<;_VHYG#:]F?3/:YW_>QK.PSM=CK->6C;(427
MV8?XQIY"<W^ZV82'8;ST\;H[G'(=;H9V?SS!6YZ.$6__!U!+ P04    "  /
MAF%-CAMQ([ !  #2 P  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;'U3
MVX[4, S]E2@?L)G)= &-VDH[BQ!(((T6 <^9UFVCS:4DZ73Y>YRT4\I2\=+8
MKL_QL>/DHW7/O@,(Y$4KXPO:A= ?&?-5!UKX.]N#P3^-=5H$=%W+?.] U FD
M%>.[W1NFA32TS%/L[,K<#D%) V='_*"U<+].H.Q8T#V]!9YDVX488&7>BQ:^
M0OC6GQUZ;&&II0;CI37$05/0A_WQE,7\E/!=PNA7-HF=7*Q]CLZGNJ"[* @4
M5"$R"#RN\ A*12*4\7/FI$O)"%S;-_8/J7?LY2(\/%KU0]:A*^@[2FIHQ*#"
MDQT_PMS//25S\Y_A"@K3HQ*L45GETY=4@P]6SRPH18N7Z90FG>/,?X-M _@,
MX*\ ;"J4E+\7092YLR-QT^Q[$:]X?^0XFRH&TRC2/Q3O,7HM]_<\9]=(-.><
MIAR^SEDR&+(O)?A6B1/_!\ZWX8=-A8<$/_RE\+!-D&T29(D@^V^+6SG9JR)L
M-5,-KDW;Y$EE!Y,V>15=%O:!ISOYDSYM^Q?A6FD\N=B -YOFWU@; *7L[G"%
M.GQ@BZ.@"=%\B[:;UFQR@NWG%\269US^!E!+ P04    "  /AF%-;I92>+0!
M  #2 P  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;'U386_;(!#]*X@?
M4!*2M%%D6VHZ39NT25&G;9^)?;91@?, Q]V_'V#7\S9K7X [[KU[=QS9@/;%
MM0">O&IE7$Y;[[L38ZYL00MWAQV8<%.CU<('TS;,=19$E4!:,;[9W#,MI*%%
MEGP76V38>R4-7"QQO=;"_CR#PB&G6_KF>)9-ZZ.#%5DG&O@"_FMWL<%B,TLE
M-1@GT1 +=4X?MZ?S/L:G@&\2!K<XDUC)%?$E&A^KG&ZB(%!0^L@@PG:#)U J
M$@49/R9..J>,P.7YC?U]JCW4<A4.GE!]EY5O<WJDI():],H_X_ !IGH.E$S%
M?X(;J! >E80<)2J75E+VSJ.>6((4+5['79JT#^/-X3C!U@%\ O 9<$QYV)@H
M*7\GO"@RBP.Q8^\[$9]X>^*A-V5TIE:DNR#>!>^MV!X.&;M%HBGF/,;P9<P<
MP0+[G(*OI3CS?^!\';Y;5;A+\-T?"N_7"?:K!/M$L/]OB6LQ#W\E88N>:K!-
MFB9'2NQ-FN2%=Q[81Y[>Y'?X..V?A6VD<>2*/KQLZG^-Z"%(V=R%$6K#!YL-
M!;6/QX=PMN.8C8;';OI!;/[&Q2]02P,$%     @ #X9A33:3)LFV 0  T@,
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MO,>SG<9L,KSIYQ_$EF]<_@)02P,$%     @ #X9A3<N/<H6T 0  T@,  !@
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M=V]R:W-H965T<R]S:&5E=#$P+GAM;'U3VV[;, S]%4$?4"6*TQ:!;:!I46S
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M-AY?-O:_-L8#2ME=X0BU^,$60T'MP_$6SW8:L\GPII]_$%N^<?$.4$L#!!0
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M@\V&A,J'XR<\VW',1L.;;OI!;/[&^2]02P,$%     @ #X9A3:GFMM^U 0
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MH [Q>(=G-X[9: 3;33^(S=^X^ -02P,$%     @ #X9A37T=2XNS 0  T@,
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MSV8:L\EPV,\_B"W?N/P%4$L#!!0    (  ^&84VOT_BBM $  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;'U386_<( S]*X@?4.Z2=.M.2:1>
MIVF35NG4:>UG+G$25, 9D$O[[P<D3;,MVA? QN_YV9A\1/-L.P!'7I34MJ"=
M<_V!,5MUH+B]PAZTOVG0*.Z\:5IF>P.\CB E6;+;?6"*"TW+//I.ILQQ<%)H
M.!EB!Z6X>3V"Q+&@>_KF>!!MYX*#E7G/6_@![F=_,MYB"TLM%&@K4!,#34%O
M]X=C%N)CP*. T:[.)%1R1GP.QK>ZH+L@""14+C!POUW@#J0,1%[&KYF3+BD#
M<'U^8_\2:_>UG+F%.Y1/HG9=06\HJ:'A@W0/.'Z%N9YK2N;BO\,%I \/2GR.
M"J6-*ZD&ZU#-+%Z*XB_3+G3<Q^DF36;8-B"9 <D"N(EYV)0H*O_,'2]S@R,Q
M4^]['IYX?TA\;ZK@C*V(=UZ\]=Y+N?^4YNP2B.:8XQ23K&.6".;9EQ3)5HIC
M\@\\V8:GFPK3"$__4)AM$V2;!%DDR/Y;XE;,]5])V*JG"DP;I\F2"@<=)WGE
M70;V-CXB>P^?IOV>FU9H2\[H_,O&_C>(#KR4W94?H<Y_L,60T+AP_.C/9AJS
MR7#8SS^(+=^X_ U02P,$%     @ #X9A32#@"U"T 0  T@,  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL?5-A;]L@$/TKB!]0$I*U661;:CI-F[1)
M4:=MGXE]ME&!\P#'W;\?8-?S6FM?@#ONO7MW'-F ]LFU )X\:V5<3EOONR-C
MKFQ!"W>#'9AP4Z/5P@?3-LQU%D250%HQOMG<,BVDH466?&=;9-A[)0V<+7&]
MUL+^/H'"(:=;^N)XE$WKHX,562<:^ ;^>W>VP6(S2R4U&"?1$ MU3N^WQ],^
MQJ> 'Q(&MSB36,D%\2D:GZN<;J(@4%#ZR"#"=H4'4"H2!1F_)DXZIXS Y?F%
M_6.J/=1R$0X>4/V4E6]S>J"D@EKTRC_B\ FF>MY1,A7_!:Z@0GA4$G*4J%Q:
M2=D[CWIB"5*T>!YW:=(^C#=\-\'6 7P"\!EP2'G8F"@I_R"\*#*+ [%C[SL1
MGWA[Y*$W972F5J2[(-X%[[78OK_-V#4233&G,88O8^8(%MCG%'PMQ8F_@?-U
M^&Y5X2[!=_\HO%LGV*\2[!/!_K\EKL4<7B5ABYYJL$V:)D=*[$V:Y(5W'MA[
MGM[D;_@X[5^%;:1QY((^O&SJ?XWH(4C9W(01:L,'FPT%M8_'NW"VXYB-AL=N
M^D%L_L;%'U!+ P04    "  /AF%-8W>0"1X"   $!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6QU5=N.VR 0_17+'[ 8<E\YEI*MJE9JI6BKML_$
MF<36@G&!Q-N_+V#'M=C)BX'AS#DSC!GR3NDW4P'8Y%V*QFS3RMKVF1!35B"Y
M>5(M-&[GK+3DUBWUA9A6 S\%)RD(R[(ED;QNTB(/MH,N<G6UHF[@H!-SE9+K
MOWL0JMNF-+T;7NM+9;V!%'G++_ #[,_VH-V*C"RG6D)C:M4D&L[;=$>?]Y1Y
MAX#X54-G)O/$IW)4ZLTOOIZV:>8C @&E]13<#3=X 2$\DXOCST":CIK><3J_
MLW\.R;MDCMS BQ*_ZY.MMNDZ34YPYE=A7U7W!8:$%FDR9/\-;B <W$?B-$HE
M3/@FY=58)0<6%XKD[_U8-V'L!OZ[&^[ !@<6.9!>*$3^B5M>Y%IUB>X/O^6^
MQO29N;,IO3$<1=ASP1MGO15TL\G)S1,-F'V/85/,B"".?91@F,2>?7!GN/L,
MC7 6W&=3]<42)YBC!/- ,)_J9UF4(H9YD.0"%5D@!"P2P3 S7&2)BBP1@GDD
M@F$6N,@*%5DA!,M(!,.L<)$U*K)&"-:1"(;9X"(;5&3SD8#&A<<P#PI/,_P&
M90A%7'H4]*#V],%-I0A%7'T4]*#\%+VN.\H0BO@'0$'Q'T F34B"OH3V:Y)2
M79O0^R?6L<7O0H<G_^']^_"=ZTO=F.2HK&N%H6&=E;+@8LF>W+VJW),T+@2<
MK9^NW%SW?;E?6-4.;PX9'[[B'U!+ P04    "  /AF%-M'2YU;@!  #2 P
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MN'"\]6<SC=ED.-W//X@LW[C\"U!+ P04    "  /AF%-4C2NML0!   W!
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MSNWU^);'P*IN&E,R_U?D_P!02P,$%     @ #X9A3>&C-?FW 0  T@,  !D
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MX-E.8S89WO3S#V++-R[^ E!+ P04    "  /AF%-"(O)T=$!  "<!   &0
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MC<>7C?VOC?& J>RN<(1:_&"+H:#VX?@)SW8:L\GPII]_$%N^<?$74$L#!!0
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MG[B>^RB\-%6M3 &E<4<J^ ;J>W<1>H4FE:)AT,J&MXZ ,G&?O=,Y,'@+^-%
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MWA$_J#Q4C0HV0IO3S9U!>R$T,Y+PR41<FFMI''"VU[:[,'W9G\W]0(MVN'?
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ML>QN0]U$B::_Z07#=7/]%U!+ P04    "  /AF%-FO%$]DT"  !U!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6R-5>UNVR 4?17+#U ,_FSD1&J^
MM$F;5'7:]ILX)+:*C0<D[MY^@*GK.*S)'P.7<P[G<BUNWC'^*DI"I/=6TT;,
M_5+*=@: *$I28_' 6M*HG0/C-99JR8] M)S@O2'5%* @2$"-J\9?Y";VS!<Y
M.TE:->29>^)4UYC_71+*NKD/_?? 2W4LI0Z 1=[B(_E!Y,_VF:L5&%3V54T:
M4;'&X^0P]Y_@;)MIO '\JD@G1G-/9[)C[%4OON[G?J -$4H*J16P&LYD12C5
M0LK&'ZOI#T=JXGC^KKXUN:M<=EB0%:._J[TLYW[F>WMRP"<J7UCWA=A\8M^S
MR7\C9T(57#M19Q2,"O/UBI.0K+8JRDJ-W_JQ:LS8]3MQ9FEN K($-! 0_)00
M6D)X+R&RA.B#\+FEV!+B>T](+"&9$$!_6>;VUUCB1<Y9Y_'^_VFQ_DWA+%'U
M+730E-/LJ0((%3TO0OB8@[,6LIAECT$C3!I?0M;7$#@@@#(PN$ N%TMT10]1
M<'G$RH6!$QLN#+K$;.[0V;HPH3NAT'FMH1$(+P0BMT#D%(B,0#2^4)A.ZM)C
M4H-I#&9Z9]>([#&87MI-F8U+!OVGP+$SG?@JG1!-_J%E?,O'^B9B>XV <0H#
MM]7$:35Q6$W< JE3(+V_]IE3(',XF-1^W6/B4:+QY @P>@)JPH_F 1=>P4Z-
MU/9&T:%'/"']A$SB2SA;04=\#6>;_LGYD.\;TG?,CU4CO!V3ZN$RS\N!,4F4
M\>!!>2Y5#QP6E!RDGJ9JSOM.T"\D:VV3 T.G7?P#4$L#!!0    (  ^&84TE
M(1T_<P(  -H)   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;)56VXZ;
M,!3\%<0'Q!<@D!5!:K:J6JF5HJW:/CN)$] "IK83MG]?V[ HR1Y+Y 7?YLPY
M8QCLO!?R596<Z^"MJ5NU#DNMNR>$U+[D#5,+T?'6K!R%;)@V0WE"JI.<'5Q0
M4R.*\1(UK&K#(G=S6UGDXJSKJN5;&:ASTS#Y;\-KT:]#$KY/O%2G4ML)5.0=
M._&?7/_JMM*,T,1RJ!K>JDJT@>3'=?B)/&UH; ,<XG?%>W75#ZR4G1"O=O#M
ML ZQK8C7?*\M!3/-A3_SNK9,IHZ_(VDXY;2!U_UW]B].O!&S8XH_B_I/==#E
M.LS"X,"/[%SK%]%_Y:.@) Q&]=_YA=<&;BLQ.?:B5NX9[,]*BV9D,:4T[&UH
MJ]:U_;"29F,8'$#' #H%4!> AD2N\L],LR*7H@_DL/D=L^^8/%&S-WL[Z;;"
MK9GBE9F]%!'-<G2Q1"-F,V#H#68U89#AGY)0, EU!-$-00P31"!!Y CB:X((
MWU4Y8%8.TSH,)0N<PFEB,$T,I"$P00(2)/.%+D&")5 !O1,Z8 B^4HH7GC)3
M,$L*9(E@@@PDR.;K7($$JQDZ!TQR_4+A%'8KH$\; TD\51*/.\A\H03^]@F=
M(74$$7+S3C&)/#8CL$T(Y)/$0P%;@,0/*(9-0)(YBA-8<>93#/N%0(99>BA@
M,Y#T <6P'4@V1_$ (O1&L<]W!/8-@8SC^<=1V!84S]=+85M0,D/O"+K3&WOT
M4L_) ;DG\U# IJ#1 WIA4U#H8/B@-_[PO\)W6=#5J6QO/3^8/%6M"G9"FP/>
M'<-'(30W='AAB$IST9H&-3]JVTU-7PZWC6&@13?>I-!TG2O^ U!+ P04
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M7K:?,=H+)8_F$TW0?2=:_0=02P,$%     @ #X9A33<VYP]& @  \@8  !D
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M 8T+ D>AIK&<L[X+]PM!V^&&<<9K+O\'4$L#!!0    (  ^&84V[=FDQM0$
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M;SUAS!#/WGW@=Z+D WW<U.C$Q#+F:S),M6'#<*<FMC/^VY#_ U!+ P04
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M[LO^%+%_J.5%G9!ZMV/:U7]02P,$%     @ #X9A30(98WRR @  9@H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULE591;YLP$/XKB/<5&PR&*HFT
M-IHV:9.J3MV>W<1)4 $SXR3=OY]M" KV464O8)OOOOON[#N\. OYUATX5\%[
M737=,CPHU=Y'4;<Y\)IU=Z+EC?ZR$[)F2D_E/NI:R=G6&M55%".4134KFW"U
ML&M/<K401U65#7^207>L:R;_/O!*G)<A#B\+S^7^H,Q"M%JT;,]_<O72/DD]
MBT:6;5GSIBM%$TB^6X:?\?T:4V-@$;]*?NZNQH$)Y56(-S/YMEV&R"CB%=\H
M0\'TZ\0?>549)JWCST :CCZ-X?7XPO[%!J^#>64=?Q35[W*K#LLP#X,MW[%C
MI9[%^2L? DK#8(C^.S_Q2L.-$NUC(ZK./H/-L5.B'EBTE)J]]^^RL>_SP'\Q
M@PWBP2 >#3#YT" 9#));#<A@0!R#J _%YF;-%%LMI#@'LM_>EIE3A.^)SO[&
M+-IDVV\Z/9U>/:T((HOH9(@&S$./B:\P\13QZ",2@J:8-<!"1TBD18Y*8U!I
M;.V3:Q\YA@D2D""Q!&02:NJ$VF.HQ306\RG/$8+=$- -\=PDZ0Q!"A*DMP>:
M@009$&CF!.ICDA0[N_HQ9B*$@D(H((0Z0JB7\9AF"+FGQX?-Y#0'E>2 DMQ1
MTF/2Z[VG6>%F9>W#9I04H)+BAE-8^$JRN'"V<.VC9H1@!)<^ J04;NTC+_&X
MB&F:N-6-;E8STXBP?]I(-D,!=PC\'RT"PST"0TW"K1T E)!\Q@_<)+#?)?S2
M&$"3VHC3PFNLQ$L]F5305!#<='!Z0X4,H,G!C+U2A5!Y-M/K,=S",-3#W#(9
M0!-'V#N8 "B=.U=P&\-0'_,*!6AD<4*I*\>'D111-SO1U?_;W,!^,+DOFRYX
M%4I?!>P/>R>$XIH2W>G8#OK2-TXJOE-F2/58]C>??J)$.]SJHO%JN?H'4$L#
M!!0    (  ^&84V,<2@C*P(  '0&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;(U5VXZ;,!#]%<0'K+DE(2N"M%!5K=1*T5;=/CMD$M#:F-I.V/Y]
M?2$L!:?M"]C#.6?.#'C(>L9?10T@O3=*6K'S:RF[1X1$50/%XH%UT*HG)\8I
MEFK+STAT'/#1D"A!41"L$<5-Z^>9B>UYGK&+)$T+>^Z)"Z68_RJ L'[GA_XM
M\-R<:ZD#*,\Z?(9O(+]W>ZYV:%0Y-A1:T;#6XW#:^4_A8[G5> -X:: 7D[6G
M*SDP]JHWGX\[/]"&@$ EM0)6MRN40(@64C9^#IK^F%(3I^N;^D=3NZKE@ 64
MC/QHCK+>^:GO'>&$+T0^L_X3#/6L?&\H_@M<@2BX=J)R5(P(<_6JBY",#BK*
M"L5O]MZTYMX/^C>:FQ -A&@DJ-Q_(\0#(7XG)*9XZ\R4^@%+G&><]1ZW+ZO#
M^IL('V/5S$H'3>_,,U6M4-%KGH1!AJY::, 4%A--,.&(0$I]3!&Y4A31@A[]
MF:!<(C9K=X;8641L^/&$'Z=W+"9.@<0()!.!;3AK@H5L#*2UD&"&*9>8P.UB
MY72Q6KA(PCMEK)T"Z__OP\8IL/EW'RQD-:DQ3N-9'Y:8.WU(G2Y21Q]FGTR1
M+E(DZW1F8XFY8V/KM+%UV)A56FP7;WPU.SWE$C)W@2:'E0(_F[DFO(I=6JF/
MQ20ZCLZG2!_V6;Q0(]5.P'<9.X^_8GYN6N$=F%2CQ!SX$V,2E,'@076H5K^
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MP# 91MA/[,9 C BG*,%6?R#&T$=)&L(B(U!DU!.9QI;&&A)W$GV)<(2LPN<
M#,5Q:I6] &!I%-B-70(PY75T0]L0U#;L:TLM;34DO2IZ$%HUSP&4/\#VEP-0
MP2"TNKD$,][X_\6@K!@P-H8)$I @><+8R;/&[@-O&!MB!(T-,=XS=@J*3!\;
M.WW.V  ,,C8 @XP-P.X86UWKX$7@/[9V@WGD;0@&F!N" >Z&D]KV]CH77D'Y
MSDP?PEFS0RFULSNG[83S$N@+TSJ?H=$< ><+/1&9"_9"7X]3/PG?9:5P5DRJ
M:]I<IEO&)%7%^P/EN;V:X-I-3K=2+V.UYO484V\DJYH1S6OGQ.E_4$L#!!0
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MPQ-/>$PQ*9YY;0G(DP \Q.%))CP?6,S0#$\*\J0 #W5XTBD/103',,\"Y%D
M/)%S&!83G@2E$8D=.7=A(SD8P8<337<<8S,I9LXW!FIRQ7:@Q4 M00&;>4<8
M/,./F !,B<O4@C 94K%@8#EC*O@D8^ H,]<O.M"8"@5S.QS#9QY' -7"I8H
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M@%GW&#S!H%O$QD<0QD9,;"(8P\!0&&OL.< .!8#@,$,*)II:^_0FQ!D'!'1
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M==@#(1R+[/TG<2I*<:T/DQH?N!PF8DS[NZV?<-+I>]L;_CP4_P!02P,$%
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M:/#&B?;6..L+Q^(8+RT2O$,%"!-=-&G+D.+07VP$UO98 5L+DW%@.WCG08*
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MB8)'Q__"T@1?F2/]#FO;ALTXXG:[Q46 ^#YH^^,NYFQV>P-_/.Q1#N ;I_J
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M$E#*J?0!U-F$;-(6(*:YHUV95/"L3FX!(@MB:UYA<Y!JY?K-96D)L5Y"8)9
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MO8-E,RYOTOK!S-$?JBPRH#DG^2$&XA(%&/4:/FAAV@8N]V*#&; 8,WI.-6M
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M#'244,IZ\4W&\:S8O=HZB04/D5*2340\1>,JEER/2H1&;4 CW41Z9JH-Y_K
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M8DDJ+C,-"Q=TKQ]L4D9OZ>1?&=#T:36EQ[F?DZ718\%KHUQ1M!%&_HLC6&N
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M!8F\H=?Q$OB&,6TSI S1)#A41M"66K0,$3&6C1D:FB*^FKS74]V,/0B^MU]
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M38+++=0"ZT*=C[O=R^=_4$L#!!0    (  ^&84WAJ<'%:P(  .4-   -
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M+RYR96QS4$L! A0#%     @ #X9A32?HAPZ"    L0   !
M ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  /AF%->NF*NN\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ #X9A33T'[%)" @
MN <  !@              ( !7Q   'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    (  ^&84T _3\G3P4  )0:   8              "  =<2
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  /AF%-ASFE
MPG(%  !2'   &               @ %<&   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ #X9A38X;<2.P 0  T@,  !@
M ( !!!X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  ^&
M84UNEE)XM $  -(#   8              "  >H?  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  /AF%--I,FR;8!  #2 P  &
M        @ '4(0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    (  ^&84UMQJ8!M $  -(#   9              "
M 6DK  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ #X9A
M35IQ'ANU 0  T@,  !D              ( !5"T  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  /AF%-0J)$>K4!  #2 P  &0
M        @ % +P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   (  ^&84U1T%LDL@$  -(#   9              "  2PQ  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ #X9A3>7M37VT 0  T@,
M !D              ( !%3,  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  /AF%-J>:VW[4!  #2 P  &0              @ $ -0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  ^&84U]'4N+
MLP$  -(#   9              "  >PV  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ #X9A3:_3^**T 0  T@,  !D
M ( !UC@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  /
MAF%-(. +4+0!  #2 P  &0              @ '!.@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  ^&84UC=Y )'@(   0'   9
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M970R-BYX;6Q02P$"% ,4    "  /AF%-IEXY/<4!   W!   &0
M    @ '21@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M  ^&84W>E97UMP$  -(#   9              "  <Y(  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ #X9A3<;+(?*W 0  T@,  !D
M             ( !O$H  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    "  /AF%-,U,<H<,!   W!   &0              @ &J3   >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  ^&84WAHS7YMP$
M -(#   9              "  :1.  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ #X9A30B+R='1 0  G 0  !D              ( !
MDE   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  /AF%-
M\GLRYK<!  #2 P  &0              @ &:4@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    (  ^&84TS!/W@MP$  -(#   9
M      "  8A4  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ #X9A3><H;%N7 0  6 ,  !D              ( !=E8  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  /AF%-HQHCHK,!  #5 P
M&0              @ %$6   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    (  ^&84W*9*2#G (  $$)   9              "  2Y:  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ #X9A3>S ^@_Z
M 0  ] 0  !D              ( ! 5T  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    "  /AF%-;L&.T2L"   (!P  &0
M@ $R7P  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  ^&
M84V=Y*TDU@,  &43   9              "  91A  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ #X9A3;),3U"B @  >@H  !D
M         ( !H64  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    "  /AF%-FO%$]DT"  !U!P  &0              @ %Z:   >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  ^&84TE(1T_<P(  -H)
M   9              "  ?YJ  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ #X9A327X),T7 P  &@T  !D              ( !J&T
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  /AF%-\Z*Q
M=&\#   S$@  &0              @ 'V<   >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    (  ^&84TW-N</1@(  /(&   9
M  "  9QT  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M#X9A3;MV:3&U 0  U@,  !D              ( !&7<  'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    "  /AF%-DJB)DNH!  #T!   &0
M            @ $%>0  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    (  ^&84V&;3"5=P(  $((   9              "  29[  !X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ #X9A3272\KY'!
MLA4  !D              ( !U'T  'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    "  /AF%- AEC?+("  !F"@  &0              @ %2
M@@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (  ^&84V,
M<2@C*P(  '0&   9              "  3N%  !X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ #X9A3<-_\CY= @  HP<  !D
M     ( !G8<  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M"  /AF%--$<.<KD"   S"@  &0              @ $QB@  >&PO=V]R:W-H
M965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  ^&84TKFF)CRP(   ,+   9
M              "  2&-  !X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L!
M A0#%     @ #X9A3;03..CD 0  _@0  !D              ( !(Y   'AL
M+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  /AF%-]\2.L*D"
M   :"@  &0              @ $^D@  >&PO=V]R:W-H965T<R]S:&5E=#4W
M+GAM;%!+ 0(4 Q0    (  ^&84W*R\\%X@(  .<*   9              "
M 1Z5  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ #X9A
M33,Y^2P/ P  Y0L  !D              ( !-Y@  'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    "  /AF%-/DBV@'D"  !("   &0
M        @ %]FP  >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   (  ^&84T&VXYB(@(   8&   9              "  2V>  !X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ #X9A32K #2HK @  8 8
M !D              ( !AJ   'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    "  /AF%-*(R+MU<"  !W!P  &0              @ 'HH@
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (  ^&84TBW;RF
M^@$  '(%   9              "  7:E  !X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ #X9A3<$Q?+&T 0  U ,  !D
M ( !IZ<  'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    "  /
MAF%-?794B)-V  !<MP$ %               @ &2J0  >&PO<VAA<F5D4W1R
M:6YG<RYX;6Q02P$"% ,4    "  /AF%-X:G!Q6L"  #E#0  #0
M    @ %7( $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  ^&84VX1D>20P4
M !LK   /              "  >TB 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  /AF%-VKGW5R\"   X)P  &@              @ %=* $ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  /AF%-,&^I3/4!  "/
M)@  $P              @ '$*@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    2@!* #@4  #J+ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>107</ContextCount>
  <ElementCount>265</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/DescriptionOfBusiness</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/RevenueRecognition</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/MarketableSecurities</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement</Role>
      <ShortName>FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - CONVERTIBLE NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.retrophin.com/role/ConvertibleNotesPayable</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/LossPerCommonShare</Role>
      <ShortName>LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - SHARE BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/ShareBasedCompensation</Role>
      <ShortName>SHARE BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - ACCOUNTS RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/AccountsReceivable</Role>
      <ShortName>ACCOUNTS RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/RevenueRecognitionTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/RevenueRecognition</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/MarketableSecuritiesTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/MarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/IntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - CONVERTIBLE NOTES PAYABLE CONVERTIBLE NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.retrophin.com/role/ConvertibleNotesPayableConvertibleNotesPayableTables</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE CONVERTIBLE NOTES PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/AccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/LossPerCommonShareTables</Role>
      <ShortName>LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/LossPerCommonShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - SHARE BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/ShareBasedCompensationTables</Role>
      <ShortName>SHARE BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/ShareBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/Inventory</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/DescriptionOfBusinessNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesNarrativeDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/BasisOfPresentationAndSignificantAcccountingPoliciesPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/RevenueRecognitionDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/RevenueRecognitionTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - MARKETABLE SECURITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/MarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>MARKETABLE SECURITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - MARKETABLE SECURITIES - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/MarketableSecuritiesMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - MARKETABLE SECURITIES - Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES - Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreementDetails</Role>
      <ShortName>FUTURE ACQUISITION RIGHT AND JOINT DEVELOPMENT AGREEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/FutureAcquisitionRightAndJointDevelopmentAgreement</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/DerivativeFinancialInstrumentsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/DerivativeFinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/DerivativeFinancialInstrumentsValuationAssumptionsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/FairValueMeasurementsAssetsAndLiabilitiesDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Acquisition-related Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/FairValueMeasurementsAcquisitionRelatedContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Acquisition-related Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/IntangibleAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - INTANGIBLE ASSETS - Amortizable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IntangibleAssetsAmortizableIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Amortizable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - INTANGIBLE ASSETS - Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IntangibleAssetsAmortizationDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - CONVERTIBLE NOTES PAYABLE  - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.retrophin.com/role/ConvertibleNotesPayableNarrativeDetails</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE  - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - CONVERTIBLE NOTES PAYABLE - Composition of Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.retrophin.com/role/ConvertibleNotesPayableCompositionOfNotesDetails</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE - Composition of Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - CONVERTIBLE NOTES PAYABLE - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.retrophin.com/role/ConvertibleNotesPayableScheduleOfInterestExpenseDetails</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/AccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/AccruedExpensesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - LOSS PER COMMON SHARE - EPS Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/LossPerCommonShareEpsReconciliationDetails</Role>
      <ShortName>LOSS PER COMMON SHARE - EPS Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - LOSS PER COMMON SHARE - Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/LossPerCommonShareAntidilutiveSharesDetails</Role>
      <ShortName>LOSS PER COMMON SHARE - Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - COMMITMENTS AND CONTINGENCIES - Leases and Subleases Commitment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/CommitmentsAndContingenciesLeasesAndSubleasesCommitmentDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Leases and Subleases Commitment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - SHARE BASED COMPENSATION - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/ShareBasedCompensationRestrictedStockActivityDetails</Role>
      <ShortName>SHARE BASED COMPENSATION - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - SHARE BASED COMPENSATION - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>SHARE BASED COMPENSATION - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - SHARE BASED COMPENSATION - Stock based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/ShareBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>SHARE BASED COMPENSATION - Stock based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - SHARE BASED COMPENSATION - Exercise of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/ShareBasedCompensationExerciseOfWarrantsDetails</Role>
      <ShortName>SHARE BASED COMPENSATION - Exercise of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - INCOME TAXES - Summary of Effective Tax Rate and Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IncomeTaxesSummaryOfEffectiveTaxRateAndIncomeTaxBenefitDetails</Role>
      <ShortName>INCOME TAXES - Summary of Effective Tax Rate and Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2417403 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/InventoryTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="rtrx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2419401 - Disclosure - ACCOUNTS RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.retrophin.com/role/AccountsReceivableDetails</Role>
      <ShortName>ACCOUNTS RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.retrophin.com/role/AccountsReceivable</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rtrx-20180930.xml</File>
    <File>rtrx-20180930.xsd</File>
    <File>rtrx-20180930_cal.xml</File>
    <File>rtrx-20180930_def.xml</File>
    <File>rtrx-20180930_lab.xml</File>
    <File>rtrx-20180930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001438533-18-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001438533-18-000032-xbrl.zip
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M#%AVUJ=\MNFZ4,*7BJ%6ZZ(8/LT#@B,LR_9*U*$ IJ;2SCG$B')IE\R.;'A
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MP[PN+81Q0ZRQTG-",.R.^)@6XH5OR_\\$+2M5WJ8FBAM0*"#9$I2<$Q-*.S
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MEFLIDK*2\EL;PJ$#W%9\C2")?4=S((JV^XKCN%[IKAF:9-1Q^!3)6NW6MWV
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M06 T#V2Q+!]Z=,##W_(THX.CTZ6<,2@D%.:*TH?/3&>H"$&$@55"H/!WPI!
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M\@@>EM"]P,+CI"N"SB$X)0S"3_BU#& IBO9L99AEGZ>B&78%<7[-:59A]>D
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MJ"NDY3C!'"?X0)Q@201:=0LF6-?^>!S$[9&WO_'KKVGR9U)&W+G:N?EPC3<
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M6PO)N%7KP59CBU!!-KM?!S$4IDO0.G/=#68GO!F&D[R E +J#Q@& ]/]Y8J
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MIZ<>Y\DVJ+K:D(N7&S94;G"KB7_<OJVZ<T>^9070<EI;QP[9=W'>OBF-;WR
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MRH_L6SBXX"GJZWG5GN\:NW%Z2 81YSS.>4=QWJ]10N"%R'I_0PPESGN<]]Z
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M+\N%WY-@D.7P@,]%;OY62K_IN-^#ZT$K!GA0WD+2C/(&N*\[:-D)KK.G$'G
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M6GNX,(5KQJE HB%,LK77W)%91KO.+HRC(M+VLV9[4WO?QJ/9K_B(CV$&RF7
M7D89+<[3(!K6"\&:FM&'.E1 16:7G  1!)+JOQ 6-F)_5X4ZBI-I,%F280FO
MF4LMDZ\!F4R*:_[R3GQ'_P:-.RC_7C.I^W *@O>%/ O?XVE0<ZV*#M@BZ)1"
MT<-$)\$L)1_+#Y]6%?=B4-53G[GR5]>>UNU_;L2&9(IOVU/<Y#W%S\!/W[O,
M^%I;+O;1P/Z3&MC/)$CSA$SAQ;3SN#WX3QZF(36KWPNSZB[,JKN:5+G.@>$=
M&YOU^IU@$D0#(@29\(\@RM%]DC;899YQSS/N3Y>SPC/NNV&!6Y:BGZ-! F8"
M(KLDG@H)P=",Q548Q6V(N5YCKR\Q2TR6>XII-"5Q5RU8UV/QT>-*@D&6PU6S
MX(5Y9V$TF.2X P!Q;# 8)#E\G"P@ZM ]F(?PPL;(O0$Q;'0=WEH^W\L]T9)/
MYB<LV*T]SZ$-CFS7E[\* >86L9 XM2=;6M.A"Q>LZS:9E2#Y*"O(#WGY(>];
M'_+JC0;I_)!W3[5Z>8>\*P-IZHP+3WE_)R]"D*;Y=(;1_G)T@D>MP(>#?!*P
M'_'\=>/A[#-)"+UEE&<Y?(QRJKOC$7A.$-BPT$?($A)DZ$?UA%D2_T8&N#.=
MD"<2Y=CZ?!BF V#A3("'DIX01$/ZR"R<XD$T?1;SPFX%'/TL(2F.9.F4F?R8
ML<?.0ZYRH&GY,&I?GL?A8$R_B1^ J8LY!DGE"5DL/-"3[VP"?^%H@N4APNWP
MI(2,)G #>WP2IK\C2>-!2+?=G\.,O65&DA$>!:)Y6TSCK#G(RQ.:(-#FF7PV
M3@BAM.>G\Z][9Z^:?($2GB<)IEF,@P03-T!L6GOU'R3]5A?@ULFZO<3&U@ZY
MH[TYR/*MVOH<>J!%4E0[X1.9O/105\8SJEM!P% A12FN552L):8:I.Q0CQIT
MJFKN,OAG?@;X=5:HYI32!]<_(6.X#>%U?XG3=)Y/L[(73/7^)C5?V:JZ%83^
M*3)RED5SC["@N35I43#$6_$$3-7J!$XA%2V+]@D682Y2A;ZECE(%U!I_"\NS
M&1#[?41O+KK@1 US=#U<D.QX" .CLCZ.)P_!E'XNK@!/+AI2/2'\<O.KY_[_
M['UK<^/&L?;G<W[%U-9Q'6T*H@G>:2>IHDC*4<YZ=[/2.F\^0L!0A!<$: P@
M+?WKW^X9W"A2%XH "8!=3FR1Q&6FI_N9[IZ^C-8!I\&N7,8-4(A,&(;:,916
M%0_-8A9\@O$61JA'D82%O2?1X&:&&7@^J)UIT.*FIJE8,#.V2&]%8"ULB%OT
M0M+9RJ>S;1X(UD%GZQP V O&=5UOZ-52V7;3V!0<X1LWHZQ?I[J507,K4GR*
MXZUNQ16W=F-0 [VM37I;2?6V1^K5\]J5G.J&QZ[QO-LW^ONO/X;B_,XPEC]A
M)*P,A)W NQT/0V'%#?\>7#B>^>WO__U??]VX,!,P^QG V%RI?R<WR=6$#U_X
M[&_O+B=H9OZK_9^;R3MF6_ %S.R\,^R-FY/)Q45[.)[JXVEW.&@V!TV]TQDU
M1X/!Y;N_/W+A96G\0NC^-O=[V3R ZM>-](Q+VS5<$Y]RY8K #]-E3N.5BW1Z
M9DXI?@^!\V:KPWC28UW-,"7W*U&?)<2P,\10D3^>;TE?L'00CZ[';-!J%H/[
M3ZW4$_'CN%8902H.8,_BQ/%6\^>( ,DW^L_O&RPF"T*(<>O88HX!4EF=9VX#
MROKF?*4\\4O?]GQ VC^YB/!Y&:)?WF.IARO@YMRU_PCADE H*%^HZ6<>W,BD
M+"1_X3*G+[P# %9OF0.#P@CCMZ_PD:%K6,A_\((_0D^"FV^;/%I\V>)J8?C?
MHJ0Z0!4@/9[ZX=$!?@G?9?>-*!A?CX<J5^I]<D#B> ^; _!N!??O97)11(<X
MI'_]*4_.59EQ#MXCXMUP*^U#T._\9+'P",7BPO3M6YCV+<>DDAI)_!/2%"U0
M<=*25%G0?V9?7\]=4BYP20!RN! VL@-\@VN9X0(F-8PU3M1@64'\ W@POF K
M7Q9Z %JF==T,+2QD7?_U>#$W5M'U@GB%G]Q?<!G5Z:;A.$P  >T9K"B,-\(!
M?%"*#J"AP18$ FS9/NAAS@J?;+OQ)VFKG\HZMP^SSI_5 GM^NB^)^"SYCQ (
MG^Q<\;H#_>9K2QE9(!D\SHHS;@S9'>!YC;K$6F:B7[UJ W]$D?6\\V0!^C^+
M2+"BS'8S]*/@:SSB!YGQI#QLE2Y-73"+)&QNW*/+)<2,O_.EX<O'2)4.M0(&
M-IAERU@!(!C<*XU(.3C8&:5U!A.*(%P-*19^X(V%9P%+6CX(NYME%$R>O]LF
MUQ;VS\34>\SPD,$:0.%;SY?&U^TJ(_/QRP#VC0:[B$?RU Z_[HXT'=@,X-7)
MF!^3$></X!5!9Z&\=PQU'TUN9=/&GO37\9RUV=Y4,EVQ_MP)-Q][K_6#>J^5
MD,(7%XX!EO6U.?<<F/:OR-V@X[^=^:2W85O+V#7^:ZM8H<0^L[PEBL/H^JLD
MPKFN1ROP*"M3@H$M8,<%]=J] SR(L%EY?S"0B7D@=0$Z:( /XN:T^+0G5CJ"
M*0L5L(RMP:Y!S?X(&,!ZRFH,_6@_%F8(D_5<$J%(A)YRLCW!<85Q^*_H'F)C
MPW<\=FTOHA"Y"+$5.ZV[NU.6,M"U=QNQZKG:!!(/V(('<\^27.![*\,!9DY<
M9<E^L1DY%[TR%G56N(3OLV<\H[8\DXGX6*CK)A&76U5YJ4F8\) 5RHDD&"SV
M$CC@>RP\&5)&T9OH"YZK8VO\ U$+?H^4E]@]!<H]MR/]7[)E_ /PF_HV\AO#
M<L$+Q-SS0>GD_H*Y!@9XOME'^Y+K=<U?&Q,EXTM,75.[>&OUP51OC]K-SF \
M;+4O)NUNNZ>\M</!:#*^.+2W5F\_XCN]M5[8J?UJ)GM\UY/F3E2)1GZ3K28A
MV=WBIJ<D[2>,;XYTA^F7J]]&-U>_3=GEU<?1Q_'5Z .[^GA]\^7KK]./-]>5
MMBJN;72_ K.TUZ%J#F!J"Q$6&5,P ]6@.%,S $7$G*LX =-;+  ]18!RL@P!
MF?&\*E%60,"EXLYC:\>]PQ.F!9@MZ!$R/=A@T,*XMSTG<S8- '1O6WQ+@2X#
MA-3*@%=T6H4O,F)S:&:82E$#QH,7ANC8E2'GL!C=VB'[/VP@OH\N->?1IAAA
M+K?B<T%YDI@Q-96-:7G2[2--S9G]'2Y7(>ERRY0K@3HB@ON:YOG"D</EZ/I"
M^6SU[GGGL$</DW24R$W_X-8=;F59%TF<>RG'/@6=(%C7!#\]P->PLP6K H.E
M;N9@ #P@6=5>:  982CGENV$DN,3ZB<GNZEDJ0,)*2?*)V> ,."9KG1B>%&R
M O=-6W!E]3-[3?-5*"3D!AY(KUST%W#^-RDP:PN<2;Y IQ%HV+.9.B>.GK[D
MN(^C-\G!VGLP0'?;(. K%Y^G;G\\,7;VSO* ]C+5*)W_N_<--A),A.9<6Z=#
M=&Y^GC5^Y(GU;93K!\+/(P=THN)N*R/88./TI'EKG<'H5<CGTF,-8N.>*V5(
MNLM36,)8'6ECP1[@+3@[B^-UWFO,Y8$6TW.;#8*")+]%ELTG%/O)(YB8$]))
M@3$JDJBB- [HN=J+R5(4&C8V: R+C\E 9I3,$]F(ZY&&+\4;5=L+.MKJI<CB
M!0=[=*N'(]Y)"EL8,$3MV.B&_5QM,_(XZ;$QLPT\1((=:].1/A;QI)-E!DM_
MGOSR-#1*('X SL1DKD20 ("C6Q)1S\AOG(=\C=A4\2RMFZW>E:V.LQB2GW G
M%)PKU&WTBT<0W,V!"5)WQ.VJN#G!GN=*4H+J&RHOT3T_CS;6=$_*,.-65V3M
M5.+LUA:GF&YZAB).361>G7LDGN3S-4]R+=WHZ8S3<LR9=-U"PRI>X>2@.KC[
MU<%M'[<.;I?JX&[R]--5#O:MXJKNI5*X>Q%QPWFY!LY/'WQ0.9ZW%#&Y7-N,
MLZ[$';@W=P&G4CMY%+2M3"6=EMYHYE9ZD\KD5'H/SH6AOO"%8;NH2SOV;-/,
M.+-=M@("BU<7=:M[K;]F0V?G#)/E)5WRDL63EJK342*^V.+;.3KKF(W*("8J
M8$3B7XJ0KEH5M=4;[2'(G=X8#'\H?/\[:6&LG<Q-XX"R>WELC\[=OQ0B<%64
MJW8;I*K3SDVF3EIT3F<?F]AXE.]:;&5SY_F,&-J]@D*Z M>U+ONKH>A5=4Y?
M>PB0LVOS+S=1^<LMRAX&TM]F(X:_-JX;[,:7,2&K.'=D):_-%J:+#349>/K8
M4'LBC3&WTS*]MW8,D@^1_K)E:UZCCHPQ,IR5L,5SD?#S)*HL\Z"=@W)?%U^;
M#<F]D@$S-\;WM\7A=B_TR<6PUVDW)SU]-&F-^Y=#%8=[T1F.VR.*P]T6AWOU
M<?SIURF[&?V_:;5C;K=VEI7-9&7.OA?ZF:BUP/BNP$-FXJA +?SNEKM\9@=)
MT-;[!#!V"@=2Z1@RKN&0_4LM/'/<XD3)B\2'C./$#&45L''05JQTROW4*?=P
MV!@T.[U!OYO?8?<@E\/N_KZGU7O>WCKNZT]I\I5WP11S2+W?T7__"$?_^QST
M[VL7;:?AC=S@?U7[^G1S7S\9+V$96;0<T2FO/\C=D:.+(?FQ&P#O0T!J*7YB
MG$IQ53D=SVS8N*5W)^?%K,4T(VPV\NL.EZN3N2HA:>^+/V$^O!27=P,BT8WO
M[34Z)+G[$/ M9T?5M'ER(=?5,W[D8^KA)2)1;N')Q4V[*"TB-RRJ^HGT466A
M9KL^847]L$)O;)8$IO"Q],]Z].!]SLE2\?/"A>'?V:X:I!$&7OR%PESY30&)
MLW26>/S#P$I-OO)&2QD/:N@L$1_V$4.$Z"BQE!Q*!S1TE%AJFXXXE8X22V&
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MNY.\"9W%D2O9B8Y@;1<L++22M,PQA$P0\GWLK:,"BU#QF-DN'G[ :F6:EC4
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MGGB?I'"<0R:?'"UX8]/=^U0V*^VIVQHA6UZ2)(DTV+:IU&63W1Z4=^6R?X;
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MB>6KXUN]%3<2CVBD.!5# R/E1"$TMZ5@*9:4A\X1\V$1#.6^65-FF*%8/]J
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M</&+X6_':;=Q!&_>6;-1? [Y)D<=*?.K"(Y\_P.=7I0I<O5D1+?7Z)#D[D/
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MS;:"_../B^6V7&2L3KGRN1#DK-O1NGJMNQ_D0B=*B")((D@Z#"3IC7:' (D
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M"A\SVL*E]S>N_?/?_K&/ZZ2O\-^?_PU02P,$%     @ #X9A3>V/:KRD$0
ME;L  !$   !R=')X+3(P,3@P.3,P+GAS9.U=W7/B.!)_W[_"Q]/> PDD,SN;
MJ<U<.6 ROB/ 89+9?;H2M@#5&)F5;";<7W^2C(T-LOP!LV'.5$W5$%O=K>Z?
MU.K6A_7;/UZ7KK:&A"(/WS?:5ZV&!K'M.0C/[QO/5E.W.J;9^,>GGW[[6[/Y
M^\.XKW4].UA"[&L= H$/'>T;\A?:%P?2K]J,>$OMBT>^HC5H-D,B3?QXI<Y'
M:B_@$FC ]PF:!C[L>639A3,0N/Y](\!_!L!%,P0=5@47<A&I HG7/B!SZ _
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M#Z-8Z(T_LU$<$EI(23G%VT>>G05@02'"\:?WO%E.J%F*XCL._ Z<'C'N=UQ
MJ1=MZ?"(F/7:GD_ABW=\Y(7.\VJW_R,N'"=U1_*H;ALJ3I8=C[V+,&^?$X*
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M8IA-+!?4L1@'96GD9[^U>%*5- 2DI_!\.LK1MB:53Y9$Q242AF+DF8-IQ"+
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M3_F$,@%RS_%[<BGL@&"5$HL/<1[A6[G0T:OX.4YF;979_<LG.]N!ZY5SC*)
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M<9J_G1?+/!)H1GD^3?.]8<7Z/28&,*:]X9PB[2WW#@I>\NRDYSTZA&=4D-X
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M4H]ZTG.EF*OQ;3I9SM+WUZ4]W-R<].U4:N'<,Z. 4LB)F&1)G-/:,&P%($K
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MK[:S'(Q!#HYABFOH=F+/S/!A&9S-4;&S\&'7KTR(90A;X1DW*OP',N9UB7#
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MCQ9G^:?;]/W]ZBJK;',W09G5OF_)6JEQ0D!8^QF%F7)2\U56LRDY40@,\+!
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M 36,J%U#9JM']MIX4<*PIY(%'T()&BL,$$7T!E'AO.S3E3X8_>M?A?9&",^
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M'V#V]D 4ISU0^U*@WZ]^R;ZD^7Q53>P^FQ=9GD[<ZEK<?%K$U?Q)>E6GNP0
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M=#GS]#"]3HY$=>S#^CL?J'PQ$FXVY7Z].]XU$C@.8?\?D""A00B1&P;=)LJ
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M^SB"@0<]A+V Y4)A['B^[;EN9SP -) \':K)J/$$)($WES?6%;4^7),;EH;
MCY=7[YM4Y.;RI_>7]!+!]Q\MB-#5STUF8GVX>GLIGYSH:@/!BM3TY$M6F8X
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MIX/898PS+9X4^KN=W%BZV7Q)M_M=>G5WL-T=X6W.V1V'LH]C2%T/0A X,07
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MS&TORLP)3$ G(6U$7:OG2^F:'&7B9&[)F8) Q4MRU(@4O"+GC-_GII*C>5K
M/'*\#X7.GB.AOJC(OZ9EG=WNTJ-!!_135O9E$"?$=KP(Q($3A33H#:(XQL(2
M/,Z,81T^ ?=H3#A 0E-&$BF@R--Q*"?+Y^E3T>:1/$H(]'1\JJGT&%[%I'J0
M@7-ZK8>V!8BV)D<*[5U*;OI^8I.G[?U-:G&4N*[K.ZX3(8 0!8#VM@B&4C5
M-0O3),^;DT'25M"W4MH]DD6QB;MY M45NYG!S[-(_"(M [/U<30N8ZH^TH="
M9\<:4R9\>[BBR8%.$+J$VA3"D,84V"CLK+F (*G3?*HVIEYR>*MZ<9LRB2H5
M0C/\C5R"$*%N@O+@6X$+V\:RN0S%&>W%8&U0E169G;0?NVUT[YG#W9O MH=0
M#"F. N FR(TB[/;[8ES/<X1J@R--&-:<XW[0;;,?-/VVV>VW?!M !]"Z7]?[
MLGDI67YCK0JE8A(T 9MR"O1T8RTY$-D?$W[W.I'&]MD^IVI D$9RNPP]&NO$
M"_ML1W.BE@/UEY9<K^NTN>=I^R%E?9#-\S^GJ\!W D0=-L^+8X!A$#!][ #X
M ">"6^D,&#:^N>YPS4]S\?K# =F83&D<U2K)TV0<CUQP/;#-@5ZT]]YMK0^O
MLSY!DC7$H7#>I:4AEB%])AP;S,XT<J<FD2<3U(^LGU5?BMWV8[GFX1>OOU>K
M. Z2D"8NQ$YD(]=FT]:DQQ &6.C52S.6IYA29B?C^*20=6'5/6*K;B%;6X9Y
MC(".;@@5#9VR#4;**#JE_P#6ZM!:>(C^"93T%2:%Q517BRQ13[7Y-BBI>AG4
MIZK\/M)TLZ^SK^D)'&=E1TGD.;%-<)C$U+8=-R ]'C=QI6;*YE L1&TW1_A&
ME5>YL72I\!3M9$:13Y O6IW/,#Q*J<>VVN]%M4?[*:W@>I@5VG'#P;00JJS(
MWV;KVVR7U=]7M@MC/PX\PM\TC:A+'>AVIH(8!4!XKXVJ@2DT>'/ =6'M>F02
MNT.4R1L6SLEX4]!$=$+9VRDID]A*,P5U:IMH%"@4VSMSQN5SNV;&,K2 _3*C
M72@T]AAEP27_V',[V'80I<U;@PZ$MN?;*.[M0$2$W@14__2II39M8"F+ABAG
MTB)K@*Z1"DNF84I96PTPIDE87V%.157;CQ235$EB%J>GLOC/BZD2$Z*%B ]E
ML4G3;469+Y=5M5\S/Z_N.( 5L^(CA^7%..!WZ":V3Z/>((5$JI8[PHQA;>V1
M6;PUK:S#QJ^AY.OT<H6",62*50(FXE%.=!]3>'E"(1ZBT,A$_CQ! S-U#:PN
M8RJNPY%">X\;4QJ]3OL;-.!]L<_K%0JI&_M!Z"38"3&R@SBF!Z,@DKK1<Z2I
MJ8N<97J\3:1!.*:,*4^L2JW2**<C"Y)';!8<IG."DN-3HH3KBLH,+T.Q=#DS
M6"$<R9&^19WC:OW5W4U=;'[]4&:;]&.9??Z<EBL(PM #D.+8#GSD82:J?7$R
ML#U;J&(X%9:%+/ <=R/Q=*/B;O#[E#9\N:=Q1/=*S\@6U+7>,UWCF5GU^?"H
MW1H/K,8%Z^,K[3;3\L\@X:,6@?0TY1+5W*"WT@M".ED6KE(*KU'QQ:EWZ;K:
MEUG^F4'-BNW*<P#Q6%RB"8 DH0%P:1^CPH#EVE(53:-(%A(+3A?[^2*_==_[
MP<,$<T2R"FBV]01KJXMI./.K_]P#Z^""]6%Y;299Y5U,VXVH"!MM0_$:\A@J
MA^K-DS310FK3T_CZM(X](<-"<;G;#M*$?V:%_3??9 _KW<E&:A2Z( @0<=G_
M0NC:'K3[C=0A=2*AL_:Z;!F.K?V.JW;.Q,(D_ZH%>2%]U$,;OP*Q<6)JY:)?
MSVH[HV&0K ]'5@6.<IAA52)Z3<RN6GP:R[)8]'F=BG/Q12.)"X@@.KTIS'0U
M3=6ZX\KK->^0SHKZMDL3;$<8^Z$=T8  A"(WYJ<1J1<)[2W1;]5P9#CBX>?^
MLD)3(4V>W)$E,Z.\ZIP4G1!^/4CXM!6PI_RIU+J4VV#A52UUOT3K5R.9TZB%
MC4 [*]OQW1B&E(:19P,2)S'NUWR9-/MPS#'H,79E1JWB*>BLSM:[DVUX7=+\
M0Y9;VV*W6Y=5DT!77]9E^F?M<BG*OS:Y-$"\(;ELD"Y.+EO^QLFE9!O\;N12
MUB]YN51B;EQAG]\0^&Y=_IK6?3+KV+:]\L/8"8E#7( \?MM_C.$1@H.%'HDT
M8GC&LGUSM=^%==^ ;G541Z%7M07&U.(G(%^?;#;WCEY8+=Y6-YNILO4_G N&
M>LXVT%%;GZ M])?25=MD9/'\9:ZD:^4C*5] 8<.8:T*5<"W\B:?Y=VE9IEN:
MY7P;)RJJNGJ?UBOHD83ZL1,##W@.BB)"^D,Z8>)&L5R!0\W&)-&HWYJ\X:@N
MK#R5WD*I2*!H5FZ>.Y5@TM.&6MK>#]!F*-M^D9?!W'H<DTO)I$=Z\2QOUL'*
M^,O5R-U=NN%K?B=%7FHC&F/@QB!T: RI'QXR]<ASW1%%UK&6I\Z3L]/[UBZL
MM(=LX.HUI890J3!,V08CT^4G%[ =T"[P#K87F!2N-^AJD:4HI1'?A"]C&\^@
MFJK2]:;?TV['KHT=.PDA@B (_-"+^QLR(T2I4)UAM!'3BU(L>&7UR5NZX\_!
MR#"HHGR&R!LI<AS5 DZ]',D1UBT%/I<H42IN#*J1,B^BPO/3FB4I;XNJ2JNK
MG'SC+UCOL^H+M]V=!W1] CV DM!&MN<%<1PZ=F_7=HDGMS8TWI[Q-2$.T?IA
MQS#^V2IR*WT$4NT(L0:6Q51J6GKEY*KE]6W/*WG&Z_3GBE^E:T# ]%&]#"73
MZ$]AJE.JOTH \RU:/V3U>O<V75?IU>TN^]Q4>ZN5'7BV&U$7A,#&-O* &SG'
MC"ZR55\I&&'2<,+U^-4":YUOK4V+U-IQJ%9QQ*K^:L$8RL74;@:VY23O\:L&
M#=$=2*M!:5T)$&W\58/SU W(GV;NEZ&!NIT:> 5!&V?"4\RLVK"D9E^F5W>H
MN'](\ZJQ=YWN^)7C3=GPAN]RN65PMA_6W[D^5_"6I:+K3;U*F#P'B>U ILB1
MZ[D4LWPTMIV(VI#_C=1$U"P4TZ6] WJ>M)SBMSH'^I)ZX\.;Q@FK]\+ZU/LA
M^RB5X?83G 8OI^DD)\O&6\W,S'H4WT/S[VD:<AFZ/I6S3^?R4W(L&@=N-E_2
M[7['3TQSTPDW?0H.EB4;-TTAKDJ^'W^F@P=_6Y?;C^O;7;I*[,2/(P^Y88R
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MWS2+5E -[HE)JRX>Q?>-;=+L*]_H?SQK%B,0^M#WD\AG$\( ^"")FD(*\0(
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MDOQPXX4FJ%!0DB5(3)P,,B,G1"V0V=9!'_,P(":*A"U#.%3!/SW],(8#.4%
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M!3VN/'MI21L_PD\N<=F\ZI7PJI7-J^.302L2NFPFX1,(8]_#L<-L^IU98I/
MDWR"::PYX]680^)^^FZ2=.JNCUXQT9J45VV)^ G B5],>H6N 0W3QO0R=$R?
M.T]?6-++DU#9XOV>+]!?W3$=W>XW=753[+8K$D<VA3&$3@QL+_$#B$!;'L&!
M8T.A1$O]TPUG5RTF/KH>.E16Q6!)3%K5.!.H&QBG2TZ&.J:N[JP>D'4S!5,2
MTW;CC*E-QV69$YM=O^3LN5GS*&(6,!L>A[_0U45DKV!D>I16=;? B-/;>H6I
M$P:>#7!"H._!($($)"AD\FT'MA]1N9L7Y3_?L)KVD-CTM,$D>^^B F%BZ9UI
MKN2D]$!3!^?"XH"FOEKQ&2,#2=L8_I:1IXWRX-G]B6/9$'Y/Z;XHZ^R?3;RY
MNJ-9OLXW+/=KEK1641"$T'-0$KH0>6'@NX#V)@FAKHR8C#)D6%5.L?%,;<OX
M;A[H;;:6;CA$R4>21K$JICB3$2HG/4^YY'VW60=HN$2#7)IYZ&B IP%!TD+O
M,I1)CRM/WRO2QX^:5O&.Q1?F^<'N#V5ZG^WO5Q""!$($DP@RBUY(0!CU=EW7
MQNJ"I6)M#M7:=AC'Z)42LRJB99I4#<K5P[-^Z !._*+EJX0)2]@8LI>H8Z/\
M&12S\4P)*QJ_DO C^Q7X+:O8+#&P0QN%M@N"T*7$20!D?TJ2Q'9(@J&4>DE]
MLFFEXF LCL;ZQ/%(7CXKR9*@$ADC2%)UA+DQHR^G- QIB1)="]$-->Q/-6($
M \*'<@Z;"$^W&9Y>:)-\?[;1L %V1)=O/[ .]GY]G^+B?IWE*\]S,$O 0APY
M#@YA3&.,>JC =>1.Z\P!T+ Z]:\8-@/Q4XM)4J'F:3<QH5M\D\GII5QKF3FC
M8X#1 >F=M0&7H>#S4O#TN,_\[2'^6EU5E]FF3ML'\G[.L[JZOOFY>TK"AC%@
M&:R/G3@.$Q?[#K4[F[X?)T!NX\@X6\9WC1SAM<]L6GL.4/9YNE%TBNGU=#S*
M">\)@>WFW@:9]0/#5OW9^M3BF_SYN0&N!B15#\?+T$9-OCQ[74X?0\*[<=/R
MKBCO>:&XT<^JLX9)PN;:<4A")HJ44M<YY-JA:X>AU$9<11N&<] 36.WA-=EM
MMZK4B6G2%*S)J=%SPF:2H#/4#(C/6#*7(3NCO7BZLU8+*]HFVN=2N';Z<9DS
M=6PVZE17]9>T_/AEG5\]-%=YO"_RKTP[T^WIHR-\^P<-',>!B9W@ %#'3CHG
M0$QB))=I+0R\\=3MN(7NY1Q$\UQ]XJ;7-(M?;IO+"?OIT>U'1[Q/?+5NO[]T
MQ+LM"EQT+[Y;)SY;C=-6S;RV.K<OK(/C[,M##^MCR8RO8DW;U&,*#_/TN67$
MOZ62(UNLF+,-C4=KAK%%^]R;XS[W=O"O /  CD-*"0(VI"3VW3[12-S #^0?
MVUH$;!FE5G][*_V<Y7E[MVA['Y_R>9Q%D&8Z*,_5P).'8N;HF];3%Z+RH^-%
M?1#^G<1:B18T$6%-=*#?>5PU0HFN:&JNO>:?\?[4G,:\S#\TT6,58#]DX3_R
M$P0\-FW'(28=?.SX4;B4N:XD;..SW :/RB4TBZ-J]BFMP:9=ZF2V=9D_9-,Z
M_3L)HY)-.<MD5;$W_<[#J3%:)IN@CFJW^</J+\WD^@"?>CZ!)*((@ @0'T:(
M'N #;$=R#WTM!K:0]HYY^*O%L\2H*MO <T=5$RV[\*C:=9X_7%1]W)2S1%7%
MWO1'CZJJM$P654>UV_Q1E1;E79J=>@ ]D%#/A4%LV[X=) "Z4>^![9%P*8%5
M'KGQV'J ]..&%WUWRXRS"DT^=Z@UU-8+C[8'K_]X ?=9@\X2<]6[U1\][(Y@
M9K+(.[;U%K7:2A,0^D%D4X1I: ,:LEGY ;KO$MD'SA8!6GZM5?J],])>=_AL
MF77B8\G_%=;-1%O[=ZZ-1BB98]U,KKWFGXH<-M#\+>4W+Z9;^#4MUY_3IFZ)
M639^>$[N=(<-9KKN^4D (\(<I';D(K?SDB ?N$M97C/CG?%5N!ZMU<%M%U8L
M#M@Z/L&[E*F-H2XT]_1G_KZSU"G2R9Y5L9YJ?8*W5?/B]Q]O%ZM,[YAWFZN1
M?OP[SSOF9F_ZC;(&>\'O*9M9)3X)81(%<13&K@^0Z]MA[UJ(0SKA3MLIW9IX
M)^[MR11QRSK6NJPL]K&O31=_Q]WF]Y.V:.TK?YA<Y;]>@K+PK$2XF_[_J8@\
M90O,/R3;>_ZDX_$6K]?]0Q%@G@"$H)] ZH9)X/BM?XX= R?6>A768KPR?'?!
MZ<;EY28:VKO*W-G&G+UDJ2G'TUW0_]4R#\D^L8#MU/KZ[1\]!S'&VTP;LG6W
M_/S9R..M<:_[%P  @0O\.+!I8+L4$AOT_F$0V,O(1G1[93@;.=GOO=QD1'M/
MF3L9F;.3+#49>;IY_+]:,B+9)Q:P"UU?O_VC)R/&>)MI'[ONEI\_&>EV"^Z9
M% HXY[DDI #1I-E$B*%MQYUS#HC<A=1%M+ID. TYLS5^N2F)WOXR=SXR6U=9
M:C)R0LA_M3Q$IB_,N2U?;V?]HV<@9DB;>C._B3:?/_>06'%RB6M3&A(W<$D4
M,B\QI;UK)(KH9.< IG1JNG,"BIM ?F<*_\=9<!?M.7]T=3=!V1(7W.7:6U39
MR?W#KOB>IC=I^37K[M-^YND!9>-4];&HU[O3O^<O>;XOZK^G]76Z*3[GV3_3
M[0KY*+$3!M,C((HP\ CI2_*.$Q.IY\7G0VEX[O=SOF[?$SR\-;(YS>V5GBZ?
ML4G%YG*_C]:4FY[U/EF=4]:Y^=K)9K=V7L8F68_F<]PQ]C.U]3VMK:-OTP9@
M8TTT$%7G[Q;+")4+X*%8VH!=2%!K*\!L0M9]B_^<LR(L-,<!)3"!3NC!("(
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M.-BA<6O.3R(B=:9GL!'+ M9" PTVT(%3N(5T$(/]@C4J>6HZ]09O[S^,;9A
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MY(LW=ITP(,Q#(7.0UTV.IM2#4J]!#?G^L2J"T]G\&IEZ3:!,G7Q58),US;I
MGC"3E<$S(MZI#71IFUXP!GOP2GTPC UU$6GJD<96B)T01P&. Y\F*.:5"6.=
M+0<SZ0V8^A9&%I*V;!XD)4H$JHJ)+>Z&R8D4;>8%Y80,*4G1(6]NHJ+EPYNR
MHL^(_*H)O<_*VWQ[^[DL_K6[(\7]PW+[N$!AXKC,H3B)B(M3Z/D>)*[GQ'&2
M0$=UN43/QCCK)!TVT( #+3K5Y1%-&F771>PSJ+4@HDJ>N7605PGI70 91N'T
M0F/$BQ=+'B98D1>;R_OE9M/=$KSP^4#+=UGD1:'KHM0+H2NL^ 'UD<M'7&HB
MH_;=XXA+C>GPDK6JIBBR):LE]HC2TA!)CLQ)QQ/_>R5#CZFY2(4F^A<2,80%
M]1L'_[$L\^8N M[MLFI78\BSYOJI!4M(B-P0(DH#)X@"2)V81#"*B>-%:22U
MDF+:IF4I.;UCJ0,*.J2@@]K>>:/X(H$QVONU9TK&U33)$-F6;^KK9>\51;/%
M_SPN S#NU9OWYIED[3UEK,K=@A1[8>EA6>X>Q:&]^BUQ%P<H)B&)PB@)$I2Z
M)/1;,[Z?QDQ& K6_W++6G6*JCY*"/P4L2573IZQ?OD9A2TVGE(F2423NYXD:
M\3\]5Z*WB'A%<@9S-JVV#(=?&&H[\FKQ/7O@K>5N667HMLSJ2QV>6V[?[B8$
MH=ASL4?#Q'4\)PE<M[.-'"BUU\RLQ?%UY;W'ZVW2^[[<3,/L8 UZCU1C*B3-
MSQO29)[?Z?7*@D^%S1:I\@A*MJV6W^Z6Y?URE>UW^6JYJ<ZWJ]_:)_!0&*=>
M[#@(NW[*4LS"@'46$\:DC@Z;L&-;Q00Z\ P>$/A4WMD82&6_=HW-HJ)BO4F@
MSDNC0YE4>:5D/$8U[Y(:P*SD8R2]%+PB\R:)F\&=4J8\*<PWJ^%"3O]KG^\>
M_V>QX0Q6K?7 30(HKK+R?>(D+/92&+36 Y:$4N?$3=N<0N#/1#<Z PU<T.(=
M+E-:E.N+OVVV#22"5XDVF!BT&!^>)&PS;S!A:$9@4 )YA1[%9#*$X/DFED%>
M2229X:S)+#M_R6Z7FV89JYYU(=C'*'19''L1@1&)4N1T%M)0[HE$G>^UG#AJ
M.-TMJ2I3IEH<O;_0;),>-:578<;$$O,SS]]87M;E9_JE96WDQ?#6H;K;I)V/
M"!Q,8$P"ZM#4#=/0BU@W'Q&$CMQK]<I?.L[^$K593'5FWN_IUDA1Z^:R?)C;
M1?+F]*(V*]-W;CW8+S:,:/DM_>#[\B'?+3?YO\6+%M6NNKCY8_M0%C^R];>R
M>! /-&<5_;G:[-?9FG'OT'W!/_MW79WBQ_9W'B]*_M-_9JM=+4",0I@X$:5.
M AV"&(PH[I"2.)#:2#\E/LMBTT)1*BPF#5>_;'V42*DIH&20[#Q#;Y[)GETL
M4\9M'CM>)F6@F$\O4LL<K85VK)F$-(9I@'V48"]EGA,$W5@SC+U0ZH2#WC>/
MI=9*M:$F27)*:X\?38TTL4ZMK))/6.C1-SVVYJ%,FM@+$^U%91GBZR5R',CM
MW);+^]:.BV,2!G&(:1PDQ.=2$]#.#HNC0'[!0>?;;2\M<$R?."C0HE*9SM8B
M2V:IP#9/BHL"SRC2FOK7XDIEDM\V9YK3^<K<24[:O^+NF]/S0ZB9PT3\(/R%
MJ4:B5E1]SZJ,_^X=VJ[3[$>V*1[JYXG*4CQ(V6P2VM:O$ET5W[)2O%7$BO)B
M=\<5##^*2[CJ@B^*TS3R HIQX!#J10E,N\V0(?131Z48&P>19;GNG !+<474
MT0UPXL<9Z#P!NP*TO@#^#]!X<U9?-*<U:A\IJG+5X_P"JI97QHNEE;+5"/T]
MY>ZXX9U'F3RRS\64'6JT?"*0M5//(8P3FH1Q%'DQ=5/H$!P>L*&8CI1/%!!]
MH'RB-:\P4ERM9Q1+(9TNHTPR%6(D '9RBD: /WQ.T?'97$[19EQZXK<]N,#'
M0S_R2CQJGY7WW9XC#WD!"KT0XCA$?%3$@J@S&?F,2NT.,&+(]K1PBPT<P($:
MG>+T\" J)6>+QV)1<?+X#0*5ISH,S2;WL-0WN6R"W'D(GAE7GD\]F^-'5IY>
M/57^^"7?9N>[[+Y:\!H;^32BB1\Y3H@(XZK868UQ*K41WI0MRR+UQI4+C^!/
M 1'4&!4+S\'LRHG6F,2JZ=8P3JUHUSMD]<B7*9KGH6#&O"GL-,;1AN[BWC&Q
M35RL.=!EN<W6"Y:& 4EPC$@:,LK"Q$\/&#T:2UT.-@VR,8?RZY/!W_)T\+<Z
M&?P]G S^BG;PMSKQ"V2U8Z,-Z'6B;7U@;SG04PSP3UT"M#_&<QOFOPR'G>'^
M@+#/(X=,Y+NYX?_@"$CM^/BV?!0P*F[VZBZ[>!#6K@JT^J]]7F;'R^V<!'L$
M>2&B"8X"2B-".L/(=:0NYC=HSO:40 NR%@T>"U#4.(6<+!NDX%KIZDJ33$OL
M'QF?9,49@XY?#A!PA*"!"*X*T()4O!K4)+\*>T[&YUEO$XH)ON6VI4@Q\M8^
M%;-TSF#CBF&'"FM-3R%?H/4Z%\:6F^]9;6PM!>5ROUKQ_[O9;T[2X._YA@_"
M"O[W"X:2, Q)F/"$!MT@8"[T6J0Q0DSJ_.F4^"QGI*-7H&S= @_R6>H,5 ?_
MG@R-[@\>*@CM5$U (O-]@.BKI<J3P'<> 04Y/P-'UYZ,EW[_2(%72,D?H 'H
MY? )&X)<ZK?#_%NUPL1QGD%Q,34#Q7QZG4+YTIGF@^OK?%MWP0;<X?*^XT)7
MOLH6/G)P&$1NDH9)3!+BLJ!;V8I]FDB=@+5BV'+!T<$5\Z$=WK.NPEAVD,]
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M%AE#)9.XG"#?WC8_'4N^1>@Z)$8H0E[J8B?R7,<]U&\LB.2O [ '82;%SNH
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MJVF>Q ZFR150A<H>0;02D7GHHQW7BA%:M.*<^VZYJX_D7]R(^VO8IOC7\5
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M]+QN"XL7.$FD,O@T:':4]8A*3)*=W%S4/) B]GQUZQ+UM6SBZB,^0+UN9R#
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MYX)RG-5:Q$Z*J1<&08A#+M7,=>/V8EL<N#!4VGIL"8+E.<##J.JA =G<.=O
M[.ZN&:R39F(Q=' [6AC,#G>_G02F!0Y.D$^MK#+L:HV*C81KKLIKUDGID;-!
M3DV5JZ<("(L]S_=\G%*?N3Z.,.QR0Y DKM*CC";M6M9@V:)U(]'K[<? 3/EJ
MBWXK->R,Y/9-%@=4LSJQF*NP&O!,L:[59\_\*W*+T(\I"P@*($M\_E,:>_Y!
MPRE+%KMBM]S(*:A!LTH">D HW8V_JC_+8^M=N/<C(*>?$Y&O)I\:[[O-]?6V
M'OFT$(IYJ*<-Q[1?6E/D;J!V-M=\R3_UYGJ^GXB7;T*(7.+@V#TLIX<>2A4?
M:!@)E$K'-_("Y\$!XR]P&H_7(!6>,E!&%?JU@'V0%S@58Z"N[[:"/&OMM^:T
M7%ZPR[GT.<7V//%5@<0FQS+C,+GMW>,WWK=V:+NF_-,'\2N+R(]<!'WFN&X4
M(YK$"'5)*W3YG]56V0P:MK[2]HU_?B>&SL4-N,E_<D'165,S2;6<I(_-L=[)
MQNY$^ZX +4S0X3P#-=*S>J+H ';DPX[2)/;HKH5(S$-;;3CV_%BD+>ZT-?)\
MN^,M.!>SR\U"7^HCZ+$T\ *$*:7(IX[3V4TCJ+@-=+@]ZXI8UUD/R[P^#RD>
M@&CQF1%&=7XU]= .L<9D\ AODJT%[]*E(GC:5,]4Y_3]>4_>!C*EK6KHQS+?
MB"4S5I27RTUV>7@"0%R4O(BC@'I)[$,:8Y@PG/*BLT41.22% S5NH/51:T"U
M=Q+&Z9O]_*GT5$.1F&F_->7=>[W8*(NR%TFOLFQ="1)^7^Z$M<?B1CQ_=;*)
MW/%B%#B(88S=D* PI>[!;H)=J8OVS5FSO-C<86R>=;MO48H>+)XKU'NMT S+
M_?7*- 0KUBM/N/W]A%L!4>^M0C/<JMU4/2['VA=7#^1:^BKK=^EX)9.8IW(>
M%UT;]*>PU>@&UGQBZ+Q[_#W;W17KT^=@7)Q27ELR!SH4!G[JAH'7F6=NZ@PL
M]G3-CCZN/4 #GT!6@QXXM-4F7'.$:Y5I8P/=!B5H8$[WP)4L>RK5]-  S+2,
M'NS6>_6S&=[,+YTO?)+$,7+B(&((.V$*4=A=&QYAW_$,;#O2,3OMMJ/33_/#
M0JOA+4A:T3"]^&TT$-87N.>Z?&UDB5HZ%//04!N.:2\U*W(W4$</+VI)KG4'
MQ$<XQ#%.,0U2)XD]U*UUQZ$34"-;D$R#&GT+TL$!XUN0C,=KD I/&2BC"OU:
MP#[(%B3%&*CKNZT@SUK[K3DMEQ?L<JXX*<&*\KW+VE_!NT"1CP+*O#2$/HRI
M#WV_RV-Q"B'3FJFPA,7^(E4#7\P,GMQ9]ZE[*T+Y08@IXJ4TT3%EH(;,?M33
M2T?DX GTPQFLQ[-74\8DDR)Z3+\_4V(Y@O.0_Y%\?7U.912&Y58H&T 7-Y_W
M2_%^49:M?\^W^?W^_GOQN-SL'A?0BQWHTC3A(Q+B\5S##J\_<J.1Y$8J0\;&
ME.O; TAPWZ $90-39?UL.+\R"Y/C$#M(7B]NP!$=:.&![U,PJK(<.2JS>FN1
M5W=9,Q%8['<W?"P*UOM,3.6_W8!_&[HJ^1XK;RY)&J-S#NN1YIPIK#0YM:+_
M>_;0SOA?W-1GC.M=,32)/$Q=-\$,Q:F7Q#SIM+82[#F.QEWY>H8TI%_GX?.C
M_A?U,?S#ZYAJ%;DFF7*5MD4"M23^B$?PUEQ?D/8])66E*GZ5E9YJ=QB+\ZAB
M!_I0F&Q7RJ^QU5LNQ+3I>57M>;&;G;RB&<*0L20(? K#A!L/7+>[#2:!OJ-T
M)?Y 4Z/NB,M^9N4J;_:TZKW!.Y18R<'^>)PJEIM/Z.R@3?<,;S]1?8-Q,PS/
M0Z=,.?/R>39S'.DHU^6N6/UU\5#/R=*VZZX7-&*N'W@LP<)^C*(@\0Z*Z2.D
M*UYZUB;3KTK !46#5U_$-#E6US'[] Z1LAH=:.&! [[IU.Q5NB0%;1C5\].T
M@?[TR)H)IH;59'4E^*78WO+AU'U=$?I^ZD+JL<#A%OT8>RCH3C\A/A1-AQ=G
MZC9'53G7<0.Q7O,C*W=Y<^9HFQ=E?8;!2+FFP?F0NLTNW:8*N&9@*6!^XA&\
MGV"(*<F><E6GS__\I-"(5U)UWE#6=";&GIA+,/*B(*#0ITY(&:+IX9UR%"0P
M55OHUC9C?5'D@$ST0MXU$D/:IT^L^CR9>48-3)5-J65OD2,Y8Z;%YSS4:K@;
M/?-F WA1W)US<7-<(]ZNZSJQTT925'SXZ\4.PP32V,-NB"#D_^VN T4>PJ[6
M/IS!5L=<PEWS(("\*R'$C34WA\T;*X%6:YO-<.(E:[4Q&1^TMLNI/NZ*$30W
M@]5#\49ZN;:Y1^8]\M[?#6.,_GF(GW&O7M_A8I@UG1%L=WZ)%65=*;ZVHP;'
M"4P832&*_" 25:,7="@2G&C/U)FP;7E$VXRFCGJH>S+(..7J ]FQV1XRH/WE
M<-CRIBA_;<>T,]A2J$:GY C79&!F(I^VO.L9\9IGT?S9H46 */()BI+8C7EQ
M&T$''@#XKN<;.(.I8U9)1 V=P1RNJ29YEY/3B2A74U*-LSQS/:G3(Z 60C$/
M[;3AF/:I&D7N9!63WMQD*U[]TI^K.]YTL^]\_'JQ%9AX&2S^3QRB_['<U ?G
M$XJ"V D\3%,_\GTOI:P[O(/3 $.5ZM.H8<NE9X-5C!JS%BTH.5S0_%R!8EN+
MJIIFFF5>3C4G(UU--X]\=T"!0"IXKN54C-CK'T[@CBN<*D3V2*>5>,Q#/.VX
M5HS0GM4$]'5CW[(R%Y>./'T+:9$D0>*XJ4]\G!"7,<K<;A(!4X2)2M%IU/ 8
M96?3D?-&*^L^7/^02?3A$9B7$]#)2%<3T#=5\@PT6,$K3[F-JZ J3/8HJ)6
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M]_E.S'>(VW@X$&XRVZX>FWLMF$\]!W/Y#Q ?A?M12B(/D]!+(Q(Z+I':)&+
MC/6JL0,'D+@0\@A/[2X<$X1*3#:.QZ5JU3@?&A7F(L>C4V]6\GQ[4Y3W32E^
M_0C$[XNYA-61[?HZM2/PH1.7O82\-85IAL493&8:<J0PWL+D=^]\R7=Y,_M
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M81R3F-N#Q'7< .(NCR$G<=F0 8:V4<MCB..%WK3:Y?>U6K!E7H()[FZ6Y<S
M5*TT[?/LW,/=TIR65>1-^HK)U5VVWF^RBQN6;_-=]B7_D:W/MSO>4G,."E55
MMJNN!+ZK[.<.<VK^6L"8^"Z-8!CX+F-BEPI*ZPNXF.=R2,'B1U9>%](71EI
MH-)U3\%*=]X.M+C!N(']J<;=3<764P'YP0FPK+U0O/[11FCDRK2I8Z)6E+T9
MC"-BT$ &?]:@@4 -:MC_=^2[%=6)[=%<FV&:A_Q:]?#Y_876V505Y:(/"=N+
M!ZS;F>1Z;P[]*6Y=S)Y!)"SV8LI@FJ XP"RD 8X[B(F7$#VU'@7:J#*^/($+
ML@:OGF"/$S8U)9]=O&Q)_!EHO &G[H#6G]GHOXEP2"2&4:,^KXPQKNMOI)()
M^)?-,?]<BHMY=[]G]?WU3NICE_H^MQ2E:0 #@L5M$EX:AWX8$J4;X-6^V?)^
MM1;,N+W\"0,]W52/J7GT,TWLA8FVHG 2HGF?H;BYXF9XIZP6A#),G""@D8/\
M( F0$_BMC2#$*)8^^:?\S99;^O%)G5V+2&&GNSI-_>6'?8;4ZH<C.5=CD*.P
MP=\J27I;]Q7(DMN._]S'MS;::W,Q@RWT^M@+$ZWAN22>1NP+_^E__+?N$_X/
M\3+%__AO_P]02P,$%     @ #X9A35C4L.,";@  R'H% !4   !R=')X+3(P
M,3@P.3,P7W!R92YX;6SLO6MW&[>R)OQ]?D7>S.<DN%_.FCVS<,WQC!-Y6=XG
M,Y]ZT61+X@G%UFF2CK5__0N0;$J6>&D2W<T6'>_M6*8;(.JIIPM50*'P/_[7
MU_O)#U_R<C8NIO_X$?X,?OPAGPZ+T7AZ^X\?_WG]D[HV[][]^+_^YW_['__?
M3S_]7_WQ_0^V&"[N\^G\!U/F@WD^^N&O\?SNAS]&^>S/'V[*XOZ'/XKRS_&7
MP4\_K1K]L/QA,I[^^6_Q/Y\'L_R'K[/QO\V&=_G]X'TQ',R7WWTWGS_\VR^_
M_/777S]__5Q.?B[*VU\0 /B73:N=3\2__50]]E/\Z">(?L+PYZ^ST8\_! FG
ML^5WU_B2ZO&OKY[_"R^?AE+*7Y;_NGET-M[V8.@6_O)_?WM_O93SI_%T-A],
MA_F/__.__?##"HZRF.0?\YL?XI___/CNFT[*?%X6#W?CZ<_#XOZ7^,0O:C@L
M%M/Y[&,^S .^GR=QL,N.[LK\YA\_EO/R:Q >"B QB*+_]]TMYH\/^3]^G(WO
M'^)GOS0X)IO/!^/)[/BAO6C8X C+13YR7Q_RZ2RO,ZYMC[<TFOI@[6G5TM@^
M1:4<.[1O&S4U,CV8C6=7-Q_*?!8,S])>J.GH>GP['=^,AX/I/(QB2:=@M3X4
MD_%PG,]^'Y1E>/)+74(V^1WGE+OZLPUY7_;=I9POAM*$>#NZ;$HJ4]S?C^=Q
MJIR%KS;%\LO"Y%IC]#6:=C!*-1J-(W"#R;OI35'>+U&L^3HE=MN!=._S,-W'
M3Z\7P6;%GY\>3A?RB-X[D+6>+:_=07,CGH[BM!&_:Q;>PE'T)_5@$OVDZ[L\
MG]<8<MT>NAOSAT$9(+S+Y\'.3-(%V-I=J])<!WN9+VEP=6,&LSL_*?XZ31-[
M>^I,AJN'O%P:F16M[Q_*_"XT"//V^V*6+EB][AN4-H1K\W%X'W\OYF%.'CS6
M"04.-&MY=!&58K:T^E<WRW^H;6%/ZZ]U>;9^7-?,GMYGRW(=ZS0?V4W+HX^1
M]F@QR:]NWDWG>?#\YNNP)$V:NMTV)9W-RQ 11_C\>!KF@7%TE&;S<KGJ<E"(
M>JV[&6M-W(_JI)N1UWN3C^FCFW'_QV"R6 4[L]GB_F$Y*S6BA1H=-R?A;%B.
M'U;&72]FXVE^>);>VZC5D1UK,X_JI+&1KQ=M@X?B@EL_?WP6>AT<<(VV38W3
M#\9EI%K^6XB9%F5>R^3M;=3JR-3POQ;CE1_R,9]$QW 3-<VCNS@>K5W#FMQH
M]$O:E3QA;>#D#MN5:#;+EX'O^_'@\W@2!E/;2SVUOU;EJ3>%U6C:V"@7\_ %
MS]D\OKV+5N5_%^.X*/(EGQ0/2T-S6^;+@1P<_,D]GD^FNI1*[;@I"=]-PX\A
M"OEZF$M;'FUA%"F6Y\AN6AC]]>+^?E ^7MVXFYM\&&?\\/''8-2#:C>/Z7R:
MWXSK4J69WEN0M9X%VMF@N1'-!]/;&-6M3/+A 6U_OJWQJ/LB!)W_BK*__*?:
M##BUQ[9E.NK=K-U%6Z,^<:0=C:[NZ[2O57-C^Q*FG*)\/#R<%P\V/H+:2MO^
M?./CJ:NFK8\W-9JX\OPA+^..3C&]OAN4!Q>(=[=H;TPJA#&C\601)ZKE!W7?
MP!.Z:D\*]Q"S6(KI,#CYQQB\XWMJ3X9ZI#W4KJGQ_38H_PR2Q[77?+@HEZ'3
MH;'M:]/FN%+<T5/[:U6>+^&;XD>^**\'S_\E1:BZG;8IV;;/$F2JT5V;TM1[
M8P^W;&J,'T-(.EWDT7[=3L=UUA5WMVAO3#7U?;!A>R.LI]=#[9H:W]+(Z\%R
M]_L^;GK56C'>WZK=L;FO>3D<S_*KFS_BFGK]7:@3NVM7FH_Y;%Z.A\N,@V+X
MIXHQ_7A>U^=-Z;-=N9;?O 7L8[9KTWON0,:KY49/(WH[W%^[\M2S3'7:GC3.
MY_GZ<C7.:7X;MT/>#S[G+Q*MMK6;E.4WS>)! 1D/"D"V'/FVWAH>Z>_YO-G!
MONRPX?$&9W]<C-RT88BW=]O*V*_G@[)AS'=UW/#X/^7E+&]VY*^[;'K,Q7PP
M:7C,K[IL;LPG$&/^>I@U6?#P+!7]??A@_7SL]_23/ZMOR[_.\^DH'RW/%E7?
M-RF&VP1;"G4SF'U>2K:8_70[&#S\$DWX+_ED/JL^61KUGP!<GZ+Z[^N/LZ<A
MS-3GX$<,AIL]M4F$X1\_AN_-]CR="2,9481H3@"!5!*I.1  <H>IE%9^*]HD
MG@\KRC62[<KVOAA,9\O,KT_E8!3W3*[F=WGY3 CW=3A9Q+-Q:C(I_HHYNB&@
M-64>0O:X-A(:!E7H,+H_]X#2Y-=DF"D/D!/$,\XY9H(C4J&)+'1UT'S.3%4.
M?RC*45[^XT?XXP_A7V[RLEQ/BGN.SRUI.G]E7@;E\!6_OVVX?N*7AV66\T_#
MN_%D5+6.IPD;Y%/1&S4$H2O3\,M6V]"2U=CJ+KXIXP$]DMI(CH1UC% D@]*-
M=PQ"H"1#M>C>CFROT0Z^F5F4Y;.L@RU"[FN686B81PA0S0T'UA-D\5I:SX56
ME_]RU]9WT1JLG;VLN\^==OB*KG.>8][2<DB#29U7=4^K# 55(2R-P)Y!AY7E
MSBU-H]<V#,*>_Y5=C[X:?/Y-QM9X-IP4,3.JSM1^8H^9#O,7ME9J9 $7AF$I
M1(41@PI=UHO>"%MVO/#M(G\66W#N6;MYDP"U)<XB@A$4!C+*M*5+T*UGA"-\
MBDEXO1(5/\E^+;[DY33FQWW,/P]>'WQZ-O*]SV=AHE#<$2NT0XX(AS'<C-D[
M5"MLN8Q7M+;VBN9Q?7H!6Y\:XBMX/9@,RF Y:OEQ6QIDR'/$!6+2*!]B$:40
MJJ3CE"F1P!ITV:QI%-C#M-EA/M;?_K%X'$SFCX/IKM3[7>:D;OM,&Z<)YEIH
M&>8]YB" JI*'* P3B((OFRAMXIS*FV?.Q\>@F]#=71C;L^SMW8;EE&XRCI&&
MTF".L3&>N0"AW4CG*4A@$?E^6-02W V2Z3J?A&:WO^;3P.M)&)P:W8^GXRA[
M3( [FE7U^LN Q<$)1X1HYA66X<W9@,J=UBD^$/TNZ=4*[EWY2,L\@L5POBB#
M"/%%*;]L<ZOW/9YAQ@FW%B*L>7 !K9+8KR43WHB4P)<=RZC@H'XNWA"G&@2V
M0=/T6PBR ZL'T[Q8S.I;H&^:9=H+S:35@'('$)#(:%*-W@A3*T#<00O^71J:
M%'@[CKF>C;IVV/6Z3<:AU8H#3Y03$KGP FA<R8@-2Z&0.)I"K_:P^TRAIK$]
MRZ+9MH2C-[UF1B%TX?_44>U#@&L0HV:UPTB=PKI6@-B.K$_U45XS9JF&.BOG
M]3O)C-0."J\T@L%X.4X,)A42W"GR_:S$U>9$T1'8W;SJS9?J[- RO*X[6<,P
M[&Z4*0ZU!U1Q)KD./T)#F;% 6<8LE;C6V]"2I'L.?7R>OSZELTWNFEUDR$M$
MJ-+>.RHA5L KM$*!A^!)U=ID;,HF=!%'-$&(E]-].UCWUR1LK_OZADU!L,C&
M.F8<#-I GF@%H#$(:&>45O5<WG8D?2J=&!2S'/=C':=@7[,,,2&-)%#((*;#
M)A#>KZ5UF&)Z66Y $VHO6D.WJQ#Q]_RO9T"4Q33\.%S5K%D)4)];QW:5,2-!
M@-A(R[66,@0[@*X0L<!:E)*,U<.MO!;XUC+B'2Y[+K<$U#=; NNX<R7"_E70
M0ZTS3(2%V%"E&( ,6>4,7P/LN2(ISDP/]P);8%KS()^\0&K"([%P\Z=R/)A\
M,X)]1JINTPP0Q3RFTH77 3-KH/*P>D4(-RF38 \W_!JD2DL(=V>$EN=_?8 H
M[G1'"/X8S^_,8C8O[O.R_C1X7$>9,-ICY "D07IKF%321C2\L)I(G;+VTL,=
MP%9,4XMX=\6^;54%#LY\NQME# L#%+<,F&"*F4'<^^H=HY:8+G<!WR2K&L.V
M*P8]%1N>U;=5NQMEP29C[T.P0KUB"A( (*JDE(*E9";T<,.P!08UAFU7#-I6
MN/38&+!V'YDTWEH-,18A' FVUZKPZJPQ<!CH3G<3WR*_VH*Z*[JY03D->,3R
M5\L*!_5)=J!EI@'QU"GJI >4*"5HM=)B(70L)?-3?A?4:A;@_JQ7[[V>[ TO
M4VO-G$22>XH(1)H&$C'-" DO.L;(U[*E+>UD[\._UBYVK0XRB14V-@257#,!
M,0$8H34"5'J:\LJ_M=VJVF1XN87=!M+=O/NU+_?K\!W?,Z:G4W,U7ONC^LD0
M),9YI)T/^B$02$31*KE 8B.9/^>&50TYZFUA'=-1AK5SECGH*("84:C5^GA"
M0$0@W^E!T"XL0TM\>;73U:(2SFXTZE<,O7B#XJW&*OP.?IZ4!"KDI-:&8<L-
M1<[5.O]2=V%_,[!OQK6JY[QS27]?H\R3&-]0(:BB4A%N#<?KT3. 3*=N0?N1
M0$N:+5J"^\1 <U;.G[TTX6\O7YCP4?8^O+^W2Y69P2Q77\?;<J*V/YA%$1S3
M@#JK0\@$I3>^DD*2I,W"'I&F2746#>+9'2L^A>^SQ?U@O.VLZ;[',^NIU8B&
M$%H+K#@C'KI*(F-DRAGD'C$D59T[67$RDB?O&7^LIO]WT^'/7WZ^OONSS"?C
MW_+[SWFY:V;9UR93TA(F",/4($JT%\B0];BY4_5*L+Q%!IRBNJ(=4-LT%":&
MOWD9T)D__CZXWS>!;'LT \01XH&!!&%L,8&,H;4DPGIS(9E-+4TA#2#:)C<^
MY@^+>'XYF,/JHK"7(]X[J]1NGR'B'!?4PV!8!= (,U=96L&5O) "*>DJ+]H'
M]^29Y[?PM>-IK0EGRZ.94 (8(8W#1!H87':H*R,K&+HD3Z,%S16-@GMZPMH.
M"_E^/,W?S?/[G6=Z#S;,K(2$ N2M9\IR$C,1;"6!IB:E.D6/\AI;F&=:P3>!
M(55IE=4EE>_SV\'$Y[D:?8DU4C\,'I_?M/F:)G5:9XYH0HPV1CC+@63Q$/M:
M%JF]O)#2ETTKMF@;Z)-)4WW[[&,^OO^\"(".8@Z<'9?Y,&AN,!U=W=R,AWGY
M;CI;E'& 9E"6XX#\+B*=WF-F &/:&\XITMYR[Z#@E<Q.>OX=.+R)Y.H,_*[R
M.S8"[5F+WCR3(:H<8E(!RRR$8=A4T$H&P&&*=7HK,]GI!$J%LRM*K"WDS!?E
M<JC7^7P^^?9R^>UG^'>URBA'"CG#C!"  86IXE6,H!3D*7:G1]GZ+=.F.8 [
MLRW%;/8,@O4Q?C6/)O$Q?+C,B]MG=^JTS[1G7AB-K8%"8\=#V,$JV8E)JOW6
MH]3\MFU2"U"??8/X?1[BU/CI]2)$'_'GIX>_TWUBA 25CB%HI00&X##GP##S
M"*66)>;/EWBRO(/BF3"[MI/W/I\)10&4AB#/@.?$.HQH)1]E(*7X48^BIY9U
M7S2/].EUUJI5IAUK^Z\?RABRDD##%(68*0@-TK :F0X6\;(XD*B=HB$8TQ6\
M<S5^VV.9\Q8 2(2"CAE/*!9D,SKE\(6\Z"EJV:K9D]!+6/MXODZ\?UE]V[.9
MH= *8#T*D3*4F)*G<6(*^$5J^5@5%<V"V.:>W'70PG)DO^;%;3D(?MPP^)B[
M-VUW/I^%& >$@"=8-\LD@ A2S"J9#-2U$FC[OY#5K(UO$M%669+?OASAWIW:
MG<\'6ZDE8%HJC066AEIO7243M.!""N8UI->B>41/GCBN!U,[SF\+HTQ1/A1E
M$&[_[+&S01:+@7%FF54(8:F] T\CCA=K71 'TK56M !I/5,QJVS%+!_^?%M\
M^64V?RA7MB+^],I.A,^RW__?-HNP^I?,0B!]<)00XA*'D,<0X]>#)!9<2M6B
M9O5^&G9=K2:^G 7?[]F8/]@FXQ)XS007CD$O U 6H4I&[B2[C)V,9CV(IE'M
M;H\KNL73T<>HK*K>S=[]KBW/9U@3P@QE(AZH18@ZK4@E&S7UUL[Z/Y,TJ.-7
MVU[IJ)Y]2?G,Y;7/LVH,@IG0G%J(E-?20,;LZJY !PG0ME:QK7;P>"KH_"$H
M,2_GC]>+S_^9#^>?BJOR>6'7JX?E14C3VR4+CRO,?5K7&=+!BGKO@?",8"68
MP+Q"31EV8>N0+3%J9P'O3I32E;D)UB/8PM%38=)\I..U.,/\^B[/Y^>S-YNX
M\NK&CZ=A0./!Y$,Q6QZ[K&%FZC3/H T3@- (,A^F%"4TAL1H+YF$1!-1*WFV
M'>G5;!; KU/TX9L'LS"-<6$PT0QAR-4R5*HD,L)TNN[0Q6'F9M7\LCQW"K9=
M>9BK0:ZO":E-F!?/9]))@3&E@(#@@0N%%:\@HIZ;3F>,3LICG*C:K0Q) [,K
MHIC!+%9GC7^X_UJ,OPPFRQFS=DI,K?89-%X)3R53(?#7\?H*52%)97C9+I-(
M)S/@9=6$%C#NS!!U>/<$@XPB3;5G4$GO&*(DUL<3%$AEB4P)B(]>8GM[+&L)
MYLZ(MKYW_F,^S,,K$N3X/=]SJVN=9IG0GA,G@ZC &,IX@%*LH622)A6S/'I-
M[@T2JCEHNR+1N^F7,+BB? PCW4.:YX]EC%'FJ?-<48,U4Y(S6DE"%4O9T#DZ
ME_CMD20!RL[2S\O\83"N+K0+$_%R*?(;&/:EH1]NG3G@*+,".^W#;R"LM!5X
M#+.DHJ9'9PR_/0HUCW#'S/HT^+K7 7K^6.:E!A!9R:VVB#*B",)K2;A7+N6B
M@3Z6Z&Z#*:< >9; O6[ G@'!I9'! V/8(B@4,KB:33DP+J5N^_%5MUN_8[5A
M-R4!R>X,Q6IQ^<-DL#QJ$</ Y54J^_V4?<TR[*@W%A( F1%(4>>\K"0U&J;D
M,O8X6DI>W&D0TTX3%5;B_UY,AP=MR];G,\Q4"/ H=,Q*(;B!)KP0*]F$LO66
MQ=]>,)3,ER; [(HHD<OSQ]_R^5TQBH[Y;'[HD.6.%ADSCBA) <7<&L\YBI?U
MK.633*<8EQX'1<ED:0;.KNCBQ]/Q/'\__I*'P<X'T]MQB/'75-\[+^UOF''+
MI'5!2.XML<@H*W4E+74ZI4I:_7!(KL@SS>=O@3B-(MH5?WXMBM%?X\ED#U.J
M1S*&!,1AW$(:I) V2+K*NY->V922K$>'/6_(H)R(7[?1SL$P)Z.Q3 7PD'.E
M36"L8MQ7H^<:I?@>O8UO&MJ&/!*[SE(@GRZZC^>AY\7PS[MB$C0R6\V!-?:L
MZW:1H4!^HI'E (1IE'IFB'GBOG:7%NFTFO[0$NIGX%W][(C=C3(;IE0*)*<V
MH D-)$16ZP5*FGI7?;^EG>WFU;^;7VE8=[WQ^&'P&/>XZF\Y?ML@LQ((#S#F
MD 83K3D0&S,?U[-2UO#ZSJ23%;UCQS$)V0YY4RZ"/E[!L)\ZV]MD(2ADDGJK
ML%5 0\"MJ+;.5+3PES;'M<.>1L#MF$ ?B\?!Y"CZO&R1,8L-$! IK1SU"#A(
M*OFBM"GYH;U<VFN//(G0=KHB?)3EV=$BXY989QG@,?6,2Q1$<I5\&KL4ZO1R
MH:\%ZC0#[>D%3X;!<5L%!Q_S24SU?RI8&@\ C$?+DPO%[E(H=3O(",<:,F:<
ML98H(*AD5<QAF'0IDU0O\QP:)$NK2'>6;%Q, ^SSN#89<PH/6YWM#3(A-+ >
M&F+#Q,R$Q^&OE71$J O+@6C!Y#2":U>L>;H1^Z@9:U^SC"!%"':82P4]X5!"
M4(4$!FN?8HF.7E!\8Y:H!7S/M_ASU*)/Q@SE7$BFO(VU_YGDOK*J5LJD*[Z.
MOWR\]67H%CB3C.F99JI::1,[VV280N4#0@I(KZ6&@LN-C)#:E*6=O@?G[2P2
M-@7UN>*M^FDX6QME@DB@M0!6(V(EQPRJ*JJTCIB4G/.^!^SM$*HQK!/"L&\7
M$/92Y$"+3 )GO=4<6@H%=! "CM9C=M#B"ZEOWCH[FH6Y_0B]#F>.[BI32%B@
M'098:&-DO R^2AYQ5"55+.M[U-X*G=K6P!F\Z7IN=.91O#8<Q]H6D!JEPOM3
MF=)XU42*63H^;N_2?VY]J_1(:+NBR$EY'?N0PAAS#YF64EH2/#O*-R\"02+E
M0&;?P_9V*-08UAT>F5KI:#GR0]4)MCP=Y#+QC B&0#F!J 5 5;&KT]1U>@=O
M-]E Z2I^?8XJ$=;NXOC[^V):BRLO'PV.OT#$ <"DD\0R [FN]E\\$4E%*WH9
MM;= E$1,.]M)'XV6#ME@\F$P'KV;FL'#.'@'ST:_;U/]8.,,&N9$"!$0"[\0
M1%CX"CXO%4Y)7NYEN-X"DQI'N2MN?8SW^DSSD1N4T^#EST(XN;A?+!U_F]^,
MA^-]KM#AQAE"@"'# ($<,Z2L16[]1H4!H:34Z%YNP+? K<91[C #J!IH51XU
M*.PN#U'DE_S==%C<Y_$>K=_S^=7-I\'7_9E!Q_24(:"D(=)@3AP-[UJ8ZVF%
M1[Q6^=+6!-JP:*U"?KX([ZC(+I-,"\Y0O)S;6R2$4!5Z"&IF4S9B>[@DT *-
MDC'MRXF/>FM(6YMFVG-,K 30>0,!-@!5B0L(>F52KE_I]\9LZPM+3>#]Q+#S
M5JW]L$3W+I_'*PF^'>*%E; %7BF$D0(>0D4H AY;S0@)_[%>XEI9F5VLWP2-
M7)5+B4;+^/!#7E[?!2W57M+9U4&&B8>$"(6"]10R! 1$TPT"D*2L%/9TE:=)
M6NQ=[VD(\_.L&"Y'.E.+^5U1CO^5CVHS[67#3.,@HS<$!?N',"!&H4I:IXU*
M">I[NCS4&<,2L3XGL][-9HNC6;5JE"F+)86>2<ZT9@PQJ5DEI5"LTRM@+I)1
M)^%\3C9=+>:S^6 Z&D]OCZ34LY89, +%)7CJD-8R5L8"KI)7<9HR%_9TB:AC
M7IT.]AGV04[PN6JTSIQQ(=R0 BD!09!<>8+7<GMF5:>WWK]YDC4/^!F(=H2K
MM:=5)J -+U0(,)&@7+ P\3M=R6E)4G'47E9^Z8I8B4"?C5 '/:P=+3(D. B3
M/8,^VF5& G"59?9&F)2-_UXFCW1+I)- /AN)ZCE6^YIE@CC#!9;"XO#:*&$)
MEBM).0B3?XI7=?2:X^71Z72DS[C:N(%H=G43;^OPD^*O7MR5M1G,<0N,KYIE
M1GJ('.?,64RC2JD'1ML02"D+!:OEY;4C;;Q;( SW0UE\&0=\]>,_9[$6WN;>
M-36<C[^L3AXM\VT7X;/U/P8-UL"EF2_(E#;,AXE5>.IH^!$)0BH$I90I6Q5]
M7YA,H%/1 UUT-5D%X9ZV?_<3\NFY#'DGA<!>AK$CB36!3JQE<23X;Y?&JZXI
M\)J!)X/?75K;?R[6%60_%1_S81'F[.4E+$\C_U34!+'.'7(M?%WP)ZWUCAFD
MA7-:2 2EJI!58?+O<I6]_9-,9R9U#S3875&!H/O@PD;@PL^3?$F.Z4C=%^5\
M_*]=!4^.:9XQ98'G3EGGA;902Z;M6G)O)$C9(>KAA;OG)<^KX@2-ZZ<[9J[4
MNH+MT^#K^F(;G4_SF[W9H@=:9@8B3:0-4;GAW@/J>8C)E_)J$(*IR[OQH5^,
M;%(Y)Y\E?3<-EB"?S9\N98NX_5[,\]G31ULX5K]Q%F_P$I3KX! Y "07 O%*
M$LI-2FYH_6W,3?GVVQB8?_H^K%]K2CJ9;O$0:Q"Z&M.:\[OXM?WI3#DO.?>*
M Z&)$41B"*NQ I]48[>'I]G[PZ1&U-%A+GRYFN6?3?%7-W8\6]6$#9/_AS*_
M'R_N9_6N-CFMP\SCH',(I$?. .9@B -%A8[P-J4VV0F75WQ/UJ]3Q75&ZV]D
M6"^\3V]-,5L*LA%J'Y%K=A$1<,I[&HN]20LPMJ)"  95I&SA]["L7K\XVXZ.
M3IZWES+/PF!\46ZN:-TU;6]]."/0 $Z,)1H22;6EE%4>!B0:I11[J+_=^ET:
MPL:4TMDAHKCEIP?+W;3[Z&0<6G[9WB#3BF'BC1,26A'<6 F5JZ1S$G5Z#.2[
M"W ;T4E7C/.#<;E,IWJ"\.KFCT%9#O;/I7O;91!") PGRC/I)14LO&9K69&V
M)N4LKOQ[ MW+OB85<_*L:>X&T]M\/-T,IK@YLI9V_1XR',7A,EATX;$3G&B.
M*YDX!TEU3,#?;-L]L[:FHZZ,GU[,QM-\-@MV^G/P-.-(=PB@XOMSNTII68G]
M+D95B^5N_O8FU=G!1[C'C'8T@HR&7U@AJ!"U&'G#@4(5_C8X/"GOR-];,/LM
M<C]UW-UICB?WVQ:+S_.;Q:2ZGFCO48[=S3((C# 2,D*@)E(R2V*!DY6DF."D
MN\9ZN!G>*S8WJ)C.?-RBS,>WTU6A[>'CI_"2S0($089?!^-IA$_G-^&9_95!
MCN@E0Y!!Z62\8Q(%/\L#!:OH$EM,D\SMJ5L_WP]%V]-45XQ=UD'9[#I$!'=O
M&!ULDU$E*$?8$F& EDQX0FTE(\9)^?ZP_K[1=[D"U;1RNB)@&&.9#V:YS5=_
M/D-E77"L1AY<_4ZR\*[%6[E)<&&,1T9!C*O57!SO5TBAZ-&GYKZS&;TU-9V/
MK)5#LC>3XYCFF08(4(.1DUX("H-?X]:9A)H@8KJYWK;#";T-4ASD73+NYV-<
MM;.POP;XWG89U=8HBPSV@"E#O6*Z\IZ)8_6*U22GI5TZQTX'_(QS;_0>GDS_
M\CK[X^;=+1UDQB(L')+QHA@$I(4"5XEVA%C3396-2Z=; \B??QI=7R,=TX9?
M70U\TL2ZK\,LWC#C,*.4:19>3X^06/LQFH9PK=-"KNV[@F>=:!O40U^LXZG4
MW-E+9KS F&"BK2,>$<TUK-Y6*B5*L9,]#$UZ8"5/![_#DXDUH[,]'*S?2<:(
M<)X:1:&7)/QD!2:;5]'YE"/V1Q?$:K^LY_E/-+:CES.S<Y7CV>()\"._($.8
M$!D7*AA4R  MT,9^,*SLQ1W#Z?($>+NZZ&SS</"X7B1;WA96YD',,/;YXX?)
M8#H/;DLLP_L0']FWE5B[DXR3,)]!X@%"7"@GA5+5^\Q0^/NEK?)T39Z7>XEM
M:>9L_'P7%#^]C=>Q'HS2#[;-+ DNE;<44Z6=<RK>%U/);#GLQCY^QVQ,5$B'
M&1;#/!_-? #T>C#)KV[4E\%X$@,[7Y3QD^M\N"B7P,5+@O=G71S550:94\9C
MA8 "R#!CA*]B1.8)3KFUX'C']%Q5"3HC:+O:.9O1/)VNQ_64"4X=EB(6)=%0
M>FT#VFL\.# VI0[!J?O@%\W75M63<J1G^1I%O'X;S.,('HN;>"[X\,'O.FTS
M@(6B0'FM-6)&,>O01@ZI4:<58"_6*+:ECK-9P=6-(K_E\[MB5.]@;MTN,J2M
M"PZ*!Q X2(E%C%;9U]PCV\UYQN_8[C6CE_XM'S6R1)01(X500%#NE0;,0L6J
M@U%<$Y 2YAQ=CO9LBYM=<;,UO9R9G9N3PFTM;A[Y!1DU1&FFA;;:40NDP*I2
MD&" =AH97=KB9KNZZ-@#"+[PH;,=6^0][!:<UF^F.%'4>6P9)% X @FIWGIA
M(>RF+.OY?876*+;=5^A$6:='3*M!7MW\NAC$<Z3!Y?YM/!W?+^X_%H^#R=8K
M"^LUS" 6()@&*\,$8W! T&_.X0<)^/>RQMDVW5K11E>&\F/^L/:HKVZ6F0('
MEH6V/I\YR;%V"$GME;!8"EAM!VNI,4@)@OI;C>W,UJT)39QC&3W>X1"ORZQ5
M"F%_PXQ!YH/#0XF#3 :I*4+5(JR$!*0<;>AA.MNYI],F=7&6#9QX\\/5PQ(-
M]S4OA^/9@5OT#K3-'/>(T%B2.\HNXM5;>/.V$:6^B]7(<_"O"76<U_@M3?;[
M8GH;)JK[([8.]_20$6(1=-A3$&0F0F-%JSU4%;R-E,.(/:RMUB,Z-J>4<_A]
M-5FXJTDFM<*<4@>) \QYY>RF.(*B$G9SY]7EQQD-ZZ'CI9AG!0>KZ]ZKMV99
M@/#PHLNA'K(08'EMH!-8(Z8@#/^O\ID55CKE&H?ZE=F^'QZVHY9SS,K5II(O
MRJ7]/G)-\+B>,BTDE-Y9J#BA/,X*F%9X2"U3G,8>%G [-TE;54[_-F8:V7S)
MJ'**&,6E0"+,'1P"N$&!H*33LB>4?3O7OF%7'&U-,5W1T]W<Y,,P$;BOPV5E
MK8]AZKN:1IG"C!#_B)OT7P:3 SD7QW232:>H !1K9PDG!,?[5=9(:$MU-_EF
MG5G15G8 6\2[*^9M'^R'O!S';)!OC\+M8=XQW6124@F0)89H:9#WSJ/*G]%.
MZ92K1XY?]&G=-K;"O!;Q/B_S5+#D9?D8C/:R:.?1E'O1/@LSB47<"(R=UL@!
MC%151<$@Y%.V\(Y>T7E8JB?PH9Q?"N/2X+XPJB'N#0@O&@]67@BFH:_V)XU1
M+"6IYNA4L175W+3=^/F<1#L*[">BG?6VZ6<N[W19?[W,[T*#\9=O+I'M_ KJ
M55VOS4#K%4_;UB*31$"OH4!6 6 48&&N,18")YR-)6SJO )M+==^R:>+/$:Q
M,02)H_UC/+\SB]D\2%(&#VZR&*V+H(3_C_:7VSRAM\P3#P@D 'A# "%2(2@K
M;.*'G>0N=5FI(8TAK]9LVT:\L_*9U5']=9'%.FF?.]MD'F/F60B<J:<AI)62
M([:6T0$(4EC5PV+#3;.J*5P[<V2*6<R0*HI1G$&N\_++>)C/KHO)OEWXW8W"
M',V AT)SA;DF4!&A526E8+*;PH&=L:<!;;_T59J"MKM=RUD>OBLZ6#98U$FQ
M/,!^N'[OWG99T(5CGAHJC3:$26H$K&0U7*04Q>JA$6J>1DVBVQ63KO-)Z//V
MUWP:T)C$(EVC^_%T')&8!X?V,*7J=9"%N,$:" &&@BB./.";2=QY)KHI!/B&
MN=4*S%V1[/UX/KY=JNTZG\\G>3UCM:=5!HAAP%K-@-;4&!#16\OI(:875K^O
M>3HUA^W)"?^=WM]DC8\%78@&T!(ED*%"5#(Q(CNMK]?%2:GF&-,NTATZ3/-R
M,8RGMZ>W09KR=N\6\;;',P@M1()#'*^.1T1)$6SM6C(J:0J'>IA5V(I[E KJ
MV8+[8X+Z3$,I)'9 ::HL@XA#2BN9G$S*AN[A8>/FB9**:.<L>;I1H0Y/GI[.
M-+-( &\ LY)03:S@&[F0@]UZQ:TSI;5EGY,1[2QOJ9@6WPYV3>TZ9\4/M<V
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MKA .>*?L$]8/@>3J=9KFMS'EXOM[G7JBW3?Z_ESG\_GDVT2\]M^@9U^::<
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M%&I"/'35R(G&%Q8ZI2NP: G9DSGQ; )<?C^B^^FPZ_D,4.&"&542>HF0AMX
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M4__]'_\/4$L! A0#%     @ #X9A35M8&=?$,0$ N 02 !$
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M !4              ( !65(" ')T<G@M,C Q.# Y,S!?<')E+GAM;%!+!08
1    !@ & (H!  ".P (    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
